{"PMC7278248": [["Warum Tiger im Zoo erkranktenAus dem Bronx Zoo in New York wurde von Tigern und L\u00f6wen berichtet, die nach einer SARS-CoV-2-Infektion respiratorische Symptome entwickelten.", [["CoV", "TEST", 117, 120]]]], "PMC2679399": [["BackgroundThe global loss of biological diversity affects the well being of both animals and people.", [["people", "ORGANISM", 93, 99], ["people", "SPECIES", 93, 99], ["The global loss of biological diversity", "PROBLEM", 10, 49], ["global", "OBSERVATION_MODIFIER", 14, 20], ["loss", "OBSERVATION_MODIFIER", 21, 25], ["biological diversity", "OBSERVATION", 29, 49]]], ["Human impact on ecosystems and ecological processes is well documented.", [["Human", "ORGANISM", 0, 5], ["Human", "SPECIES", 0, 5]]], ["Habitat destruction and species loss have led to ecosystem disruptions that include, among other impacts, the alteration of disease transmission patterns (i.e., emerging diseases), the accumulation of toxic pollutants and the invasion of alien species and pathogens [1].", [["species loss", "DISEASE", 24, 36], ["Habitat destruction", "PROBLEM", 0, 19], ["species loss", "PROBLEM", 24, 36], ["ecosystem disruptions", "PROBLEM", 49, 70], ["disease transmission patterns", "PROBLEM", 124, 153], ["emerging diseases", "PROBLEM", 161, 178], ["toxic pollutants", "PROBLEM", 201, 217], ["the invasion of alien species", "PROBLEM", 222, 251], ["pathogens", "PROBLEM", 256, 265], ["destruction", "OBSERVATION", 8, 19], ["species loss", "OBSERVATION", 24, 36], ["ecosystem disruptions", "OBSERVATION", 49, 70], ["toxic pollutants", "OBSERVATION", 201, 217], ["alien species", "OBSERVATION", 238, 251]]], ["Ecological perturbations are creating a medium for new disease patterns and health manifestations.", [["Ecological perturbations", "PROBLEM", 0, 24], ["new disease patterns", "PROBLEM", 51, 71], ["health manifestations", "PROBLEM", 76, 97]]], ["For example, in the marine environment, new variants of Vibrio cholerae have been identified within red tide algal blooms.", [["Vibrio cholerae", "ORGANISM", 56, 71], ["Vibrio cholerae", "SPECIES", 56, 71], ["Vibrio cholerae", "SPECIES", 56, 71], ["Vibrio cholerae", "PROBLEM", 56, 71], ["red tide algal blooms", "PROBLEM", 100, 121], ["new", "OBSERVATION_MODIFIER", 40, 43], ["Vibrio cholerae", "OBSERVATION", 56, 71], ["tide", "OBSERVATION_MODIFIER", 104, 108], ["algal blooms", "OBSERVATION", 109, 121]]], ["These toxic blooms are occurring in greater frequency and size throughout the temperate coastal zones of the world.", [["toxic blooms", "DISEASE", 6, 18], ["These toxic blooms", "PROBLEM", 0, 18], ["toxic", "OBSERVATION_MODIFIER", 6, 11], ["blooms", "OBSERVATION", 12, 18], ["greater", "OBSERVATION_MODIFIER", 36, 43], ["frequency", "OBSERVATION_MODIFIER", 44, 53], ["size", "OBSERVATION_MODIFIER", 58, 62], ["temperate", "OBSERVATION_MODIFIER", 78, 87], ["coastal zones", "ANATOMY_MODIFIER", 88, 101]]], ["In arid zones of the southwestern United States, Brazil and Argentina, hantavirus epidemics have emerged in ecosystems that exhibit habitat degradation and climatic disturbances [2].", [["hantavirus epidemics", "DISEASE", 71, 91], ["hantavirus epidemics", "PROBLEM", 71, 91], ["habitat degradation", "PROBLEM", 132, 151], ["climatic disturbances", "PROBLEM", 156, 177], ["arid", "OBSERVATION_MODIFIER", 3, 7], ["zones", "OBSERVATION_MODIFIER", 8, 13], ["hantavirus", "OBSERVATION", 71, 81]]], ["When the natural resilience of ecosystems is stressed and barriers to disease transmission are reduced the emergence, resurgence and redistribution of infectious diseases are obvious symptoms of a deteriorating planet.", [["infectious diseases", "DISEASE", 151, 170], ["disease transmission", "PROBLEM", 70, 90], ["infectious diseases", "PROBLEM", 151, 170], ["obvious symptoms", "PROBLEM", 175, 191], ["a deteriorating planet", "PROBLEM", 195, 217], ["redistribution", "OBSERVATION_MODIFIER", 133, 147], ["infectious", "OBSERVATION_MODIFIER", 151, 161], ["deteriorating", "OBSERVATION_MODIFIER", 197, 210], ["planet", "OBSERVATION", 211, 217]]], ["According to the World Health Organization [3], 30 new diseases have been described in people including AIDS, Legionnaire's disease, and toxic E. coli infections since the mid 1970s.", [["AIDS", "DISEASE", 104, 108], ["Legionnaire's disease", "DISEASE", 110, 131], ["toxic E. coli infections", "DISEASE", 137, 161], ["people", "ORGANISM", 87, 93], ["E. coli", "ORGANISM", 143, 150], ["people", "SPECIES", 87, 93], ["E. coli", "SPECIES", 143, 150], ["E. coli", "SPECIES", 143, 150], ["30 new diseases", "PROBLEM", 48, 63], ["AIDS", "PROBLEM", 104, 108], ["Legionnaire's disease", "PROBLEM", 110, 131], ["toxic E. coli infections", "PROBLEM", 137, 161], ["new", "OBSERVATION_MODIFIER", 51, 54], ["diseases", "OBSERVATION", 55, 63], ["toxic", "OBSERVATION_MODIFIER", 137, 142], ["coli infections", "OBSERVATION", 146, 161]]], ["Diseases like tuberculosis, temperate-zone malaria, hemorrhagic dengue fever and diphtheria are also re-emerging as threats.BackgroundAnthropogenic change can be considered the primary factor causing the emergence of infectious diseases including vector-borne diseases.", [["tuberculosis", "DISEASE", 14, 26], ["temperate-zone malaria", "DISEASE", 28, 50], ["hemorrhagic dengue fever", "DISEASE", 52, 76], ["diphtheria", "DISEASE", 81, 91], ["infectious diseases", "DISEASE", 217, 236], ["vector-borne diseases", "DISEASE", 247, 268], ["hemorrhagic dengue fever", "SPECIES", 52, 76], ["Diseases", "PROBLEM", 0, 8], ["tuberculosis", "PROBLEM", 14, 26], ["temperate-zone malaria", "PROBLEM", 28, 50], ["hemorrhagic dengue fever", "PROBLEM", 52, 76], ["diphtheria", "PROBLEM", 81, 91], ["BackgroundAnthropogenic change", "PROBLEM", 124, 154], ["infectious diseases", "PROBLEM", 217, 236], ["vector-borne diseases", "PROBLEM", 247, 268], ["tuberculosis", "OBSERVATION", 14, 26], ["temperate", "OBSERVATION_MODIFIER", 28, 37], ["zone", "OBSERVATION_MODIFIER", 38, 42], ["malaria", "OBSERVATION", 43, 50], ["hemorrhagic", "OBSERVATION_MODIFIER", 52, 63], ["dengue", "OBSERVATION_MODIFIER", 64, 70], ["Anthropogenic", "OBSERVATION", 134, 147], ["infectious", "OBSERVATION", 217, 227]]], ["Global warming, human population growth, deforestation, globalisation, wildlife trade and pollution of oceans and freshwater bodies may have an impact on the prevalence and distribution of infectious pathogens.", [["deforestation", "DISEASE", 41, 54], ["human", "ORGANISM", 16, 21], ["human", "SPECIES", 16, 21], ["human", "SPECIES", 16, 21], ["Global warming", "PROBLEM", 0, 14], ["deforestation", "PROBLEM", 41, 54], ["wildlife trade", "TREATMENT", 71, 85], ["freshwater bodies", "TREATMENT", 114, 131], ["infectious pathogens", "PROBLEM", 189, 209], ["warming", "OBSERVATION_MODIFIER", 7, 14], ["infectious", "OBSERVATION_MODIFIER", 189, 199], ["pathogens", "OBSERVATION", 200, 209]]], ["The dynamics of disease emergence from wildlife are complex and bring human and domestic animal populations into increasing contact with wild animals potentially infecting wildlife with new pathogens causing high mortality, decline and even local extinctions.", [["human", "ORGANISM", 70, 75], ["human", "SPECIES", 70, 75], ["human", "SPECIES", 70, 75], ["disease", "PROBLEM", 16, 23], ["new pathogens", "PROBLEM", 186, 199], ["high mortality", "PROBLEM", 208, 222], ["disease", "OBSERVATION", 16, 23]]], ["In some cases, wildlife will survive infection and will become reservoirs.", [["infection", "DISEASE", 37, 46], ["infection", "PROBLEM", 37, 46], ["infection", "OBSERVATION", 37, 46]]], ["As human populations continue to augment exponentially and globalisation is imminent with increased travel and trade, these anthropogenic pressures on wildlife habitat and populations also will increase.", [["human", "ORGANISM", 3, 8], ["human", "SPECIES", 3, 8], ["human", "SPECIES", 3, 8], ["these anthropogenic pressures", "TREATMENT", 118, 147], ["wildlife habitat", "TREATMENT", 151, 167], ["anthropogenic", "OBSERVATION_MODIFIER", 124, 137], ["pressures", "OBSERVATION_MODIFIER", 138, 147]]], ["The result can be predicted as a continuing spillover of new pathogens shared among wildlife, domestic animals and humans [4,5].Global climate change and disease emergence ::: Conservation medicine: ecological health in practiceClimate change is one of the most pressing ecological health concerns today.", [["humans", "ORGANISM", 115, 121], ["humans", "SPECIES", 115, 121], ["humans", "SPECIES", 115, 121], ["Global climate change", "PROBLEM", 128, 149], ["climate", "OBSERVATION", 135, 142], ["disease", "OBSERVATION", 154, 161]]], ["By all scientific evidence climate change is a reality.", [["climate", "OBSERVATION", 27, 34]]], ["The effects of climate change in promoting the spread of infectious disease from more tropical ranges to temperate areas are being observed in such diseases as malaria and dengue fever [2,9,12].", [["infectious disease", "DISEASE", 57, 75], ["malaria", "DISEASE", 160, 167], ["dengue fever", "DISEASE", 172, 184], ["climate change", "PROBLEM", 15, 29], ["infectious disease", "PROBLEM", 57, 75], ["such diseases", "PROBLEM", 143, 156], ["malaria", "PROBLEM", 160, 167], ["dengue fever", "PROBLEM", 172, 184], ["climate", "OBSERVATION_MODIFIER", 15, 22], ["change", "OBSERVATION_MODIFIER", 23, 29], ["spread", "OBSERVATION_MODIFIER", 47, 53], ["infectious", "OBSERVATION", 57, 67]]], ["The impact of climate change on all ecological processes is profound: increased precipitation in some regions and drought in others; increased erosion of the coastal zone with rising sea levels; and the inability of many species to adapt to the relatively rapid changes in climatic regimes potentially resulting in mass extinctions [13,14].", [["climate change", "TREATMENT", 14, 28], ["increased precipitation", "PROBLEM", 70, 93], ["increased erosion of the coastal zone", "PROBLEM", 133, 170], ["rising sea levels", "PROBLEM", 176, 193], ["climatic regimes", "TREATMENT", 273, 289], ["mass extinctions", "PROBLEM", 315, 331], ["climate change", "OBSERVATION", 14, 28], ["profound", "OBSERVATION_MODIFIER", 60, 68], ["increased", "OBSERVATION_MODIFIER", 70, 79], ["precipitation", "OBSERVATION_MODIFIER", 80, 93], ["drought", "OBSERVATION_MODIFIER", 114, 121], ["increased", "OBSERVATION_MODIFIER", 133, 142], ["erosion", "OBSERVATION", 143, 150], ["coastal", "ANATOMY_MODIFIER", 158, 165], ["zone", "ANATOMY_MODIFIER", 166, 170], ["rising", "OBSERVATION_MODIFIER", 176, 182], ["sea levels", "OBSERVATION", 183, 193], ["mass", "OBSERVATION", 315, 319]]], ["Changes in atmospheric volatilisation and deposition of pollutants are of equal concern.", [["Changes in atmospheric volatilisation", "PROBLEM", 0, 37], ["atmospheric volatilisation", "OBSERVATION", 11, 37], ["deposition", "OBSERVATION_MODIFIER", 42, 52], ["pollutants", "OBSERVATION", 56, 66]]], ["The impacts of climate change on biodiversity are still underestimated.", [["climate change on biodiversity", "TREATMENT", 15, 45], ["impacts", "OBSERVATION_MODIFIER", 4, 11], ["climate change", "OBSERVATION", 15, 29], ["biodiversity", "OBSERVATION_MODIFIER", 33, 45], ["underestimated", "OBSERVATION_MODIFIER", 56, 70]]], ["Up to 37% of over 1,000 animal and plant species in six regions of the planet are at risk of extinction from climate change.", [["plant species", "TREATMENT", 35, 48], ["extinction", "OBSERVATION", 93, 103], ["climate change", "OBSERVATION", 109, 123]]], ["A more recent example described by Rausch et al. [17] hypothesized that retreating sea ice is changing the feeding behavior of pagophilic pinnipeds such as the walrus (Odobenus rosmarus) with a usual diet of benthic invertebrates inhabiting coastal waters to a depth of approximately 100 m now shifting to a more pelagic diet including ring seals (Pusa hispida) due to the retreating ice substrate, thus inducing to modification of the helminth fauna.", [["Odobenus rosmarus", "ORGANISM", 168, 185], ["Pusa hispida", "ORGANISM", 348, 360], ["Odobenus rosmarus", "SPECIES", 168, 185], ["Pusa hispida", "SPECIES", 348, 360], ["Odobenus rosmarus", "SPECIES", 168, 185], ["Pusa hispida", "SPECIES", 348, 360], ["pagophilic pinnipeds", "PROBLEM", 127, 147], ["the walrus (Odobenus rosmarus", "TREATMENT", 156, 185], ["ring seals (Pusa hispida", "TREATMENT", 336, 360], ["the retreating ice substrate", "TREATMENT", 369, 397], ["ring seals", "OBSERVATION", 336, 346], ["helminth fauna", "OBSERVATION", 436, 450]]], ["A higher prevalence of trichinellosis caused by Trichinella spiralis has been observed with a huge zoonotic potential to indigenous peoples feeding on these pinnipeds.", [["trichinellosis", "DISEASE", 23, 37], ["Trichinella spiralis", "DISEASE", 48, 68], ["Trichinella spiralis", "ORGANISM", 48, 68], ["Trichinella spiralis", "SPECIES", 48, 68], ["Trichinella spiralis", "SPECIES", 48, 68], ["trichinellosis", "PROBLEM", 23, 37], ["Trichinella spiralis", "PROBLEM", 48, 68], ["higher prevalence", "OBSERVATION_MODIFIER", 2, 19], ["trichinellosis", "OBSERVATION", 23, 37], ["Trichinella spiralis", "OBSERVATION", 48, 68]]], ["Trichinellosis is widespread worldwide with a generally low prevalence and restricted to specific areas in Europe.", [["Trichinellosis", "DISEASE", 0, 14], ["Trichinellosis", "PROBLEM", 0, 14], ["widespread", "OBSERVATION_MODIFIER", 18, 28], ["worldwide", "OBSERVATION_MODIFIER", 29, 38], ["low prevalence", "OBSERVATION_MODIFIER", 56, 70]]], ["Low intensity infections occur in wildlife (wild boar, red fox, raccoon dog, polar bear, rodents), keeping alive the risk of infection to humans [18].Global climate change and disease emergence ::: Conservation medicine: ecological health in practiceCurrent evidence suggests that inter-annual and inter-decadal climate variability have a direct influence on the epidemiology of vector-borne diseases.", [["infections", "DISEASE", 14, 24], ["infection", "DISEASE", 125, 134], ["vector-borne diseases", "DISEASE", 379, 400], ["boar", "ORGANISM_SUBDIVISION", 49, 53], ["red fox", "ORGANISM", 55, 62], ["raccoon dog", "ORGANISM", 64, 75], ["humans", "ORGANISM", 138, 144], ["boar", "SPECIES", 49, 53], ["raccoon dog", "SPECIES", 64, 75], ["humans", "SPECIES", 138, 144], ["red fox", "SPECIES", 55, 62], ["raccoon dog", "SPECIES", 64, 75], ["humans", "SPECIES", 138, 144], ["Low intensity infections", "PROBLEM", 0, 24], ["infection", "PROBLEM", 125, 134], ["Global climate change", "PROBLEM", 150, 171], ["inter-annual and inter-decadal climate variability", "PROBLEM", 281, 331], ["borne diseases", "PROBLEM", 386, 400], ["intensity", "OBSERVATION_MODIFIER", 4, 13], ["infections", "OBSERVATION", 14, 24], ["infection", "OBSERVATION", 125, 134], ["climate", "OBSERVATION", 157, 164], ["disease", "OBSERVATION", 176, 183]]], ["Opportunists that multiply rapidly such as insects, rodents and microorganisms colonize stressed environments at higher rates.Global climate change and disease emergence ::: Conservation medicine: ecological health in practiceBecause they are sensitive to climate, the distribution and number of vectors are also affected by climate change.", [["Global climate change", "PROBLEM", 126, 147], ["multiply", "OBSERVATION_MODIFIER", 18, 26], ["rapidly", "OBSERVATION_MODIFIER", 27, 34], ["climate", "OBSERVATION", 133, 140], ["disease", "OBSERVATION", 152, 159], ["distribution", "OBSERVATION_MODIFIER", 269, 281]]], ["According to the IPCC 2007 Climate Change Report , climate change has already altered the distribution of some disease vectors.", [["some disease vectors", "PROBLEM", 106, 126], ["distribution", "OBSERVATION_MODIFIER", 90, 102], ["some", "OBSERVATION_MODIFIER", 106, 110], ["disease", "OBSERVATION", 111, 118]]], ["There is evidence that the geographic range of ticks and mosquitoes that carry disease has changed in response to climate change.", [["carry disease", "PROBLEM", 73, 86], ["geographic", "OBSERVATION_MODIFIER", 27, 37], ["range", "OBSERVATION_MODIFIER", 38, 43]]], ["Tick and mosquito vectors have extended their range North in Sweden and Canada and into higher altitudes in other countries worldwide.", [["Tick and mosquito vectors", "TREATMENT", 0, 25]]], ["While future climate change is expected to continue to alter the distribution of disease vectors, it is important to recognize that there are several other factors (such as changes in land use, population density and human behavior) that can also change the distribution of disease vectors as well as the extent of infection.Global climate change and disease emergence ::: Conservation medicine: ecological health in practiceClimate is closely associated with the natural history of vectors so warmer temperatures will increase their range and distribution including altitudinal gradients.", [["infection", "DISEASE", 315, 324], ["human", "ORGANISM", 217, 222], ["human", "SPECIES", 217, 222], ["human", "SPECIES", 217, 222], ["disease vectors", "PROBLEM", 81, 96], ["disease vectors", "PROBLEM", 274, 289], ["infection", "PROBLEM", 315, 324], ["Global climate change", "PROBLEM", 325, 346], ["warmer temperatures", "TREATMENT", 494, 513], ["disease", "OBSERVATION", 81, 88], ["disease", "OBSERVATION", 274, 281], ["infection", "OBSERVATION", 315, 324], ["climate", "OBSERVATION", 332, 339], ["disease", "OBSERVATION", 351, 358], ["altitudinal gradients", "OBSERVATION", 567, 588]]], ["Ixodes pacificus is the main tick vector for transmission of Anaplasma phagocytophilum and Borrelia burgdorferi to large vertebrates in California.", [["Anaplasma phagocytophilum", "DISEASE", 61, 86], ["Borrelia burgdorferi", "DISEASE", 91, 111], ["Ixodes pacificus", "ORGANISM", 0, 16], ["Anaplasma phagocytophilum", "ORGANISM", 61, 86], ["Borrelia burgdorferi", "ORGANISM", 91, 111], ["Ixodes pacificus", "SPECIES", 0, 16], ["Anaplasma phagocytophilum", "SPECIES", 61, 86], ["Borrelia burgdorferi", "SPECIES", 91, 111], ["Ixodes pacificus", "SPECIES", 0, 16], ["Anaplasma phagocytophilum", "SPECIES", 61, 86], ["Borrelia burgdorferi", "SPECIES", 91, 111], ["Anaplasma phagocytophilum", "PROBLEM", 61, 86], ["Anaplasma phagocytophilum", "OBSERVATION", 61, 86], ["large", "OBSERVATION_MODIFIER", 115, 120], ["vertebrates", "OBSERVATION_MODIFIER", 121, 132], ["California", "ANATOMY_MODIFIER", 136, 146]]], ["A recent study examined spatial and temporal relationships among A. phagocytophilum-and B. burgdorferi-exposed coyotes (Canis latrans) with vegetation type and climate.", [["A. phagocytophilum", "ORGANISM", 65, 83], ["B. burgdorferi", "ORGANISM", 88, 102], ["coyotes", "ORGANISM", 111, 118], ["Canis latrans", "ORGANISM", 120, 133], ["A. phagocytophilum", "SPECIES", 65, 83], ["B. burgdorferi", "SPECIES", 88, 102], ["Canis latrans", "SPECIES", 120, 133], ["A. phagocytophilum", "SPECIES", 65, 83], ["B. burgdorferi", "SPECIES", 88, 102], ["Canis latrans", "SPECIES", 120, 133], ["A recent study", "TEST", 0, 14], ["A. phagocytophilum", "TEST", 65, 83], ["B. burgdorferi", "TEST", 88, 102], ["vegetation", "OBSERVATION", 140, 150]]], ["The overall seroprevalences were 39.5% and 18.9%, respectively.", [["The overall seroprevalences", "TEST", 0, 27]]], ["Increased sero-prevalence was a positive function of rainfall [19].Vector-borne diseases: a threat to human health and conservation ::: Conservation medicine: ecological health in practiceThe role of emerging vector-borne diseases on global health cannot be underestimated within the context of conservation medicine.", [["Vector-borne diseases", "DISEASE", 67, 88], ["human", "ORGANISM", 102, 107], ["human", "SPECIES", 102, 107], ["human", "SPECIES", 102, 107], ["Increased sero-prevalence", "PROBLEM", 0, 25], ["borne diseases", "PROBLEM", 216, 230], ["conservation medicine", "TREATMENT", 295, 316]]], ["Parasitic vector-borne diseases are classical emerging infectious diseases in human populations such as leishmaniosis, Lyme disease and ehrlichiosis among others.", [["Parasitic vector-borne diseases", "DISEASE", 0, 31], ["infectious diseases", "DISEASE", 55, 74], ["leishmaniosis", "DISEASE", 104, 117], ["Lyme disease", "DISEASE", 119, 131], ["ehrlichiosis", "DISEASE", 136, 148], ["human", "ORGANISM", 78, 83], ["ehrlichiosis", "CANCER", 136, 148], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 78, 83], ["Parasitic vector-borne diseases", "PROBLEM", 0, 31], ["classical emerging infectious diseases in human populations", "PROBLEM", 36, 95], ["leishmaniosis", "PROBLEM", 104, 117], ["Lyme disease", "PROBLEM", 119, 131], ["ehrlichiosis", "PROBLEM", 136, 148], ["infectious", "OBSERVATION_MODIFIER", 55, 65], ["leishmaniosis", "OBSERVATION", 104, 117], ["Lyme disease", "OBSERVATION", 119, 131], ["ehrlichiosis", "OBSERVATION", 136, 148]]], ["Eukaryotic parasites are among the most significant agents of emerging diseases of wildlife and domestic animals [20].", [["Eukaryotic parasites", "DISEASE", 0, 20], ["Eukaryotic parasites", "PROBLEM", 0, 20], ["parasites", "OBSERVATION", 11, 20]]], ["Parasites are part of biological diversity; however, pathogenic species may pose a threat to conservation of their natural hosts or of new species of hosts.", [["Parasites", "CELL", 0, 9], ["Parasites", "PROBLEM", 0, 9], ["pathogenic species", "PROBLEM", 53, 71], ["new species of hosts", "PROBLEM", 135, 155], ["biological", "OBSERVATION_MODIFIER", 22, 32], ["diversity", "OBSERVATION", 33, 42], ["new", "OBSERVATION_MODIFIER", 135, 138]]], ["In fact, when the new hosts become infected with these novel parasites, the pathogenicity and epidemiology of the infection become unpredictable.", [["infection", "DISEASE", 114, 123], ["these novel parasites", "PROBLEM", 49, 70], ["the pathogenicity", "PROBLEM", 72, 89], ["the infection", "PROBLEM", 110, 123], ["infected", "OBSERVATION", 35, 43], ["infection", "OBSERVATION", 114, 123]]], ["The introduction of a parasite to a new environment may or may not affect population density of the host, but runs the risk of introducing non-indigenous parasitic infections [18].Vector-borne diseases: a threat to human health and conservation ::: Conservation medicine: ecological health in practiceVector-borne diseases of wildlife have implications for wildlife conservation, for evaluating wildlife-domestic interactions, and for determining their public health significance.", [["parasitic infections", "DISEASE", 154, 174], ["Vector-borne diseases", "DISEASE", 180, 201], ["human", "ORGANISM", 215, 220], ["human", "SPECIES", 215, 220], ["human", "SPECIES", 215, 220], ["a parasite", "TREATMENT", 20, 30], ["introducing non-indigenous parasitic infections", "PROBLEM", 127, 174], ["wildlife conservation", "TREATMENT", 357, 378]]], ["Both parasite and host adapt to one another in a mutual co-existence [21].", [["parasite", "OBSERVATION_MODIFIER", 5, 13]]], ["When a population of free-ranging wildlife is exposed to an emerging infectious or parasitic disease the response of the host might be to (a) resist the parasite, (b) develop severe clinical parasitism or (c) adapt to the new parasite and become a carrier.", [["infectious or parasitic disease", "DISEASE", 69, 100], ["parasitic disease", "PROBLEM", 83, 100], ["severe clinical parasitism", "PROBLEM", 175, 201], ["infectious", "OBSERVATION", 69, 79], ["parasitic disease", "OBSERVATION", 83, 100], ["severe", "OBSERVATION_MODIFIER", 175, 181], ["parasitism", "OBSERVATION", 191, 201]]], ["The source of exposure may be from: (1) domestic animals, (2) re-introduction of wild animals (raised in captive propagation programmes) and/or (3) the spread of a related species in new habitats [18].Cross-species transmission ::: Conservation medicine: ecological health in practiceThe importance of parasites in wild mammals and their association with domestic animals and humans cannot be overemphasised.", [["humans", "ORGANISM", 376, 382], ["humans", "SPECIES", 376, 382], ["humans", "SPECIES", 376, 382], ["wild animals", "PROBLEM", 81, 93], ["captive propagation programmes", "TREATMENT", 105, 135], ["a related species", "PROBLEM", 162, 179], ["parasites", "PROBLEM", 302, 311], ["parasites", "OBSERVATION", 302, 311]]], ["Forrester [22] reported that 119 parasites and infectious diseases were interchangeable between wild and domestic mammals in Florida.", [["infectious diseases", "DISEASE", 47, 66], ["infectious diseases", "PROBLEM", 47, 66], ["infectious", "OBSERVATION", 47, 57]]], ["From these, more than 46% were helminths (45 nematodes, five cestodes, four trematodes and one acanthocephalan) when wild and domestic swine were included.", [["helminths", "DISEASE", 31, 40], ["swine", "ORGANISM", 135, 140], ["swine", "SPECIES", 135, 140], ["swine", "SPECIES", 135, 140]]], ["In addition, 10% (seven nematodes, four cestodes and one trematode) were considered zoonotic.Cross-species transmission ::: Conservation medicine: ecological health in practiceThe movement of wild animals can also introduce exotic diseases into the native population and conversely, can expose translocated animals to diseases for which they have not developed resistance.", [["exotic diseases", "PROBLEM", 224, 239], ["movement", "OBSERVATION_MODIFIER", 180, 188]]], ["Several species are susceptible to diseases of domestic animals and humans.", [["humans", "ORGANISM", 68, 74], ["humans", "SPECIES", 68, 74], ["humans", "SPECIES", 68, 74], ["Several species", "PROBLEM", 0, 15], ["species", "OBSERVATION", 8, 15], ["domestic animals", "OBSERVATION", 47, 63]]], ["Emerging parasites in new hosts are becoming more evident as diagnostic techniques are refined, wildlife-human-domestic animal interactions increase and new diseases are identified [18].Cross-species transmission ::: Conservation medicine: ecological health in practiceThe threat of disease transmission from domestic animals to wildlife has become recognised as an increasing concern within the conservation community in recent years.", [["human", "ORGANISM", 105, 110], ["human", "SPECIES", 105, 110], ["human", "SPECIES", 105, 110], ["Emerging parasites in new hosts", "PROBLEM", 0, 31], ["new diseases", "PROBLEM", 153, 165], ["disease transmission", "PROBLEM", 283, 303], ["parasites", "OBSERVATION", 9, 18], ["threat", "OBSERVATION_MODIFIER", 273, 279], ["disease", "OBSERVATION", 283, 290]]], ["Domestic dogs pose a significant risk as reservoirs for infectious diseases, especially for wild canids.", [["infectious diseases", "DISEASE", 56, 75], ["dogs", "ORGANISM", 9, 13], ["dogs", "SPECIES", 9, 13], ["infectious diseases", "PROBLEM", 56, 75]]], ["As human populations expand into wild habitats with their pets and livestock the greater the risk of emerging infections reaching rare species or vice versa.", [["infections", "DISEASE", 110, 120], ["human", "ORGANISM", 3, 8], ["human", "SPECIES", 3, 8], ["human", "SPECIES", 3, 8], ["emerging infections", "PROBLEM", 101, 120], ["infections", "OBSERVATION", 110, 120]]], ["Population density represents a disease risk in these situations where feral dogs have established large packs.", [["dogs", "ORGANISM", 77, 81], ["dogs", "SPECIES", 77, 81], ["feral", "SPECIES", 71, 76], ["Population density", "PROBLEM", 0, 18], ["a disease risk in these situations", "PROBLEM", 30, 64], ["feral dogs", "PROBLEM", 71, 81], ["large packs", "TREATMENT", 99, 110], ["density", "OBSERVATION", 11, 18], ["disease", "OBSERVATION", 32, 39], ["large", "OBSERVATION_MODIFIER", 99, 104], ["packs", "OBSERVATION_MODIFIER", 105, 110]]], ["Dogs may exist in very high densities, so where infection was once sporadic it may turn potentially into an epidemic that in the right circumstances may spillover to wild populations [23].", [["infection", "DISEASE", 48, 57], ["Dogs", "ORGANISM", 0, 4], ["very high densities", "PROBLEM", 18, 37], ["infection", "PROBLEM", 48, 57], ["sporadic", "PROBLEM", 67, 75], ["very", "OBSERVATION_MODIFIER", 18, 22], ["high", "OBSERVATION_MODIFIER", 23, 27], ["densities", "OBSERVATION", 28, 37], ["infection", "OBSERVATION", 48, 57], ["right", "ANATOMY_MODIFIER", 129, 134]]], ["A classical example is the devastating outbreak of canine distemper in Serengeti lions (Panthera leo).", [["canine distemper", "DISEASE", 51, 67], ["canine distemper", "ORGANISM", 51, 67], ["Serengeti lions", "ORGANISM", 71, 86], ["Panthera leo", "ORGANISM", 88, 100], ["canine distemper", "SPECIES", 51, 67], ["canine distemper", "SPECIES", 51, 67], ["Serengeti lions", "SPECIES", 71, 86], ["Panthera leo", "SPECIES", 88, 100], ["devastating", "OBSERVATION_MODIFIER", 27, 38], ["canine distemper", "OBSERVATION", 51, 67], ["Serengeti lions", "OBSERVATION", 71, 86]]], ["It was estimated that the disease killed over 1000 lions, a third of the Serengeti the population, before spreading North across the border in the Masai Mara National Reserve in Kenya by August 1994, with a neurologic syndrome.", [["neurologic", "ANATOMY", 207, 217], ["neurologic syndrome", "DISEASE", 207, 226], ["the disease", "PROBLEM", 22, 33], ["a neurologic syndrome", "PROBLEM", 205, 226], ["disease", "OBSERVATION", 26, 33], ["population", "OBSERVATION_MODIFIER", 87, 97], ["border", "ANATOMY_MODIFIER", 133, 139], ["neurologic syndrome", "OBSERVATION", 207, 226]]], ["Over 85% of the surviving Serengeti lions were found with anti-CDV antibodies.", [["Serengeti", "ORGANISM", 26, 35], ["anti-CDV antibodies", "GENE_OR_GENE_PRODUCT", 58, 77], ["anti-CDV antibodies", "PROTEIN", 58, 77], ["Serengeti lions", "SPECIES", 26, 41], ["anti-CDV", "SPECIES", 58, 66], ["anti-CDV antibodies", "PROBLEM", 58, 77]]], ["Also, uncounted hyaenas, bat-eared foxes and leopards were also affected [24].", [["foxes", "ORGANISM", 35, 40], ["bat-eared foxes", "SPECIES", 25, 40]]], ["Speculation exists on how this outbreak was initiated, as village dogs rarely get sufficiently close to a lion to pass on the virus, and there are likely other reservoir hosts.", [["dogs", "ORGANISM", 66, 70], ["dogs", "SPECIES", 66, 70], ["the virus", "PROBLEM", 122, 131], ["reservoir hosts", "OBSERVATION", 160, 175]]], ["Spotted hyaenas (Crocuta crocuta) are probably the final link in the chain, because they mix with lions at the kill [23-25].", [["Spotted hyaenas", "ORGANISM", 0, 15], ["Crocuta crocuta", "ORGANISM", 17, 32], ["Crocuta crocuta", "SPECIES", 17, 32], ["Spotted hyaenas", "SPECIES", 0, 15], ["Crocuta crocuta", "SPECIES", 17, 32]]], ["Canine distemper may have played a part in the extinction of the marsupial wolf Thylacinus spp. in the early 20th century, and it pushed the black-footed ferret (Mustela nigripes) of North America to the brink of extinction in the 1970s [23,26].", [["distemper", "DISEASE", 7, 16], ["Canine distemper", "ORGANISM", 0, 16], ["marsupial", "ORGANISM", 65, 74], ["wolf", "ORGANISM", 75, 79], ["Thylacinus spp.", "ORGANISM", 80, 95], ["ferret", "ORGANISM", 154, 160], ["Mustela nigripes", "ORGANISM", 162, 178], ["Canine", "SPECIES", 0, 6], ["Thylacinus spp.", "SPECIES", 80, 95], ["ferret", "SPECIES", 154, 160], ["Mustela nigripes", "SPECIES", 162, 178], ["Canine distemper", "SPECIES", 0, 16], ["black-footed ferret", "SPECIES", 141, 160], ["Mustela nigripes", "SPECIES", 162, 178], ["distemper", "OBSERVATION", 7, 16], ["black", "OBSERVATION_MODIFIER", 141, 146]]], ["During the early 1990s rabies claimed more than half of the Ethiopian wolves (Canis simensis) in the Bale Mountain National Park.", [["rabies", "DISEASE", 23, 29], ["Canis simensis", "ORGANISM", 78, 92], ["Canis simensis", "SPECIES", 78, 92], ["Ethiopian wolves", "SPECIES", 60, 76], ["Canis simensis", "SPECIES", 78, 92]]], ["Rabies was also responsible for the death of African wild dogs (Lycaon pictus) in the Masai Mara reserve in Kenya in 1989 and in the Serengeti in 1990 [27].Cross-species transmission ::: Conservation medicine: ecological health in practiceAn assessment of which pathogens might pose a problem and their patterns of infection in natural hosts is necessary with increasing awareness of disease as an endangering process.", [["Rabies", "DISEASE", 0, 6], ["death", "DISEASE", 36, 41], ["infection", "DISEASE", 315, 324], ["Rabies", "ORGANISM", 0, 6], ["dogs", "ORGANISM", 58, 62], ["Lycaon pictus", "ORGANISM", 64, 77], ["dogs", "SPECIES", 58, 62], ["Lycaon pictus", "SPECIES", 64, 77], ["African wild dogs", "SPECIES", 45, 62], ["Lycaon pictus", "SPECIES", 64, 77], ["practiceAn assessment", "TEST", 231, 252], ["a problem", "PROBLEM", 283, 292], ["infection in natural hosts", "PROBLEM", 315, 341], ["disease", "PROBLEM", 384, 391], ["infection", "OBSERVATION", 315, 324]]], ["The exposure of sympatric Ethiopian wolves and domestic dogs to canine distemper virus (CDV), canine adenovirus (CAV) and canine parvovirus (CPV) in the Bale region, Ethiopia, has been documented [28].", [["canine distemper", "DISEASE", 64, 80], ["canine adenovirus (CAV) and canine parvovirus (CPV)", "DISEASE", 94, 145], ["dogs", "ORGANISM_SUBDIVISION", 56, 60], ["canine distemper virus", "ORGANISM", 64, 86], ["CDV", "ORGANISM", 88, 91], ["canine adenovirus", "ORGANISM", 94, 111], ["CAV", "ORGANISM", 113, 116], ["canine parvovirus", "ORGANISM", 122, 139], ["CPV", "ORGANISM", 141, 144], ["dogs", "SPECIES", 56, 60], ["canine distemper virus", "SPECIES", 64, 86], ["canine", "SPECIES", 94, 100], ["canine parvovirus", "SPECIES", 122, 139], ["Ethiopian wolves", "SPECIES", 26, 42], ["canine distemper virus", "SPECIES", 64, 86], ["CDV", "SPECIES", 88, 91], ["canine", "SPECIES", 94, 100], ["CAV", "SPECIES", 113, 116], ["canine parvovirus", "SPECIES", 122, 139], ["CPV", "SPECIES", 141, 144], ["sympatric Ethiopian wolves", "TREATMENT", 16, 42], ["domestic dogs", "TREATMENT", 47, 60], ["canine distemper virus", "PROBLEM", 64, 86], ["canine adenovirus (CAV)", "PROBLEM", 94, 117], ["canine parvovirus", "PROBLEM", 122, 139], ["sympatric Ethiopian wolves", "OBSERVATION", 16, 42], ["distemper virus", "OBSERVATION", 71, 86]]], ["The wolf population in the region declined in the late 1980s and early 1990s, with rabies responsible for a dramatic population reduction between 1990 and 1992.", [["rabies", "DISEASE", 83, 89], ["rabies", "SPECIES", 83, 89], ["a dramatic population reduction", "PROBLEM", 106, 137], ["wolf", "OBSERVATION_MODIFIER", 4, 8], ["population", "OBSERVATION_MODIFIER", 9, 19], ["region", "ANATOMY_MODIFIER", 27, 33]]], ["Although the population declined further up until 1995, it is not possible to assess whether the concurrent canine distemper epidemic in park dogs also affected wolves.", [["distemper", "DISEASE", 115, 124], ["canine distemper", "ORGANISM", 108, 124], ["dogs", "ORGANISM", 142, 146], ["canine", "SPECIES", 108, 114], ["dogs", "SPECIES", 142, 146], ["canine distemper", "SPECIES", 108, 124], ["distemper", "OBSERVATION", 115, 124]]], ["Nevertheless, with evidence of rabies, CDV, CAV and CPV infections in sympatric domestic dogs and Ethiopian wolves, canid diseases clearly pose a significant threat to the future persistence of this Ethiopian wolf population [28].Anaplasmosis ::: Vector-borne diseases and wild canidsAnaplasma phagocytophilum (formerly Ehrlichia phagocytophila, Ehrlichia equi and Anaplasma phagocytophila) is the causative agent of granulocytic ehrlichiosis (anaplasmosis) in humans, horses, sheep, cattle, dogs and cats.", [["granulocytic", "ANATOMY", 417, 429], ["rabies", "DISEASE", 31, 37], ["CPV infections", "DISEASE", 52, 66], ["canid diseases", "DISEASE", 116, 130], ["Anaplasmosis", "DISEASE", 230, 242], ["Vector-borne diseases", "DISEASE", 247, 268], ["Anaplasma phagocytophilum", "DISEASE", 284, 309], ["Ehrlichia phagocytophila", "DISEASE", 320, 344], ["Anaplasma phagocytophila", "DISEASE", 365, 389], ["granulocytic ehrlichiosis", "DISEASE", 417, 442], ["anaplasmosis", "DISEASE", 444, 456], ["rabies", "ORGANISM", 31, 37], ["CDV", "ORGANISM", 39, 42], ["CPV", "ORGANISM", 52, 55], ["dogs", "ORGANISM", 89, 93], ["Anaplasma phagocytophilum", "ORGANISM", 284, 309], ["Ehrlichia phagocytophila", "ORGANISM", 320, 344], ["Ehrlichia equi", "ORGANISM", 346, 360], ["Anaplasma phagocytophila", "ORGANISM", 365, 389], ["granulocytic ehrlichiosis", "ORGANISM", 417, 442], ["anaplasmosis", "ORGANISM", 444, 456], ["humans", "ORGANISM", 461, 467], ["horses", "ORGANISM_SUBDIVISION", 469, 475], ["sheep", "ORGANISM", 477, 482], ["cattle", "ORGANISM", 484, 490], ["dogs", "ORGANISM", 492, 496], ["cats", "ORGANISM", 501, 505], ["dogs", "SPECIES", 89, 93], ["Anaplasma phagocytophilum", "SPECIES", 284, 309], ["Ehrlichia phagocytophila", "SPECIES", 320, 344], ["Ehrlichia equi", "SPECIES", 346, 360], ["Anaplasma phagocytophila", "SPECIES", 365, 389], ["humans", "SPECIES", 461, 467], ["horses", "SPECIES", 469, 475], ["sheep", "SPECIES", 477, 482], ["cattle", "SPECIES", 484, 490], ["dogs", "SPECIES", 492, 496], ["cats", "SPECIES", 501, 505], ["rabies", "SPECIES", 31, 37], ["CDV", "SPECIES", 39, 42], ["CAV", "SPECIES", 44, 47], ["CPV", "SPECIES", 52, 55], ["Ethiopian wolves", "SPECIES", 98, 114], ["Anaplasma phagocytophilum", "SPECIES", 284, 309], ["Ehrlichia phagocytophila", "SPECIES", 320, 344], ["Ehrlichia equi", "SPECIES", 346, 360], ["Anaplasma phagocytophila", "SPECIES", 365, 389], ["humans", "SPECIES", 461, 467], ["horses", "SPECIES", 469, 475], ["sheep", "SPECIES", 477, 482], ["cattle", "SPECIES", 484, 490], ["rabies", "PROBLEM", 31, 37], ["CDV", "PROBLEM", 39, 42], ["CAV", "PROBLEM", 44, 47], ["CPV infections", "PROBLEM", 52, 66], ["canid diseases", "PROBLEM", 116, 130], ["Vector-borne diseases", "PROBLEM", 247, 268], ["wild canids", "PROBLEM", 273, 284], ["Anaplasma phagocytophilum", "PROBLEM", 284, 309], ["Ehrlichia phagocytophila", "TEST", 320, 344], ["Ehrlichia equi and Anaplasma phagocytophila", "PROBLEM", 346, 389], ["granulocytic ehrlichiosis", "PROBLEM", 417, 442], ["anaplasmosis", "PROBLEM", 444, 456], ["rabies", "OBSERVATION", 31, 37], ["CAV", "ANATOMY", 44, 47], ["granulocytic ehrlichiosis", "OBSERVATION", 417, 442]]], ["Over 450 European sheep ticks (Ixodes ricinus) collected from 100 red foxes (Vulpes vulpes) in Hungary were tested for the pathogen as 112 pools each containing five or fewer ticks from one fox.", [["sheep ticks", "ORGANISM", 18, 29], ["Ixodes ricinus", "ORGANISM", 31, 45], ["Vulpes vulpes", "ORGANISM", 77, 90], ["sheep", "SPECIES", 18, 23], ["Ixodes ricinus", "SPECIES", 31, 45], ["Vulpes vulpes", "SPECIES", 77, 90], ["European sheep ticks", "SPECIES", 9, 29], ["Ixodes ricinus", "SPECIES", 31, 45], ["red foxes", "SPECIES", 66, 75], ["Vulpes vulpes", "SPECIES", 77, 90], ["the pathogen", "PROBLEM", 119, 131]]], ["Six foxes were found infected in the PCR-based test [29].", [["foxes", "ORGANISM", 4, 9], ["Six foxes", "PROBLEM", 0, 9], ["the PCR", "TEST", 33, 40], ["infected", "OBSERVATION_MODIFIER", 21, 29]]], ["The epidemiological consequences of these findings are unknown.Babesiosis ::: Vector-borne diseases and wild canidsYoung coyotes (Canis latrans) were experimentally infected with Babesia gibsoni developing pale mucous membranes, splenomegaly and a positive haeme reaction in urine.", [["pale mucous membranes", "ANATOMY", 206, 227], ["urine", "ANATOMY", 275, 280], ["Babesiosis", "DISEASE", 63, 73], ["Vector-borne diseases", "DISEASE", 78, 99], ["Babesia gibsoni", "DISEASE", 179, 194], ["splenomegaly", "DISEASE", 229, 241], ["Young coyotes", "ORGANISM", 115, 128], ["Canis latrans", "ORGANISM", 130, 143], ["Babesia gibsoni", "ORGANISM", 179, 194], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 211, 227], ["urine", "ORGANISM_SUBSTANCE", 275, 280], ["Canis latrans", "SPECIES", 130, 143], ["Babesia gibsoni", "SPECIES", 179, 194], ["Young coyotes", "SPECIES", 115, 128], ["Canis latrans", "SPECIES", 130, 143], ["Babesia gibsoni", "SPECIES", 179, 194], ["Vector-borne diseases", "PROBLEM", 78, 99], ["wild canids", "PROBLEM", 104, 115], ["Babesia gibsoni", "PROBLEM", 179, 194], ["pale mucous membranes", "PROBLEM", 206, 227], ["splenomegaly", "PROBLEM", 229, 241], ["a positive haeme reaction in urine", "PROBLEM", 246, 280], ["pale", "OBSERVATION_MODIFIER", 206, 210], ["mucous membranes", "OBSERVATION", 211, 227], ["splenomegaly", "OBSERVATION", 229, 241], ["positive", "OBSERVATION_MODIFIER", 248, 256], ["haeme reaction", "OBSERVATION", 257, 271]]], ["One of the coyotes exhibited mild depression and anorexia.", [["depression", "DISEASE", 34, 44], ["anorexia", "DISEASE", 49, 57], ["mild depression", "PROBLEM", 29, 44], ["anorexia", "PROBLEM", 49, 57], ["mild", "OBSERVATION_MODIFIER", 29, 33], ["depression", "OBSERVATION", 34, 44], ["anorexia", "OBSERVATION", 49, 57]]], ["The mild clinical signs coupled with the high level and long duration of parasitemia indicated that coyotes could serve as reservoirs of this emerging disease [30].Bartonellosis ::: Vector-borne diseases and wild canidsBartonella vinsonii subsp. berkhoffii was originally isolated from a dog with infectious endocarditis and was recently identified as a zoonotic agent causing human endocarditis.", [["parasitemia", "DISEASE", 73, 84], ["Bartonellosis", "DISEASE", 164, 177], ["Vector-borne diseases", "DISEASE", 182, 203], ["infectious endocarditis", "DISEASE", 297, 320], ["endocarditis", "DISEASE", 383, 395], ["canids", "ORGANISM", 213, 219], ["Bartonella vinsonii", "ORGANISM", 219, 238], ["berkhoffii", "ORGANISM", 246, 256], ["dog", "ORGANISM", 288, 291], ["human", "ORGANISM", 377, 382], ["Bartonella vinsonii subsp", "SPECIES", 219, 244], ["berkhoffii", "SPECIES", 246, 256], ["dog", "SPECIES", 288, 291], ["human", "SPECIES", 377, 382], ["coyotes", "SPECIES", 100, 107], ["Bartonella vinsonii subsp", "SPECIES", 219, 244], ["berkhoffii", "SPECIES", 246, 256], ["human", "SPECIES", 377, 382], ["The mild clinical signs", "PROBLEM", 0, 23], ["the high level", "PROBLEM", 37, 51], ["parasitemia", "PROBLEM", 73, 84], ["this emerging disease", "PROBLEM", 137, 158], ["Bartonellosis", "PROBLEM", 164, 177], ["Vector-borne diseases", "PROBLEM", 182, 203], ["wild canidsBartonella vinsonii subsp", "PROBLEM", 208, 244], ["infectious endocarditis", "PROBLEM", 297, 320], ["a zoonotic agent", "TREATMENT", 352, 368], ["human endocarditis", "PROBLEM", 377, 395], ["mild", "OBSERVATION_MODIFIER", 4, 8], ["infectious", "OBSERVATION_MODIFIER", 297, 307], ["endocarditis", "OBSERVATION", 308, 320], ["endocarditis", "OBSERVATION", 383, 395]]], ["An epidemiological study was conducted following a child bitten by a coyote who developed clinical signs compatible with Bartonella infection in California.", [["Bartonella infection", "DISEASE", 121, 141], ["An epidemiological study", "TEST", 0, 24], ["clinical signs", "PROBLEM", 90, 104], ["Bartonella infection", "PROBLEM", 121, 141], ["compatible with", "UNCERTAINTY", 105, 120], ["Bartonella infection", "OBSERVATION", 121, 141]]], ["Among 109 coyotes from central coastal California, 31 animals (28%) were found to be bacteremic with B. vinsonii subsp. berkhoffii and 83 animals (76%) presented antibodies.", [["bacteremic", "DISEASE", 85, 95], ["B. vinsonii", "ORGANISM", 101, 112], ["berkhoffii", "ORGANISM", 120, 130], ["antibodies", "PROTEIN", 162, 172], ["B. vinsonii subsp", "SPECIES", 101, 118], ["berkhoffii", "SPECIES", 120, 130], ["B. vinsonii subsp", "SPECIES", 101, 118], ["berkhoffii", "SPECIES", 120, 130], ["bacteremic", "PROBLEM", 85, 95], ["B. vinsonii subsp", "PROBLEM", 101, 118], ["central", "ANATOMY_MODIFIER", 23, 30], ["coastal", "ANATOMY_MODIFIER", 31, 38], ["bacteremic", "OBSERVATION", 85, 95]]], ["Further studies are necessary to elucidate the mode of transmission especially to identify potential vectors and to determine how humans become infected [31].Borreliosis ::: Vector-borne diseases and wild canidsDifferent Borrelia species and serotypes were tested for their sensitivity to serum complement from various animals and humans; and wolves were identified as a probable reservoir in nature [32].", [["serum", "ANATOMY", 289, 294], ["Borreliosis", "DISEASE", 158, 169], ["Vector-borne diseases", "DISEASE", 174, 195], ["humans", "ORGANISM", 130, 136], ["Borrelia species", "ORGANISM", 221, 237], ["serum", "ORGANISM_SUBSTANCE", 289, 294], ["humans", "ORGANISM", 331, 337], ["humans", "SPECIES", 130, 136], ["humans", "SPECIES", 331, 337], ["humans", "SPECIES", 130, 136], ["humans", "SPECIES", 331, 337], ["Further studies", "TEST", 0, 15], ["Vector-borne diseases", "PROBLEM", 174, 195], ["wild canids", "PROBLEM", 200, 211], ["Different Borrelia species", "PROBLEM", 211, 237], ["serotypes", "PROBLEM", 242, 251], ["serum complement", "TEST", 289, 305], ["Borrelia species", "OBSERVATION", 221, 237], ["probable", "UNCERTAINTY", 371, 379], ["reservoir", "OBSERVATION_MODIFIER", 380, 389]]], ["Seven of 100 skin samples of red foxes (Vulpes vulpes) were tested positive for B. burgdorferi in Brandenburg, Germany [33].", [["skin samples", "ANATOMY", 13, 25], ["skin samples", "TISSUE", 13, 25], ["red foxes", "ORGANISM", 29, 38], ["Vulpes vulpes", "ORGANISM", 40, 53], ["B. burgdorferi", "ORGANISM", 80, 94], ["Vulpes vulpes", "SPECIES", 40, 53], ["B. burgdorferi", "SPECIES", 80, 94], ["red foxes", "SPECIES", 29, 38], ["Vulpes vulpes", "SPECIES", 40, 53], ["B. burgdorferi", "SPECIES", 80, 94], ["red foxes", "PROBLEM", 29, 38], ["skin", "ANATOMY", 13, 17], ["red foxes", "OBSERVATION", 29, 38]]], ["A new species denominated Candidatus B. texasensis was isolated in 1998 from an adult male Dermacentor variabilis tick feeding on a coyote from Texas, characterised with several molecular techniques, but isolation attempts were not fruitful [34].", [["B. texasensis", "ORGANISM", 37, 50], ["Dermacentor variabilis", "ORGANISM", 91, 113], ["tick", "ORGANISM", 114, 118], ["B. texasensis", "SPECIES", 37, 50], ["Dermacentor variabilis", "SPECIES", 91, 113], ["B. texasensis", "SPECIES", 37, 50], ["Dermacentor variabilis", "SPECIES", 91, 113], ["A new species denominated Candidatus B. texasensis", "PROBLEM", 0, 50], ["several molecular techniques", "TREATMENT", 170, 198], ["isolation attempts", "TREATMENT", 204, 222], ["new", "OBSERVATION_MODIFIER", 2, 5]]], ["Coyotes have been previously used as sentinels of Lyme disease to correlate with infection in humans in the USA.", [["Lyme disease", "DISEASE", 50, 62], ["infection", "DISEASE", 81, 90], ["humans", "ORGANISM", 94, 100], ["humans", "SPECIES", 94, 100], ["humans", "SPECIES", 94, 100], ["Lyme disease", "PROBLEM", 50, 62], ["infection in humans", "PROBLEM", 81, 100], ["Lyme", "OBSERVATION", 50, 54], ["infection", "OBSERVATION", 81, 90]]], ["One thousand canine sera (917 dogs, 83 coyotes) obtained from field personnel were screened with an ELISA test and results were validated by Western blot and indirect fluorescent antibody (IFA) tests at reference laboratories.", [["sera", "ANATOMY", 20, 24], ["canine", "ORGANISM", 13, 19], ["sera", "ORGANISM_SUBSTANCE", 20, 24], ["dogs", "ORGANISM", 30, 34], ["indirect fluorescent antibody", "PROTEIN", 158, 187], ["IFA", "PROTEIN", 189, 192], ["canine", "SPECIES", 13, 19], ["dogs", "SPECIES", 30, 34], ["canine", "SPECIES", 13, 19], ["an ELISA test", "TEST", 97, 110], ["indirect fluorescent antibody", "TEST", 158, 187]]], ["A total of 22/1000 canines were confirmed serologically positive (21 dogs and 1 coyote; seroprevalence 2.3% and 1.2%, respectively).", [["canines", "CANCER", 19, 26], ["dogs", "ORGANISM", 69, 73], ["dogs", "SPECIES", 69, 73], ["A total of 22/1000 canines", "TEST", 0, 26], ["seroprevalence", "TEST", 88, 102]]], ["The low prevalence of seropositivity in sentinel canines suggests the Lyme disease hazard is minimal in San Diego, California [35].Canine heartworm ::: Vector-borne diseases and wild canidsCanine heartworm caused by Dirofilaria immitis affects wild canids and may be a factor impacting the health and population dynamics of coyotes.", [["Lyme disease", "DISEASE", 70, 82], ["Vector-borne diseases", "DISEASE", 152, 173], ["Canine heartworm", "DISEASE", 189, 205], ["Dirofilaria immitis", "DISEASE", 216, 235], ["canines", "ORGAN", 49, 56], ["Canine", "ORGANISM", 131, 137], ["Canine heartworm", "ORGANISM", 189, 205], ["Dirofilaria immitis", "ORGANISM", 216, 235], ["Canine", "SPECIES", 131, 137], ["Canine", "SPECIES", 189, 195], ["Dirofilaria immitis", "SPECIES", 216, 235], ["Canine", "SPECIES", 131, 137], ["Canine heartworm", "SPECIES", 189, 205], ["Dirofilaria immitis", "SPECIES", 216, 235], ["seropositivity in sentinel canines", "PROBLEM", 22, 56], ["the Lyme disease hazard", "PROBLEM", 66, 89], ["Vector-borne diseases", "PROBLEM", 152, 173], ["wild canids", "PROBLEM", 178, 189], ["Canine heartworm", "PROBLEM", 189, 205], ["Dirofilaria immitis", "PROBLEM", 216, 235], ["low prevalence", "OBSERVATION_MODIFIER", 4, 18], ["sentinel canines", "ANATOMY", 40, 56], ["Lyme disease", "OBSERVATION", 70, 82], ["minimal", "OBSERVATION_MODIFIER", 93, 100], ["Dirofilaria immitis", "OBSERVATION", 216, 235]]], ["Coyotes may serve also as a potential reservoir for transmission of these parasites to domestic dogs.", [["dogs", "ORGANISM", 96, 100], ["dogs", "SPECIES", 96, 100], ["a potential reservoir", "TREATMENT", 26, 47]]], ["Almost a 1000 coyotes were surveyed in Illinois for the presence of heartworm identifying a statewide prevalence of 16%.", [["heartworm", "ORGANISM", 68, 77]]], ["The authors concluded that heartworm disease is only a minor factor influencing coyote population dynamics in Illinois and possesses perhaps low risk to the domestic canine population [36].Canine heartworm ::: Vector-borne diseases and wild canidsAs part of a multifaceted ecologic study of maned wolves (Chrysocyon brachyurus) and other canids in the large, remote Noel Kempff Mercado National Park in northeastern Bolivia, 40 domestic dogs in two villages and at two smaller settlements bordering the national park were sampled for exposure to canine diseases.", [["heartworm disease", "DISEASE", 27, 44], ["Vector-borne diseases", "DISEASE", 210, 231], ["canine diseases", "DISEASE", 546, 561], ["heartworm", "ORGANISM", 27, 36], ["coyote", "ORGANISM", 80, 86], ["canine", "ORGANISM", 166, 172], ["Canine", "ORGANISM", 189, 195], ["Chrysocyon brachyurus", "ORGANISM", 305, 326], ["dogs", "ORGANISM", 437, 441], ["canine", "ORGANISM", 546, 552], ["canine", "SPECIES", 166, 172], ["Canine", "SPECIES", 189, 195], ["Chrysocyon brachyurus", "SPECIES", 305, 326], ["dogs", "SPECIES", 437, 441], ["canine", "SPECIES", 166, 172], ["Canine", "SPECIES", 189, 195], ["Chrysocyon brachyurus", "SPECIES", 305, 326], ["canine", "SPECIES", 546, 552], ["heartworm disease", "PROBLEM", 27, 44], ["a minor factor", "PROBLEM", 53, 67], ["Vector-borne diseases", "PROBLEM", 210, 231], ["wild canids", "PROBLEM", 236, 247], ["a multifaceted ecologic study", "TEST", 258, 287], ["canine diseases", "PROBLEM", 546, 561], ["heartworm", "ANATOMY", 27, 36], ["disease", "OBSERVATION", 37, 44], ["low risk", "OBSERVATION_MODIFIER", 141, 149], ["large", "OBSERVATION_MODIFIER", 352, 357]]], ["High levels of exposure were found to CDV and CPV, both of which are known to cause mortality in maned wolves and other carnivores.", [["CDV", "ORGANISM", 38, 41], ["CPV", "ORGANISM", 46, 49], ["CDV", "SPECIES", 38, 41], ["CPV", "SPECIES", 46, 49], ["CDV", "PROBLEM", 38, 41], ["CPV", "PROBLEM", 46, 49]]], ["Moderate to high levels of exposure were found to rabies virus, E. canis, and Toxoplasma gondii, as well as significant levels of infection with D. immitis.", [["Toxoplasma gondii", "DISEASE", 78, 95], ["infection", "DISEASE", 130, 139], ["D. immitis", "DISEASE", 145, 155], ["rabies virus", "ORGANISM", 50, 62], ["E. canis", "ORGANISM", 64, 72], ["Toxoplasma gondii", "ORGANISM", 78, 95], ["D. immitis", "ORGANISM", 145, 155], ["E. canis", "SPECIES", 64, 72], ["Toxoplasma gondii", "SPECIES", 78, 95], ["D. immitis", "SPECIES", 145, 155], ["rabies virus", "SPECIES", 50, 62], ["E. canis", "SPECIES", 64, 72], ["Toxoplasma gondii", "SPECIES", 78, 95], ["D. immitis", "SPECIES", 145, 155], ["Moderate to high levels of exposure", "PROBLEM", 0, 35], ["rabies virus", "PROBLEM", 50, 62], ["E. canis", "PROBLEM", 64, 72], ["Toxoplasma gondii", "PROBLEM", 78, 95], ["infection", "PROBLEM", 130, 139], ["D. immitis", "PROBLEM", 145, 155], ["high levels", "OBSERVATION_MODIFIER", 12, 23], ["Toxoplasma gondii", "OBSERVATION", 78, 95], ["infection", "OBSERVATION", 130, 139], ["immitis", "OBSERVATION", 148, 155]]], ["This study reports evidence of exposure to several diseases in the domestic dogs bordering the park.", [["dogs", "ORGANISM", 76, 80], ["dogs", "SPECIES", 76, 80], ["This study", "TEST", 0, 10], ["several diseases", "PROBLEM", 43, 59], ["evidence of", "UNCERTAINTY", 19, 30], ["several", "OBSERVATION_MODIFIER", 43, 50], ["diseases", "OBSERVATION", 51, 59]]], ["Contact between wild carnivores and dogs has been documented in the sampled villages, therefore dogs likely pose a substantial risk to the carnivores within and near the park.", [["dogs", "ORGANISM", 36, 40], ["dogs", "ORGANISM", 96, 100], ["dogs", "SPECIES", 36, 40]]], ["Further measures should be undertaken to decrease the risk of spillover infection from domestic animals into the wild species of this region [37].", [["infection", "DISEASE", 72, 81], ["Further measures", "TREATMENT", 0, 16], ["spillover infection", "PROBLEM", 62, 81], ["spillover infection", "OBSERVATION", 62, 81]]], ["Maned wolves are neotropic canids, listed as a CITES Appendix II species, with a distribution in Argentina, Brazil, Bolivia and Paraguay.", [["neotropic canids", "TREATMENT", 17, 33], ["Appendix", "ANATOMY", 53, 61]]], ["Primary threats to the survival of free-ranging wolves include habitat loss, road kills and shooting by farmers.", [["habitat loss", "DISEASE", 63, 75], ["habitat loss", "PROBLEM", 63, 75], ["habitat loss", "OBSERVATION", 63, 75]]], ["An additional threat is the risk of morbidity and mortality due to infectious and parasitic diseases [37].", [["infectious and parasitic diseases", "DISEASE", 67, 100], ["morbidity", "PROBLEM", 36, 45], ["infectious", "PROBLEM", 67, 77], ["parasitic diseases", "PROBLEM", 82, 100], ["morbidity", "OBSERVATION", 36, 45], ["infectious", "OBSERVATION", 67, 77], ["parasitic", "OBSERVATION_MODIFIER", 82, 91]]], ["It has been documented that captive maned wolves are susceptible to, and die from, common infectious diseases of domestic dogs including CDV, CPV, rabies virus and CAV.", [["infectious diseases of domestic dogs including CDV, CPV, rabies virus", "DISEASE", 90, 159], ["CAV", "DISEASE", 164, 167], ["dogs", "ORGANISM", 122, 126], ["CDV", "ORGANISM", 137, 140], ["CPV", "ORGANISM", 142, 145], ["rabies virus", "ORGANISM", 147, 159], ["dogs", "SPECIES", 122, 126], ["rabies virus", "SPECIES", 147, 159], ["CDV", "SPECIES", 137, 140], ["CPV", "SPECIES", 142, 145], ["rabies virus", "SPECIES", 147, 159], ["CAV", "SPECIES", 164, 167], ["domestic dogs", "PROBLEM", 113, 126], ["CDV", "PROBLEM", 137, 140], ["CPV", "PROBLEM", 142, 145], ["rabies virus", "PROBLEM", 147, 159], ["rabies virus", "OBSERVATION", 147, 159], ["CAV", "ANATOMY", 164, 167]]], ["A survey documenting these agents indicated that free-ranging wolves in the same park in Bolivia have been exposed to multiple infectious and parasitic agents of domestic carnivores, including the viruses previously mentioned, canine coronavirus, rabies virus, Leptospira interrogans spp., T. gondii and D. immitis, and may be at increased disease risk due to these pathogens originating in the domestic dog population [38].Canine Ehrlichiosis ::: Vector-borne diseases and wild canidsA seroepidemiological survey was conducted to investigate the prevalence of antibodies reactive with the Ehrlichia canis and E. phagocytophila (newly named Anaplasma phagocytophilum) genogroup antigens, and the spotted-fever group rickettsiae antigens in jackals (Canis aureus syriacus) in Israel, to assess the possible role of this species in the epidemiology of these diseases.", [["canine coronavirus", "DISEASE", 227, 245], ["rabies virus", "DISEASE", 247, 259], ["Leptospira interrogans spp.", "DISEASE", 261, 288], ["T. gondii and D. immitis", "DISEASE", 290, 314], ["Ehrlichiosis", "DISEASE", 431, 443], ["Vector-borne diseases", "DISEASE", 448, 469], ["Ehrlichia canis", "DISEASE", 590, 605], ["Anaplasma phagocytophilum", "DISEASE", 641, 666], ["fever", "DISEASE", 704, 709], ["canine coronavirus", "ORGANISM", 227, 245], ["rabies virus", "ORGANISM", 247, 259], ["Leptospira interrogans spp.", "ORGANISM", 261, 288], ["T. gondii", "ORGANISM", 290, 299], ["D. immitis", "ORGANISM", 304, 314], ["dog", "ORGANISM", 404, 407], ["Canine", "ORGANISM", 424, 430], ["Ehrlichia canis", "ORGANISM", 590, 605], ["E. phagocytophila", "ORGANISM", 610, 627], ["Anaplasma phagocytophilum", "ORGANISM", 641, 666], ["rickettsiae", "ORGANISM", 716, 727], ["jackals", "ORGANISM", 740, 747], ["Canis aureus syriacus", "ORGANISM", 749, 770], ["antibodies", "PROTEIN", 561, 571], ["genogroup antigens", "PROTEIN", 668, 686], ["canine coronavirus", "SPECIES", 227, 245], ["rabies virus", "SPECIES", 247, 259], ["Leptospira interrogans", "SPECIES", 261, 283], ["spp.", "SPECIES", 284, 288], ["T. gondii", "SPECIES", 290, 299], ["D. immitis", "SPECIES", 304, 314], ["Canine", "SPECIES", 424, 430], ["Ehrlichia canis", "SPECIES", 590, 605], ["E. phagocytophila", "SPECIES", 610, 627], ["Anaplasma phagocytophilum", "SPECIES", 641, 666], ["spotted-fever group", "SPECIES", 696, 715], ["Canis aureus", "SPECIES", 749, 761], ["syriacus", "SPECIES", 762, 770], ["canine coronavirus", "SPECIES", 227, 245], ["rabies virus", "SPECIES", 247, 259], ["Leptospira interrogans spp.", "SPECIES", 261, 288], ["T. gondii", "SPECIES", 290, 299], ["D. immitis", "SPECIES", 304, 314], ["Canine", "SPECIES", 424, 430], ["Ehrlichia canis", "SPECIES", 590, 605], ["E. phagocytophila", "SPECIES", 610, 627], ["Anaplasma phagocytophilum", "SPECIES", 641, 666], ["spotted-fever group rickettsiae", "SPECIES", 696, 727], ["Canis aureus syriacus", "SPECIES", 749, 770], ["A survey", "TEST", 0, 8], ["these agents", "TREATMENT", 21, 33], ["multiple infectious and parasitic agents of domestic carnivores", "PROBLEM", 118, 181], ["the viruses", "PROBLEM", 193, 204], ["canine coronavirus", "PROBLEM", 227, 245], ["rabies virus", "PROBLEM", 247, 259], ["Leptospira interrogans spp.", "TEST", 261, 288], ["increased disease risk", "PROBLEM", 330, 352], ["these pathogens", "PROBLEM", 360, 375], ["Vector-borne diseases", "PROBLEM", 448, 469], ["antibodies reactive", "PROBLEM", 561, 580], ["the Ehrlichia canis", "PROBLEM", 586, 605], ["E. phagocytophila", "PROBLEM", 610, 627], ["newly named Anaplasma phagocytophilum) genogroup antigens", "PROBLEM", 629, 686], ["the spotted-fever group rickettsiae antigens in jackals", "PROBLEM", 692, 747], ["Canis aureus syriacus", "PROBLEM", 749, 770], ["this species", "PROBLEM", 814, 826], ["these diseases", "PROBLEM", 850, 864], ["multiple", "OBSERVATION_MODIFIER", 118, 126], ["infectious", "OBSERVATION", 127, 137], ["parasitic", "OBSERVATION_MODIFIER", 142, 151], ["Ehrlichiosis", "OBSERVATION", 431, 443], ["Ehrlichia canis", "OBSERVATION", 590, 605], ["diseases", "OBSERVATION", 856, 864]]], ["A total of 53 serum samples were tested and antibodies were detected in 36% to E. canis, 26% were positive to E. chaffeensis.", [["serum samples", "ANATOMY", 14, 27], ["serum samples", "ORGANISM_SUBSTANCE", 14, 27], ["E. canis", "ORGANISM", 79, 87], ["E. chaffeensis", "ORGANISM", 110, 124], ["antibodies", "PROTEIN", 44, 54], ["E. canis", "SPECIES", 79, 87], ["E. chaffeensis", "SPECIES", 110, 124], ["E. canis", "SPECIES", 79, 87], ["E. chaffeensis", "SPECIES", 110, 124], ["A total of 53 serum samples", "TEST", 0, 27], ["antibodies", "TEST", 44, 54], ["E. canis", "TEST", 79, 87]]], ["In addition, 26% were seropositive to E. phagocytophila [39].", [["E. phagocytophila", "ORGANISM", 38, 55], ["E. phagocytophila", "SPECIES", 38, 55], ["E. phagocytophila", "SPECIES", 38, 55]]], ["In another study performed in coyotes from California, a total of 68/149 (46%) samples were seropositive to E. equi, two (1%) to E. risticii (newly named Neorickettsia risticii) and none of the samples had antibodies reactive to E. canis demonstrating that coyotes have been exposed to granulocytic ehrlichiae and E. risticii and may play a role in the epidemiology of these ehrlichial agents in California [40].", [["samples", "ANATOMY", 79, 86], ["samples", "ANATOMY", 194, 201], ["granulocytic ehrlichiae", "DISEASE", 286, 309], ["samples", "CANCER", 79, 86], ["E. equi", "ORGANISM", 108, 115], ["E. risticii", "ORGANISM", 129, 140], ["Neorickettsia risticii", "ORGANISM", 154, 176], ["samples", "CANCER", 194, 201], ["E. canis", "ORGANISM", 229, 237], ["coyotes", "ORGANISM", 257, 264], ["granulocytic ehrlichiae", "CELL", 286, 309], ["E. risticii", "ORGANISM", 314, 325], ["antibodies", "PROTEIN", 206, 216], ["E. equi", "SPECIES", 108, 115], ["E. risticii", "SPECIES", 129, 140], ["Neorickettsia risticii", "SPECIES", 154, 176], ["E. canis", "SPECIES", 229, 237], ["E. risticii", "SPECIES", 314, 325], ["E. equi", "SPECIES", 108, 115], ["E. risticii", "SPECIES", 129, 140], ["Neorickettsia risticii", "SPECIES", 154, 176], ["E. canis", "SPECIES", 229, 237], ["coyotes", "SPECIES", 257, 264], ["E. risticii", "SPECIES", 314, 325], ["another study", "TEST", 3, 16], ["samples", "TEST", 79, 86], ["E. equi", "TEST", 108, 115], ["E. risticii", "TEST", 129, 140], ["the samples", "TEST", 190, 201], ["antibodies reactive", "PROBLEM", 206, 225], ["E. canis", "PROBLEM", 229, 237], ["granulocytic ehrlichiae", "OBSERVATION", 286, 309]]], ["Red foxes and grey foxes (Urocyon cinereoargenteus) were evaluated for their susceptibility to experimental infection with E. chaffeensis, the causative agent of human monocytotropic ehrlichiosis [41].", [["infection", "DISEASE", 108, 117], ["monocytotropic ehrlichiosis", "DISEASE", 168, 195], ["Red foxes", "ORGANISM", 0, 9], ["grey foxes", "ORGANISM", 14, 24], ["Urocyon cinereoargenteus", "ORGANISM", 26, 50], ["E. chaffeensis", "ORGANISM", 123, 137], ["human", "ORGANISM", 162, 167], ["Urocyon cinereoargenteus", "SPECIES", 26, 50], ["E. chaffeensis", "SPECIES", 123, 137], ["human", "SPECIES", 162, 167], ["Red foxes", "SPECIES", 0, 9], ["grey foxes", "SPECIES", 14, 24], ["Urocyon cinereoargenteus", "SPECIES", 26, 50], ["E. chaffeensis", "SPECIES", 123, 137], ["human monocytotropic ehrlichiosis", "SPECIES", 162, 195], ["Red foxes", "TEST", 0, 9], ["grey foxes", "TEST", 14, 24], ["experimental infection", "PROBLEM", 95, 117], ["E. chaffeensis", "PROBLEM", 123, 137], ["human monocytotropic ehrlichiosis", "PROBLEM", 162, 195], ["foxes", "OBSERVATION", 4, 9], ["grey foxes", "OBSERVATION", 14, 24], ["infection", "OBSERVATION", 108, 117]]], ["The results imply that red foxes, but not grey foxes, are potential vertebrate reservoirs illustrating the need to verify serologic evidence of E. chaffeensis infection among wild animals.Canine visceral leishmaniosis (CVL) ::: Vector-borne diseases and wild canidsCVL has been recently documented in wild canids in endemic regions of Europe.", [["visceral leishmaniosis", "ANATOMY", 195, 217], ["chaffeensis infection", "DISEASE", 147, 168], ["Canine visceral leishmaniosis", "DISEASE", 188, 217], ["Vector-borne diseases", "DISEASE", 228, 249], ["canidsCVL", "CHEMICAL", 259, 268], ["red foxes", "ORGANISM", 23, 32], ["grey foxes", "ORGANISM", 42, 52], ["E. chaffeensis", "ORGANISM", 144, 158], ["Canine", "ORGANISM", 188, 194], ["E. chaffeensis", "SPECIES", 144, 158], ["Canine", "SPECIES", 188, 194], ["red foxes", "SPECIES", 23, 32], ["grey foxes", "SPECIES", 42, 52], ["E. chaffeensis", "SPECIES", 144, 158], ["Canine visceral leishmaniosis", "SPECIES", 188, 217], ["red foxes", "PROBLEM", 23, 32], ["grey foxes", "PROBLEM", 42, 52], ["vertebrate reservoirs", "TREATMENT", 68, 89], ["E. chaffeensis infection", "PROBLEM", 144, 168], ["Canine visceral leishmaniosis", "PROBLEM", 188, 217], ["Vector-borne diseases", "PROBLEM", 228, 249], ["wild canidsCVL", "PROBLEM", 254, 268], ["red foxes", "OBSERVATION", 23, 32], ["not", "UNCERTAINTY", 38, 41], ["grey foxes", "OBSERVATION", 42, 52], ["chaffeensis", "OBSERVATION_MODIFIER", 147, 158], ["infection", "OBSERVATION", 159, 168], ["visceral", "ANATOMY", 195, 203], ["leishmaniosis", "OBSERVATION", 204, 217], ["CVL", "ANATOMY", 219, 222]]], ["Pathologic and parasitologic analysis of a grey wolf (Canis lupus) found dead and confirmed by PCR, indicated that lesions associated with infection by L. infantum were typical for CVL commonly described in dogs [42].", [["lesions", "ANATOMY", 115, 122], ["infection by L. infantum", "DISEASE", 139, 163], ["grey wolf", "ORGANISM", 43, 52], ["Canis lupus", "ORGANISM", 54, 65], ["lesions", "PATHOLOGICAL_FORMATION", 115, 122], ["L. infantum", "ORGANISM", 152, 163], ["CVL", "ORGANISM", 181, 184], ["dogs", "ORGANISM", 207, 211], ["Canis lupus", "SPECIES", 54, 65], ["L. infantum", "SPECIES", 152, 163], ["dogs", "SPECIES", 207, 211], ["grey wolf", "SPECIES", 43, 52], ["Canis lupus", "SPECIES", 54, 65], ["L. infantum", "SPECIES", 152, 163], ["parasitologic analysis", "TEST", 15, 37], ["a grey wolf (Canis lupus", "PROBLEM", 41, 65], ["dead", "PROBLEM", 73, 77], ["PCR", "TEST", 95, 98], ["lesions", "PROBLEM", 115, 122], ["infection", "PROBLEM", 139, 148], ["L. infantum", "PROBLEM", 152, 163], ["CVL", "TREATMENT", 181, 184], ["lesions", "OBSERVATION", 115, 122], ["infection", "OBSERVATION", 139, 148]]], ["A serologic survey of captive wolves in southwestern Europe determined that three of 33 wolves (9%) presented low levels of antibodies to L. infantum infection using an ELISA test [43].", [["L. infantum infection", "DISEASE", 138, 159], ["L. infantum", "ORGANISM", 138, 149], ["antibodies", "PROTEIN", 124, 134], ["L. infantum", "SPECIES", 138, 149], ["L. infantum", "SPECIES", 138, 149], ["A serologic survey", "TEST", 0, 18], ["low levels of antibodies", "PROBLEM", 110, 134], ["L. infantum infection", "PROBLEM", 138, 159], ["an ELISA test", "TEST", 166, 179], ["infection", "OBSERVATION", 150, 159]]], ["An epizootiological survey of leishmaniosis in 67 foxes (Vulpes vulpes) was conducted in Guadalajara, Spain, identifying a prevalence of 74% positives determined by molecular methods [44].Canine visceral leishmaniosis (CVL) ::: Vector-borne diseases and wild canidsVisceral leishmaniosis occurs in many parts of the world and dogs are considered a major reservoir host for human infections.", [["visceral leishmaniosis", "ANATOMY", 195, 217], ["Visceral leishmaniosis", "ANATOMY", 265, 287], ["leishmaniosis", "DISEASE", 30, 43], ["Canine visceral leishmaniosis", "DISEASE", 188, 217], ["Vector-borne diseases", "DISEASE", 228, 249], ["Visceral leishmaniosis", "DISEASE", 265, 287], ["infections", "DISEASE", 379, 389], ["foxes", "ORGANISM", 50, 55], ["Vulpes vulpes", "ORGANISM", 57, 70], ["Canine", "ORGANISM", 188, 194], ["dogs", "ORGANISM", 326, 330], ["human", "ORGANISM", 373, 378], ["Vulpes vulpes", "SPECIES", 57, 70], ["Canine", "SPECIES", 188, 194], ["dogs", "SPECIES", 326, 330], ["human", "SPECIES", 373, 378], ["Vulpes vulpes", "SPECIES", 57, 70], ["Canine visceral leishmaniosis", "SPECIES", 188, 217], ["human", "SPECIES", 373, 378], ["leishmaniosis", "PROBLEM", 30, 43], ["Canine visceral leishmaniosis", "PROBLEM", 188, 217], ["Vector-borne diseases", "PROBLEM", 228, 249], ["wild canids", "PROBLEM", 254, 265], ["Visceral leishmaniosis", "PROBLEM", 265, 287], ["human infections", "PROBLEM", 373, 389], ["leishmaniosis", "OBSERVATION", 30, 43], ["visceral", "ANATOMY", 195, 203], ["leishmaniosis", "OBSERVATION", 204, 217], ["CVL", "ANATOMY", 219, 222], ["leishmaniosis", "OBSERVATION", 274, 287], ["infections", "OBSERVATION", 379, 389]]], ["Human visceral leishmaniosis has recently emerged as an opportunistic infection among individuals co-infected with HIV/AIDS and in persons taking immunosuppressive drugs.", [["visceral leishmaniosis", "ANATOMY", 6, 28], ["visceral leishmaniosis", "DISEASE", 6, 28], ["opportunistic infection", "DISEASE", 56, 79], ["HIV/AIDS", "DISEASE", 115, 123], ["Human", "ORGANISM", 0, 5], ["visceral leishmaniosis", "CANCER", 6, 28], ["persons", "ORGANISM", 131, 138], ["Human", "SPECIES", 0, 5], ["HIV", "SPECIES", 115, 118], ["persons", "SPECIES", 131, 138], ["Human visceral leishmaniosis", "SPECIES", 0, 28], ["HIV", "SPECIES", 115, 118], ["Human visceral leishmaniosis", "PROBLEM", 0, 28], ["an opportunistic infection", "PROBLEM", 53, 79], ["HIV/AIDS", "PROBLEM", 115, 123], ["immunosuppressive drugs", "TREATMENT", 146, 169], ["visceral", "ANATOMY", 6, 14], ["leishmaniosis", "OBSERVATION", 15, 28], ["opportunistic", "OBSERVATION_MODIFIER", 56, 69], ["infection", "OBSERVATION", 70, 79]]], ["Royspal et al. [45] reported 3 naturally infected foxhounds from Virginia by culture.", [["culture", "TEST", 77, 84], ["infected", "OBSERVATION", 41, 49]]], ["The disease has been documented extensively in Brazil.", [["The disease", "PROBLEM", 0, 11], ["disease", "OBSERVATION", 4, 11]]], ["Among 15 captive canids from a zoo in Belo Horizonte, Minas Gerais, Brazil, two animals, a bush dog (Spheotos venaticos) and a hoary fox (Lycalopex vetulus), were serologically positive and developed clinical signs of CVL, whereas three other canids, including a crab-eating fox (Cerdocyon thous), a maned wolf and a hoary fox had positive serological results without clinical signs [46].", [["CVL", "DISEASE", 218, 221], ["dog", "ORGANISM", 96, 99], ["Spheotos venaticos", "ORGANISM", 101, 119], ["hoary fox", "ORGANISM", 127, 136], ["Lycalopex vetulus", "ORGANISM", 138, 155], ["CVL", "ORGANISM", 218, 221], ["fox", "ORGANISM", 323, 326], ["dog", "SPECIES", 96, 99], ["Spheotos venaticos", "SPECIES", 101, 119], ["Lycalopex vetulus", "SPECIES", 138, 155], ["bush dog", "SPECIES", 91, 99], ["Spheotos venaticos", "SPECIES", 101, 119], ["hoary fox", "SPECIES", 127, 136], ["Lycalopex vetulus", "SPECIES", 138, 155], ["hoary fox", "SPECIES", 317, 326], ["a hoary fox (Lycalopex vetulus", "TREATMENT", 125, 155], ["clinical signs of CVL", "PROBLEM", 200, 221], ["CVL", "OBSERVATION", 218, 221]]], ["During 1999\u20132003 parasitology and serology tests were performed in domestic (n = 1568) and wild jackals (Canis aureus, n = 10), red foxes (n = 10) and wolves (n = 10) in Iran demonstrating that 10% of wild canids were infected by L. infantum.", [["Canis aureus", "ORGANISM", 105, 117], ["canids", "ORGANISM", 206, 212], ["L. infantum", "ORGANISM", 230, 241], ["jackals", "SPECIES", 96, 103], ["Canis aureus", "SPECIES", 105, 117], ["L. infantum", "SPECIES", 230, 241], ["Canis aureus", "SPECIES", 105, 117], ["red foxes", "SPECIES", 128, 137], ["L. infantum", "SPECIES", 230, 241], ["serology tests", "TEST", 34, 48], ["wild jackals (Canis aureus", "PROBLEM", 91, 117], ["red foxes", "TEST", 128, 137], ["wild canids", "PROBLEM", 201, 212]]], ["Ten out of 11 Leishmania spp. isolated from dogs and wild canines were identified as L. infantum and one other as L. tropica by molecular and biochemical techniques [47].Hepatozoonosis ::: Vector-borne diseases and wild canidsThe first PCR detection of Hepatozoon canis in a naturally infected red fox from Slovakia, a Rhipicephalus sanguineus-free region, was recently performed [48].", [["Hepatozoonosis", "DISEASE", 170, 184], ["Vector-borne diseases", "DISEASE", 189, 210], ["Hepatozoon canis", "DISEASE", 253, 269], ["Leishmania spp", "ORGANISM", 14, 28], ["dogs", "ORGANISM", 44, 48], ["canines", "ORGAN", 58, 65], ["L. infantum", "ORGANISM", 85, 96], ["L. tropica", "ORGANISM", 114, 124], ["Hepatozoon canis", "ORGANISM", 253, 269], ["red fox", "ORGANISM", 294, 301], ["Rhipicephalus sanguineus", "ORGANISM", 319, 343], ["dogs", "SPECIES", 44, 48], ["L. infantum", "SPECIES", 85, 96], ["L. tropica", "SPECIES", 114, 124], ["Hepatozoon canis", "SPECIES", 253, 269], ["Rhipicephalus sanguineus", "SPECIES", 319, 343], ["L. infantum", "SPECIES", 85, 96], ["L. tropica", "SPECIES", 114, 124], ["Hepatozoon canis", "SPECIES", 253, 269], ["red fox", "SPECIES", 294, 301], ["Rhipicephalus sanguineus", "SPECIES", 319, 343], ["Leishmania spp", "PROBLEM", 14, 28], ["Vector-borne diseases", "PROBLEM", 189, 210], ["wild canids", "PROBLEM", 215, 226], ["The first PCR detection", "TEST", 226, 249], ["Hepatozoon canis", "PROBLEM", 253, 269], ["a Rhipicephalus sanguineus-free region", "PROBLEM", 317, 355], ["Leishmania spp", "OBSERVATION", 14, 28], ["Hepatozoon canis", "OBSERVATION", 253, 269]]], ["It is believed that the infection was spread by infected R. sanguineus that might have been brought to Slovakia by travellers, golden jackals, or foxes migrating because of expansion of golden jackals and environmental and climate changes.", [["infection", "DISEASE", 24, 33], ["R. sanguineus", "ORGANISM", 57, 70], ["golden jackals", "ORGANISM", 127, 141], ["R. sanguineus", "SPECIES", 57, 70], ["R. sanguineus", "SPECIES", 57, 70], ["golden jackals", "SPECIES", 127, 141], ["the infection", "PROBLEM", 20, 33], ["infected R. sanguineus", "PROBLEM", 48, 70], ["golden jackals", "PROBLEM", 127, 141], ["golden jackals", "PROBLEM", 186, 200], ["infection", "OBSERVATION", 24, 33], ["infected", "OBSERVATION_MODIFIER", 48, 56], ["expansion", "OBSERVATION_MODIFIER", 173, 182], ["golden jackals", "OBSERVATION", 186, 200]]], ["A seroepidemiological survey was conducted to investigate the prevalence of antibodies reactive with E. canis and H. canis antigens in free-ranging red foxes in Israel.", [["E. canis", "ORGANISM", 101, 109], ["H. canis", "ORGANISM", 114, 122], ["foxes", "ORGANISM", 152, 157], ["antibodies", "PROTEIN", 76, 86], ["E. canis and H. canis antigens", "PROTEIN", 101, 131], ["E. canis", "SPECIES", 101, 109], ["H. canis", "SPECIES", 114, 122], ["E. canis", "SPECIES", 101, 109], ["H. canis", "SPECIES", 114, 122], ["red foxes", "SPECIES", 148, 157], ["A seroepidemiological survey", "TEST", 0, 28], ["antibodies reactive", "PROBLEM", 76, 95], ["E. canis", "PROBLEM", 101, 109], ["H. canis antigens", "TEST", 114, 131]]], ["Of 84 fox sera assayed, 36% were seropositive for E. canis by IFA test and 24% were positive using the ELISA test.", [["sera", "ANATOMY", 10, 14], ["fox", "ORGANISM", 6, 9], ["sera", "ORGANISM_SUBSTANCE", 10, 14], ["E. canis", "ORGANISM", 50, 58], ["E. canis", "SPECIES", 50, 58], ["E. canis", "SPECIES", 50, 58], ["fox sera", "TEST", 6, 14], ["E. canis", "TEST", 50, 58], ["IFA test", "TEST", 62, 70], ["the ELISA test", "TEST", 99, 113]]], ["Canine ehrlichiosis and hepatozoonosis appear to be endemic in the wild red fox populations in Israel, and foxes may serve as a reservoir for infection of domestic dogs and other wild canine species [49].Wild canids as sentinels of ecological healthThe canidae family includes 16 recent genera distributed in most land masses of the world.", [["Canine ehrlichiosis", "DISEASE", 0, 19], ["hepatozoonosis", "DISEASE", 24, 38], ["infection", "DISEASE", 142, 151], ["Canine ehrlichiosis", "ORGANISM", 0, 19], ["dogs", "ORGANISM", 164, 168], ["canidae", "GENE_OR_GENE_PRODUCT", 253, 260], ["canidae family", "PROTEIN", 253, 267], ["Canine", "SPECIES", 0, 6], ["dogs", "SPECIES", 164, 168], ["canine", "SPECIES", 184, 190], ["Canine ehrlichiosis", "SPECIES", 0, 19], ["red fox", "SPECIES", 72, 79], ["Canine ehrlichiosis", "PROBLEM", 0, 19], ["hepatozoonosis", "PROBLEM", 24, 38], ["a reservoir", "TREATMENT", 126, 137], ["infection of domestic dogs", "PROBLEM", 142, 168], ["ehrlichiosis", "OBSERVATION", 7, 19], ["appear to be", "UNCERTAINTY", 39, 51], ["endemic", "OBSERVATION_MODIFIER", 52, 59], ["most land", "OBSERVATION_MODIFIER", 309, 318], ["masses", "OBSERVATION", 319, 325]]], ["Nine of the 36 canid taxa are threatened: Darwin's fox, island fox and red wolf are listed as Critically Endangered, while Ethiopian wolf, African wild dog and dhole (Cuon aplinus) are endangered.", [["island fox", "ORGANISM", 56, 66], ["red wolf", "ORGANISM", 71, 79], ["dog", "ORGANISM", 152, 155], ["Cuon aplinus", "ORGANISM", 167, 179], ["dog", "SPECIES", 152, 155], ["Cuon aplinus", "SPECIES", 167, 179], ["red wolf", "SPECIES", 71, 79], ["Ethiopian wolf", "SPECIES", 123, 137], ["African wild dog", "SPECIES", 139, 155], ["Cuon aplinus", "SPECIES", 167, 179]]], ["Others are rare and even declining, while many wild canids like coyotes are common, therefore they are involved in major wildlife management issues (such as disease transmission, predation on livestock, sport hunting, fur trade).", [["rare", "OBSERVATION_MODIFIER", 11, 15]]], ["Many wild canid species may serve as sentinels of ecological health as they may be critical to proactively identify potentially pathogenic canine vector-borne diseases emerging parasites.Wild canids as sentinels of ecological healthSentinel species are the proverbial \"canaries in the mine shaft\".", [["canine", "ORGANISM", 139, 145], ["Wild canids", "ORGANISM", 187, 198], ["mine shaft", "MULTI-TISSUE_STRUCTURE", 285, 295], ["canine", "SPECIES", 139, 145], ["canine", "SPECIES", 139, 145], ["Many wild canid species", "PROBLEM", 0, 23], ["borne diseases emerging parasites", "PROBLEM", 153, 186], ["ecological healthSentinel species", "PROBLEM", 215, 248], ["mine shaft", "ANATOMY", 285, 295]]], ["The scientific information generated by the sentinel species should empower stakeholders to take mitigative action or support predictive capabilities.", [["mitigative action", "TREATMENT", 97, 114]]], ["The \"utility\" of the species selected should consider its value and relevance to decision makers, conservationists and to society at large.", [["the species", "PROBLEM", 17, 28]]], ["Assessing the health an ecosystem will require of a \"suite\" of sentinel species including different trophic levels, ecological roles, taxa and different spatial/temporal scales.", [["sentinel species", "PROBLEM", 63, 79], ["different trophic levels", "TEST", 90, 114], ["taxa", "TREATMENT", 134, 138], ["different spatial/temporal scales", "TREATMENT", 143, 176], ["sentinel species", "OBSERVATION", 63, 79]]], ["It will require conservation medicine teams to apply transdisciplinary efforts.", [["conservation medicine teams", "TREATMENT", 16, 43], ["transdisciplinary efforts", "TREATMENT", 53, 78]]], ["It will require the involvement of decision makers and the general public to change our behaviour towards the planet [50,51].Wild canids as sentinels of ecological healthSentinel species may assist in increasing monitoring efficiency at the ecosystem level.", [["Wild canids", "ORGANISM", 125, 136], ["ecological healthSentinel species", "TREATMENT", 153, 186]]], ["They can be utilised during rapid risk assessments to provide information on the environmental conditions of an area during an emerging parasitic disease outbreak.", [["parasitic disease", "DISEASE", 136, 153], ["rapid risk assessments", "TEST", 28, 50], ["an emerging parasitic disease outbreak", "PROBLEM", 124, 162], ["parasitic disease", "OBSERVATION", 136, 153]]], ["Sentinel species or health indicator species can be selected for their ability to reflect environmental perturbations.", [["Sentinel species", "PROBLEM", 0, 16], ["health indicator species", "PROBLEM", 20, 44]]], ["Given the complexity of ecosystems, sentinel species should be thought of as being specific to particular environmental conditions during a pandemic.", [["sentinel species", "PROBLEM", 36, 52], ["a pandemic", "PROBLEM", 138, 148], ["sentinel species", "OBSERVATION", 36, 52]]], ["In some cases, an assemblage of species may be suitable for providing a 'umbrella' effect in monitoring the cumulative impacts of multiple environmental variables that create the complexity of an emerging canine vector-borne disease [50,51].Wild canids as sentinels of ecological healthOn the one hand, wild canid populations may suffer severe epizootics and declines related to domestic dog diseases; on the other hand, there are species like jackals, coyotes and foxes that are highly adaptable to ecosystems and human-impacted environments and are reservoirs of several diseases of zoonotic or domestic animal importance including rabies, parvovirus infection, canine distemper and mange.", [["canine vector-borne disease", "DISEASE", 205, 232], ["epizootics", "DISEASE", 344, 354], ["domestic dog diseases", "DISEASE", 379, 400], ["zoonotic or domestic animal importance", "DISEASE", 585, 623], ["rabies", "DISEASE", 634, 640], ["parvovirus infection", "DISEASE", 642, 662], ["canine distemper", "DISEASE", 664, 680], ["canine", "ORGANISM", 205, 211], ["Wild canids", "ORGANISM", 241, 252], ["hand", "ORGANISM_SUBDIVISION", 297, 301], ["dog", "ORGANISM_SUBDIVISION", 388, 391], ["human", "ORGANISM", 515, 520], ["parvovirus", "ORGANISM", 642, 652], ["canine distemper", "ORGANISM", 664, 680], ["canine", "SPECIES", 205, 211], ["human", "SPECIES", 515, 520], ["canine distemper", "SPECIES", 664, 680], ["canine", "SPECIES", 205, 211], ["human", "SPECIES", 515, 520], ["canine distemper", "SPECIES", 664, 680], ["a 'umbrella' effect", "PROBLEM", 70, 89], ["multiple environmental variables", "PROBLEM", 130, 162], ["borne disease", "PROBLEM", 219, 232], ["severe epizootics", "PROBLEM", 337, 354], ["domestic dog diseases", "PROBLEM", 379, 400], ["rabies", "PROBLEM", 634, 640], ["parvovirus infection", "PROBLEM", 642, 662], ["severe", "OBSERVATION_MODIFIER", 337, 343], ["epizootics", "OBSERVATION", 344, 354], ["parvovirus infection", "OBSERVATION", 642, 662]]], ["These species are ideal to monitor vector-borne diseases.", [["borne diseases", "PROBLEM", 42, 56]]], ["In addition, wild caninds adapted to the human condition host innumerable parasites, bacteria and viruses, which in turn may contribute to density-dependent mortality.", [["human", "ORGANISM", 41, 46], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 41, 46], ["innumerable parasites", "PROBLEM", 62, 83], ["bacteria", "PROBLEM", 85, 93], ["viruses", "PROBLEM", 98, 105], ["density-dependent mortality", "PROBLEM", 139, 166], ["innumerable", "OBSERVATION_MODIFIER", 62, 73], ["parasites", "OBSERVATION", 74, 83], ["density", "OBSERVATION", 139, 146], ["dependent", "OBSERVATION_MODIFIER", 147, 156], ["mortality", "OBSERVATION", 157, 166]]], ["By increasing wildlife-domestic animal interactions the potential of spread of disease to domestic dog populations is real [25,52].", [["dog", "ORGANISM", 99, 102], ["disease", "PROBLEM", 79, 86]]], ["Further research is necessary to identify wild reservoirs, susceptible hosts and zoonotic interactions for all canine vector-borne diseases at a global level and to establish protective measures to dwindling wild canid populations such as wolves to ensure their long-term survival.Competing interestsThe author declares that they have no competing interests.", [["canine", "ORGANISM", 111, 117], ["canine", "SPECIES", 111, 117], ["canine", "SPECIES", 111, 117], ["all canine vector", "TREATMENT", 107, 124], ["borne diseases", "PROBLEM", 125, 139], ["protective measures", "TREATMENT", 175, 194]]]], "PMC7108310": [["IntroductionIn 1346, the Mongol army that was laying siege to the Crimean city of Kaffa hurled the corpses of plague victims over the city walls, an event that likely seeded the epidemic that infected the besieged city.", [["plague", "OBSERVATION_MODIFIER", 110, 116]]], ["The disease subsequently spread across Europe as the Black Death, killing 24 million people in the next six years [1], [2].", [["Death", "DISEASE", 59, 64], ["people", "ORGANISM", 85, 91], ["people", "SPECIES", 85, 91], ["The disease", "PROBLEM", 0, 11], ["disease", "OBSERVATION", 4, 11], ["spread", "OBSERVATION_MODIFIER", 25, 31]]], ["It was not until the 20th century, though, that advances in microbiology spurred widespread research into the production and weaponization of biological threat agents.", [["biological threat agents", "TREATMENT", 142, 166]]], ["The biological arms race that took off during World War II and escalated with Cold War tensions was thankfully tempered by the United Nation's 1972 Biological Weapons Convention (BWC), which prohibited the development, production, and stockpiling of bioweapons and their delivery systems [1], [2], [3], [4].", [["[2]", "SIMPLE_CHEMICAL", 293, 296], ["[3]", "SIMPLE_CHEMICAL", 298, 301], ["[4]", "SIMPLE_CHEMICAL", 303, 306]]], ["Examples such as the 2001 anthrax attacks in the United States, which led to 22 cases of confirmed anthrax, five deaths, and required prophylactic antibiotics for 10,000 people, underscore the need for vigilance and the urgency behind the development of superior sensors and monitoring techniques for weapons of mass destruction (WMD) threats [1], [2].IntroductionBioagents include bacteria, viruses, and toxins, and they need not be intentionally disseminated in order to pose a threat to human health [1].", [["anthrax attacks", "DISEASE", 26, 41], ["anthrax", "DISEASE", 99, 106], ["deaths", "DISEASE", 113, 119], ["people", "ORGANISM", 170, 176], ["human", "ORGANISM", 490, 495], ["people", "SPECIES", 170, 176], ["human", "SPECIES", 490, 495], ["human", "SPECIES", 490, 495], ["prophylactic antibiotics", "TREATMENT", 134, 158], ["vigilance", "TREATMENT", 202, 211], ["the urgency", "PROBLEM", 216, 227], ["superior sensors", "TEST", 254, 270], ["monitoring techniques", "TEST", 275, 296], ["mass destruction", "PROBLEM", 312, 328], ["IntroductionBioagents", "TREATMENT", 352, 373], ["bacteria", "PROBLEM", 382, 390], ["viruses", "PROBLEM", 392, 399], ["toxins", "PROBLEM", 405, 411], ["mass", "OBSERVATION", 312, 316]]], ["Moreover, the need to detect members of this diverse group with specificity, sensitivity, and rapidity augments an already substantial challenge.", [["sensitivity", "TEST", 77, 88]]], ["Traditional detection methods, which include assays based on biochemical and immunological recognition, biomolecular techniques such as polymerase chain reaction (PCR), or cell culture, often require ample time (hours to days), leaving a clinician to essentially guess as to the identity of the pathogen or toxin.", [["cell culture", "ANATOMY", 172, 184], ["cell", "CELL", 172, 176], ["Traditional detection methods", "TEST", 0, 29], ["assays", "TEST", 45, 51], ["immunological recognition", "TEST", 77, 102], ["biomolecular techniques", "TREATMENT", 104, 127], ["polymerase chain reaction", "PROBLEM", 136, 161], ["PCR", "TEST", 163, 166], ["cell culture", "TEST", 172, 184], ["the pathogen", "PROBLEM", 291, 303], ["toxin", "PROBLEM", 307, 312]]], ["For environmental monitoring purposes and the initiation of containment and prophylactic treatment of exposed individuals, these techniques leave significant room for improvement.IntroductionIn recent years, efforts in the field of bioagent detection have taken advantage of the burgeoning use of nanomaterials (NMs) throughout the scientific community to create novel sensors.", [["environmental monitoring purposes", "TEST", 4, 37], ["containment", "TREATMENT", 60, 71], ["prophylactic treatment", "TREATMENT", 76, 98], ["bioagent detection", "TREATMENT", 232, 250], ["nanomaterials (NMs", "TREATMENT", 297, 315]]], ["In addition to the properties unique to nanoscale materials, the disposability and small size of NMs make them well-suited to application in portable and multiplexed sensors.", [["NMs", "SIMPLE_CHEMICAL", 97, 100], ["nanoscale materials", "TREATMENT", 40, 59], ["the disposability and small size of NMs", "PROBLEM", 61, 100], ["small", "OBSERVATION_MODIFIER", 83, 88], ["size", "OBSERVATION_MODIFIER", 89, 93]]], ["Relying on intrinsic NM properties in conjunction with immunogenic or other biological recognition mechanisms, detection schemes exploiting colorimetric, photoluminescence (PL), electrochemical, plasmon resonance, and other responses have been explored [6], [7], [8], [9], [10], [11], [12], [13], [14].", [["[6]", "SIMPLE_CHEMICAL", 253, 256], ["[7], [8], [9]", "SIMPLE_CHEMICAL", 258, 271], ["[10], [11]", "SIMPLE_CHEMICAL", 273, 283], ["[12], [13]", "SIMPLE_CHEMICAL", 285, 295], ["[14]", "SIMPLE_CHEMICAL", 297, 301], ["intrinsic NM properties", "TREATMENT", 11, 34], ["electrochemical, plasmon resonance", "TEST", 178, 212]]], ["Here we examine a range of bioagents and the nanoscale sensors that have been recently developed to detect them.", [["bioagents", "TREATMENT", 27, 36], ["the nanoscale sensors", "TEST", 41, 62]]], ["Building on the foundation laid by an earlier review from this group that focused on the devices under development for bio-threat agent detection, we examine the most novel and innovative ways in which NMs are being applied to this problem [15].", [["NMs", "SIMPLE_CHEMICAL", 202, 205], ["bio-threat agent detection", "TREATMENT", 119, 145]]], ["Many of the techniques highlighted are research-based prototypes not yet ready for integration into commercial devices, but they already offer promise when compared to the current \u2018gold standards\u2019 for detection and highlight areas in which nanosensors are able to outperform the traditional detection paradigms.", [["integration into commercial devices", "TREATMENT", 83, 118]]], ["Rather than an exhaustive review of these sensors, our focus is on highlighting select NMs and how they have been applied to detecting biothreat agents.Bacteria ::: Overview of bioagentsBacteria are unicellular organisms that reproduce by replication and cause disease either through invasion of host tissue or release of a toxin.", [["tissue", "ANATOMY", 301, 307], ["NMs", "CANCER", 87, 90], ["biothreat agents", "SIMPLE_CHEMICAL", 135, 151], ["Bacteria", "CELL", 186, 194], ["tissue", "TISSUE", 301, 307], ["toxin", "PROTEIN", 324, 329], ["these sensors", "TEST", 36, 49], ["biothreat agents", "TREATMENT", 135, 151], ["Bacteria", "PROBLEM", 152, 160], ["Bacteria", "PROBLEM", 186, 194], ["unicellular organisms", "PROBLEM", 199, 220], ["disease", "PROBLEM", 261, 268], ["invasion of host tissue", "PROBLEM", 284, 307], ["a toxin", "PROBLEM", 322, 329], ["unicellular organisms", "OBSERVATION", 199, 220], ["host tissue", "OBSERVATION", 296, 307]]], ["Modern biological warfare began during World War I when German agents infected animals shipped from the United States and other neutral countries to Allied Forces with anthrax and glanders [4].", [["anthrax", "DISEASE", 168, 175]]], ["The diseases caused by bacteria, however, have long histories; Bacillus anthracis, the causative agent of anthrax, has been proposed as a possible cause of the fifth and sixth plagues mentioned in Exodus.", [["Bacillus anthracis", "DISEASE", 63, 81], ["anthrax", "DISEASE", 106, 113], ["Bacillus anthracis", "ORGANISM", 63, 81], ["Bacillus anthracis", "SPECIES", 63, 81], ["Bacillus anthracis", "SPECIES", 63, 81], ["The diseases", "PROBLEM", 0, 12], ["bacteria", "PROBLEM", 23, 31], ["Bacillus anthracis", "PROBLEM", 63, 81], ["diseases", "OBSERVATION", 4, 12], ["bacteria", "OBSERVATION", 23, 31]]], ["Likewise, Plague (caused by Yersinia pestis) played a substantial role both in natural epidemics (e.g., the Black Death) and in bioweapons programs in the 20th century.", [["Plague", "DISEASE", 10, 16], ["Yersinia pestis", "DISEASE", 28, 43], ["Death", "DISEASE", 114, 119], ["Yersinia pestis", "ORGANISM", 28, 43], ["Yersinia pestis", "SPECIES", 28, 43], ["Yersinia pestis", "SPECIES", 28, 43]]], ["Interestingly, Y. pestis still sees occasional outbreaks in the American Southwest, typically originating from small mammal and rodent vectors, although modern antibiotics have significantly reduced mortality [17].", [["Y. pestis", "DISEASE", 15, 24], ["Y. pestis", "ORGANISM", 15, 24], ["Y. pestis", "SPECIES", 15, 24], ["rodent", "SPECIES", 128, 134], ["Y. pestis", "SPECIES", 15, 24], ["rodent vectors", "TREATMENT", 128, 142], ["modern antibiotics", "TREATMENT", 153, 171], ["occasional", "OBSERVATION_MODIFIER", 36, 46], ["outbreaks", "OBSERVATION_MODIFIER", 47, 56], ["small mammal", "OBSERVATION_MODIFIER", 111, 123]]], ["The diversity of bacteria is reflected in the range of diseases they cause, infectious doses, etc. For example, while the mortality rate of untreated inhalation anthrax is greater than 90%, the mortality rate of brucellosis, caused by one of six Brucella species, is 2\u20135%.", [["anthrax", "DISEASE", 161, 168], ["brucellosis", "DISEASE", 212, 223], ["bacteria", "PROBLEM", 17, 25], ["untreated inhalation anthrax", "PROBLEM", 140, 168], ["brucellosis", "PROBLEM", 212, 223], ["six Brucella species", "PROBLEM", 242, 262], ["diversity", "OBSERVATION_MODIFIER", 4, 13], ["bacteria", "OBSERVATION", 17, 25], ["infectious", "OBSERVATION_MODIFIER", 76, 86], ["greater", "OBSERVATION_MODIFIER", 172, 179], ["brucellosis", "OBSERVATION", 212, 223]]], ["Paradoxically, as few as 10 organisms are required to cause brucellosis, however, while an infectious dose of B. anthracis is 10,000 spores.Bacteria ::: Overview of bioagentsThe development of antibiotics is undoubtedly one of the most important advances in human health in the 20th century, but antibiotics may have limited effectiveness against weaponized or genetically engineered disease strains [2], [16].", [["brucellosis", "DISEASE", 60, 71], ["B. anthracis", "ORGANISM", 110, 122], ["human", "ORGANISM", 258, 263], ["[16]", "SIMPLE_CHEMICAL", 405, 409], ["B. anthracis", "SPECIES", 110, 122], ["human", "SPECIES", 258, 263], ["B. anthracis", "SPECIES", 110, 122], ["human", "SPECIES", 258, 263], ["brucellosis", "PROBLEM", 60, 71], ["B. anthracis", "PROBLEM", 110, 122], ["Bacteria", "PROBLEM", 140, 148], ["bioagents", "TREATMENT", 165, 174], ["antibiotics", "TREATMENT", 193, 204], ["antibiotics", "TREATMENT", 296, 307], ["genetically engineered disease strains", "PROBLEM", 361, 399], ["brucellosis", "OBSERVATION", 60, 71], ["antibiotics", "OBSERVATION", 193, 204]]], ["Moreover, even in the absence of genetic engineering, natural antibiotic resistance seen in diseases such as tuberculosis, which still causes more than a million fatalities annually, may prove to be one of the most substantial health challenges of the next century [18].Viruses ::: Overview of bioagentsViruses are infectious agents that require a host for propagation, a trait that has caused them to excel at finding new hosts [19], [20].", [["tuberculosis", "DISEASE", 109, 121], ["fatalities", "DISEASE", 162, 172], ["natural antibiotic resistance", "TREATMENT", 54, 83], ["diseases", "PROBLEM", 92, 100], ["tuberculosis", "PROBLEM", 109, 121], ["bioagents", "TREATMENT", 294, 303], ["Viruses", "PROBLEM", 303, 310], ["infectious agents", "TREATMENT", 315, 332], ["antibiotic resistance", "OBSERVATION", 62, 83], ["diseases", "OBSERVATION", 92, 100], ["tuberculosis", "OBSERVATION", 109, 121], ["infectious", "OBSERVATION", 315, 325]]], ["Whereas many of the bacteria that were weaponized are only poorly transmissible from person to person, viruses are the pathogens that seed pandemics.", [["person", "SPECIES", 85, 91], ["person", "SPECIES", 95, 101], ["the bacteria", "PROBLEM", 16, 28], ["viruses", "PROBLEM", 103, 110], ["the pathogens", "PROBLEM", 115, 128], ["bacteria", "OBSERVATION", 20, 28]]], ["In Boston in 1752, for example, only 174 susceptible people (i.e., those who had not been previously infected or inoculated and remained in the city) escaped infection with smallpox during a significant outbreak [21].", [["infection", "DISEASE", 158, 167], ["smallpox", "DISEASE", 173, 181], ["people", "ORGANISM", 53, 59], ["people", "SPECIES", 53, 59], ["escaped infection", "PROBLEM", 150, 167], ["smallpox", "PROBLEM", 173, 181], ["infection", "OBSERVATION", 158, 167]]], ["Although the disease was eradicated in 1980 through the World Health Organization's worldwide campaign, this extraordinary infectivity, along with the corresponding virulence reflected by the high mortality rate, ensures that smallpox remains among the most high-priority bioagents.Viruses ::: Overview of bioagentsWhile the public response to the 2014 West Africa outbreak of Ebola \u2013 a virus in the hemorrhagic fever family, many of whose members were weaponized \u2013 demonstrates the power that diseases with high mortality rates and dramatic presentation have on the human psyche, commonplace endemic diseases should not be underestimated.", [["smallpox", "DISEASE", 226, 234], ["Ebola \u2013 a virus", "DISEASE", 377, 392], ["hemorrhagic fever", "DISEASE", 400, 417], ["Ebola \u2013 a virus", "ORGANISM", 377, 392], ["human", "ORGANISM", 567, 572], ["Ebola", "SPECIES", 377, 382], ["human", "SPECIES", 567, 572], ["human", "SPECIES", 567, 572], ["the disease", "PROBLEM", 9, 20], ["this extraordinary infectivity", "PROBLEM", 104, 134], ["the corresponding virulence", "PROBLEM", 147, 174], ["smallpox", "TREATMENT", 226, 234], ["bioagents", "TREATMENT", 306, 315], ["Ebola", "PROBLEM", 377, 382], ["a virus", "PROBLEM", 385, 392], ["the hemorrhagic fever", "PROBLEM", 396, 417], ["high mortality rates", "PROBLEM", 508, 528], ["commonplace endemic diseases", "PROBLEM", 581, 609], ["disease", "OBSERVATION", 13, 20], ["Ebola", "OBSERVATION", 377, 382], ["hemorrhagic", "OBSERVATION_MODIFIER", 400, 411]]], ["The Spanish Flu of 1918\u201319 caused an estimated 20\u201350 million deaths worldwide, and new strains of influenza are constantly emerging through mutation and genetic recombination, requiring the development of a new vaccine every year.", [["Flu of 1918\u201319", "CHEMICAL", 12, 26], ["deaths", "DISEASE", 61, 67], ["influenza", "DISEASE", 98, 107], ["influenza", "PROBLEM", 98, 107], ["a new vaccine", "TREATMENT", 205, 218], ["influenza", "OBSERVATION", 98, 107]]], ["Other viruses appear seemingly out of nowhere, as was the case with Severe Acute Respiratory Syndrome (SARS) in 2003 and Middle East Respiratory Syndrome (MERS) in 2012.", [["Acute Respiratory Syndrome", "DISEASE", 75, 101], ["SARS", "DISEASE", 103, 107], ["Middle East Respiratory Syndrome", "DISEASE", 121, 153], ["MERS", "DISEASE", 155, 159], ["Severe Acute Respiratory Syndrome (SARS)", "SPECIES", 68, 108], ["Other viruses", "PROBLEM", 0, 13], ["Severe Acute Respiratory Syndrome", "PROBLEM", 68, 101], ["SARS", "PROBLEM", 103, 107], ["Middle East Respiratory Syndrome", "PROBLEM", 121, 153], ["viruses", "OBSERVATION", 6, 13], ["Severe", "OBSERVATION_MODIFIER", 68, 74], ["Acute", "OBSERVATION_MODIFIER", 75, 80], ["Respiratory Syndrome", "OBSERVATION", 81, 101], ["Middle", "ANATOMY_MODIFIER", 121, 127], ["Respiratory Syndrome", "OBSERVATION", 133, 153]]], ["Both qualify as emerging infectious diseases, defined as diseases that have increased in incidence in the past twenty years or show signs of a likely increase in the near future [22], [23], [24].", [["infectious diseases", "DISEASE", 25, 44], ["emerging infectious diseases", "PROBLEM", 16, 44], ["diseases", "PROBLEM", 57, 65], ["infectious", "OBSERVATION", 25, 35], ["increased", "OBSERVATION_MODIFIER", 76, 85], ["likely", "UNCERTAINTY", 143, 149], ["increase", "OBSERVATION_MODIFIER", 150, 158]]], ["While some bacterial species fall into the category of emerging diseases (e.g., multidrug-resistant M. tuberculosis), viruses have assumed a higher public profile in recent years as outbreaks threaten to turn into pandemics.", [["multidrug-resistant M. tuberculosis", "DISEASE", 80, 115], ["M. tuberculosis", "ORGANISM", 100, 115], ["M. tuberculosis", "SPECIES", 100, 115], ["M. tuberculosis", "SPECIES", 100, 115], ["some bacterial species", "PROBLEM", 6, 28], ["emerging diseases", "PROBLEM", 55, 72], ["multidrug-resistant M. tuberculosis", "PROBLEM", 80, 115], ["viruses", "PROBLEM", 118, 125], ["bacterial species", "OBSERVATION", 11, 28], ["tuberculosis", "OBSERVATION", 103, 115]]], ["Because limited viral equivalents to antibiotics currently exist, treatment for the diseases they cause is typically palliative.Toxins ::: Overview of bioagentsBecause toxins can originate from diverse sources, including animals, plants, and microbes, they are defined not by their source but by their common properties: they are chemicals that elicit a toxic response and are neither man-made nor volatile.", [["antibiotics", "TREATMENT", 37, 48], ["treatment", "TREATMENT", 66, 75], ["the diseases", "PROBLEM", 80, 92], ["bioagents", "TREATMENT", 151, 160], ["toxins", "PROBLEM", 168, 174]]], ["Unlike bacteria and viruses, which replicate under suitable circumstances, toxins lack the ability to propagate themselves and spread to new hosts.", [["Unlike bacteria", "PROBLEM", 0, 15], ["viruses", "PROBLEM", 20, 27], ["bacteria", "OBSERVATION", 7, 15], ["viruses", "OBSERVATION", 20, 27]]], ["Botulinum neurotoxin (BoNT), among the best-researched bioagents, is the most lethal toxin known.", [["Botulinum neurotoxin", "CHEMICAL", 0, 20], ["BoNT", "CHEMICAL", 22, 26], ["Botulinum neurotoxin", "SIMPLE_CHEMICAL", 0, 20], ["BoNT", "GENE_OR_GENE_PRODUCT", 22, 26]]], ["A protein toxin produced by the bacterium Clostridium botulinum, causative agent of botulism, its LD50 (lethal dose to 50% of the sample population) is a mere 0.1 \u03bcg/70 kg intravenously.", [["intravenously", "ANATOMY", 172, 185], ["botulism", "DISEASE", 84, 92], ["LD50", "CHEMICAL", 98, 102], ["bacterium", "ORGANISM", 32, 41], ["Clostridium botulinum", "ORGANISM", 42, 63], ["protein toxin", "PROTEIN", 2, 15], ["Clostridium botulinum", "SPECIES", 42, 63], ["Clostridium botulinum", "SPECIES", 42, 63], ["A protein toxin", "TEST", 0, 15], ["the bacterium Clostridium botulinum", "PROBLEM", 28, 63], ["botulism", "PROBLEM", 84, 92], ["the sample population", "TREATMENT", 126, 147]]], ["A thousand-fold less toxic, ricin is a protein found in the seeds of the castor bean plant and has a history of use in assassinations and murders, such as the Bulgarian secret police's 1978 assassination of Bulgarian dissident Georgi Markov, in which a ricin pellet likely obtained from the KGB was injected into his leg by a \u2018pedestrian\u2019 agent using a modified umbrella.", [["leg", "ANATOMY", 317, 320], ["ricin", "CHEMICAL", 28, 33], ["ricin", "GENE_OR_GENE_PRODUCT", 28, 33], ["castor bean", "ORGANISM", 73, 84], ["KGB", "ORGANISM", 291, 294], ["leg", "ORGANISM_SUBDIVISION", 317, 320], ["castor bean", "SPECIES", 73, 84], ["castor bean", "SPECIES", 73, 84], ["A thousand-fold less toxic", "PROBLEM", 0, 26], ["a protein", "PROBLEM", 37, 46], ["a ricin pellet", "TREATMENT", 251, 265], ["a modified umbrella", "TREATMENT", 351, 370], ["fold less", "OBSERVATION_MODIFIER", 11, 20], ["toxic", "OBSERVATION_MODIFIER", 21, 26], ["castor bean plant", "OBSERVATION", 73, 90], ["leg", "ANATOMY", 317, 320]]], ["A third protein toxin, staphylococcal enterotoxin B (SEB), produced by the bacterium Staphylococcus aureus, is an incapacitant at low doses, while the high doses required to elicit mortality give the agent an excellent \u2018safety ratio.\u2019", [["staphylococcal enterotoxin B", "CHEMICAL", 23, 51], ["SEB", "CHEMICAL", 53, 56], ["Staphylococcus aureus", "DISEASE", 85, 106], ["staphylococcal enterotoxin B", "GENE_OR_GENE_PRODUCT", 23, 51], ["SEB", "GENE_OR_GENE_PRODUCT", 53, 56], ["bacterium Staphylococcus aureus", "ORGANISM", 75, 106], ["protein toxin", "PROTEIN", 8, 21], ["staphylococcal enterotoxin B", "PROTEIN", 23, 51], ["SEB", "PROTEIN", 53, 56], ["Staphylococcus aureus", "SPECIES", 85, 106], ["Staphylococcus aureus", "SPECIES", 85, 106], ["A third protein toxin", "TEST", 0, 21], ["staphylococcal enterotoxin B (SEB)", "PROBLEM", 23, 57], ["the bacterium Staphylococcus aureus", "PROBLEM", 71, 106], ["the agent", "TREATMENT", 196, 205], ["Staphylococcus aureus", "OBSERVATION", 85, 106]]], ["Mycotoxins, produced by fungi, include trichothecenes (T-2 toxins), ochratoxin, and aflatoxin.", [["Mycotoxins", "CHEMICAL", 0, 10], ["trichothecenes", "CHEMICAL", 39, 53], ["T-2 toxins", "CHEMICAL", 55, 65], ["ochratoxin", "CHEMICAL", 68, 78], ["aflatoxin", "CHEMICAL", 84, 93], ["Mycotoxins", "CHEMICAL", 0, 10], ["trichothecenes", "CHEMICAL", 39, 53], ["ochratoxin", "CHEMICAL", 68, 78], ["aflatoxin", "CHEMICAL", 84, 93], ["Mycotoxins", "SIMPLE_CHEMICAL", 0, 10], ["T-2 toxins", "SIMPLE_CHEMICAL", 55, 65], ["ochratoxin", "SIMPLE_CHEMICAL", 68, 78], ["aflatoxin", "SIMPLE_CHEMICAL", 84, 93], ["Mycotoxins", "TREATMENT", 0, 10], ["trichothecenes", "TEST", 39, 53], ["ochratoxin", "TREATMENT", 68, 78], ["aflatoxin", "TREATMENT", 84, 93]]], ["Since these are low molecular weight compounds, these toxins result in symptoms more common to chemical agents.", [["low molecular weight compounds", "PROBLEM", 16, 46], ["these toxins", "PROBLEM", 48, 60], ["symptoms", "PROBLEM", 71, 79], ["chemical agents", "TREATMENT", 95, 110], ["low molecular", "OBSERVATION_MODIFIER", 16, 29]]], ["Some T-2 toxins are vesicants (blister agents) 400 times more potent than mustard gas, and their effects are observed in minutes rather than hours or days.", [["blister", "ANATOMY", 31, 38], ["T-2", "GENE_OR_GENE_PRODUCT", 5, 8], ["vesicants", "SIMPLE_CHEMICAL", 20, 29], ["mustard", "SIMPLE_CHEMICAL", 74, 81], ["blister agents", "TREATMENT", 31, 45], ["mustard gas", "TEST", 74, 85]]], ["Antitoxins have been developed for some toxins, although the requirement for rapid administration (e.g., before the onset of symptoms for BoNT) limits their utility in non-prophylactic situations.Culture ::: Current detection methodsCulture is suited to the identification of both bacteria and viruses.", [["Antitoxins", "TREATMENT", 0, 10], ["some toxins", "PROBLEM", 35, 46], ["rapid administration", "TREATMENT", 77, 97], ["symptoms", "PROBLEM", 125, 133], ["Culture", "TEST", 196, 203], ["Current detection methodsCulture", "TEST", 208, 240], ["both bacteria", "PROBLEM", 276, 289], ["viruses", "PROBLEM", 294, 301]]], ["Bacterial cultures are typically grown on a nutrient-containing substrate from clinical or environmental samples, while viral cultures must be grown in host cells.", [["Bacterial cultures", "ANATOMY", 0, 18], ["samples", "ANATOMY", 105, 112], ["cultures", "ANATOMY", 126, 134], ["cells", "ANATOMY", 157, 162], ["Bacterial cultures", "CELL", 0, 18], ["host cells", "CELL", 152, 162], ["host cells", "CELL_TYPE", 152, 162], ["Bacterial cultures", "TEST", 0, 18], ["a nutrient-containing substrate from clinical or environmental samples", "PROBLEM", 42, 112], ["viral cultures", "TEST", 120, 134], ["host cells", "OBSERVATION", 152, 162]]], ["Obtaining a sample that contains the pathogen can be difficult (e.g., bacteria may not be found in the blood in the early stages of the disease and will be absent if a patient has already begun antibiotic treatment), and the difficulty in culturing some agents can generate false negatives [1], [19].", [["sample", "ANATOMY", 12, 18], ["blood", "ANATOMY", 103, 108], ["blood", "ORGANISM_SUBSTANCE", 103, 108], ["patient", "ORGANISM", 168, 175], ["patient", "SPECIES", 168, 175], ["a sample", "TEST", 10, 18], ["the pathogen", "PROBLEM", 33, 45], ["bacteria", "PROBLEM", 70, 78], ["the blood", "PROBLEM", 99, 108], ["the disease", "PROBLEM", 132, 143], ["antibiotic treatment", "TREATMENT", 194, 214], ["the difficulty in culturing", "PROBLEM", 221, 248], ["disease", "OBSERVATION", 136, 143]]], ["Moreover, reaching an identifiable stage of growth can be slow, typically requiring several days.", [["growth", "OBSERVATION", 44, 50], ["slow", "OBSERVATION_MODIFIER", 58, 62]]], ["Some samples are even more extreme; culture of M. tuberculosis, for example, requires nine days or more [26], [27], [28], while Brucella species can take up to three weeks and are isolated from blood with 10\u201390% success [1], [2], [29].", [["samples", "ANATOMY", 5, 12], ["blood", "ANATOMY", 194, 199], ["tuberculosis", "DISEASE", 50, 62], ["M. tuberculosis", "ORGANISM", 47, 62], ["Brucella species", "ORGANISM", 128, 144], ["blood", "ORGANISM_SUBSTANCE", 194, 199], ["M. tuberculosis", "SPECIES", 47, 62], ["M. tuberculosis", "SPECIES", 47, 62], ["Some samples", "TEST", 0, 12], ["culture", "TEST", 36, 43], ["M. tuberculosis", "PROBLEM", 47, 62], ["Brucella species", "PROBLEM", 128, 144], ["blood", "TEST", 194, 199], ["more extreme", "OBSERVATION_MODIFIER", 22, 34], ["tuberculosis", "OBSERVATION", 50, 62]]], ["To further complicate matters, while phenotypic diagnosis via microscopy can be used to identify inclusion bodies from poxvirus infections, this method is insufficient to differentiate individual poxviridae species, meaning that smallpox and the related pox species are indistinguishable by culture.", [["poxvirus infections", "DISEASE", 119, 138], ["smallpox", "DISEASE", 229, 237], ["poxvirus", "ORGANISM", 119, 127], ["pox", "ORGANISM", 254, 257], ["pox", "SPECIES", 254, 257], ["microscopy", "TEST", 62, 72], ["inclusion bodies", "PROBLEM", 97, 113], ["poxvirus infections", "PROBLEM", 119, 138], ["individual poxviridae species", "PROBLEM", 185, 214], ["smallpox", "TREATMENT", 229, 237], ["the related pox species", "PROBLEM", 242, 265], ["culture", "TEST", 291, 298], ["poxvirus", "OBSERVATION_MODIFIER", 119, 127], ["infections", "OBSERVATION", 128, 138], ["pox species", "OBSERVATION", 254, 265]]], ["A final consideration is that many of the bioagents mentioned here are extremely pathogenic, and culturing them can invite substantial risk and may require extensive containment facilities.", [["extremely pathogenic", "PROBLEM", 71, 91], ["extensive containment facilities", "TREATMENT", 156, 188], ["pathogenic", "OBSERVATION", 81, 91]]], ["Examples of cultured B. anthracis and Burkholderia pseudomallei are shown in Fig. 1.Immunoassays ::: Current detection methods", [["B. anthracis", "ORGANISM", 21, 33], ["Burkholderia pseudomallei", "ORGANISM", 38, 63], ["B. anthracis", "SPECIES", 21, 33], ["Burkholderia pseudomallei", "SPECIES", 38, 63], ["B. anthracis", "SPECIES", 21, 33], ["Burkholderia pseudomallei", "SPECIES", 38, 63], ["Burkholderia pseudomallei", "PROBLEM", 38, 63]]]], "e215418a1acf4fbecd49b57a2941584c833bf262": [["Clinical characteristics of children and young people hospitalised with covid-19 in the United Kingdom using the ISARIC WHO Clinical Characterisation Protocol: prospective multicentre observational cohort study Swann OV, Holden, KA, Turtle L et al.Supplementary MethodsReadmissions / transfers NHS / CHI numbers were reviewed for the cohort to allow identification of children who were included more than once.", [["children", "ORGANISM", 28, 36], ["people", "ORGANISM", 47, 53], ["children", "ORGANISM", 368, 376], ["children", "SPECIES", 28, 36], ["people", "SPECIES", 47, 53], ["children", "SPECIES", 368, 376]]], ["In this case, features of the illness at the time of the earliest presentation (observations, blood tests, symptoms) were incorporated into that admission, in order to reflect the earliest state of health of the child during that illness.Supplementary MethodsWHO preliminary case definition for MIS-C, coagulation criteria Prothrombin time (PT) normal reference ranges are age, reagent and analyser-specific (1) .", [["blood", "ANATOMY", 94, 99], ["illness", "DISEASE", 30, 37], ["blood", "ORGANISM_SUBSTANCE", 94, 99], ["child", "ORGANISM", 212, 217], ["MIS-C", "SIMPLE_CHEMICAL", 295, 300], ["Prothrombin", "GENE_OR_GENE_PRODUCT", 323, 334], ["the illness", "PROBLEM", 26, 37], ["blood tests", "TEST", 94, 105], ["symptoms", "PROBLEM", 107, 115], ["MIS", "TEST", 295, 298], ["coagulation criteria", "TEST", 302, 322], ["Prothrombin time", "TEST", 323, 339], ["PT", "TEST", 341, 343], ["analyser", "TEST", 390, 398], ["illness", "OBSERVATION", 30, 37]]], ["Since local reference ranges were unknown, a PT value >14 seconds for term neonates and older children and >16 seconds in preterm neonates was considered above the upper limit of normal based on published neonatal and paediatric cohorts (2) (3) (4) .Recoding of paediatric comorbidity variables:Free text comorbidity information and review of medications on admission was used to enrich and recode children into comorbidity categories more relevant to the paediatric population.", [["neonates", "ORGANISM", 75, 83], ["children", "ORGANISM", 94, 102], ["neonates", "ORGANISM", 130, 138], ["children", "ORGANISM", 398, 406], ["children", "SPECIES", 94, 102], ["children", "SPECIES", 398, 406], ["a PT value", "TEST", 43, 53], ["term neonates", "PROBLEM", 70, 83], ["preterm neonates", "TEST", 122, 138], ["paediatric comorbidity variables", "PROBLEM", 262, 294], ["medications", "TREATMENT", 343, 354], ["upper limit", "OBSERVATION_MODIFIER", 164, 175], ["normal", "OBSERVATION", 179, 185]]], ["Two paediatric clinical reviewers (Authors OVS and LP) matched free-text comorbidity descriptions for all included children against case report form (CRF) coded comorbidities, and created new paediatric categories based on commonly occurring paediatric comorbidities not coded for in the CRF.", [["CRF", "DISEASE", 150, 153], ["CRF", "DISEASE", 288, 291], ["children", "ORGANISM", 115, 123], ["children", "SPECIES", 115, 123], ["LP", "TEST", 51, 53], ["paediatric comorbidities", "PROBLEM", 242, 266], ["the CRF", "PROBLEM", 284, 291]]], ["Revised paediatric comorbidity coding included the generation of categories for genetic, metabolic, neurodisability and other endocrine (excluding diabetes) comorbidities.", [["endocrine", "ANATOMY", 126, 135], ["neurodisability", "DISEASE", 100, 115], ["diabetes", "DISEASE", 147, 155], ["Revised paediatric comorbidity", "PROBLEM", 0, 30], ["diabetes) comorbidities", "PROBLEM", 147, 170]]], ["This free-text review process also highlighted that children had been inconsistently coded into the original haematological and oncological variables, requiring the creation of a combined category for haematological / oncological / immunological diagnoses.Recoding of paediatric comorbidity variables:In a complementary process, recorded medications on admission were reviewed for all included children.", [["haematological", "ANATOMY", 201, 215], ["children", "ORGANISM", 52, 60], ["children", "ORGANISM", 394, 402], ["children", "SPECIES", 52, 60], ["children", "SPECIES", 394, 402], ["haematological / oncological", "TREATMENT", 201, 229], ["medications", "TREATMENT", 338, 349]]], ["Participants were systematically searched for free text entries of medications, or combinations of medications, associated with specific paediatric conditions.", [["Participants", "SPECIES", 0, 12], ["medications", "TREATMENT", 67, 78], ["medications", "TREATMENT", 99, 110]]], ["For example, inhaled corticosteroids or long-acting B2 agonists were considered to imply a diagnosis of asthma unless an alternative respiratory condition was recorded.", [["respiratory", "ANATOMY", 133, 144], ["asthma", "DISEASE", 104, 110], ["corticosteroids", "CHEMICAL", 21, 36], ["long-acting B2 agonists", "SIMPLE_CHEMICAL", 40, 63], ["inhaled corticosteroids", "TREATMENT", 13, 36], ["long-acting B2 agonists", "TREATMENT", 40, 63], ["asthma", "PROBLEM", 104, 110], ["an alternative respiratory condition", "PROBLEM", 118, 154], ["asthma", "OBSERVATION", 104, 110]]], ["Nebulised colomycin was considered to imply a chronic respiratory condition.", [["respiratory", "ANATOMY", 54, 65], ["colomycin", "CHEMICAL", 10, 19], ["colomycin", "CHEMICAL", 10, 19], ["colomycin", "SIMPLE_CHEMICAL", 10, 19], ["Nebulised colomycin", "TREATMENT", 0, 19], ["a chronic respiratory condition", "PROBLEM", 44, 75], ["chronic", "OBSERVATION_MODIFIER", 46, 53], ["respiratory condition", "OBSERVATION", 54, 75]]], ["One child was receiving Orkambi, specific to Cystic Fibrosis.", [["Orkambi", "CHEMICAL", 24, 31], ["Cystic Fibrosis", "DISEASE", 45, 60], ["child", "ORGANISM", 4, 9], ["Orkambi", "TREATMENT", 24, 31], ["Cystic Fibrosis", "PROBLEM", 45, 60], ["Cystic", "OBSERVATION_MODIFIER", 45, 51], ["Fibrosis", "OBSERVATION", 52, 60]]], ["The combination of baclofen and hyoscine was considered to imply neurodisability.", [["baclofen", "CHEMICAL", 19, 27], ["hyoscine", "CHEMICAL", 32, 40], ["neurodisability", "DISEASE", 65, 80], ["baclofen", "CHEMICAL", 19, 27], ["hyoscine", "CHEMICAL", 32, 40], ["baclofen", "SIMPLE_CHEMICAL", 19, 27], ["hyoscine", "SIMPLE_CHEMICAL", 32, 40], ["baclofen", "TREATMENT", 19, 27], ["hyoscine", "TREATMENT", 32, 40]]], ["Similar searches were undertaken for insulins, anti-convulsant, anti-hypertensive and cardiac drugs.", [["cardiac", "ANATOMY", 86, 93], ["anti-convulsant", "SIMPLE_CHEMICAL", 47, 62], ["cardiac", "ORGAN", 86, 93], ["insulins", "TREATMENT", 37, 45], ["anti-convulsant", "TREATMENT", 47, 62], ["anti-hypertensive", "TREATMENT", 64, 81], ["cardiac drugs", "TREATMENT", 86, 99]]], ["Drug combinations were compared against free-text and coded comorbidities, and conditions recoded were necessary.", [["Drug combinations", "TREATMENT", 0, 17], ["coded comorbidities", "PROBLEM", 54, 73]]], ["Searches were also undertaken for any immunosuppressive or immunomodulatory drugs recorded on admission.", [["any immunosuppressive", "TREATMENT", 34, 55], ["immunomodulatory drugs", "TREATMENT", 59, 81]]], ["Results were compared against coding for presence of immunosuppressive drugs and recoded where necessary.Symptom clustering analysis:Hierarchical clustering was used to partition the symptoms in groups such that symptoms within a group tend to appear together.", [["immunosuppressive drugs", "TREATMENT", 53, 76], ["Symptom clustering analysis", "PROBLEM", 105, 132], ["Hierarchical clustering", "PROBLEM", 133, 156], ["the symptoms in groups", "PROBLEM", 179, 201], ["symptoms", "PROBLEM", 212, 220]]], ["This was performed using agglomerative hierarchical clustering, a 'bottom-up' approach, that starts by assigning each symptom to its own group, and then successively merging pair of groups that are closest to each other (5) .", [["a 'bottom-up' approach", "TREATMENT", 64, 86]]], ["'Complete linkage' clustering was used where the distance between two groups is defined as the maximum distance between a pair of symptoms belonging to one group each.", [["Complete linkage' clustering", "TREATMENT", 1, 29], ["symptoms", "PROBLEM", 130, 138], ["maximum", "OBSERVATION_MODIFIER", 95, 102]]], ["The distance between two symptoms was characterised by Jaccard distance where Jaccard distance is calculated by subtracting the Jaccard index from 1 (6) .", [["The distance between two symptoms", "PROBLEM", 0, 33], ["the Jaccard index", "TEST", 124, 141], ["distance", "OBSERVATION_MODIFIER", 4, 12]]], ["Jaccard index is a measure of similarity that computes the ratio of the number of times two symptoms appear together in the data and the number of times either of them appears in the data.", [["Jaccard index", "TEST", 0, 13], ["two symptoms", "PROBLEM", 88, 100]]], ["The index varies between 0 and 1 with 0 implying that the two symptoms never appear together (no co-occurrence), and 1 implying that the two symptoms only appear together (cooccurrence only).", [["The index varies", "TEST", 0, 16], ["the two symptoms", "PROBLEM", 54, 70], ["the two symptoms", "PROBLEM", 133, 149], ["index", "OBSERVATION_MODIFIER", 4, 9]]], ["The result of hierarchical clustering was summarised using dendrogram which shows how the groups were merged together starting from individual symptoms, and the relative distances among these groups (shown as height).", [["hierarchical clustering", "PROBLEM", 14, 37], ["individual symptoms", "PROBLEM", 132, 151], ["hierarchical", "OBSERVATION_MODIFIER", 14, 26]]], ["A threshold can be applied on the distance between groups to choose a specific number of clusters.", [["A threshold", "TREATMENT", 0, 11]]], ["The optimal number of clusters was chosen using average silhouette index which measures the separation among clusters, i.e., a higher average silhouette index is better (7) .", [["average silhouette index", "TEST", 48, 72], ["a higher average silhouette index", "PROBLEM", 125, 158], ["optimal", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18], ["clusters", "OBSERVATION_MODIFIER", 22, 30], ["separation", "OBSERVATION_MODIFIER", 92, 102], ["clusters", "OBSERVATION_MODIFIER", 109, 117], ["higher", "OBSERVATION_MODIFIER", 127, 133], ["average", "OBSERVATION_MODIFIER", 134, 141], ["silhouette", "OBSERVATION_MODIFIER", 142, 152], ["index", "OBSERVATION_MODIFIER", 153, 158]]], ["The optimal number of clusters were found to be 4 (see Figure A) for 20 symptoms.", [["20 symptoms", "PROBLEM", 69, 80]]], ["We included symptoms with >2% prevalence across the cohort, and therefore, bleeding (1.69%, 11/651) and ear pain (1.23%, 8/651) were excluded from the analysis.Symptom clustering analysis:Bootstrapping was performed to assess the stability of the clustering, i.e., the generation of 1000 new datasets of the same size by resampling the original dataset with replacement.", [["ear", "ANATOMY", 104, 107], ["bleeding", "DISEASE", 75, 83], ["ear pain", "DISEASE", 104, 112], ["ear", "ORGAN", 104, 107], ["symptoms", "PROBLEM", 12, 20], ["bleeding", "PROBLEM", 75, 83], ["ear pain", "PROBLEM", 104, 112], ["the analysis", "TEST", 147, 159], ["Bootstrapping", "TEST", 188, 201], ["replacement", "TREATMENT", 358, 369], ["bleeding", "OBSERVATION", 75, 83], ["ear", "ANATOMY", 104, 107], ["pain", "OBSERVATION", 108, 112], ["size", "OBSERVATION_MODIFIER", 313, 317], ["replacement", "OBSERVATION", 358, 369]]], ["The optimal number of clusters was computed in the resampled data and 4 clusters was observed to be most frequent (see Figure B ).", [["clusters", "OBSERVATION_MODIFIER", 22, 30]]], ["The cluster assignment of a pair of symptoms was checked over 1000 bootstraps assuming there are 4 clusters in each and observed that the same pair of symptoms are usually put in the same cluster random samples (see Figure C) .", [["a pair of symptoms", "PROBLEM", 26, 44], ["symptoms", "PROBLEM", 151, 159]]], ["The average adjusted Rand index between cluster assignments on the original data and that in a bootstrap is 0.56 (where adjusted Rand index of 0 implies that the two cluster assignments are independent, and 1 implies that they are the same (8)).", [["a bootstrap", "TEST", 93, 104], ["Rand index", "TEST", 129, 139]]], ["The clustering of the original data is presented in Figure 1 in the main text.", [["main", "OBSERVATION_MODIFIER", 68, 72]]], ["These analyses were performed in R using packages dendextend, mclust and gplots.", [["These analyses", "TEST", 0, 14]]], ["Figure 1 in the main text.", [["main", "OBSERVATION_MODIFIER", 16, 20]]], ["The fourth cluster (chest pain and joint pain) was a lose association.Symptoms by age groupWe plotted symptoms on admission against age (in 5-year bands) and used chi-square tests for trend to investigate how these varied.", [["chest", "ANATOMY", 20, 25], ["joint", "ANATOMY", 35, 40], ["chest pain", "DISEASE", 20, 30], ["pain", "DISEASE", 41, 45], ["chest", "ORGANISM_SUBDIVISION", 20, 25], ["joint", "ORGANISM_SUBDIVISION", 35, 40], ["The fourth cluster (chest pain", "PROBLEM", 0, 30], ["joint pain", "PROBLEM", 35, 45], ["Symptoms", "PROBLEM", 70, 78], ["plotted symptoms", "PROBLEM", 94, 110], ["chi-square tests", "TEST", 163, 179], ["fourth", "OBSERVATION_MODIFIER", 4, 10], ["cluster", "OBSERVATION_MODIFIER", 11, 18], ["chest", "ANATOMY", 20, 25], ["joint", "ANATOMY", 35, 40]]], ["We grouped symptoms according to two sets of clinical case definitions based on those in use in the United Kingdom (9): fever with at least one of cough, nasal discharge or congestion, shortness of breath, sore throat, or wheezing; and either cough or fever.Symptoms by age groupFurther information on MIS-C cases:Symptoms by age groupInformation on intravenous immunoglobulin use and immunomodulatory therapy was not routinely collected using the CRF.", [["nasal", "ANATOMY", 154, 159], ["intravenous", "ANATOMY", 350, 361], ["fever", "DISEASE", 120, 125], ["cough", "DISEASE", 147, 152], ["congestion", "DISEASE", 173, 183], ["shortness of breath", "DISEASE", 185, 204], ["sore throat", "DISEASE", 206, 217], ["wheezing", "DISEASE", 222, 230], ["cough", "DISEASE", 243, 248], ["fever", "DISEASE", 252, 257], ["CRF", "DISEASE", 448, 451], ["nasal", "ORGANISM_SUBDIVISION", 154, 159], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 350, 361], ["immunoglobulin", "SIMPLE_CHEMICAL", 362, 376], ["immunoglobulin", "PROTEIN", 362, 376], ["grouped symptoms", "PROBLEM", 3, 19], ["fever", "PROBLEM", 120, 125], ["cough", "PROBLEM", 147, 152], ["nasal discharge", "PROBLEM", 154, 169], ["congestion", "PROBLEM", 173, 183], ["shortness of breath", "PROBLEM", 185, 204], ["sore throat", "PROBLEM", 206, 217], ["wheezing", "PROBLEM", 222, 230], ["cough", "PROBLEM", 243, 248], ["fever", "PROBLEM", 252, 257], ["Symptoms", "PROBLEM", 258, 266], ["Symptoms", "PROBLEM", 314, 322], ["intravenous immunoglobulin use", "TREATMENT", 350, 380], ["immunomodulatory therapy", "TREATMENT", 385, 409], ["the CRF", "PROBLEM", 444, 451], ["nasal", "ANATOMY", 154, 159], ["congestion", "OBSERVATION", 173, 183], ["wheezing", "OBSERVATION", 222, 230], ["cough", "OBSERVATION", 243, 248]]], ["As such, when patients met the criteria for MIS-C, the recruiting centre was contacted directly to request this information.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22]]], ["As such, these variables were only available for children who met the MIS-C criteria and not across the whole cohort.Co-infections in Multisystem Inflammatory Syndrome in Children and Adolescents (MIS-C)Available data on tests for other infectious diseases were reviewed for the children meeting the Multisystem Inflammatory Syndrome in Children and Adolescents (MIS-C) and those with significant growth on blood or cerebrospinal fluid culture were excluded.Co-infections in Multisystem Inflammatory Syndrome in Children and Adolescents (MIS-C)The following positive results were documented in the 52 remaining children:Co-infections in Multisystem Inflammatory Syndrome in Children and Adolescents (MIS-C)-Supplementary TablesSupp Table ASupp Table N. Comorbidities stratified by Multisystem Inflammatory Disease in Children and Adolescents (MIS-C).", [["blood", "ANATOMY", 407, 412], ["cerebrospinal fluid", "ANATOMY", 416, 435], ["Co-infections", "DISEASE", 117, 130], ["Multisystem Inflammatory Syndrome", "DISEASE", 134, 167], ["infectious diseases", "DISEASE", 237, 256], ["Inflammatory Syndrome", "DISEASE", 312, 333], ["Co-infections", "DISEASE", 458, 471], ["Multisystem Inflammatory Syndrome", "DISEASE", 475, 508], ["Co-infections", "DISEASE", 620, 633], ["Multisystem Inflammatory Syndrome", "DISEASE", 637, 670], ["Inflammatory Disease", "DISEASE", 793, 813], ["children", "ORGANISM", 49, 57], ["children", "ORGANISM", 279, 287], ["blood", "ORGANISM_SUBSTANCE", 407, 412], ["cerebrospinal", "ORGANISM_SUBSTANCE", 416, 429], ["children", "ORGANISM", 611, 619], ["children", "SPECIES", 49, 57], ["Children", "SPECIES", 171, 179], ["children", "SPECIES", 279, 287], ["Children", "SPECIES", 337, 345], ["Children", "SPECIES", 512, 520], ["children", "SPECIES", 611, 619], ["Children", "SPECIES", 674, 682], ["Children", "SPECIES", 817, 825], ["Co-infections", "PROBLEM", 117, 130], ["Multisystem Inflammatory Syndrome", "PROBLEM", 134, 167], ["tests", "TEST", 221, 226], ["other infectious diseases", "PROBLEM", 231, 256], ["the Multisystem Inflammatory Syndrome", "PROBLEM", 296, 333], ["significant growth", "PROBLEM", 385, 403], ["blood or cerebrospinal fluid culture", "TEST", 407, 443], ["Co-infections", "PROBLEM", 458, 471], ["Multisystem Inflammatory Syndrome", "PROBLEM", 475, 508], ["Multisystem Inflammatory Syndrome", "PROBLEM", 637, 670], ["Multisystem Inflammatory Disease", "PROBLEM", 781, 813], ["Multisystem", "OBSERVATION_MODIFIER", 134, 145], ["Inflammatory Syndrome", "OBSERVATION", 146, 167], ["Multisystem", "OBSERVATION_MODIFIER", 300, 311], ["Inflammatory Syndrome", "OBSERVATION", 312, 333], ["significant", "OBSERVATION_MODIFIER", 385, 396], ["growth", "OBSERVATION_MODIFIER", 397, 403], ["cerebrospinal", "ANATOMY", 416, 429], ["Multisystem", "OBSERVATION_MODIFIER", 475, 486], ["Inflammatory Syndrome", "OBSERVATION", 487, 508], ["Multisystem", "OBSERVATION_MODIFIER", 637, 648], ["Inflammatory Syndrome", "OBSERVATION", 649, 670], ["Multisystem", "OBSERVATION_MODIFIER", 781, 792], ["Inflammatory Disease", "OBSERVATION", 793, 813]]], ["Immunosuppressant use includes oral but not inhaled steroids.", [["oral", "ANATOMY", 31, 35], ["steroids", "CHEMICAL", 52, 60], ["steroids", "CHEMICAL", 52, 60], ["oral", "ORGANISM_SUBDIVISION", 31, 35], ["Immunosuppressant use", "TREATMENT", 0, 21], ["oral", "TREATMENT", 31, 35], ["inhaled steroids", "TREATMENT", 44, 60]]], ["Prematurity = born < 37 weeks gestation.", [["Prematurity", "DISEASE", 0, 11], ["Prematurity", "PROBLEM", 0, 11]]], ["Analysis byFisher's exact test.", [["Analysis byFisher's exact test", "TEST", 0, 30]]]], "dfecd0326d12adc820a764de98db9addf7c2bd68": [["The major motor activity consists of generalized tonic movements of the limbs in extension with purposeless limb movement and paddling, almost as if they were running in place.", [["limbs", "ANATOMY", 72, 77], ["limb", "ANATOMY", 108, 112], ["limbs", "ORGANISM_SUBDIVISION", 72, 77], ["limb", "ORGANISM_SUBDIVISION", 108, 112], ["generalized tonic movements of the limbs in extension", "PROBLEM", 37, 90], ["paddling", "TREATMENT", 126, 134], ["major", "OBSERVATION_MODIFIER", 4, 9], ["motor activity", "OBSERVATION", 10, 24], ["generalized", "OBSERVATION_MODIFIER", 37, 48], ["tonic movements", "OBSERVATION", 49, 64], ["limbs", "ANATOMY", 72, 77], ["limb", "ANATOMY", 108, 112], ["movement", "OBSERVATION", 113, 121]]], ["Opisthotonos and claw extension as well as mouthchomping and pupillary dilation may occur.", [["claw", "ANATOMY", 17, 21], ["claw", "ORGANISM_SUBDIVISION", 17, 21], ["claw extension", "PROBLEM", 17, 31], ["mouthchomping", "TREATMENT", 43, 56], ["pupillary dilation", "PROBLEM", 61, 79], ["claw extension", "OBSERVATION", 17, 31], ["pupillary dilation", "OBSERVATION", 61, 79]]], ["At times, tonic flexion (emprosthotonus) is observed} These movements can be followed by moderate to severe muscle twitching (clonic phase).", [["muscle", "ANATOMY", 108, 114], ["muscle twitching", "DISEASE", 108, 124], ["muscle", "ORGAN", 108, 114], ["tonic flexion (emprosthotonus)", "PROBLEM", 10, 40], ["moderate to severe muscle twitching (clonic phase", "PROBLEM", 89, 138], ["moderate", "OBSERVATION_MODIFIER", 89, 97], ["severe", "OBSERVATION_MODIFIER", 101, 107], ["muscle", "ANATOMY", 108, 114], ["twitching", "OBSERVATION", 115, 124]]], ["During clonic seizures, the cat may or may not lose consciousness.", [["seizures", "DISEASE", 14, 22], ["cat", "ORGANISM", 28, 31], ["clonic seizures", "PROBLEM", 7, 22]]], ["During this activity, the cat may jump into the air violently as if thrown and may be quite aggressive and agitated.", [["cat", "ORGANISM", 26, 29], ["agitated", "PROBLEM", 107, 115], ["air", "ANATOMY", 48, 51]]], ["Autonomic release (urination and defecation) usually accompanies the motor activity as well as facial twitching, salivation, kicking, piloerection and chewing} The post-lctal period is similar to that described in the canine.", [["facial", "ANATOMY", 95, 101], ["salivation", "DISEASE", 113, 123], ["piloerection", "DISEASE", 134, 146], ["canine", "ORGANISM", 218, 224], ["canine", "SPECIES", 218, 224], ["Autonomic release (urination and defecation", "PROBLEM", 0, 43], ["facial twitching", "PROBLEM", 95, 111], ["salivation", "PROBLEM", 113, 123], ["facial", "ANATOMY", 95, 101], ["twitching", "OBSERVATION", 102, 111]]]], "PMC7138175": [["Missed or delayed diagnosisMost current recommendations for SARS-CoV-2 screening aim at limiting diagnostic testing to symptomatic, high-risk patients; others are instructed to self-isolation/quarantine.", [["SARS", "DISEASE", 60, 64], ["patients", "ORGANISM", 142, 150], ["patients", "SPECIES", 142, 150], ["SARS", "PROBLEM", 60, 64], ["CoV", "TEST", 65, 68], ["diagnostic testing", "TEST", 97, 115]]], ["Full blood counts will be performed only in patients with signs of severity and confirmed SARS-CoV-2 infection.", [["blood", "ANATOMY", 5, 10], ["SARS-CoV-2 infection", "DISEASE", 90, 110], ["blood", "ORGANISM_SUBSTANCE", 5, 10], ["patients", "ORGANISM", 44, 52], ["CoV-2", "ORGANISM", 95, 100], ["patients", "SPECIES", 44, 52], ["SARS-CoV-2", "SPECIES", 90, 100], ["Full blood counts", "TEST", 0, 17], ["severity", "PROBLEM", 67, 75], ["SARS", "PROBLEM", 90, 94], ["CoV", "PROBLEM", 95, 98], ["2 infection", "PROBLEM", 99, 110], ["infection", "OBSERVATION", 101, 110]]], ["As 50\u201375 % of patients with acute leukemia are febrile at diagnosis [3], they are at high risk of missed or delayed diagnosis.", [["acute leukemia", "ANATOMY", 28, 42], ["acute leukemia", "DISEASE", 28, 42], ["febrile", "DISEASE", 47, 54], ["patients", "ORGANISM", 14, 22], ["acute leukemia", "CANCER", 28, 42], ["patients", "SPECIES", 14, 22], ["acute leukemia", "PROBLEM", 28, 42], ["febrile", "PROBLEM", 47, 54], ["acute", "OBSERVATION_MODIFIER", 28, 33], ["leukemia", "OBSERVATION", 34, 42]]], ["This also applies to other oncological conditions such as primary mediastinal lymphoma or lung cancer, which often present with a cough with or without fever, symptoms that are likely to be considered trivial after a negative SARS-CoV-2 test.Delay or deferral in chemotherapyIn addition to diagnosis delay, most patients may suffer from postponed chemotherapy, due to a shortage of isolation beds and blood products or the wish to avoid immunosuppressive treatments.", [["primary mediastinal lymphoma", "ANATOMY", 58, 86], ["lung cancer", "ANATOMY", 90, 101], ["blood", "ANATOMY", 401, 406], ["primary mediastinal lymphoma", "DISEASE", 58, 86], ["lung cancer", "DISEASE", 90, 101], ["cough", "DISEASE", 130, 135], ["fever", "DISEASE", 152, 157], ["mediastinal lymphoma", "CANCER", 66, 86], ["lung cancer", "CANCER", 90, 101], ["patients", "ORGANISM", 312, 320], ["blood", "ORGANISM_SUBSTANCE", 401, 406], ["patients", "SPECIES", 312, 320], ["other oncological conditions", "PROBLEM", 21, 49], ["primary mediastinal lymphoma", "PROBLEM", 58, 86], ["lung cancer", "PROBLEM", 90, 101], ["a cough", "PROBLEM", 128, 135], ["fever", "PROBLEM", 152, 157], ["symptoms", "PROBLEM", 159, 167], ["CoV-2 test", "TEST", 231, 241], ["deferral in chemotherapy", "TREATMENT", 251, 275], ["chemotherapy", "TREATMENT", 347, 359], ["isolation beds", "TREATMENT", 382, 396], ["blood products", "TREATMENT", 401, 415], ["immunosuppressive treatments", "TREATMENT", 437, 465], ["mediastinal", "ANATOMY", 66, 77], ["lymphoma", "OBSERVATION", 78, 86], ["lung", "ANATOMY", 90, 94], ["cancer", "OBSERVATION", 95, 101]]], ["Delay in chemotherapy initiation may negatively affect prognosis, particularly in young (<60 years-old) patients with favorable- or intermediate-risk disease.", [["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["chemotherapy initiation", "TREATMENT", 9, 32], ["intermediate-risk disease", "PROBLEM", 132, 157], ["risk disease", "OBSERVATION", 145, 157]]], ["Indeed, they could progress to high-risk disease following the acquisition of additional genetic anomalies, and hyperleukocytosis (or increased blasts count in MDS) [4,5].", [["blasts", "ANATOMY", 144, 150], ["genetic anomalies", "DISEASE", 89, 106], ["hyperleukocytosis", "DISEASE", 112, 129], ["MDS", "DISEASE", 160, 163], ["blasts", "CELL", 144, 150], ["high-risk disease", "PROBLEM", 31, 48], ["additional genetic anomalies", "PROBLEM", 78, 106], ["hyperleukocytosis", "PROBLEM", 112, 129], ["increased blasts count", "PROBLEM", 134, 156], ["MDS", "PROBLEM", 160, 163], ["hyperleukocytosis", "OBSERVATION", 112, 129]]], ["More treatments may then be needed to achieve a deep complete remission before allogeneic stem cell transplantation.Delay or deferral in hematopoietic stem cell transplantation (HSCT)Hematopoietic stem cell transplantation is particularly affected by the COVID-19 pandemic, as both donor and recipient must be healthy for the procedure to be feasible and successful.", [["stem cell", "ANATOMY", 90, 99], ["hematopoietic stem cell", "ANATOMY", 137, 160], ["HSCT", "ANATOMY", 178, 182], ["Hematopoietic stem cell", "ANATOMY", 183, 206], ["stem cell", "CELL", 90, 99], ["hematopoietic stem cell", "CELL", 137, 160], ["Hematopoietic stem cell", "CELL", 183, 206], ["a deep complete remission", "TREATMENT", 46, 71], ["allogeneic stem cell transplantation", "TREATMENT", 79, 115], ["hematopoietic stem cell transplantation", "TREATMENT", 137, 176], ["Hematopoietic stem cell transplantation", "TREATMENT", 183, 222], ["the COVID", "TEST", 251, 260], ["the procedure", "TREATMENT", 322, 335], ["allogeneic stem cell transplantation", "OBSERVATION", 79, 115], ["hematopoietic stem cell transplantation", "OBSERVATION", 137, 176], ["Hematopoietic stem cell transplantation", "OBSERVATION", 183, 222]]], ["Delays in the identification of compatible donors are expected and represent a particular challenge when siblings are abroad.", [["donors", "ORGANISM", 43, 49]]], ["The use of home swab kits is a vital resource to enable HLA testing, particularly when access to hospitals for family is restricted.", [["home swab kits", "TREATMENT", 11, 25], ["HLA testing", "TEST", 56, 67]]], ["All future donors need to be tested for COVID-19.", [["COVID-19", "CHEMICAL", 40, 48], ["donors", "ORGANISM", 11, 17], ["All future donors", "TREATMENT", 0, 17], ["COVID", "TEST", 40, 45]]], ["Deferring allogeneic HSCT is recommended if possible; however, transmission from donor to recipient, either in the transfusion of blood products or cellular therapies, has not been yet reported [8].", [["blood", "ANATOMY", 130, 135], ["cellular", "ANATOMY", 148, 156], ["blood", "ORGANISM_SUBSTANCE", 130, 135], ["cellular", "CELL", 148, 156], ["allogeneic HSCT", "TREATMENT", 10, 25], ["blood products", "TREATMENT", 130, 144], ["cellular therapies", "TREATMENT", 148, 166]]], ["Literature data on the impact of delayed transplant is ambiguous, obscured by differences in stem cell source and disease subtype.", [["stem cell", "ANATOMY", 93, 102], ["stem cell", "CELL", 93, 102], ["Literature data", "TEST", 0, 15], ["delayed transplant", "TREATMENT", 33, 51], ["disease subtype", "PROBLEM", 114, 129], ["transplant", "OBSERVATION", 41, 51], ["stem cell source", "OBSERVATION", 93, 109]]], ["However, if a delay in transplant results in the reappearance of a significant minimal residual disease (MRD), a negative impact on survival is well established [9].", [["MRD", "DISEASE", 105, 108], ["a delay in transplant", "PROBLEM", 12, 33], ["a significant minimal residual disease", "PROBLEM", 65, 103], ["significant", "OBSERVATION_MODIFIER", 67, 78], ["minimal", "OBSERVATION_MODIFIER", 79, 86], ["residual", "OBSERVATION_MODIFIER", 87, 95], ["disease", "OBSERVATION", 96, 103]]], ["Furthermore, to ensure the possibility of the graft, EBMT strongly recommends securing stem cell product by freezing HSCs prior to conditioning, or to have a back-up donor [7].", [["graft", "ANATOMY", 46, 51], ["stem cell", "ANATOMY", 87, 96], ["HSCs", "ANATOMY", 117, 121], ["graft", "TISSUE", 46, 51], ["stem cell", "CELL", 87, 96], ["HSCs", "CELL", 117, 121], ["HSCs", "CELL_TYPE", 117, 121], ["the graft", "TREATMENT", 42, 51], ["securing stem cell product", "TREATMENT", 78, 104], ["a back-up donor", "TREATMENT", 156, 171], ["graft", "OBSERVATION", 46, 51]]], ["It is not presently known if cryo-conservation would negatively impact engraftment success; the use of less favorable stem cell sources in case of optimal donor unavailability might.Shortfall of blood productsBlood products shortage has already begun in most affected countries.", [["stem cell", "ANATOMY", 118, 127], ["blood", "ANATOMY", 195, 200], ["Blood", "ANATOMY", 209, 214], ["stem cell", "CELL", 118, 127], ["blood", "ORGANISM_SUBSTANCE", 195, 200], ["Blood", "ORGANISM_SUBSTANCE", 209, 214], ["blood products", "PROTEIN", 195, 209], ["blood products", "TREATMENT", 195, 209], ["Blood products shortage", "TREATMENT", 209, 232], ["stem cell sources", "OBSERVATION", 118, 135], ["blood products", "OBSERVATION", 195, 209]]], ["Volunteer donors are desisting due to self-isolation, travel restriction and fear of virus transmission.", [["donors", "ORGANISM", 10, 16], ["self-isolation", "TREATMENT", 38, 52], ["travel restriction", "TREATMENT", 54, 72], ["virus transmission", "PROBLEM", 85, 103], ["virus", "OBSERVATION", 85, 90]]], ["Furthermore, cautious eviction of any symptomatic donor is applied; whereas conditions for safely resuming donation after a suspect or confirmed SARS-CoV-2 infection are uncertain.", [["SARS-CoV-2 infection", "DISEASE", 145, 165], ["SARS-CoV-2", "ORGANISM", 145, 155], ["any symptomatic donor", "PROBLEM", 34, 55], ["SARS", "PROBLEM", 145, 149], ["CoV-2 infection", "PROBLEM", 150, 165], ["infection", "OBSERVATION", 156, 165]]], ["Cancellation of elective surgery, and to a lesser extent, cessation of activities with confinement, help to reduce the need for blood products.", [["blood", "ANATOMY", 128, 133], ["blood", "ORGANISM_SUBSTANCE", 128, 133], ["elective surgery", "TREATMENT", 16, 32], ["blood products", "TREATMENT", 128, 142], ["elective", "OBSERVATION_MODIFIER", 16, 24], ["surgery", "OBSERVATION", 25, 32], ["lesser extent", "OBSERVATION_MODIFIER", 43, 56]]], ["Nonetheless, most transfusion societies call for conservative transfusions policies in strict adherence to evidence-based guidelines for patient\u2019s blood management [10].Interruption of maintenance therapyMost treatment protocols for acute lymphoblastic leukemia (ALL) include up to two years of maintenance therapy [11].", [["blood", "ANATOMY", 147, 152], ["acute lymphoblastic leukemia", "ANATOMY", 233, 261], ["ALL", "ANATOMY", 263, 266], ["acute lymphoblastic leukemia", "DISEASE", 233, 261], ["ALL", "DISEASE", 263, 266], ["patient", "ORGANISM", 137, 144], ["blood", "ORGANISM_SUBSTANCE", 147, 152], ["acute lymphoblastic leukemia", "CANCER", 233, 261], ["ALL", "CANCER", 263, 266], ["patient", "SPECIES", 137, 144], ["conservative transfusions policies", "TREATMENT", 49, 83], ["patient\u2019s blood management", "TREATMENT", 137, 163], ["maintenance therapy", "TREATMENT", 185, 204], ["Most treatment protocols", "TREATMENT", 204, 228], ["acute lymphoblastic leukemia", "PROBLEM", 233, 261], ["maintenance therapy", "TREATMENT", 295, 314], ["acute", "OBSERVATION_MODIFIER", 233, 238], ["lymphoblastic leukemia", "OBSERVATION", 239, 261]]], ["As of March 19th, GRAALL-14 investigators instruct physicians to omit vincristine and prednisone in maintenance therapy whilst continuing 6-mercapto-purine and methotrexate.", [["vincristine", "CHEMICAL", 70, 81], ["prednisone", "CHEMICAL", 86, 96], ["6-mercapto-purine", "CHEMICAL", 138, 155], ["methotrexate", "CHEMICAL", 160, 172], ["vincristine", "CHEMICAL", 70, 81], ["prednisone", "CHEMICAL", 86, 96], ["6-mercapto-purine", "CHEMICAL", 138, 155], ["methotrexate", "CHEMICAL", 160, 172], ["vincristine", "SIMPLE_CHEMICAL", 70, 81], ["prednisone", "SIMPLE_CHEMICAL", 86, 96], ["6-mercapto-purine", "SIMPLE_CHEMICAL", 138, 155], ["methotrexate", "SIMPLE_CHEMICAL", 160, 172], ["vincristine", "TREATMENT", 70, 81], ["prednisone", "TREATMENT", 86, 96], ["maintenance therapy", "TREATMENT", 100, 119], ["continuing 6-mercapto-purine", "TREATMENT", 127, 155], ["methotrexate", "TREATMENT", 160, 172]]], ["The impact on patient survival and relapse rate of dose-reduction and/or drug eviction is not known.Targeted therapiesRecently, the therapeutic landscape has evolved towards targeted therapies.", [["patient", "ORGANISM", 14, 21], ["patient", "SPECIES", 14, 21], ["patient survival", "TREATMENT", 14, 30], ["relapse rate of dose-reduction", "TREATMENT", 35, 65], ["targeted therapies", "TREATMENT", 174, 192], ["therapeutic landscape", "OBSERVATION", 132, 153]]], ["They are used in addition to standard chemotherapy in fit patients, or as monotherapy in frail patients.", [["patients", "ORGANISM", 58, 66], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 58, 66], ["patients", "SPECIES", 95, 103], ["standard chemotherapy", "TREATMENT", 29, 50], ["monotherapy", "TREATMENT", 74, 85]]], ["The first breakthrough in AML therapy was represented by the approval of midostaurin for FLT3\u2010mutated AML [12].", [["AML", "ANATOMY", 26, 29], ["AML", "ANATOMY", 102, 105], ["AML", "DISEASE", 26, 29], ["midostaurin", "CHEMICAL", 73, 84], ["AML", "DISEASE", 102, 105], ["midostaurin", "CHEMICAL", 73, 84], ["AML", "CANCER", 26, 29], ["midostaurin", "SIMPLE_CHEMICAL", 73, 84], ["FLT3", "GENE_OR_GENE_PRODUCT", 89, 93], ["FLT3", "PROTEIN", 89, 93], ["AML therapy", "TREATMENT", 26, 37], ["midostaurin", "TREATMENT", 73, 84], ["FLT3\u2010mutated AML", "TREATMENT", 89, 105], ["breakthrough", "OBSERVATION_MODIFIER", 10, 22], ["AML therapy", "OBSERVATION", 26, 37]]], ["Princeps study, in addition to chemotherapy backbone, showed no difference in infectious complications or neutropenia [12].", [["neutropenia", "DISEASE", 106, 117], ["Princeps study", "TEST", 0, 14], ["chemotherapy backbone", "TREATMENT", 31, 52], ["difference in infectious complications", "PROBLEM", 64, 102], ["neutropenia", "PROBLEM", 106, 117], ["no", "UNCERTAINTY", 61, 63], ["infectious", "OBSERVATION_MODIFIER", 78, 88], ["neutropenia", "OBSERVATION", 106, 117]]], ["The next\u2010generation, more potent and selective FLT3 inhibitors quizartinib, crenolanib, gilteritinib are under clinical evaluation, showing similar profiles.Targeted therapiesIsocitrate dehydrogenase (IDH) inhibitors, ivosidenib or enasidenib may be active, in AML with IDH1 or IDH2 mutations, respectively [13].", [["AML", "ANATOMY", 261, 264], ["quizartinib", "CHEMICAL", 63, 74], ["crenolanib", "CHEMICAL", 76, 86], ["gilteritinib", "CHEMICAL", 88, 100], ["ivosidenib", "CHEMICAL", 218, 228], ["enasidenib", "CHEMICAL", 232, 242], ["AML", "DISEASE", 261, 264], ["quizartinib", "CHEMICAL", 63, 74], ["crenolanib", "CHEMICAL", 76, 86], ["gilteritinib", "CHEMICAL", 88, 100], ["ivosidenib", "CHEMICAL", 218, 228], ["enasidenib", "CHEMICAL", 232, 242], ["FLT3", "GENE_OR_GENE_PRODUCT", 47, 51], ["quizartinib", "SIMPLE_CHEMICAL", 63, 74], ["crenolanib", "SIMPLE_CHEMICAL", 76, 86], ["gilteritinib", "SIMPLE_CHEMICAL", 88, 100], ["therapiesIsocitrate dehydrogenase", "GENE_OR_GENE_PRODUCT", 166, 199], ["IDH", "GENE_OR_GENE_PRODUCT", 201, 204], ["ivosidenib", "SIMPLE_CHEMICAL", 218, 228], ["enasidenib", "SIMPLE_CHEMICAL", 232, 242], ["AML", "CANCER", 261, 264], ["IDH1", "GENE_OR_GENE_PRODUCT", 270, 274], ["IDH2", "GENE_OR_GENE_PRODUCT", 278, 282], ["therapiesIsocitrate dehydrogenase", "PROTEIN", 166, 199], ["IDH", "PROTEIN", 201, 204], ["selective FLT3 inhibitors quizartinib", "TREATMENT", 37, 74], ["crenolanib", "TREATMENT", 76, 86], ["gilteritinib", "TREATMENT", 88, 100], ["clinical evaluation", "TEST", 111, 130], ["Targeted therapiesIsocitrate dehydrogenase (IDH) inhibitors", "TREATMENT", 157, 216], ["ivosidenib", "TREATMENT", 218, 228], ["enasidenib", "TREATMENT", 232, 242], ["AML", "PROBLEM", 261, 264], ["IDH1", "PROBLEM", 270, 274], ["IDH2 mutations", "PROBLEM", 278, 292], ["active", "OBSERVATION_MODIFIER", 250, 256]]], ["Both inhibitors act as differentiating agents with the occurrence, in 10\u201320 % of patients, of a differentiation syndrome, which requires prompt corticosteroid administration and often intensive care support.", [["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["Both inhibitors", "TREATMENT", 0, 15], ["a differentiation syndrome", "PROBLEM", 94, 120], ["prompt corticosteroid administration", "TREATMENT", 137, 173], ["often intensive care support", "TREATMENT", 178, 206], ["differentiation syndrome", "OBSERVATION", 96, 120]]], ["No information is yet available on the risk of severe respiratory failure in patients treated with these agents and exposed to SARS-CoV-2.Targeted therapiesSimilar severe respiratory adverse effects frequently occur in patients with promyelocytic leukemia treated with arsenic trioxide (ATO) and all-trans retinoic acid (ATRA), in the absence of chemotherapy.", [["respiratory", "ANATOMY", 54, 65], ["respiratory", "ANATOMY", 171, 182], ["promyelocytic leukemia", "ANATOMY", 233, 255], ["respiratory failure", "DISEASE", 54, 73], ["SARS", "DISEASE", 127, 131], ["promyelocytic leukemia", "DISEASE", 233, 255], ["arsenic trioxide", "CHEMICAL", 269, 285], ["ATO", "CHEMICAL", 287, 290], ["all-trans retinoic acid", "CHEMICAL", 296, 319], ["ATRA", "CHEMICAL", 321, 325], ["arsenic trioxide", "CHEMICAL", 269, 285], ["ATO", "CHEMICAL", 287, 290], ["all-trans retinoic acid", "CHEMICAL", 296, 319], ["ATRA", "CHEMICAL", 321, 325], ["patients", "ORGANISM", 77, 85], ["SARS-CoV-2", "ORGANISM", 127, 137], ["patients", "ORGANISM", 219, 227], ["promyelocytic leukemia", "CANCER", 233, 255], ["arsenic trioxide", "SIMPLE_CHEMICAL", 269, 285], ["ATO", "SIMPLE_CHEMICAL", 287, 290], ["all-trans retinoic acid", "SIMPLE_CHEMICAL", 296, 319], ["ATRA", "SIMPLE_CHEMICAL", 321, 325], ["patients", "SPECIES", 77, 85], ["patients", "SPECIES", 219, 227], ["SARS-CoV", "SPECIES", 127, 135], ["severe respiratory failure", "PROBLEM", 47, 73], ["these agents", "TREATMENT", 99, 111], ["CoV", "TEST", 132, 135], ["Targeted therapiesSimilar severe respiratory adverse effects", "PROBLEM", 138, 198], ["promyelocytic leukemia", "PROBLEM", 233, 255], ["arsenic trioxide (ATO)", "TREATMENT", 269, 291], ["all-trans retinoic acid (ATRA", "TREATMENT", 296, 325], ["chemotherapy", "TREATMENT", 346, 358], ["severe", "OBSERVATION_MODIFIER", 47, 53], ["respiratory", "ANATOMY", 54, 65], ["failure", "OBSERVATION", 66, 73], ["severe", "OBSERVATION_MODIFIER", 164, 170], ["respiratory adverse", "OBSERVATION", 171, 190], ["promyelocytic leukemia", "OBSERVATION", 233, 255]]], ["The association of chemotherapy and ATRA, as induction therapy, may be less risky during the pandemic, with the same survival benefit, than ATRA and ATO association [14,15].", [["ATRA", "CHEMICAL", 36, 40], ["ATRA", "CHEMICAL", 140, 144], ["ATO", "CHEMICAL", 149, 152], ["ATRA", "CHEMICAL", 36, 40], ["ATRA", "CHEMICAL", 140, 144], ["ATO", "CHEMICAL", 149, 152], ["ATRA", "SIMPLE_CHEMICAL", 36, 40], ["ATRA", "SIMPLE_CHEMICAL", 140, 144], ["ATO", "SIMPLE_CHEMICAL", 149, 152], ["chemotherapy", "TREATMENT", 19, 31], ["ATRA", "TREATMENT", 36, 40], ["induction therapy", "TREATMENT", 45, 62], ["ATRA", "TREATMENT", 140, 144], ["chemotherapy", "OBSERVATION", 19, 31]]], ["ATO could be used in consolidation therapy to achieve a low relapse rate [15].Targeted therapiesImportantly, ivosidenib and ATO can both prolong QTc increasing the risk for severe arrhythmia.", [["ATO", "CHEMICAL", 0, 3], ["ivosidenib", "CHEMICAL", 109, 119], ["ATO", "CHEMICAL", 124, 127], ["arrhythmia", "DISEASE", 180, 190], ["ATO", "CHEMICAL", 0, 3], ["ivosidenib", "CHEMICAL", 109, 119], ["ATO", "CHEMICAL", 124, 127], ["ATO", "SIMPLE_CHEMICAL", 0, 3], ["ivosidenib", "SIMPLE_CHEMICAL", 109, 119], ["ATO", "SIMPLE_CHEMICAL", 124, 127], ["ATO", "TREATMENT", 0, 3], ["consolidation therapy", "TREATMENT", 21, 42], ["ATO", "TREATMENT", 124, 127], ["QTc", "TEST", 145, 148], ["severe arrhythmia", "PROBLEM", 173, 190], ["consolidation", "OBSERVATION", 21, 34], ["severe", "OBSERVATION_MODIFIER", 173, 179], ["arrhythmia", "OBSERVATION", 180, 190]]], ["Recently, non-randomized clinical trials reported a potential benefit for chloroquine on the prognosis of severe COVID-19.", [["chloroquine", "CHEMICAL", 74, 85], ["COVID", "DISEASE", 113, 118], ["chloroquine", "CHEMICAL", 74, 85], ["COVID-19", "CHEMICAL", 113, 121], ["chloroquine", "SIMPLE_CHEMICAL", 74, 85], ["chloroquine", "TREATMENT", 74, 85], ["severe COVID", "PROBLEM", 106, 118]]], ["Other anti-viral drugs, such as remdesivir, are currently under study.", [["remdesivir", "CHEMICAL", 32, 42], ["remdesivir", "CHEMICAL", 32, 42], ["remdesivir", "SIMPLE_CHEMICAL", 32, 42], ["Other anti-viral drugs", "TREATMENT", 0, 22], ["remdesivir", "TREATMENT", 32, 42], ["anti-viral drugs", "OBSERVATION", 6, 22]]], ["As both of these drugs can also prolong QTc, clinicians should be aware of these potential severe adverse effects in COVID-19 patients treated with ATO, IDH inhibitor or any tyrosine kinase inhibitor (TKI) that may prolong QTc interval.Targeted therapiesTyrosine kinase inhibitors (imatinib, dasatinib, nilotinib, and ponatinib) are currently included in the treatment of Philadelphia positive ALL, improving response rate and survival [16].", [["ALL", "ANATOMY", 394, 397], ["ATO", "CHEMICAL", 148, 151], ["tyrosine", "CHEMICAL", 174, 182], ["imatinib", "CHEMICAL", 282, 290], ["dasatinib", "CHEMICAL", 292, 301], ["nilotinib", "CHEMICAL", 303, 312], ["ponatinib", "CHEMICAL", 318, 327], ["Philadelphia positive ALL", "DISEASE", 372, 397], ["ATO", "CHEMICAL", 148, 151], ["tyrosine", "CHEMICAL", 174, 182], ["Tyrosine", "CHEMICAL", 254, 262], ["imatinib", "CHEMICAL", 282, 290], ["dasatinib", "CHEMICAL", 292, 301], ["nilotinib", "CHEMICAL", 303, 312], ["ponatinib", "CHEMICAL", 318, 327], ["patients", "ORGANISM", 126, 134], ["ATO", "SIMPLE_CHEMICAL", 148, 151], ["IDH", "SIMPLE_CHEMICAL", 153, 156], ["tyrosine kinase inhibitor", "SIMPLE_CHEMICAL", 174, 199], ["TKI", "SIMPLE_CHEMICAL", 201, 204], ["Tyrosine", "AMINO_ACID", 254, 262], ["imatinib", "SIMPLE_CHEMICAL", 282, 290], ["dasatinib", "SIMPLE_CHEMICAL", 292, 301], ["nilotinib", "SIMPLE_CHEMICAL", 303, 312], ["ponatinib", "SIMPLE_CHEMICAL", 318, 327], ["Philadelphia positive ALL", "CANCER", 372, 397], ["patients", "SPECIES", 126, 134], ["these drugs", "TREATMENT", 11, 22], ["severe adverse effects", "PROBLEM", 91, 113], ["ATO", "TREATMENT", 148, 151], ["IDH inhibitor", "TREATMENT", 153, 166], ["any tyrosine kinase inhibitor", "TREATMENT", 170, 199], ["Targeted therapies", "TREATMENT", 236, 254], ["Tyrosine kinase inhibitors", "TREATMENT", 254, 280], ["imatinib", "TREATMENT", 282, 290], ["dasatinib", "TREATMENT", 292, 301], ["nilotinib", "TREATMENT", 303, 312], ["ponatinib", "TREATMENT", 318, 327], ["Philadelphia positive ALL", "PROBLEM", 372, 397]]], ["The addition of a TKI to chemotherapy and in maintenance after HSCT adds minimal infectious toxicity.", [["TKI", "CHEMICAL", 18, 21], ["toxicity", "DISEASE", 92, 100], ["TKI", "SIMPLE_CHEMICAL", 18, 21], ["a TKI", "TREATMENT", 16, 21], ["chemotherapy", "TREATMENT", 25, 37], ["HSCT", "TREATMENT", 63, 67], ["minimal infectious toxicity", "PROBLEM", 73, 100], ["minimal", "OBSERVATION_MODIFIER", 73, 80], ["infectious", "OBSERVATION", 81, 91]]], ["However, the use of dasatinib in post-HSCT settings may increase the risk of CMV reactivation [17], which in addition to adverse effects, such as pleural effusions and lung infiltrates, demands cautious use in the COVID-19 pandemic.Targeted therapiesVenetoclax is a highly selective, oral, B cell leukemia/ lymphoma 2 (BCL-2) inhibitor with demonstrated efficacy in AML patients either alone or in combination with 5-azacitidine or decitabine [18].", [["pleural effusions", "ANATOMY", 146, 163], ["lung", "ANATOMY", 168, 172], ["oral", "ANATOMY", 284, 288], ["AML", "ANATOMY", 366, 369], ["dasatinib", "CHEMICAL", 20, 29], ["pleural effusions", "DISEASE", 146, 163], ["Venetoclax", "CHEMICAL", 250, 260], ["AML", "DISEASE", 366, 369], ["5-azacitidine", "CHEMICAL", 415, 428], ["decitabine", "CHEMICAL", 432, 442], ["dasatinib", "CHEMICAL", 20, 29], ["Venetoclax", "CHEMICAL", 250, 260], ["5-azacitidine", "CHEMICAL", 415, 428], ["decitabine", "CHEMICAL", 432, 442], ["dasatinib", "SIMPLE_CHEMICAL", 20, 29], ["CMV", "ORGANISM", 77, 80], ["pleural effusions", "PATHOLOGICAL_FORMATION", 146, 163], ["lung", "ORGAN", 168, 172], ["Venetoclax", "SIMPLE_CHEMICAL", 250, 260], ["oral", "ORGANISM_SUBDIVISION", 284, 288], ["B cell leukemia", "CANCER", 290, 305], ["/ lymphoma 2", "GENE_OR_GENE_PRODUCT", 305, 317], ["BCL-2", "GENE_OR_GENE_PRODUCT", 319, 324], ["AML", "CANCER", 366, 369], ["patients", "ORGANISM", 370, 378], ["5-azacitidine", "SIMPLE_CHEMICAL", 415, 428], ["decitabine", "SIMPLE_CHEMICAL", 432, 442], ["patients", "SPECIES", 370, 378], ["CMV", "SPECIES", 77, 80], ["dasatinib", "TREATMENT", 20, 29], ["post-HSCT settings", "TREATMENT", 33, 51], ["CMV reactivation", "PROBLEM", 77, 93], ["adverse effects", "PROBLEM", 121, 136], ["pleural effusions", "PROBLEM", 146, 163], ["lung infiltrates", "PROBLEM", 168, 184], ["the COVID", "TEST", 210, 219], ["Targeted therapies", "TREATMENT", 232, 250], ["Venetoclax", "TREATMENT", 250, 260], ["oral, B cell leukemia/ lymphoma", "TREATMENT", 284, 315], ["BCL", "TEST", 319, 322], ["inhibitor", "TREATMENT", 326, 335], ["efficacy in AML", "PROBLEM", 354, 369], ["azacitidine", "TREATMENT", 417, 428], ["decitabine", "TREATMENT", 432, 442], ["CMV reactivation", "OBSERVATION", 77, 93], ["pleural", "ANATOMY", 146, 153], ["effusions", "OBSERVATION", 154, 163], ["lung", "ANATOMY", 168, 172], ["infiltrates", "OBSERVATION", 173, 184], ["cell leukemia", "OBSERVATION", 292, 305]]], ["However, prolonged neutropenia with increased risks of bacterial or fungal lung infections, is observed in AML patients treated with venetoclax [19].", [["lung", "ANATOMY", 75, 79], ["AML", "ANATOMY", 107, 110], ["neutropenia", "DISEASE", 19, 30], ["fungal lung infections", "DISEASE", 68, 90], ["AML", "DISEASE", 107, 110], ["venetoclax", "CHEMICAL", 133, 143], ["venetoclax", "CHEMICAL", 133, 143], ["lung", "ORGAN", 75, 79], ["AML", "CANCER", 107, 110], ["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["prolonged neutropenia", "PROBLEM", 9, 30], ["bacterial or fungal lung infections", "PROBLEM", 55, 90], ["venetoclax", "TREATMENT", 133, 143], ["prolonged", "OBSERVATION_MODIFIER", 9, 18], ["neutropenia", "OBSERVATION", 19, 30], ["increased", "OBSERVATION_MODIFIER", 36, 45], ["bacterial", "OBSERVATION_MODIFIER", 55, 64], ["fungal", "OBSERVATION_MODIFIER", 68, 74], ["lung", "ANATOMY", 75, 79], ["infections", "OBSERVATION", 80, 90]]], ["Since this combined treatment is most frequently indicated in elderly AML patients unfit for intensive therapy and allogeneic transplantation, the risk of respiratory failure may be highly increased if they contract COVID-19.Investigational therapies and clinical studiesAs illustrated by the waiving of maintenance therapy in the GRAAL-14 protocol, other ongoing clinical studies are likely to be affected by modification in therapy protocol, increased subject withdrawal, and excess SARS-CoV-2-related mortality.", [["AML", "ANATOMY", 70, 73], ["respiratory", "ANATOMY", 155, 166], ["AML", "DISEASE", 70, 73], ["respiratory failure", "DISEASE", 155, 174], ["COVID-19", "CHEMICAL", 216, 224], ["AML", "CANCER", 70, 73], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["this combined treatment", "TREATMENT", 6, 29], ["intensive therapy", "TREATMENT", 93, 110], ["allogeneic transplantation", "TREATMENT", 115, 141], ["respiratory failure", "PROBLEM", 155, 174], ["COVID", "TEST", 216, 221], ["Investigational therapies", "TREATMENT", 225, 250], ["clinical studies", "TEST", 255, 271], ["maintenance therapy", "TREATMENT", 304, 323], ["the GRAAL-14 protocol", "TREATMENT", 327, 348], ["other ongoing clinical studies", "TEST", 350, 380], ["therapy protocol", "TREATMENT", 426, 442], ["increased subject withdrawal", "PROBLEM", 444, 472], ["excess SARS", "PROBLEM", 478, 489], ["respiratory failure", "OBSERVATION", 155, 174]]], ["These elements will permanently impact studies, impairing the strength of the results and rendering their interpretation complex.Prophylactic measuresPatients with recent or ongoing treatment for leukemia are to be protected from COVID-19, isolated at home, given the opportunity to work in home office whenever possible, and tested for SARS-CoV-2 infection following local or WHO guidelines.", [["leukemia", "ANATOMY", 196, 204], ["leukemia", "DISEASE", 196, 204], ["SARS-CoV-2 infection", "DISEASE", 337, 357], ["Patients", "ORGANISM", 150, 158], ["leukemia", "CANCER", 196, 204], ["SARS-CoV-2", "ORGANISM", 337, 347], ["Patients", "SPECIES", 150, 158], ["SARS-CoV", "SPECIES", 337, 345], ["studies", "TEST", 39, 46], ["Prophylactic measures", "TREATMENT", 129, 150], ["leukemia", "PROBLEM", 196, 204], ["SARS", "PROBLEM", 337, 341], ["CoV", "PROBLEM", 342, 345], ["2 infection", "PROBLEM", 346, 357], ["leukemia", "OBSERVATION", 196, 204]]], ["If possible, consultation appointments should be reduced to a vital minimum to avoid spread infection of SARS-CoV-2 infection in the hematology clinic.Prophylactic measuresLeukemia patients are immunocompromised and should have up-to-date, vaccination status, notably against Streptococcus pneumoniae [20].", [["infection", "DISEASE", 92, 101], ["SARS-CoV-2 infection", "DISEASE", 105, 125], ["measuresLeukemia", "DISEASE", 164, 180], ["Streptococcus pneumoniae", "DISEASE", 276, 300], ["SARS-CoV-2", "ORGANISM", 105, 115], ["patients", "ORGANISM", 181, 189], ["Streptococcus pneumoniae", "ORGANISM", 276, 300], ["patients", "SPECIES", 181, 189], ["Streptococcus pneumoniae", "SPECIES", 276, 300], ["SARS-CoV-2", "SPECIES", 105, 115], ["Streptococcus pneumoniae", "SPECIES", 276, 300], ["spread infection", "PROBLEM", 85, 101], ["SARS", "PROBLEM", 105, 109], ["CoV", "PROBLEM", 110, 113], ["2 infection", "PROBLEM", 114, 125], ["Prophylactic measuresLeukemia", "TREATMENT", 151, 180], ["immunocompromised", "PROBLEM", 194, 211], ["vaccination status", "TEST", 240, 258], ["Streptococcus pneumoniae", "PROBLEM", 276, 300], ["immunocompromised", "OBSERVATION", 194, 211]]], ["Bacterial secondary infection can complicate viral infections, a situation well known in influenza, and plausible for COVID-19 infection.", [["secondary infection", "DISEASE", 10, 29], ["viral infections", "DISEASE", 45, 61], ["influenza", "DISEASE", 89, 98], ["infection", "DISEASE", 127, 136], ["COVID-19", "ORGANISM", 118, 126], ["COVID-19", "SPECIES", 118, 126], ["Bacterial secondary infection", "PROBLEM", 0, 29], ["viral infections", "PROBLEM", 45, 61], ["influenza", "PROBLEM", 89, 98], ["COVID-19 infection", "PROBLEM", 118, 136], ["secondary", "OBSERVATION_MODIFIER", 10, 19], ["infection", "OBSERVATION", 20, 29], ["viral", "OBSERVATION_MODIFIER", 45, 50], ["infections", "OBSERVATION", 51, 61], ["infection", "OBSERVATION", 127, 136]]], ["The benefit of vaccination against Streptococcus pneumonia, may be worth investigating in clinical trials.Prophylactic measuresIn conclusion, COVID-19 will result in numerous casualties.", [["Streptococcus pneumonia", "DISEASE", 35, 58], ["Streptococcus pneumonia", "ORGANISM", 35, 58], ["Streptococcus pneumonia", "SPECIES", 35, 58], ["vaccination", "TREATMENT", 15, 26], ["Streptococcus pneumonia", "PROBLEM", 35, 58], ["Prophylactic measuresIn conclusion", "TREATMENT", 106, 140], ["COVID", "TEST", 142, 147]]], ["Acute leukemia patients are at a higher risk of severe complications for several reasons.", [["Acute leukemia", "ANATOMY", 0, 14], ["Acute leukemia", "DISEASE", 0, 14], ["Acute leukemia", "CANCER", 0, 14], ["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["Acute leukemia", "PROBLEM", 0, 14], ["severe complications", "PROBLEM", 48, 68], ["leukemia", "OBSERVATION", 6, 14], ["severe", "OBSERVATION_MODIFIER", 48, 54], ["complications", "OBSERVATION", 55, 68]]], ["As the presenting symptoms can be similar, health care practitioners should imperatively keep the possibility of acute leukemia in mind.", [["acute leukemia", "ANATOMY", 113, 127], ["acute leukemia", "DISEASE", 113, 127], ["acute leukemia", "CANCER", 113, 127], ["the presenting symptoms", "PROBLEM", 3, 26], ["acute leukemia", "PROBLEM", 113, 127], ["acute", "OBSERVATION_MODIFIER", 113, 118], ["leukemia", "OBSERVATION", 119, 127]]], ["Intensive chemotherapies and transplantations may be waived, or delayed, due to resources shortages or in line with the recommendations of transplantation societies.", [["Intensive chemotherapies", "TREATMENT", 0, 24], ["transplantations", "TREATMENT", 29, 45], ["transplantation societies", "TREATMENT", 139, 164]]], ["Targeted therapies could potentially be used.", [["Targeted therapies", "TREATMENT", 0, 18]]], ["However, physicians should be aware of their interactions with other drugs used to treat SARS-CoV-2-related infections/complications such as antibiotics, anti-viral drugs and various other drugs that prolong QTc or impact targeted-therapy pharmacokinetics.", [["SARS", "DISEASE", 89, 93], ["infections", "DISEASE", 108, 118], ["SARS-CoV-2", "ORGANISM", 89, 99], ["other drugs", "TREATMENT", 63, 74], ["SARS", "PROBLEM", 89, 93], ["CoV", "PROBLEM", 94, 97], ["related infections", "PROBLEM", 100, 118], ["complications", "PROBLEM", 119, 132], ["antibiotics", "TREATMENT", 141, 152], ["anti-viral drugs", "TREATMENT", 154, 170], ["various other drugs", "TREATMENT", 175, 194], ["prolong QTc", "TREATMENT", 200, 211], ["impact targeted", "TREATMENT", 215, 230], ["therapy pharmacokinetics", "TREATMENT", 231, 255]]], ["The points discussed above should be considered in all patients with acute leukemia in order to best tailor individual therapeutic decisions and, whenever possible, mitigate the impact of the pandemic.Author contributionSB and MG conceived the study, performed the research and literature review, and wrote the manuscript.", [["leukemia", "ANATOMY", 75, 83], ["acute leukemia", "DISEASE", 69, 83], ["patients", "ORGANISM", 55, 63], ["acute leukemia", "CANCER", 69, 83], ["patients", "SPECIES", 55, 63], ["acute leukemia", "PROBLEM", 69, 83], ["the pandemic", "PROBLEM", 188, 200], ["the study", "TEST", 240, 249], ["acute", "OBSERVATION_MODIFIER", 69, 74], ["leukemia", "OBSERVATION", 75, 83]]], ["JCK wrote the manuscript.", [["JCK", "PROTEIN", 0, 3]]]], "PMC7445151": [["IntroductionCoronaviruses (CoVs), enveloped RNA viruses, are characterized by spikes on their surface and belong to Nidovirales order 1.", [["surface", "ANATOMY", 94, 101], ["IntroductionCoronaviruses", "GENE_OR_GENE_PRODUCT", 0, 25], ["CoVs", "GENE_OR_GENE_PRODUCT", 27, 31], ["surface", "CELLULAR_COMPONENT", 94, 101], ["CoVs", "PROTEIN", 27, 31], ["IntroductionCoronaviruses (CoVs)", "PROBLEM", 0, 32], ["enveloped RNA viruses", "PROBLEM", 34, 55], ["RNA viruses", "OBSERVATION", 44, 55], ["spikes", "OBSERVATION_MODIFIER", 78, 84]]], ["They are responsible for a growing economic, social, and mortality burden in humans over the last decades.", [["humans", "ORGANISM", 77, 83], ["humans", "SPECIES", 77, 83], ["humans", "SPECIES", 77, 83]]], ["The spectrum of diseases associated with human CoVs range from the common cold to severe acute respiratory syndrome (SARS-CoV), and Middle East respiratory syndrome (MERS-CoV).", [["acute respiratory syndrome", "DISEASE", 89, 115], ["SARS-CoV)", "DISEASE", 117, 126], ["Middle East respiratory syndrome", "DISEASE", 132, 164], ["human", "ORGANISM", 41, 46], ["CoVs", "CANCER", 47, 51], ["MERS-CoV", "ORGANISM", 166, 174], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 41, 46], ["SARS-CoV", "SPECIES", 117, 125], ["Middle East respiratory syndrome (MERS-CoV", "SPECIES", 132, 174], ["diseases", "PROBLEM", 16, 24], ["human CoVs range", "PROBLEM", 41, 57], ["severe acute respiratory syndrome", "PROBLEM", 82, 115], ["SARS-CoV)", "PROBLEM", 117, 126], ["Middle East respiratory syndrome", "PROBLEM", 132, 164], ["diseases", "OBSERVATION", 16, 24], ["severe", "OBSERVATION_MODIFIER", 82, 88], ["acute", "OBSERVATION_MODIFIER", 89, 94], ["respiratory syndrome", "OBSERVATION", 95, 115], ["Middle", "ANATOMY_MODIFIER", 132, 138], ["respiratory syndrome", "OBSERVATION", 144, 164]]], ["Since December 2019, a newly discovered coronavirus (SARS-CoV-2) was the causative agent of the current pandemic of infectious disease (COVID-19).", [["infectious disease", "DISEASE", 116, 134], ["coronavirus", "ORGANISM", 40, 51], ["SARS-CoV-2", "ORGANISM", 53, 63], ["SARS-CoV-2", "SPECIES", 53, 63], ["a newly discovered coronavirus (SARS", "PROBLEM", 21, 57], ["CoV", "TEST", 58, 61], ["infectious disease", "PROBLEM", 116, 134], ["COVID", "TEST", 136, 141], ["coronavirus", "OBSERVATION", 40, 51], ["infectious", "OBSERVATION", 116, 126]]], ["Unfortunately, there are no effective approved antiviral agents for these coronavirus strains 2,3.IntroductionNatural products provide a wealth of biologically active molecules with antiviral activity, and thus may have utility as potential therapeutic agents against coronavirus infections 4.", [["coronavirus", "DISEASE", 74, 85], ["coronavirus infections", "DISEASE", 268, 290], ["coronavirus", "ORGANISM", 74, 85], ["coronavirus", "ORGANISM", 268, 279], ["antiviral agents", "TREATMENT", 47, 63], ["these coronavirus strains", "PROBLEM", 68, 93], ["IntroductionNatural products", "TREATMENT", 98, 126], ["antiviral activity", "TREATMENT", 182, 200], ["therapeutic agents", "TREATMENT", 241, 259], ["coronavirus infections", "PROBLEM", 268, 290], ["no", "UNCERTAINTY", 25, 27], ["effective", "OBSERVATION_MODIFIER", 28, 37], ["antiviral activity", "OBSERVATION", 182, 200]]], ["One of these products is Nigella sativa (NS), which has displayed several anti-viral properties 5.IntroductionNS is a well-known food supplement and medicinal plant in different cultures.", [["Nigella sativa", "CHEMICAL", 25, 39], ["Nigella sativa", "ORGANISM", 25, 39], ["Nigella sativa", "SPECIES", 25, 39], ["Nigella sativa", "SPECIES", 25, 39], ["Nigella sativa (NS", "TREATMENT", 25, 43], ["several anti-viral properties", "TREATMENT", 66, 95], ["IntroductionNS", "TREATMENT", 98, 112], ["a well-known food supplement", "TREATMENT", 116, 144], ["medicinal plant", "TREATMENT", 149, 164], ["different cultures", "TEST", 168, 186], ["Nigella sativa", "OBSERVATION", 25, 39], ["anti-viral properties", "OBSERVATION", 74, 95]]], ["The seeds of NS contain several active compounds in the classes of fixed oil, essential oil, saponins and alkaloids.", [["oil", "ANATOMY", 73, 76], ["oil", "ANATOMY", 88, 91], ["saponins", "CHEMICAL", 93, 101], ["oil", "ORGANISM_SUBSTANCE", 73, 76], ["oil", "ORGANISM_SUBSTANCE", 88, 91], ["saponins", "SIMPLE_CHEMICAL", 93, 101], ["alkaloids", "SIMPLE_CHEMICAL", 106, 115], ["NS", "TREATMENT", 13, 15], ["fixed oil", "TREATMENT", 67, 76], ["alkaloids", "TREATMENT", 106, 115], ["several", "OBSERVATION_MODIFIER", 24, 31], ["active", "OBSERVATION_MODIFIER", 32, 38], ["compounds", "OBSERVATION", 39, 48], ["oil", "OBSERVATION_MODIFIER", 88, 91]]], ["In the literature, NS exhibited several pharmacological properties including anti-inflammatory, anti-microbial, and immunostimulatory activities 5,6.IntroductionThe safety and efficacy of NS used for many human diseases has been established in several randomized clinical studies 7.", [["NS", "CHEMICAL", 188, 190], ["human", "ORGANISM", 205, 210], ["human", "SPECIES", 205, 210], ["human", "SPECIES", 205, 210], ["NS", "TREATMENT", 19, 21], ["anti-inflammatory", "TREATMENT", 77, 94], ["anti-microbial", "TREATMENT", 96, 110], ["immunostimulatory activities", "TEST", 116, 144], ["NS", "TREATMENT", 188, 190], ["many human diseases", "PROBLEM", 200, 219], ["clinical studies", "TEST", 263, 279], ["several", "OBSERVATION_MODIFIER", 32, 39], ["pharmacological properties", "OBSERVATION", 40, 66], ["anti-inflammatory", "OBSERVATION_MODIFIER", 77, 94]]], ["We also used NS oil in a randomized double-blind placebo-controlled trial on asthmatic patients with acceptable safety and efficacy profile 8.", [["NS oil", "ANATOMY", 13, 19], ["asthmatic", "DISEASE", 77, 86], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["NS oil", "TREATMENT", 13, 19], ["a randomized double-blind placebo", "TREATMENT", 23, 56], ["asthmatic patients", "TREATMENT", 77, 95]]], ["Moreover, several meta-analyses have confirmed the beneficial effects and safety of NS on hyperlipidemia, type 2 diabetes, obesity, hypertension, and asthma 9, 10, 11, 12, 13.", [["hyperlipidemia", "DISEASE", 90, 104], ["type 2 diabetes", "DISEASE", 106, 121], ["obesity", "DISEASE", 123, 130], ["hypertension", "DISEASE", 132, 144], ["asthma", "DISEASE", 150, 156], ["NS", "TREATMENT", 84, 86], ["hyperlipidemia", "PROBLEM", 90, 104], ["type 2 diabetes", "PROBLEM", 106, 121], ["obesity", "PROBLEM", 123, 130], ["hypertension", "PROBLEM", 132, 144], ["asthma", "PROBLEM", 150, 156], ["hyperlipidemia", "OBSERVATION", 90, 104], ["diabetes", "OBSERVATION", 113, 121], ["obesity", "OBSERVATION", 123, 130], ["hypertension", "OBSERVATION", 132, 144], ["asthma", "OBSERVATION", 150, 156]]], ["Oral NS oil dosing of up to 5 grams daily for up to 12 weeks is believed to be possibly safe 14.IntroductionIn in vitro studies, the antiviral activities of NS on different viruses were documented in the literature 5.", [["Oral", "ANATOMY", 0, 4], ["oil", "ANATOMY", 8, 11], ["Oral NS oil dosing", "TREATMENT", 0, 18], ["vitro studies", "TEST", 114, 127], ["NS", "TREATMENT", 157, 159], ["different viruses", "PROBLEM", 163, 180], ["believed to be possibly", "UNCERTAINTY", 64, 87]]], ["NS oil suppresses the viral load of Murine cytomegalovirus in infected mice to an undetectable level 15.", [["oil", "ANATOMY", 3, 6], ["Murine cytomegalovirus in infected", "DISEASE", 36, 70], ["oil", "ORGANISM_SUBSTANCE", 3, 6], ["Murine", "ORGANISM", 36, 42], ["cytomegalovirus", "ORGANISM", 43, 58], ["mice", "ORGANISM", 71, 75], ["Murine", "SPECIES", 36, 42], ["mice", "SPECIES", 71, 75], ["Murine cytomegalovirus", "SPECIES", 36, 58], ["mice", "SPECIES", 71, 75], ["NS oil", "TREATMENT", 0, 6], ["Murine cytomegalovirus", "PROBLEM", 36, 58], ["viral load", "OBSERVATION", 22, 32], ["Murine cytomegalovirus", "OBSERVATION", 36, 58]]], ["NS honey was found to inhibit HIV-1 replication 16.", [["HIV-1", "ORGANISM", 30, 35], ["HIV-1", "SPECIES", 30, 35], ["HIV-1", "SPECIES", 30, 35], ["NS honey", "TREATMENT", 0, 8], ["honey", "OBSERVATION", 3, 8]]], ["NS had virucidal activity against herpes simplex and hepatitis A virus infections 16.", [["NS", "CHEMICAL", 0, 2], ["herpes simplex and hepatitis A virus infections", "DISEASE", 34, 81], ["herpes simplex", "ORGANISM", 34, 48], ["hepatitis A virus", "ORGANISM", 53, 70], ["herpes simplex", "SPECIES", 34, 48], ["hepatitis A virus", "SPECIES", 53, 70], ["hepatitis A virus", "SPECIES", 53, 70], ["NS", "TREATMENT", 0, 2], ["virucidal activity", "TREATMENT", 7, 25], ["herpes simplex", "PROBLEM", 34, 48], ["hepatitis A virus infections", "PROBLEM", 53, 81], ["virucidal activity", "OBSERVATION_MODIFIER", 7, 25]]], ["NS decreased the coronavirus load in infected HeLa cells with stimulated interleukin-8 secretion and down-regulation of Transient Receptor Potential genes expression such as TRPM6, TRPA1, TRPC4 and TRPM7 17.", [["HeLa cells", "ANATOMY", 46, 56], ["coronavirus", "ORGANISM", 17, 28], ["HeLa cells", "CELL", 46, 56], ["interleukin-8", "GENE_OR_GENE_PRODUCT", 73, 86], ["TRPM6", "GENE_OR_GENE_PRODUCT", 174, 179], ["TRPA1", "GENE_OR_GENE_PRODUCT", 181, 186], ["TRPC4", "GENE_OR_GENE_PRODUCT", 188, 193], ["TRPM7 17", "GENE_OR_GENE_PRODUCT", 198, 206], ["HeLa cells", "CELL_LINE", 46, 56], ["interleukin-8", "PROTEIN", 73, 86], ["TRPM6", "PROTEIN", 174, 179], ["TRPA1", "PROTEIN", 181, 186], ["TRPC4", "PROTEIN", 188, 193], ["TRPM7 17", "PROTEIN", 198, 206], ["NS", "TREATMENT", 0, 2], ["the coronavirus load", "PROBLEM", 13, 33], ["infected HeLa cells", "TREATMENT", 37, 56], ["stimulated interleukin", "TEST", 62, 84], ["TRPM6", "TEST", 174, 179], ["TRPA1", "TEST", 181, 186], ["TRPC4", "TEST", 188, 193], ["TRPM7", "TEST", 198, 203], ["decreased", "OBSERVATION_MODIFIER", 3, 12], ["coronavirus load", "OBSERVATION", 17, 33], ["infected HeLa cells", "OBSERVATION", 37, 56]]], ["Hepatitis C virus (HCV) replication was inhibited by NS 18.", [["Hepatitis C", "DISEASE", 0, 11], ["Hepatitis C virus", "ORGANISM", 0, 17], ["HCV", "ORGANISM", 19, 22], ["Hepatitis C virus", "SPECIES", 0, 17], ["Hepatitis C virus", "SPECIES", 0, 17], ["HCV", "SPECIES", 19, 22], ["Hepatitis C virus", "PROBLEM", 0, 17], ["(HCV) replication", "TREATMENT", 18, 35], ["NS", "TREATMENT", 53, 55]]], ["NS inhibited the growth of influenza virus H5N1 in in vitro19.IntroductionIn a human clinical study, patients with HCV infection showed significant improvement in HCV viral load after 3 months of NS treatment 20.", [["influenza virus H5N1", "DISEASE", 27, 47], ["HCV infection", "DISEASE", 115, 128], ["influenza virus H5N1", "ORGANISM", 27, 47], ["human", "ORGANISM", 79, 84], ["patients", "ORGANISM", 101, 109], ["HCV", "ORGANISM", 115, 118], ["HCV", "ORGANISM", 163, 166], ["influenza virus H5N1", "SPECIES", 27, 47], ["human", "SPECIES", 79, 84], ["patients", "SPECIES", 101, 109], ["influenza virus H5N1", "SPECIES", 27, 47], ["human", "SPECIES", 79, 84], ["HCV", "SPECIES", 115, 118], ["HCV", "SPECIES", 163, 166], ["NS", "TREATMENT", 0, 2], ["influenza virus H5N1", "TREATMENT", 27, 47], ["a human clinical study", "TEST", 77, 99], ["HCV infection", "PROBLEM", 115, 128], ["HCV viral load", "PROBLEM", 163, 177], ["NS treatment", "TREATMENT", 196, 208], ["growth", "OBSERVATION_MODIFIER", 17, 23], ["influenza virus H5N1", "OBSERVATION", 27, 47], ["significant", "OBSERVATION_MODIFIER", 136, 147], ["improvement", "OBSERVATION_MODIFIER", 148, 159], ["HCV viral load", "OBSERVATION", 163, 177]]], ["A case report of treatment with NS for 6 months showed a sustained seroreversion in a 46-year-old HIV patient and was also reported in an additional 6 HIV cases 21,22.IntroductionIn recent years, in-silico molecular docking studies on natural products enable computational screening approaches for assessing their therapeutic potential.", [["HIV", "ORGANISM", 98, 101], ["patient", "ORGANISM", 102, 109], ["HIV", "SPECIES", 98, 101], ["patient", "SPECIES", 102, 109], ["HIV", "SPECIES", 98, 101], ["HIV", "SPECIES", 151, 154], ["NS", "TREATMENT", 32, 34], ["a sustained seroreversion", "PROBLEM", 55, 80], ["natural products", "TREATMENT", 235, 251], ["computational screening approaches", "TREATMENT", 259, 293]]], ["These studies utilize bioinformatics techniques and can be used to discover how candidate drugs cause therapeutic activity by predicting interactions between drugs and proteins, and analysis of impact on biological pathways and functions23.IntroductionThe aim of this mini literature review is to explore any published manuscript or preprint on in-silico studies of the specific anti-coronavirus potential of NS.MethodsA literature search for scientific published manuscripts or preprint in-silico studies found in electronic databases (PubMed, Science Direct, Scopus, and Google Scholar) was performed using the terms Nigella sativa, black seed, coronavirus, SARS-CoV-2 and COVID-19.", [["SARS", "DISEASE", 660, 664], ["Nigella sativa", "ORGANISM", 619, 633], ["black seed", "ORGANISM", 635, 645], ["coronavirus", "ORGANISM", 647, 658], ["SARS-CoV-2", "ORGANISM", 660, 670], ["Nigella sativa", "SPECIES", 619, 633], ["coronavirus", "SPECIES", 647, 658], ["Nigella sativa", "SPECIES", 619, 633], ["SARS-CoV", "SPECIES", 660, 668], ["These studies", "TEST", 0, 13], ["bioinformatics techniques", "TREATMENT", 22, 47], ["drugs", "TREATMENT", 90, 95], ["drugs and proteins", "TREATMENT", 158, 176], ["NS", "TREATMENT", 409, 411], ["black seed", "PROBLEM", 635, 645], ["coronavirus", "PROBLEM", 647, 658], ["SARS", "TEST", 660, 664], ["CoV", "TEST", 665, 668], ["COVID", "TEST", 675, 680]]], ["Studies were searched for electronically between the years 1990 and 2020.ResultsIn this mini literature review, there were at least eight in-silico studies that explored the effects of NS compounds on SARS-CoV-2.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 201, 211], ["SARS-CoV", "SPECIES", 201, 209], ["silico studies", "TEST", 141, 155], ["NS compounds", "TREATMENT", 185, 197]]], ["A summary of those studies is presented in Table 1.", [["those studies", "TEST", 13, 26]]], ["However, there have been no reported clinical trials on NS in human coronavirus cases at this time.ResultsMolecular docking of compounds from NS and some antiviral drugs was performed to determine their binding affinity with SARS-CoV-2 related molecular targets such as 6LU7, 2GTB, 6Y2E, ACE2 and HSPA5.", [["coronavirus", "DISEASE", 68, 79], ["human", "ORGANISM", 62, 67], ["coronavirus", "ORGANISM", 68, 79], ["NS", "SIMPLE_CHEMICAL", 142, 144], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 225, 235], ["6LU7", "GENE_OR_GENE_PRODUCT", 270, 274], ["2GTB", "GENE_OR_GENE_PRODUCT", 276, 280], ["6Y2E", "GENE_OR_GENE_PRODUCT", 282, 286], ["ACE2", "GENE_OR_GENE_PRODUCT", 288, 292], ["HSPA5", "GENE_OR_GENE_PRODUCT", 297, 302], ["6LU7", "PROTEIN", 270, 274], ["2GTB", "PROTEIN", 276, 280], ["6Y2E", "PROTEIN", 282, 286], ["ACE2", "PROTEIN", 288, 292], ["HSPA5", "PROTEIN", 297, 302], ["human", "SPECIES", 62, 67], ["human coronavirus", "SPECIES", 62, 79], ["NS", "TREATMENT", 56, 58], ["NS", "TREATMENT", 142, 144], ["some antiviral drugs", "TREATMENT", 149, 169], ["SARS", "PROBLEM", 225, 229], ["CoV", "TEST", 230, 233], ["ACE2", "TREATMENT", 288, 292], ["HSPA5", "TREATMENT", 297, 302], ["no", "UNCERTAINTY", 25, 27]]], ["The binding of some natural compounds might prevent the adhesion of coronavirus to host epithelial cells.", [["epithelial cells", "ANATOMY", 88, 104], ["coronavirus", "ORGANISM", 68, 79], ["host epithelial cells", "CELL", 83, 104], ["host epithelial cells", "CELL_TYPE", 83, 104], ["coronavirus", "PROBLEM", 68, 79], ["host epithelial cells", "OBSERVATION", 83, 104]]], ["Nigelledine, an alkaloid in NS, docked with 6LU7 active sites showed an energy complex score close to chloroquine and better than hydroxychloroquine and favipiravir. \u03b1-Hederin, a saponin in NS, docked with 2GTB active sites showed an energy score better than chloroquine, hydroxychloroquine and favipiravir 24.", [["Nigelledine", "CHEMICAL", 0, 11], ["chloroquine", "CHEMICAL", 102, 113], ["hydroxychloroquine", "CHEMICAL", 130, 148], ["favipiravir", "CHEMICAL", 153, 164], ["\u03b1-Hederin", "CHEMICAL", 166, 175], ["chloroquine", "CHEMICAL", 259, 270], ["hydroxychloroquine", "CHEMICAL", 272, 290], ["favipiravir", "CHEMICAL", 295, 306], ["Nigelledine", "CHEMICAL", 0, 11], ["chloroquine", "CHEMICAL", 102, 113], ["hydroxychloroquine", "CHEMICAL", 130, 148], ["favipiravir", "CHEMICAL", 153, 164], ["saponin", "CHEMICAL", 179, 186], ["chloroquine", "CHEMICAL", 259, 270], ["hydroxychloroquine", "CHEMICAL", 272, 290], ["favipiravir", "CHEMICAL", 295, 306], ["Nigelledine", "SIMPLE_CHEMICAL", 0, 11], ["chloroquine", "SIMPLE_CHEMICAL", 102, 113], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 130, 148], ["favipiravir", "SIMPLE_CHEMICAL", 153, 164], ["\u03b1-Hederin", "SIMPLE_CHEMICAL", 166, 175], ["saponin", "SIMPLE_CHEMICAL", 179, 186], ["2GTB", "SIMPLE_CHEMICAL", 206, 210], ["chloroquine", "SIMPLE_CHEMICAL", 259, 270], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 272, 290], ["favipiravir", "SIMPLE_CHEMICAL", 295, 306], ["Nigelledine", "TREATMENT", 0, 11], ["an alkaloid in NS", "TREATMENT", 13, 30], ["an energy complex score", "PROBLEM", 69, 92], ["chloroquine", "TREATMENT", 102, 113], ["hydroxychloroquine", "TREATMENT", 130, 148], ["favipiravir", "TREATMENT", 153, 164], ["a saponin in NS", "TREATMENT", 177, 192], ["chloroquine", "TREATMENT", 259, 270], ["hydroxychloroquine", "TREATMENT", 272, 290], ["favipiravir", "TREATMENT", 295, 306], ["alkaloid", "OBSERVATION_MODIFIER", 16, 24]]], ["Thymoquinone, the main essential oil constituent of NS, had a binding affinity with 6LU7, ACE2 and HSPA5 active sites with a score less than hydroxychloroquine in 6LU7 and ACE2 25,26.", [["oil", "ANATOMY", 33, 36], ["Thymoquinone", "CHEMICAL", 0, 12], ["hydroxychloroquine", "CHEMICAL", 141, 159], ["Thymoquinone", "CHEMICAL", 0, 12], ["hydroxychloroquine", "CHEMICAL", 141, 159], ["Thymoquinone", "SIMPLE_CHEMICAL", 0, 12], ["oil", "ORGANISM_SUBSTANCE", 33, 36], ["6LU7", "GENE_OR_GENE_PRODUCT", 84, 88], ["ACE2", "GENE_OR_GENE_PRODUCT", 90, 94], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 141, 159], ["ACE2", "GENE_OR_GENE_PRODUCT", 172, 176], ["6LU7", "PROTEIN", 84, 88], ["ACE2", "PROTEIN", 90, 94], ["HSPA5", "PROTEIN", 99, 104], ["ACE2 25,26", "PROTEIN", 172, 182], ["Thymoquinone", "TREATMENT", 0, 12], ["NS", "TREATMENT", 52, 54], ["a binding affinity", "PROBLEM", 60, 78], ["ACE2", "TREATMENT", 90, 94], ["HSPA5 active sites", "TREATMENT", 99, 117], ["hydroxychloroquine", "TREATMENT", 141, 159], ["ACE2", "TEST", 172, 176], ["oil", "OBSERVATION_MODIFIER", 33, 36], ["constituent", "OBSERVATION_MODIFIER", 37, 48]]], ["Also, Hederagenin, a saponin in NS, docked with 6LU7, 6Y2E, ACE2 and GRP78 active sites showed a binding score less than Saquinavir in 6LU7 and 6Y2E 27,28.", [["Hederagenin", "CHEMICAL", 6, 17], ["Saquinavir", "CHEMICAL", 121, 131], ["Hederagenin", "CHEMICAL", 6, 17], ["saponin", "CHEMICAL", 21, 28], ["Saquinavir", "CHEMICAL", 121, 131], ["Hederagenin", "SIMPLE_CHEMICAL", 6, 17], ["saponin", "SIMPLE_CHEMICAL", 21, 28], ["6LU7", "GENE_OR_GENE_PRODUCT", 48, 52], ["6Y2E", "GENE_OR_GENE_PRODUCT", 54, 58], ["ACE2", "GENE_OR_GENE_PRODUCT", 60, 64], ["GRP78", "GENE_OR_GENE_PRODUCT", 69, 74], ["Saquinavir", "SIMPLE_CHEMICAL", 121, 131], ["6LU7, 6Y2E, ACE2 and GRP78 active sites", "DNA", 48, 87], ["a saponin in NS", "TREATMENT", 19, 34], ["ACE2", "TREATMENT", 60, 64], ["a binding score", "PROBLEM", 95, 110], ["Saquinavir", "TREATMENT", 121, 131]]], ["Thymohydroquinone showed moderate docking energy with SARS\u2212CoV\u22122 Main-protease (6LU7), endoribonucleoase (Nsp15/NendoU), ADP\u2212ribose\u22121\u2033\u2212phosphatase (ADRP), RNA\u2212dependent RNA polymerase (RdRp), the binding domain of the SARS\u2212CoV\u22122 spike protein (rS), and human ACE2 29.", [["Thymohydroquinone", "CHEMICAL", 0, 17], ["Thymohydroquinone", "CHEMICAL", 0, 17], ["ADP\u2212ribose", "CHEMICAL", 121, 131], ["Thymohydroquinone", "SIMPLE_CHEMICAL", 0, 17], ["CoV\u22122", "GENE_OR_GENE_PRODUCT", 59, 64], ["Main-protease", "GENE_OR_GENE_PRODUCT", 65, 78], ["6LU7", "GENE_OR_GENE_PRODUCT", 80, 84], ["endoribonucleoase", "GENE_OR_GENE_PRODUCT", 87, 104], ["Nsp15", "GENE_OR_GENE_PRODUCT", 106, 111], ["NendoU", "GENE_OR_GENE_PRODUCT", 112, 118], ["ADP\u2212ribose\u22121\u2033\u2212phosphatase", "GENE_OR_GENE_PRODUCT", 121, 146], ["ADRP", "GENE_OR_GENE_PRODUCT", 148, 152], ["RNA\u2212dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 155, 183], ["SARS\u2212CoV\u22122", "GENE_OR_GENE_PRODUCT", 218, 228], ["rS", "GENE_OR_GENE_PRODUCT", 244, 246], ["human", "ORGANISM", 253, 258], ["ACE2 29", "GENE_OR_GENE_PRODUCT", 259, 266], ["CoV\u22122 Main-protease", "PROTEIN", 59, 78], ["6LU7", "PROTEIN", 80, 84], ["endoribonucleoase", "PROTEIN", 87, 104], ["Nsp15", "PROTEIN", 106, 111], ["NendoU", "PROTEIN", 112, 118], ["ADP\u2212ribose\u22121\u2033\u2212phosphatase", "PROTEIN", 121, 146], ["ADRP", "PROTEIN", 148, 152], ["RNA\u2212dependent RNA polymerase", "PROTEIN", 155, 183], ["RdRp", "PROTEIN", 185, 189], ["binding domain", "PROTEIN", 196, 210], ["SARS\u2212CoV\u22122 spike protein", "PROTEIN", 218, 242], ["rS", "PROTEIN", 244, 246], ["human ACE2 29", "PROTEIN", 253, 266], ["human", "SPECIES", 253, 258], ["human", "SPECIES", 253, 258], ["Thymohydroquinone", "TEST", 0, 17], ["moderate docking energy", "PROBLEM", 25, 48], ["CoV", "TEST", 59, 62], ["ADP\u2212ribose", "TEST", 121, 131], ["RNA\u2212dependent RNA polymerase (RdRp", "PROBLEM", 155, 189], ["the SARS", "PROBLEM", 214, 222], ["CoV", "TEST", 223, 226], ["human ACE2", "TEST", 253, 263], ["moderate", "OBSERVATION_MODIFIER", 25, 33], ["docking energy", "OBSERVATION", 34, 48]]], ["Nigellidine showed high binding affinity SARS\u2212CoV\u22122 enzymes and proteins such as N- terminus-protenase (QHD43415_3), main-protease (6LU7), non-structural protein 2 (NSP2), spike-glycoprotein(6vsb), and nucleocapsid (QHD43423).", [["Nigellidine", "CHEMICAL", 0, 11], ["Nigellidine", "CHEMICAL", 0, 11], ["N", "CHEMICAL", 81, 82], ["Nigellidine", "SIMPLE_CHEMICAL", 0, 11], ["QHD43415_3", "GENE_OR_GENE_PRODUCT", 104, 114], ["6LU7", "GENE_OR_GENE_PRODUCT", 132, 136], ["non-structural protein 2", "GENE_OR_GENE_PRODUCT", 139, 163], ["NSP2", "GENE_OR_GENE_PRODUCT", 165, 169], ["spike-glycoprotein", "GENE_OR_GENE_PRODUCT", 172, 190], ["6vsb", "GENE_OR_GENE_PRODUCT", 191, 195], ["nucleocapsid", "GENE_OR_GENE_PRODUCT", 202, 214], ["QHD43423", "GENE_OR_GENE_PRODUCT", 216, 224], ["high binding affinity SARS\u2212CoV\u22122 enzymes", "PROTEIN", 19, 59], ["N- terminus", "PROTEIN", 81, 92], ["protenase", "PROTEIN", 93, 102], ["QHD43415_3", "PROTEIN", 104, 114], ["main-protease", "PROTEIN", 117, 130], ["6LU7", "PROTEIN", 132, 136], ["non-structural protein 2", "PROTEIN", 139, 163], ["NSP2", "PROTEIN", 165, 169], ["spike", "PROTEIN", 172, 177], ["glycoprotein", "PROTEIN", 178, 190], ["6vsb", "PROTEIN", 191, 195], ["nucleocapsid", "PROTEIN", 202, 214], ["QHD43423", "PROTEIN", 216, 224], ["Nigellidine", "TREATMENT", 0, 11], ["high binding affinity SARS", "PROBLEM", 19, 45], ["CoV\u22122 enzymes", "TEST", 46, 59], ["proteins", "TEST", 64, 72], ["non-structural protein", "TEST", 139, 161], ["NSP2", "TEST", 165, 169], ["spike-glycoprotein", "PROBLEM", 172, 190]]], ["Nigellidine had high binding energy with human receptors, inflammatory signal molecules and other proteins such as human IL1R (1itb), TNFR1 (1ncf), TNFR2 (3alq) 30.ResultsTherefore, the natural compounds found in NS such as nigellidine, \u03b1-Hederin, hederagenin, thymohydroquinone and thymoquinone were potentially active compounds that might inhibit coronavirus.", [["Nigellidine", "CHEMICAL", 0, 11], ["nigellidine", "CHEMICAL", 224, 235], ["\u03b1-Hederin", "CHEMICAL", 237, 246], ["hederagenin", "CHEMICAL", 248, 259], ["thymohydroquinone", "CHEMICAL", 261, 278], ["thymoquinone", "CHEMICAL", 283, 295], ["Nigellidine", "CHEMICAL", 0, 11], ["nigellidine", "CHEMICAL", 224, 235], ["\u03b1-Hederin", "CHEMICAL", 237, 246], ["hederagenin", "CHEMICAL", 248, 259], ["thymohydroquinone", "CHEMICAL", 261, 278], ["thymoquinone", "CHEMICAL", 283, 295], ["Nigellidine", "SIMPLE_CHEMICAL", 0, 11], ["human", "ORGANISM", 41, 46], ["human", "ORGANISM", 115, 120], ["IL1R", "GENE_OR_GENE_PRODUCT", 121, 125], ["1itb", "GENE_OR_GENE_PRODUCT", 127, 131], ["TNFR1", "GENE_OR_GENE_PRODUCT", 134, 139], ["TNFR2 (3alq) 30", "GENE_OR_GENE_PRODUCT", 148, 163], ["NS", "SIMPLE_CHEMICAL", 213, 215], ["nigellidine", "SIMPLE_CHEMICAL", 224, 235], ["\u03b1-Hederin", "SIMPLE_CHEMICAL", 237, 246], ["hederagenin", "SIMPLE_CHEMICAL", 248, 259], ["thymohydroquinone", "SIMPLE_CHEMICAL", 261, 278], ["thymoquinone", "SIMPLE_CHEMICAL", 283, 295], ["coronavirus", "ORGANISM", 349, 360], ["human receptors", "PROTEIN", 41, 56], ["inflammatory signal molecules", "PROTEIN", 58, 87], ["human IL1R", "PROTEIN", 115, 125], ["1itb", "PROTEIN", 127, 131], ["TNFR1", "PROTEIN", 134, 139], ["1ncf", "PROTEIN", 141, 145], ["TNFR2 (3alq) 30", "PROTEIN", 148, 163], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 115, 120], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 115, 120], ["Nigellidine", "TREATMENT", 0, 11], ["high binding energy", "PROBLEM", 16, 35], ["human receptors", "TREATMENT", 41, 56], ["inflammatory signal molecules", "PROBLEM", 58, 87], ["other proteins", "TREATMENT", 92, 106], ["human IL1R (1itb)", "TREATMENT", 115, 132], ["the natural compounds", "PROBLEM", 182, 203], ["NS", "TREATMENT", 213, 215], ["nigellidine", "TREATMENT", 224, 235], ["hederagenin", "TREATMENT", 248, 259], ["thymohydroquinone", "TREATMENT", 261, 278], ["thymoquinone", "TREATMENT", 283, 295], ["potentially active compounds", "PROBLEM", 301, 329], ["coronavirus", "PROBLEM", 349, 360]]], ["Preclinical evidence is required to determine the activity of NS against coronavirus.", [["coronavirus", "DISEASE", 73, 84], ["coronavirus", "ORGANISM", 73, 84], ["NS", "TREATMENT", 62, 64], ["coronavirus", "PROBLEM", 73, 84]]], ["If proven activity resulted from preclinical investigations, a clinical phase 1 trial of NS in patients with COVID-19 is suggested to explore its clinical activity.ConclusionsThis mini literature review documented the inhibitory effects of NS compounds against SARS-CoV-2 in several molecular docking studies.", [["COVID-19", "CHEMICAL", 109, 117], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["SARS-CoV", "SPECIES", 261, 269], ["preclinical investigations", "TEST", 33, 59], ["NS", "TREATMENT", 89, 91], ["COVID", "TREATMENT", 109, 114], ["NS compounds", "TREATMENT", 240, 252], ["SARS", "PROBLEM", 261, 265], ["CoV", "TEST", 266, 269]]], ["However, to our knowledge, there is no reported clinical trial of NS in human coronavirus cases.", [["coronavirus", "DISEASE", 78, 89], ["human", "ORGANISM", 72, 77], ["coronavirus", "ORGANISM", 78, 89], ["human", "SPECIES", 72, 77], ["human coronavirus", "SPECIES", 72, 89], ["NS", "TREATMENT", 66, 68], ["no", "UNCERTAINTY", 36, 38], ["human coronavirus", "ANATOMY", 72, 89]]], ["Therefore, we propose NS as a potential phytotherapy candidate in preclinical investigations followed by clinical investigations in the treatment of coronavirus diseases such as COVID-19.", [["coronavirus diseases", "DISEASE", 149, 169], ["COVID-19", "CHEMICAL", 178, 186], ["COVID-19", "CHEMICAL", 178, 186], ["coronavirus", "ORGANISM", 149, 160], ["NS", "TREATMENT", 22, 24], ["a potential phytotherapy", "TREATMENT", 28, 52], ["preclinical investigations", "TEST", 66, 92], ["clinical investigations", "TEST", 105, 128], ["coronavirus diseases", "PROBLEM", 149, 169], ["COVID", "TEST", 178, 183], ["coronavirus diseases", "OBSERVATION", 149, 169]]], ["Also, further in-silico investigation on other natural products from traditional medicines is suggested to apply them in the treatment of COVID-19.Declaration of Competing InterestNone", [["COVID-19", "CHEMICAL", 138, 146], ["other natural products", "TREATMENT", 41, 63], ["traditional medicines", "TREATMENT", 69, 90], ["COVID", "TEST", 138, 143]]]], "58850831e20df97fd07779cb47d64399417f7877": [["Letter to the editor Sex-mediated effects of ACE2 and TMPRSS2 on the incidence and severity of COVID-19; The need for genetic implementation Keywords: COVID-19 ACE2 TMPRSS2TO THE EDITOR:Inter-individual variability regarding incidence, severity and mortality rate of Corona Virus disease 2019 (COVID-19) outbreak, was recently recorded.", [["Corona Virus disease", "DISEASE", 267, 287], ["ACE2", "GENE_OR_GENE_PRODUCT", 45, 49], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 54, 61], ["Corona Virus", "ORGANISM", 267, 279], ["ACE2", "PROTEIN", 45, 49], ["TMPRSS2", "PROTEIN", 54, 61], ["ACE2", "PROTEIN", 160, 164], ["Corona Virus disease 2019 (COVID-19", "SPECIES", 267, 302], ["ACE2", "TREATMENT", 45, 49], ["TMPRSS2", "TREATMENT", 54, 61], ["COVID", "TEST", 95, 100], ["COVID", "TEST", 151, 156], ["severity", "PROBLEM", 236, 244], ["mortality rate", "TEST", 249, 263], ["Corona Virus disease", "PROBLEM", 267, 287], ["COVID", "TEST", 294, 299], ["outbreak", "PROBLEM", 304, 312], ["Corona Virus", "ANATOMY", 267, 279]]], ["Thus, a different approach of infection analysis is required.", [["infection", "DISEASE", 30, 39], ["infection analysis", "TEST", 30, 48], ["infection", "OBSERVATION", 30, 39]]], ["Human genetics, where different genetic polymorphisms of specific genes, might account for higher susceptibility and unexpected outcomes of COVID-19 infections in different population.", [["infections", "DISEASE", 149, 159], ["Human", "ORGANISM", 0, 5], ["COVID-19", "ORGANISM", 140, 148], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["higher susceptibility", "PROBLEM", 91, 112], ["COVID", "TEST", 140, 145]]], ["Recently, it was found that both Angiotensin Converting Enzyme 2 (ACE2) and Trans-membrane protease serine type 2 (TMPRSS2), are playing a crucial role for virus entry into host cells, where, ACE2 is considered the main receptor for (S) protein spike, through which the virus can attach to the target cells.", [["cells", "ANATOMY", 178, 183], ["cells", "ANATOMY", 301, 306], ["Angiotensin", "CHEMICAL", 33, 44], ["serine", "CHEMICAL", 100, 106], ["Angiotensin Converting Enzyme 2", "GENE_OR_GENE_PRODUCT", 33, 64], ["ACE2", "GENE_OR_GENE_PRODUCT", 66, 70], ["Trans-membrane protease serine type 2", "GENE_OR_GENE_PRODUCT", 76, 113], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 115, 122], ["host cells", "CELL", 173, 183], ["ACE2", "GENE_OR_GENE_PRODUCT", 192, 196], ["cells", "CELL", 301, 306], ["Angiotensin Converting Enzyme 2", "PROTEIN", 33, 64], ["ACE2", "PROTEIN", 66, 70], ["Trans-membrane protease serine type 2", "PROTEIN", 76, 113], ["TMPRSS2", "PROTEIN", 115, 122], ["host cells", "CELL_TYPE", 173, 183], ["ACE2", "PROTEIN", 192, 196], ["target cells", "CELL_TYPE", 294, 306], ["Angiotensin Converting Enzyme", "TEST", 33, 62], ["ACE2", "TEST", 66, 70], ["Trans-membrane protease serine type", "TREATMENT", 76, 111], ["ACE2", "TEST", 192, 196], ["protein spike", "PROBLEM", 237, 250], ["the virus", "PROBLEM", 266, 275], ["target cells", "OBSERVATION", 294, 306]]], ["While TMPRSS2 cleaves the (S) protein, allowing further fusion of virus and cellular membrane.", [["cellular membrane", "ANATOMY", 76, 93], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 6, 13], ["cellular membrane", "CELLULAR_COMPONENT", 76, 93], ["TMPRSS2", "PROTEIN", 6, 13], ["(S) protein", "PROTEIN", 26, 37], ["the (S) protein", "TEST", 22, 37], ["further fusion of virus and cellular membrane", "PROBLEM", 48, 93], ["virus", "OBSERVATION", 66, 71], ["cellular membrane", "OBSERVATION", 76, 93]]], ["Between supporters and opponents to the association of ACE and TMPRSS2 genetic polymorphisms to COVID-19, we will, briefly, overview and present the available scientific knowledge, about their role in the pathogenesis of COVID-19, up to the current day.TO THE EDITOR:Angiotensin Converting Enzyme can show contradictory roles in the context of COVID-19, as the reduced activity of ACE2 has been reported to be associated with acute respiratory distress syndrome (ARDS).", [["respiratory", "ANATOMY", 432, 443], ["Angiotensin", "CHEMICAL", 267, 278], ["acute respiratory distress syndrome", "DISEASE", 426, 461], ["ARDS", "DISEASE", 463, 467], ["COVID-19", "CHEMICAL", 344, 352], ["ACE", "GENE_OR_GENE_PRODUCT", 55, 58], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 63, 70], ["Angiotensin Converting Enzyme", "GENE_OR_GENE_PRODUCT", 267, 296], ["COVID-19", "GENE_OR_GENE_PRODUCT", 344, 352], ["ACE2", "GENE_OR_GENE_PRODUCT", 381, 385], ["ACE and TMPRSS2 genetic polymorphisms", "DNA", 55, 92], ["COVID-19", "DNA", 96, 104], ["ACE2", "PROTEIN", 381, 385], ["ACE and TMPRSS2 genetic polymorphisms", "TREATMENT", 55, 92], ["COVID", "TEST", 221, 226], ["Angiotensin Converting Enzyme", "TREATMENT", 267, 296], ["COVID", "TEST", 344, 349], ["the reduced activity of ACE2", "PROBLEM", 357, 385], ["acute respiratory distress syndrome", "PROBLEM", 426, 461], ["ARDS", "PROBLEM", 463, 467], ["acute", "OBSERVATION_MODIFIER", 426, 431], ["respiratory distress", "OBSERVATION", 432, 452], ["ARDS", "OBSERVATION", 463, 467]]], ["On the other hand, the increase in ACE2 expression was related to higher risk of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) activity, and development on the early disease phase [1] .Angiotensin converting enzyme genetic polymorphismsAngiotensin Converting Enzyme (ACE) can show numerous genetic variations, such as Insertion/Deletion (Ins/Del) functional polymorphism, with the deletion allele (Del) believed to show higher ACE activity, and reduced ACE2 expression [2] .", [["acute respiratory syndrome coronavirus", "DISEASE", 88, 126], ["Angiotensin", "CHEMICAL", 200, 211], ["Angiotensin", "CHEMICAL", 251, 262], ["ACE2", "GENE_OR_GENE_PRODUCT", 35, 39], ["SARS-COV-2", "GENE_OR_GENE_PRODUCT", 130, 140], ["Angiotensin converting enzyme", "GENE_OR_GENE_PRODUCT", 200, 229], ["Angiotensin Converting Enzyme", "GENE_OR_GENE_PRODUCT", 251, 280], ["ACE", "GENE_OR_GENE_PRODUCT", 282, 285], ["ACE", "GENE_OR_GENE_PRODUCT", 442, 445], ["ACE2", "GENE_OR_GENE_PRODUCT", 468, 472], ["ACE2", "PROTEIN", 35, 39], ["Angiotensin converting enzyme", "PROTEIN", 200, 229], ["Angiotensin Converting Enzyme", "PROTEIN", 251, 280], ["ACE", "PROTEIN", 282, 285], ["Insertion/Deletion (Ins/Del) functional polymorphism", "DNA", 333, 385], ["deletion allele", "DNA", 396, 411], ["Del", "DNA", 413, 416], ["ACE", "PROTEIN", 442, 445], ["ACE2", "PROTEIN", 468, 472], ["severe acute respiratory syndrome coronavirus", "SPECIES", 81, 126], ["the increase in ACE2 expression", "PROBLEM", 19, 50], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 81, 126], ["SARS", "TEST", 130, 134], ["COV", "TEST", 135, 138], ["the early disease phase", "PROBLEM", 171, 194], ["Angiotensin converting enzyme genetic polymorphisms", "PROBLEM", 200, 251], ["Angiotensin Converting Enzyme (ACE)", "TREATMENT", 251, 286], ["numerous genetic variations", "PROBLEM", 296, 323], ["Insertion/Deletion (Ins/Del)", "TREATMENT", 333, 361], ["functional polymorphism", "PROBLEM", 362, 385], ["higher ACE activity", "PROBLEM", 435, 454], ["reduced ACE2 expression", "PROBLEM", 460, 483], ["increase", "OBSERVATION_MODIFIER", 23, 31], ["severe", "OBSERVATION_MODIFIER", 81, 87], ["acute", "OBSERVATION_MODIFIER", 88, 93], ["respiratory syndrome", "OBSERVATION", 94, 114], ["genetic polymorphisms", "OBSERVATION", 230, 251]]], ["While Delanghe et al., has found negative correlation between ACE Del allele frequency and prevalence/mortality of COVID-19 in 33 countries, [3] , Sadaat et al., has argued against the association between the Del allele and COVID-19 [4] .", [["ACE", "GENE_OR_GENE_PRODUCT", 62, 65], ["ACE", "PROTEIN", 62, 65], ["Del allele", "DNA", 209, 219], ["COVID", "DNA", 224, 229], ["ACE Del allele frequency", "TREATMENT", 62, 86], ["COVID", "TREATMENT", 115, 120]]], ["Similarly, Chiu et al., also reported that ACE2 gene polymorphisms had failed to affect the outcome of severe acute respiratory syndrome [5] .Angiotensin converting enzyme genetic polymorphismsIt is worthy to mention that ACE2 gene is located on X-chromosome, which might raise the gender-related susceptibility hypothesis, leaving females to be potentially heterozygous (with lower sensitivity against severe infection) compared to males who are definitely hemizygous [6] .", [["X-chromosome", "ANATOMY", 246, 258], ["acute respiratory syndrome", "DISEASE", 110, 136], ["Angiotensin", "CHEMICAL", 142, 153], ["infection", "DISEASE", 410, 419], ["ACE2", "GENE_OR_GENE_PRODUCT", 43, 47], ["Angiotensin converting enzyme", "GENE_OR_GENE_PRODUCT", 142, 171], ["ACE2", "GENE_OR_GENE_PRODUCT", 222, 226], ["ACE2", "PROTEIN", 43, 47], ["Angiotensin converting enzyme", "PROTEIN", 142, 171], ["ACE2 gene", "DNA", 222, 231], ["X-chromosome", "DNA", 246, 258], ["ACE2 gene polymorphisms", "PROBLEM", 43, 66], ["severe acute respiratory syndrome", "PROBLEM", 103, 136], ["Angiotensin converting enzyme genetic polymorphisms", "PROBLEM", 142, 193], ["ACE2 gene", "PROBLEM", 222, 231], ["susceptibility hypothesis", "PROBLEM", 297, 322], ["heterozygous", "PROBLEM", 358, 370], ["severe infection", "PROBLEM", 403, 419], ["severe", "OBSERVATION_MODIFIER", 103, 109], ["acute", "OBSERVATION_MODIFIER", 110, 115], ["respiratory syndrome", "OBSERVATION", 116, 136], ["genetic polymorphisms", "OBSERVATION", 172, 193], ["heterozygous", "OBSERVATION", 358, 370], ["infection", "OBSERVATION", 410, 419]]], ["This seems to be in agreement with the finding that conversion of Angiotensin II to Angiotensin (1-7) by ACE2 was higher in males, suggesting an over-expression of ACE2 in men.", [["Angiotensin II", "CHEMICAL", 66, 80], ["Angiotensin (1-7)", "CHEMICAL", 84, 101], ["Angiotensin II", "GENE_OR_GENE_PRODUCT", 66, 80], ["Angiotensin (1-7", "GENE_OR_GENE_PRODUCT", 84, 100], ["ACE2", "GENE_OR_GENE_PRODUCT", 105, 109], ["ACE2", "GENE_OR_GENE_PRODUCT", 164, 168], ["men", "ORGANISM", 172, 175], ["Angiotensin II", "PROTEIN", 66, 80], ["ACE2", "PROTEIN", 105, 109], ["ACE2", "PROTEIN", 164, 168], ["men", "SPECIES", 172, 175], ["Angiotensin II to Angiotensin", "TREATMENT", 66, 95], ["ACE2", "TEST", 105, 109]]], ["In accordance to this, men were reported to be presented with 66 %-75 % of most severe cases [7] .", [["men", "ORGANISM", 23, 26], ["men", "SPECIES", 23, 26], ["most severe cases", "PROBLEM", 75, 92]]], ["Moreover, Jin et al., has reported that men with COVID-19 are at higher risk for worse outcomes (2.4 times higher), along with higher mortality rate, independent of age [7] .TMPRSS2 genetic polymorphismsBesides the role of TMPRSS2 in assisting (S) protein priming, it is also claimed to mediate sex-related effects.", [["men", "ORGANISM", 40, 43], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 174, 181], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 223, 230], ["TMPRSS2 genetic polymorphisms", "DNA", 174, 203], ["TMPRSS2", "PROTEIN", 223, 230], ["men", "SPECIES", 40, 43], ["COVID", "TEST", 49, 54], ["TMPRSS2 genetic polymorphisms", "PROBLEM", 174, 203], ["TMPRSS2 in assisting (S) protein priming", "TREATMENT", 223, 263]]], ["Being an androgen responsive gene, single nucleotide polymorphisms (SNPs) within the TMPRSS2 gene (21q22.3), seems to have key role in the general population (rs2070788, rs7364083, rs9974589), and in a sex-related perspective (rs8134378).", [["androgen", "CHEMICAL", 9, 17], ["androgen", "GENE_OR_GENE_PRODUCT", 9, 17], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 85, 92], ["androgen responsive gene", "DNA", 9, 33], ["TMPRSS2 gene", "DNA", 85, 97], ["21q22.3", "DNA", 99, 106], ["an androgen responsive gene", "PROBLEM", 6, 33], ["single nucleotide polymorphisms (SNPs)", "TREATMENT", 35, 73], ["the TMPRSS2 gene", "TEST", 81, 97]]], ["This may explain the higher expression of SARS-COV-2 in males, that might favor the virus fusion to membrane.", [["membrane", "ANATOMY", 100, 108], ["SARS-COV-2", "GENE_OR_GENE_PRODUCT", 42, 52], ["males", "ORGANISM", 56, 61], ["membrane", "CELLULAR_COMPONENT", 100, 108], ["COV", "PROTEIN", 47, 50], ["SARS", "PROBLEM", 42, 46], ["the virus fusion", "TREATMENT", 80, 96], ["SARS", "OBSERVATION", 42, 46], ["virus fusion", "OBSERVATION", 84, 96]]], ["This comes in line with the previous genome wide association studies on A(H1N1) and A (H7N9) influenza virus back in 2015 [8] .", [["A(H1N1)", "ORGANISM", 72, 79], ["A (H7N9) influenza virus", "ORGANISM", 84, 108], ["H7N9) influenza virus", "SPECIES", 87, 108], ["A (H7N9) influenza virus", "SPECIES", 84, 108], ["A (H7N9) influenza virus", "PROBLEM", 84, 108]]], ["On the other hand, the fall in estrogen levels in post-menopausal women in turn can then affects the TMPRSS2 gene expression, as the gene is also being responsive to estrogen signaling [9, 10] .", [["estrogen", "CHEMICAL", 31, 39], ["estrogen", "CHEMICAL", 166, 174], ["estrogen", "CHEMICAL", 31, 39], ["estrogen", "CHEMICAL", 166, 174], ["estrogen", "SIMPLE_CHEMICAL", 31, 39], ["women", "ORGANISM", 66, 71], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 101, 108], ["estrogen", "SIMPLE_CHEMICAL", 166, 174], ["TMPRSS2 gene", "DNA", 101, 113], ["women", "SPECIES", 66, 71], ["the fall in estrogen levels", "PROBLEM", 19, 46], ["fall", "OBSERVATION", 23, 27]]], ["Thus, the low levels of androgens in women can suffice to sustain TMPRSS2 expression.", [["androgens", "CHEMICAL", 24, 33], ["androgens", "SIMPLE_CHEMICAL", 24, 33], ["women", "ORGANISM", 37, 42], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 66, 73], ["TMPRSS2", "PROTEIN", 66, 73], ["women", "SPECIES", 37, 42]]], ["Lamy et al., also suggested that the putative androgen dependence for the virus cell entry relative to the higher expression of TMPRSS2 in males, could explain the higher male mortality with COVID-19 [11] .", [["cell", "ANATOMY", 80, 84], ["androgen", "CHEMICAL", 46, 54], ["COVID-19", "CHEMICAL", 191, 199], ["androgen", "GENE_OR_GENE_PRODUCT", 46, 54], ["cell", "CELL", 80, 84], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 128, 135], ["TMPRSS2", "PROTEIN", 128, 135], ["the putative androgen dependence", "PROBLEM", 33, 65], ["the virus cell entry", "PROBLEM", 70, 90], ["TMPRSS2 in males", "PROBLEM", 128, 144], ["COVID", "TEST", 191, 196]]], ["However, the transcriptional inhibition as a therapeutic strategy for COVID-19 is now to be implemented in knock-out mouse models [12] .TMPRSS2 genetic polymorphismsThe actual role of ACE Del allele in the incidence and mortality of COVID-19, is still debatable, and merit further studies and investigations.", [["COVID-19", "CHEMICAL", 70, 78], ["COVID-19", "CHEMICAL", 70, 78], ["mouse", "ORGANISM", 117, 122], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 136, 143], ["ACE Del", "GENE_OR_GENE_PRODUCT", 184, 191], ["TMPRSS2 genetic polymorphisms", "DNA", 136, 165], ["ACE Del allele", "DNA", 184, 198], ["mouse", "SPECIES", 117, 122], ["mouse", "SPECIES", 117, 122], ["a therapeutic strategy", "TREATMENT", 43, 65], ["COVID", "TEST", 70, 75], ["TMPRSS2 genetic polymorphisms", "PROBLEM", 136, 165], ["ACE Del allele", "TREATMENT", 184, 198], ["COVID", "TEST", 233, 238], ["merit further studies", "TEST", 267, 288], ["investigations", "TEST", 293, 307]]], ["Both ACE2 and TMPRSS2 over gene-expression in males, may raise the hypothesis of male predominance in COVID-", [["ACE2", "GENE_OR_GENE_PRODUCT", 5, 9], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 14, 21], ["ACE2", "PROTEIN", 5, 9], ["TMPRSS2", "PROTEIN", 14, 21], ["TMPRSS2", "OBSERVATION", 14, 21]]]], "5dea6b4bb78101e3d72f8e327646d1ba19004b41": [["The virus starts the cell infection by binding to ACE2, a major hub in multiple physiological processes: this binding can block ACE2 network activity.", [["cell", "ANATOMY", 21, 25], ["infection", "DISEASE", 26, 35], ["cell", "CELL", 21, 25], ["ACE2", "GENE_OR_GENE_PRODUCT", 50, 54], ["ACE2", "GENE_OR_GENE_PRODUCT", 128, 132], ["ACE2", "PROTEIN", 50, 54], ["ACE2", "PROTEIN", 128, 132], ["The virus", "PROBLEM", 0, 9], ["the cell infection", "PROBLEM", 17, 35], ["ACE2", "TEST", 50, 54], ["this binding", "PROBLEM", 105, 117], ["virus", "OBSERVATION", 4, 9], ["cell infection", "OBSERVATION", 21, 35], ["multiple", "OBSERVATION_MODIFIER", 71, 79], ["physiological processes", "OBSERVATION", 80, 103]]], ["However, the virus will enter the host cell when TMPRSS2 cleavages ACE2.", [["cell", "ANATOMY", 39, 43], ["host cell", "CELL", 34, 43], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 49, 56], ["ACE2", "GENE_OR_GENE_PRODUCT", 67, 71], ["TMPRSS2", "PROTEIN", 49, 56], ["ACE2", "PROTEIN", 67, 71], ["the virus", "PROBLEM", 9, 18], ["TMPRSS2 cleavages ACE2", "TREATMENT", 49, 71], ["virus", "OBSERVATION", 13, 18], ["host cell", "OBSERVATION", 34, 43]]], ["The first column depicts average gene and protein expression confidence for ACE2 receptor; the second column depicts average expression confidence of TMPRSS2.", [["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 76, 89], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 150, 157], ["ACE2 receptor", "PROTEIN", 76, 89], ["TMPRSS2", "PROTEIN", 150, 157], ["ACE2 receptor", "TREATMENT", 76, 89], ["TMPRSS2", "TEST", 150, 157]]], ["The mean and standard deviation of expression confidence across 69 genes/proteins of ACE2 network are presented in third and fourth columns, respectively.", [["ACE2", "GENE_OR_GENE_PRODUCT", 85, 89], ["ACE2", "PROTEIN", 85, 89], ["ACE2 network", "TREATMENT", 85, 97], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["third", "ANATOMY_MODIFIER", 115, 120], ["fourth", "ANATOMY_MODIFIER", 125, 131], ["columns", "ANATOMY_MODIFIER", 132, 139]]], ["Notice that lungs and respiratory system are ranked as #14-15 in this list, while heart and cardiovascular system #12-13.", [["lungs", "ANATOMY", 12, 17], ["respiratory system", "ANATOMY", 22, 40], ["heart", "ANATOMY", 82, 87], ["cardiovascular", "ANATOMY", 92, 106], ["lungs", "ORGAN", 12, 17], ["heart", "ORGAN", 82, 87], ["lungs", "ANATOMY", 12, 17], ["respiratory system", "ANATOMY", 22, 40], ["heart", "ANATOMY", 82, 87], ["cardiovascular system", "ANATOMY", 92, 113]]], ["Nervous and reproductive system are ranked as, #16-17 and #1-10, respectively.Integration of ACE2 network with SARS-CoV-2/Human Interactome.To identify how ACE2 network is connected with the SARS-CoV-2/Human Interactome, we included the previously published interactome into our analysis.", [["Nervous", "ANATOMICAL_SYSTEM", 0, 7], ["ACE2", "GENE_OR_GENE_PRODUCT", 93, 97], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 111, 121], ["Human", "ORGANISM", 122, 127], ["ACE2", "GENE_OR_GENE_PRODUCT", 156, 160], ["Human", "ORGANISM", 202, 207], ["ACE2", "PROTEIN", 93, 97], ["ACE2", "PROTEIN", 156, 160], ["SARS-CoV-2", "DNA", 191, 201], ["Human", "SPECIES", 122, 127], ["Human", "SPECIES", 202, 207], ["our analysis", "TEST", 275, 287]]], ["30 We found that three proteins from our network, ACE2, CLEC4M, and TMPRSS2, are directly interacting with virus glycoprotein S. In total, 45 proteins from the complete ACE2 network are interacting with 38 from 94 human host proteins for SARS-CoV-2.", [["ACE2", "GENE_OR_GENE_PRODUCT", 50, 54], ["CLEC4M", "GENE_OR_GENE_PRODUCT", 56, 62], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 68, 75], ["ACE2", "GENE_OR_GENE_PRODUCT", 169, 173], ["human", "ORGANISM", 214, 219], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 238, 248], ["ACE2", "PROTEIN", 50, 54], ["CLEC4M", "PROTEIN", 56, 62], ["TMPRSS2", "PROTEIN", 68, 75], ["virus glycoprotein", "PROTEIN", 107, 125], ["45 proteins", "PROTEIN", 139, 150], ["ACE2", "PROTEIN", 169, 173], ["human host proteins", "PROTEIN", 214, 233], ["human", "SPECIES", 214, 219], ["human", "SPECIES", 214, 219], ["SARS-CoV", "SPECIES", 238, 246], ["ACE2", "TEST", 50, 54], ["CLEC4M", "TEST", 56, 62], ["TMPRSS2", "TEST", 68, 75], ["SARS", "TEST", 238, 242], ["CoV", "TEST", 243, 246]]], ["The strongest connection between networks was associated with INS, which interacted with 12 host proteins from SARS-CoV-2/Human Interactome.", [["INS", "GENE_OR_GENE_PRODUCT", 62, 65], ["SARS-CoV-2", "ORGANISM", 111, 121], ["Human", "ORGANISM", 122, 127], ["INS", "PROTEIN", 62, 65], ["Human", "SPECIES", 122, 127], ["SARS-CoV", "SPECIES", 111, 119], ["INS", "PROBLEM", 62, 65]]], ["Other top interactors were CAT, CCL2, CDK4, CALM1 connected with at least 6 host proteins.", [["CAT", "GENE_OR_GENE_PRODUCT", 27, 30], ["CCL2", "GENE_OR_GENE_PRODUCT", 32, 36], ["CDK4", "GENE_OR_GENE_PRODUCT", 38, 42], ["CALM1", "GENE_OR_GENE_PRODUCT", 44, 49], ["CAT", "PROTEIN", 27, 30], ["CCL2", "PROTEIN", 32, 36], ["CDK4", "PROTEIN", 38, 42], ["CALM1", "PROTEIN", 44, 49], ["host proteins", "PROTEIN", 76, 89], ["CALM1", "TREATMENT", 44, 49]]], ["Among host proteins directly interacting with virus proteins, the strongest connection with ACE2 network occurs by ALB (31 interactors form ACE2 network) and CAV1 (13 interactors) (Figure 3 ).", [["ACE2", "GENE_OR_GENE_PRODUCT", 92, 96], ["ALB", "GENE_OR_GENE_PRODUCT", 115, 118], ["ACE2", "GENE_OR_GENE_PRODUCT", 140, 144], ["CAV1", "GENE_OR_GENE_PRODUCT", 158, 162], ["virus proteins", "PROTEIN", 46, 60], ["ACE2", "PROTEIN", 92, 96], ["ALB", "PROTEIN", 115, 118], ["ACE2 network", "PROTEIN", 140, 152], ["CAV1", "PROTEIN", 158, 162], ["13 interactors", "PROTEIN", 164, 178], ["virus proteins", "TREATMENT", 46, 60], ["ACE2 network", "TREATMENT", 92, 104], ["CAV1", "ANATOMY", 158, 162]]], ["Enrichment analysis of the signaling within ACE2-tissue specific network.", [["tissue", "ANATOMY", 49, 55], ["ACE2", "GENE_OR_GENE_PRODUCT", 44, 48], ["tissue", "TISSUE", 49, 55], ["ACE2", "PROTEIN", 44, 48], ["Enrichment analysis", "TEST", 0, 19]]], ["By applying enrichment analysis for analyzing signaling pathways associated with analyzed networks we used KEGG database and Reactome databases.", [["enrichment analysis", "TEST", 12, 31], ["analyzing signaling pathways", "PROBLEM", 36, 64], ["KEGG database", "TEST", 107, 120]]], ["According to the KEGG database, only the RAS and protein digestion and absorption pathways were shared between all six compared networks ( Figure 4B ).", [["RAS", "GENE_OR_GENE_PRODUCT", 41, 44], ["RAS", "PROTEIN", 41, 44], ["the KEGG database", "TEST", 13, 30], ["the RAS and protein digestion", "PROBLEM", 37, 66], ["absorption pathways", "TEST", 71, 90]]], ["Analysis of signaling pathways using the Reactome database showed analogous pathways, for metabolism of angiotensinogen to angiotensin and peptide hormone metabolism.", [["angiotensin", "CHEMICAL", 123, 134], ["angiotensinogen", "GENE_OR_GENE_PRODUCT", 104, 119], ["angiotensin", "SIMPLE_CHEMICAL", 123, 134], ["angiotensinogen", "PROTEIN", 104, 119], ["signaling pathways", "PROBLEM", 12, 30], ["the Reactome database", "TEST", 37, 58], ["analogous pathways", "PROBLEM", 66, 84], ["angiotensinogen to angiotensin", "TREATMENT", 104, 134], ["peptide hormone metabolism", "TEST", 139, 165]]], ["Reactome pathway analysis also showed that intrinsic pathway of fibrin clot formation, neutrophil degranulation, endothelial nitric oxide synthase (eNOS) Figure 2 .", [["fibrin clot", "ANATOMY", 64, 75], ["neutrophil", "ANATOMY", 87, 97], ["nitric oxide", "CHEMICAL", 125, 137], ["nitric oxide", "CHEMICAL", 125, 137], ["fibrin", "GENE_OR_GENE_PRODUCT", 64, 70], ["clot", "ORGANISM_SUBSTANCE", 71, 75], ["neutrophil", "CELL", 87, 97], ["endothelial nitric oxide synthase", "GENE_OR_GENE_PRODUCT", 113, 146], ["eNOS) Figure 2", "GENE_OR_GENE_PRODUCT", 148, 162], ["neutrophil", "CELL_TYPE", 87, 97], ["endothelial nitric oxide synthase", "PROTEIN", 113, 146], ["eNOS", "PROTEIN", 148, 152], ["Reactome pathway analysis", "TEST", 0, 25], ["fibrin clot formation", "PROBLEM", 64, 85], ["neutrophil degranulation", "TREATMENT", 87, 111], ["endothelial nitric oxide synthase", "TREATMENT", 113, 146], ["fibrin clot", "OBSERVATION", 64, 75], ["neutrophil degranulation", "OBSERVATION", 87, 111]]], ["Predicted ACE2 interaction network.", [["ACE2", "GENE_OR_GENE_PRODUCT", 10, 14], ["ACE2", "PROTEIN", 10, 14]]], ["(A) Complete ACE2 network, visualized as two circles sorted by the number of connections (degree) with other nodes.", [["nodes", "ANATOMY", 109, 114], ["ACE2", "GENE_OR_GENE_PRODUCT", 13, 17], ["ACE2", "PROTEIN", 13, 17], ["Complete ACE2 network", "TEST", 4, 25], ["other nodes", "PROBLEM", 103, 114], ["nodes", "OBSERVATION", 109, 114]]], ["The external circle depicts the first level ACE2 interactors; the internal circle depicts the second level of interactors, with genes which do not connect directly with ACE2.", [["ACE2", "GENE_OR_GENE_PRODUCT", 44, 48], ["ACE2", "GENE_OR_GENE_PRODUCT", 169, 173], ["ACE2 interactors", "PROTEIN", 44, 60], ["ACE2", "PROTEIN", 169, 173], ["external circle", "OBSERVATION", 4, 19], ["internal", "ANATOMY_MODIFIER", 66, 74], ["interactors", "OBSERVATION", 110, 121]]], ["For clarity, we showed only the edges associated with virus-related proteins (gene id in red).", [["virus-related proteins", "PROTEIN", 54, 76], ["the edges", "PROBLEM", 28, 37], ["virus", "PROBLEM", 54, 59], ["related proteins", "PROBLEM", 60, 76], ["edges", "OBSERVATION_MODIFIER", 32, 37], ["virus", "OBSERVATION", 54, 59]]], ["Edges associated with virus-related proteins are shown in red for first-level (direct) and in grey for the second--level (indirect) ACE2 interactors.", [["ACE2", "GENE_OR_GENE_PRODUCT", 132, 136], ["ACE2", "PROTEIN", 132, 136], ["virus", "PROBLEM", 22, 27], ["related proteins", "PROBLEM", 28, 44], ["virus", "OBSERVATION", 22, 27]]], ["Inset in the top right depicts the additional information for each gene/protein, as associated processes (blue letters), associated diseases (color-label ring) and expression confidence across key tissues (black bars).", [["tissues", "ANATOMY", 197, 204], ["tissues", "TISSUE", 197, 204], ["each gene/protein", "TREATMENT", 62, 79], ["associated diseases", "PROBLEM", 121, 140], ["right", "ANATOMY_MODIFIER", 17, 22]]], ["Inset in the bottom right depict the same network including all edges.", [["bottom", "ANATOMY_MODIFIER", 13, 19], ["right", "ANATOMY_MODIFIER", 20, 25], ["all edges", "OBSERVATION", 60, 69]]], ["Notice that the closest ACE2 interactors are REN and INS, which play a central role in the pathophysiology of a number of cardiovascular disorders.", [["cardiovascular", "ANATOMY", 122, 136], ["cardiovascular disorders", "DISEASE", 122, 146], ["ACE2", "GENE_OR_GENE_PRODUCT", 24, 28], ["REN", "GENE_OR_GENE_PRODUCT", 45, 48], ["INS", "GENE_OR_GENE_PRODUCT", 53, 56], ["cardiovascular", "ANATOMICAL_SYSTEM", 122, 136], ["ACE2 interactors", "PROTEIN", 24, 40], ["REN", "PROTEIN", 45, 48], ["INS", "PROTEIN", 53, 56], ["cardiovascular disorders", "PROBLEM", 122, 146], ["central", "ANATOMY_MODIFIER", 71, 78], ["cardiovascular", "ANATOMY", 122, 136]]], ["The following interactor is KNG1, essential for blood coagulation and assembly of the kallikrein-kinin system.", [["blood", "ANATOMY", 48, 53], ["KNG1", "GENE_OR_GENE_PRODUCT", 28, 32], ["blood", "ORGANISM_SUBSTANCE", 48, 53], ["kallikrein-kinin", "GENE_OR_GENE_PRODUCT", 86, 102], ["KNG1", "PROTEIN", 28, 32], ["kallikrein", "PROTEIN", 86, 96], ["blood coagulation", "TEST", 48, 65], ["the kallikrein-kinin system", "TREATMENT", 82, 109]]], ["In the network are present 11 virus-infection related proteins forming a dense connection with ACE2 and its top interactors which can affect its functionality.", [["infection", "DISEASE", 36, 45], ["ACE2", "GENE_OR_GENE_PRODUCT", 95, 99], ["ACE2", "PROTEIN", 95, 99], ["present 11 virus", "PROBLEM", 19, 35], ["infection", "PROBLEM", 36, 45], ["a dense connection with ACE2", "PROBLEM", 71, 99], ["infection", "OBSERVATION", 36, 45], ["dense", "OBSERVATION_MODIFIER", 73, 78], ["connection", "OBSERVATION", 79, 89]]], ["(B) Subsets of ACE2 network containing only highly expressed proteins in the heart, lung, and nervous system; analogous network for virus-related proteins (right). activation, innate immune system pathway, and protein metabolism related pathways were shared across all networks, except for virus-infection related proteins networks.", [["heart", "ANATOMY", 77, 82], ["lung", "ANATOMY", 84, 88], ["nervous system", "ANATOMY", 94, 108], ["infection", "DISEASE", 296, 305], ["ACE2", "GENE_OR_GENE_PRODUCT", 15, 19], ["heart", "ORGAN", 77, 82], ["lung", "ORGAN", 84, 88], ["nervous system", "ANATOMICAL_SYSTEM", 94, 108], ["ACE2", "PROTEIN", 15, 19], ["virus-related proteins", "PROTEIN", 132, 154], ["virus-infection related proteins networks", "PROTEIN", 290, 331], ["ACE2 network", "TREATMENT", 15, 27], ["highly expressed proteins in the heart, lung, and nervous system", "PROBLEM", 44, 108], ["virus", "PROBLEM", 132, 137], ["protein metabolism related pathways", "PROBLEM", 210, 245], ["virus", "PROBLEM", 290, 295], ["infection related proteins networks", "PROBLEM", 296, 331], ["proteins", "OBSERVATION", 61, 69], ["heart", "ANATOMY", 77, 82], ["lung", "ANATOMY", 84, 88], ["nervous system", "ANATOMY", 94, 108], ["right", "ANATOMY_MODIFIER", 156, 161], ["infection", "OBSERVATION", 296, 305]]], ["Platelet activation associated with formation of blood clots was enriched in lung and heart tissue, while digestion of dietary carbohydrate (KEGG) was enriched only in the complete network ( Figure 4A ).Enrichment analysis of the disease terms associated with ACE2-tissue specific network.We performed enrichment analysis of DisGenet disease and Rare Diseases AutoRIF database using EnrichR website to evaluate phenotypes associated with ACE2 interaction in different tissues.", [["Platelet", "ANATOMY", 0, 8], ["blood clots", "ANATOMY", 49, 60], ["lung", "ANATOMY", 77, 81], ["heart tissue", "ANATOMY", 86, 98], ["tissue", "ANATOMY", 265, 271], ["tissues", "ANATOMY", 468, 475], ["DisGenet disease", "DISEASE", 325, 341], ["carbohydrate", "CHEMICAL", 127, 139], ["Platelet", "CELL", 0, 8], ["blood clots", "ORGANISM_SUBSTANCE", 49, 60], ["lung", "ORGAN", 77, 81], ["heart tissue", "TISSUE", 86, 98], ["ACE2", "GENE_OR_GENE_PRODUCT", 260, 264], ["tissue", "TISSUE", 265, 271], ["ACE2", "GENE_OR_GENE_PRODUCT", 438, 442], ["tissues", "TISSUE", 468, 475], ["dietary carbohydrate", "PROTEIN", 119, 139], ["ACE2", "PROTEIN", 260, 264], ["EnrichR website", "DNA", 383, 398], ["ACE2", "PROTEIN", 438, 442], ["Platelet activation", "PROBLEM", 0, 19], ["blood clots", "PROBLEM", 49, 60], ["lung and heart tissue", "PROBLEM", 77, 98], ["Enrichment analysis", "TEST", 203, 222], ["the disease terms", "PROBLEM", 226, 243], ["enrichment analysis", "TEST", 302, 321], ["DisGenet disease", "PROBLEM", 325, 341], ["Rare Diseases", "PROBLEM", 346, 359], ["phenotypes", "PROBLEM", 411, 421], ["ACE2 interaction in different tissues", "PROBLEM", 438, 475], ["blood clots", "OBSERVATION", 49, 60], ["lung", "ANATOMY", 77, 81], ["heart", "ANATOMY", 86, 91], ["tissue", "ANATOMY_MODIFIER", 92, 98], ["disease", "OBSERVATION", 230, 237]]], ["It enabled us to identify the disease traits which would be helpful in precise identification of the risk groups of patients with COVID-19.", [["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 116, 124], ["the disease traits", "PROBLEM", 26, 44], ["COVID", "TEST", 130, 135], ["disease", "OBSERVATION", 30, 37]]], ["This analysis guides the identification of phenotypes which can be triggered by ACE2-network alterations in selected tissues.", [["tissues", "ANATOMY", 117, 124], ["ACE2", "GENE_OR_GENE_PRODUCT", 80, 84], ["tissues", "TISSUE", 117, 124], ["ACE2", "PROTEIN", 80, 84], ["This analysis", "TEST", 0, 13], ["phenotypes", "PROBLEM", 43, 53], ["ACE2", "TEST", 80, 84]]], ["Moreover, the analysis of rare traits enabled us to precisely characterise the consequences of alterations in the groups of ACE2-network related genes.Enrichment analysis of the disease terms associated with ACE2-tissue specific network.The analysis of non-cancerous diseases in the DisGenet database revealed that the highest number of genes from all analyzed networks was associated with following disease phenotypes (in the decreasing order): obesity, hypertensive disease, non-insulin dependent DM, congestive HF, coronary artery disease and atherosclerosis and were observed in all analyzed networks ( Figure 5A ).", [["tissue", "ANATOMY", 213, 219], ["non-cancerous", "ANATOMY", 253, 266], ["coronary artery", "ANATOMY", 518, 533], ["non-cancerous diseases", "DISEASE", 253, 275], ["obesity", "DISEASE", 446, 453], ["hypertensive disease", "DISEASE", 455, 475], ["non-insulin", "DISEASE", 477, 488], ["DM", "DISEASE", 499, 501], ["congestive HF", "DISEASE", 503, 516], ["coronary artery disease", "DISEASE", 518, 541], ["atherosclerosis", "DISEASE", 546, 561], ["ACE2", "GENE_OR_GENE_PRODUCT", 124, 128], ["ACE2", "GENE_OR_GENE_PRODUCT", 208, 212], ["tissue", "TISSUE", 213, 219], ["non-cancerous", "CANCER", 253, 266], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 518, 533], ["ACE2", "PROTEIN", 124, 128], ["ACE2", "PROTEIN", 208, 212], ["the analysis", "TEST", 10, 22], ["rare traits", "PROBLEM", 26, 37], ["Enrichment analysis", "TEST", 151, 170], ["the disease terms", "PROBLEM", 174, 191], ["The analysis", "TEST", 237, 249], ["non-cancerous diseases", "PROBLEM", 253, 275], ["the DisGenet database", "TEST", 279, 300], ["following disease phenotypes", "PROBLEM", 390, 418], ["obesity", "PROBLEM", 446, 453], ["hypertensive disease", "PROBLEM", 455, 475], ["non-insulin dependent DM", "PROBLEM", 477, 501], ["congestive HF", "PROBLEM", 503, 516], ["coronary artery disease", "PROBLEM", 518, 541], ["atherosclerosis", "PROBLEM", 546, 561], ["disease", "OBSERVATION", 178, 185], ["non-cancerous diseases", "OBSERVATION", 253, 275], ["highest", "OBSERVATION_MODIFIER", 319, 326], ["obesity", "OBSERVATION", 446, 453], ["hypertensive disease", "OBSERVATION", 455, 475], ["non-insulin dependent", "OBSERVATION_MODIFIER", 477, 498], ["congestive", "OBSERVATION_MODIFIER", 503, 513], ["HF", "OBSERVATION", 514, 516], ["coronary artery", "ANATOMY", 518, 533], ["disease", "OBSERVATION", 534, 541], ["atherosclerosis", "OBSERVATION", 546, 561]]], ["Enriched terms not enriched in virus-related network, but containing virusinfection related genes were: Alzheimer's disease, heart failure, diabetes mellitus, asthma and rheumatoid arthritis.Enrichment analysis of the disease terms associated with ACE2-tissue specific network.The analysis focused on 11 virus-infection related proteins and diseases shared with other networks, except for diseases mentioned in the last paragraph, revealed that the most significant ones were, SARS, virus diseases, MI and arteriosclerosis ( Figure 5A ).", [["heart", "ANATOMY", 125, 130], ["tissue", "ANATOMY", 253, 259], ["Alzheimer's disease", "DISEASE", 104, 123], ["heart failure", "DISEASE", 125, 138], ["diabetes mellitus", "DISEASE", 140, 157], ["asthma", "DISEASE", 159, 165], ["rheumatoid arthritis", "DISEASE", 170, 190], ["infection", "DISEASE", 310, 319], ["SARS, virus diseases", "DISEASE", 477, 497], ["MI", "DISEASE", 499, 501], ["arteriosclerosis", "DISEASE", 506, 522], ["heart", "ORGAN", 125, 130], ["ACE2", "GENE_OR_GENE_PRODUCT", 248, 252], ["tissue", "TISSUE", 253, 259], ["virusinfection related genes", "DNA", 69, 97], ["ACE2", "PROTEIN", 248, 252], ["Alzheimer's disease", "PROBLEM", 104, 123], ["heart failure", "PROBLEM", 125, 138], ["diabetes mellitus", "PROBLEM", 140, 157], ["asthma", "PROBLEM", 159, 165], ["rheumatoid arthritis", "PROBLEM", 170, 190], ["Enrichment analysis", "TEST", 191, 210], ["the disease terms", "PROBLEM", 214, 231], ["The analysis", "TEST", 277, 289], ["11 virus", "PROBLEM", 301, 309], ["infection", "PROBLEM", 310, 319], ["diseases", "PROBLEM", 341, 349], ["diseases", "PROBLEM", 389, 397], ["SARS", "PROBLEM", 477, 481], ["virus diseases", "PROBLEM", 483, 497], ["MI", "PROBLEM", 499, 501], ["arteriosclerosis", "PROBLEM", 506, 522], ["virus", "OBSERVATION", 31, 36], ["heart", "ANATOMY", 125, 130], ["failure", "OBSERVATION", 131, 138], ["diabetes mellitus", "OBSERVATION", 140, 157], ["asthma", "OBSERVATION", 159, 165], ["rheumatoid arthritis", "OBSERVATION", 170, 190], ["disease", "OBSERVATION", 218, 225], ["arteriosclerosis", "OBSERVATION", 506, 522]]], ["Additional enrichment analysis of rare disease terms is shown in Figure 5B .Enrichment analysis of the disease terms associated with ACE2-tissue specific network.ACE2 network related miRNA predictions.", [["tissue", "ANATOMY", 138, 144], ["ACE2", "GENE_OR_GENE_PRODUCT", 133, 137], ["tissue", "TISSUE", 138, 144], ["ACE2", "GENE_OR_GENE_PRODUCT", 162, 166], ["ACE2", "PROTEIN", 133, 137], ["ACE2", "PROTEIN", 162, 166], ["Additional enrichment analysis", "TEST", 0, 30], ["rare disease terms", "PROBLEM", 34, 52], ["Enrichment analysis", "TEST", 76, 95], ["the disease terms", "PROBLEM", 99, 116], ["miRNA predictions", "TREATMENT", 183, 200], ["rare", "OBSERVATION_MODIFIER", 34, 38], ["disease", "OBSERVATION", 39, 46], ["disease", "OBSERVATION", 103, 110], ["miRNA predictions", "OBSERVATION", 183, 200]]], ["We found 1954 miRNAs regulating components of the ACE2 interaction network.", [["ACE2", "GENE_OR_GENE_PRODUCT", 50, 54], ["ACE2", "PROTEIN", 50, 54], ["the ACE2 interaction network", "PROBLEM", 46, 74]]], ["In further analyses, we put special focus on miRNAs which regulated the highest number of the genes from the network as well including ACE2.", [["ACE2", "GENE_OR_GENE_PRODUCT", 135, 139], ["ACE2", "PROTEIN", 135, 139], ["further analyses", "TEST", 3, 19], ["miRNAs", "TREATMENT", 45, 51]]], ["Analysis of top 10 miRNAs regulating each network (complete network, heart, lung, nervous system tissues and virus-infection related proteins network) revealed overall 16 miRNAs ( Figure 6 ).", [["heart", "ANATOMY", 69, 74], ["lung", "ANATOMY", 76, 80], ["nervous system tissues", "ANATOMY", 82, 104], ["complete network", "MULTI-TISSUE_STRUCTURE", 51, 67], ["heart", "ORGAN", 69, 74], ["lung", "ORGAN", 76, 80], ["nervous system tissues", "TISSUE", 82, 104], ["Analysis", "TEST", 0, 8], ["virus", "PROBLEM", 109, 114], ["infection", "PROBLEM", 115, 124], ["heart", "ANATOMY", 69, 74], ["lung", "ANATOMY", 76, 80], ["nervous", "ANATOMY", 82, 89], ["16 miRNAs", "OBSERVATION_MODIFIER", 168, 177]]], ["Five of them were shared between all networks (hsa-miR-302c-5p, hsa-miR-27a-3p, hsa-miR-1305, hsa-miR-587, hsa-miR-26b-5p) ( Figure 6C ).", [["hsa-miR-302c-5p", "GENE_OR_GENE_PRODUCT", 47, 62], ["hsa-miR-27a-3p", "GENE_OR_GENE_PRODUCT", 64, 78], ["hsa-miR-1305", "GENE_OR_GENE_PRODUCT", 80, 92], ["hsa-miR-587", "GENE_OR_GENE_PRODUCT", 94, 105], ["hsa-miR-26b-5p", "GENE_OR_GENE_PRODUCT", 107, 121], ["hsa-miR", "PROTEIN", 47, 54], ["hsa", "DNA", 80, 83], ["hsa", "DNA", 94, 97], ["hsa", "DNA", 107, 110], ["26b", "DNA", 115, 118], ["hsa-miR", "TEST", 47, 54], ["hsa-miR", "TEST", 80, 87], ["hsa-miR", "TEST", 94, 101], ["hsa-miR", "TEST", 107, 114]]], ["Signaling pathways associated with 36 genes regulated by those top miRNAs included: RAS pathway, AGE-RAGE signaling pathway in diabetic complications and the Apelin signaling pathway.", [["diabetic complications", "DISEASE", 127, 149], ["RAS", "GENE_OR_GENE_PRODUCT", 84, 87], ["AGE-RAGE", "GENE_OR_GENE_PRODUCT", 97, 105], ["Apelin", "GENE_OR_GENE_PRODUCT", 158, 164], ["RAS", "PROTEIN", 84, 87], ["AGE", "PROTEIN", 97, 100], ["RAGE", "PROTEIN", 101, 105], ["Apelin", "PROTEIN", 158, 164], ["Signaling pathways", "PROBLEM", 0, 18], ["RAS pathway", "TEST", 84, 95], ["diabetic complications", "PROBLEM", 127, 149]]], ["We also observed enrichment signaling pathways associated with the following diseases: Chagas disease, diseases with heightened arterial wall shear stress, atherosclerosis, Alzheimer's disease, and malaria ( Figure 6B ). performed pathway enrichment analysis in the complete ACE2 network (left-most column of symbols) and also in subsets of this network expressed in the heart, lung, and nervous system; we performed this same analysis also for 11 virus-infection related proteins (right-most column of symbols, grey numbers).", [["arterial wall", "ANATOMY", 128, 141], ["heart", "ANATOMY", 371, 376], ["lung", "ANATOMY", 378, 382], ["nervous system", "ANATOMY", 388, 402], ["Chagas disease", "DISEASE", 87, 101], ["atherosclerosis", "DISEASE", 156, 171], ["Alzheimer's disease", "DISEASE", 173, 192], ["malaria", "DISEASE", 198, 205], ["infection", "DISEASE", 454, 463], ["ACE2", "GENE_OR_GENE_PRODUCT", 275, 279], ["heart", "ORGAN", 371, 376], ["lung", "ORGAN", 378, 382], ["nervous system", "ANATOMICAL_SYSTEM", 388, 402], ["ACE2 network", "PROTEIN", 275, 287], ["Chagas disease", "PROBLEM", 87, 101], ["diseases", "PROBLEM", 103, 111], ["heightened arterial wall shear stress", "PROBLEM", 117, 154], ["atherosclerosis", "PROBLEM", 156, 171], ["Alzheimer's disease", "PROBLEM", 173, 192], ["malaria", "PROBLEM", 198, 205], ["pathway enrichment analysis", "TEST", 231, 258], ["the complete ACE2 network", "TEST", 262, 287], ["this same analysis", "TEST", 417, 435], ["11 virus", "PROBLEM", 445, 453], ["infection related proteins", "PROBLEM", 454, 480], ["Chagas disease", "OBSERVATION", 87, 101], ["arterial", "ANATOMY_MODIFIER", 128, 136], ["wall", "ANATOMY_MODIFIER", 137, 141], ["shear stress", "OBSERVATION", 142, 154], ["atherosclerosis", "OBSERVATION", 156, 171], ["Alzheimer's disease", "OBSERVATION", 173, 192], ["malaria", "OBSERVATION", 198, 205], ["left", "ANATOMY_MODIFIER", 289, 293], ["heart", "ANATOMY", 371, 376], ["lung", "ANATOMY", 378, 382], ["nervous system", "ANATOMY", 388, 402], ["right", "ANATOMY_MODIFIER", 482, 487], ["most column", "OBSERVATION_MODIFIER", 488, 499]]], ["All circles presented on the graph are associated with significantly enriched pathwyas (FDR corrected p-value <0.05).", [["significantly enriched pathwyas", "PROBLEM", 55, 86], ["p-value", "TEST", 102, 109], ["circles", "OBSERVATION_MODIFIER", 4, 11]]], ["Pathways marked with asterisks include the ACE2 gene.", [["ACE2", "GENE_OR_GENE_PRODUCT", 43, 47], ["ACE2 gene", "DNA", 43, 52], ["asterisks", "PROBLEM", 21, 30], ["marked", "OBSERVATION_MODIFIER", 9, 15]]], ["Notice that all analyzed datasets showed enrichment of pathways related to Renin-angiotensin system and Protein digestion and absorption in both databases.", [["angiotensin", "CHEMICAL", 81, 92], ["Renin-angiotensin", "GENE_OR_GENE_PRODUCT", 75, 92], ["Renin", "PROTEIN", 75, 80], ["enrichment of pathways", "PROBLEM", 41, 63], ["Renin-angiotensin system", "TREATMENT", 75, 99], ["Protein digestion", "PROBLEM", 104, 121], ["Protein digestion", "OBSERVATION", 104, 121]]], ["The pathways for \"eNOS activation\", \"Intrinsic Pathway of Fibrin Clot Formation\", \"Immune System (Reactome)\", \"AGE-RAGE signaling pathway in diabetic complications'' , and \"Apelin signaling pathway (KEEG)\" were enriched in all analyzed tissues.", [["tissues", "ANATOMY", 236, 243], ["diabetic complications", "DISEASE", 141, 163], ["NOS", "GENE_OR_GENE_PRODUCT", 19, 22], ["AGE", "SIMPLE_CHEMICAL", 111, 114], ["RAGE", "GENE_OR_GENE_PRODUCT", 115, 119], ["Apelin", "GENE_OR_GENE_PRODUCT", 173, 179], ["tissues", "TISSUE", 236, 243], ["NOS", "PROTEIN", 19, 22], ["AGE", "PROTEIN", 111, 114], ["RAGE", "PROTEIN", 115, 119], ["Apelin", "PROTEIN", 173, 179], ["Fibrin Clot Formation", "PROBLEM", 58, 79], ["diabetic complications", "PROBLEM", 141, 163], ["Fibrin Clot", "OBSERVATION", 58, 69]]], ["Specific on heart tissue, the \"Adrenergic signaling in cardiomyocytes (Reactome)\" was enriched.", [["heart tissue", "ANATOMY", 12, 24], ["cardiomyocytes", "ANATOMY", 55, 69], ["heart tissue", "TISSUE", 12, 24], ["cardiomyocytes", "CELL", 55, 69], ["cardiomyocytes", "CELL_TYPE", 55, 69], ["Specific on heart tissue", "PROBLEM", 0, 24], ["heart", "ANATOMY", 12, 17], ["tissue", "OBSERVATION", 18, 24], ["cardiomyocytes", "ANATOMY", 55, 69]]], ["Top 80 potential COVID-19 risk groups, from common and rare diseases significantly associated with ACE2 interaction networks.", [["ACE2", "GENE_OR_GENE_PRODUCT", 99, 103], ["ACE2", "PROTEIN", 99, 103], ["COVID", "TEST", 17, 22], ["rare diseases", "PROBLEM", 55, 68], ["ACE2 interaction networks", "PROBLEM", 99, 124], ["diseases", "OBSERVATION", 60, 68]]], ["This list is based on enrichment analysis of DisGeNET, analyzed through EnrichR database.", [["DisGeNET", "DNA", 45, 53], ["EnrichR database", "DNA", 72, 88], ["enrichment analysis", "TEST", 22, 41]]], ["We performed disease enrichment analysis in the complete ACE2 network (left-most column of symbols) and also in subsets of this network expressed in the heart, lung , and nervous system; we performed this same analysis also for 11 virus-infection related proteins (right-most column of symbols).", [["heart", "ANATOMY", 153, 158], ["lung", "ANATOMY", 160, 164], ["nervous system", "ANATOMY", 171, 185], ["infection", "DISEASE", 237, 246], ["ACE2", "GENE_OR_GENE_PRODUCT", 57, 61], ["heart", "ORGAN", 153, 158], ["lung", "ORGAN", 160, 164], ["nervous system", "ANATOMICAL_SYSTEM", 171, 185], ["ACE2 network", "PROTEIN", 57, 69], ["disease enrichment analysis", "TEST", 13, 40], ["the complete ACE2 network", "TEST", 44, 69], ["this same analysis", "TEST", 200, 218], ["11 virus", "PROBLEM", 228, 236], ["infection related proteins", "PROBLEM", 237, 263], ["left", "ANATOMY_MODIFIER", 71, 75], ["most column", "OBSERVATION_MODIFIER", 76, 87], ["heart", "ANATOMY", 153, 158], ["lung", "ANATOMY", 160, 164], ["nervous system", "ANATOMY", 171, 185], ["right", "ANATOMY_MODIFIER", 265, 270], ["most column", "OBSERVATION_MODIFIER", 271, 282]]], ["Diseases marked with asterisks include the ACE2 gene.", [["ACE2", "GENE_OR_GENE_PRODUCT", 43, 47], ["ACE2 gene", "DNA", 43, 52], ["Diseases", "PROBLEM", 0, 8], ["asterisks", "PROBLEM", 21, 30], ["the ACE2 gene", "TREATMENT", 39, 52]]], ["For heart, lung and nervous system tissue, we used the cutoff of expression confidence >2, obtained from Tissue2.0 database.", [["heart", "ANATOMY", 4, 9], ["lung", "ANATOMY", 11, 15], ["nervous system tissue", "ANATOMY", 20, 41], ["heart, lung and nervous system", "DISEASE", 4, 34], ["heart", "ORGAN", 4, 9], ["lung", "ORGAN", 11, 15], ["nervous system tissue", "TISSUE", 20, 41], ["heart, lung and nervous system tissue", "PROBLEM", 4, 41], ["expression confidence", "TEST", 65, 86], ["heart", "ANATOMY", 4, 9], ["lung", "ANATOMY", 11, 15], ["nervous system", "ANATOMY", 20, 34]]], ["All circles presented on the graph are associated with significantly enriched diseases terms (FDR corrected p-value <0.05).", [["significantly enriched diseases terms", "PROBLEM", 55, 92], ["FDR corrected p-value", "TEST", 94, 115], ["circles", "OBSERVATION_MODIFIER", 4, 11], ["significantly", "OBSERVATION_MODIFIER", 55, 68], ["enriched", "OBSERVATION_MODIFIER", 69, 77], ["diseases", "OBSERVATION", 78, 86]]], ["We did not include cancer-related diseases in this analysis.", [["cancer", "ANATOMY", 19, 25], ["cancer", "DISEASE", 19, 25], ["cancer", "CANCER", 19, 25], ["cancer", "PROBLEM", 19, 25], ["diseases", "PROBLEM", 34, 42], ["this analysis", "TEST", 46, 59], ["cancer", "OBSERVATION", 19, 25]]], ["Terms marked with * symbols include ACE2 gene (all except \"asthma\" include it).", [["asthma", "DISEASE", 59, 65], ["ACE2", "GENE_OR_GENE_PRODUCT", 36, 40], ["ACE2 gene", "DNA", 36, 45], ["ACE2 gene", "PROBLEM", 36, 45], ["asthma", "PROBLEM", 59, 65], ["asthma", "OBSERVATION", 59, 65]]], ["The highest number of genes was observed in disease terms shared between all of the networks: SARS, Marburg hemorrhagic fever, hyperinsulinism due to glutamate dehydrogenase deficiency, hereditary hemorrhagic telangiectasia, Ebola virus disease.", [["SARS", "DISEASE", 94, 98], ["Marburg hemorrhagic fever", "DISEASE", 100, 125], ["hyperinsulinism", "DISEASE", 127, 142], ["glutamate", "CHEMICAL", 150, 159], ["hereditary hemorrhagic telangiectasia", "DISEASE", 186, 223], ["Ebola virus disease", "DISEASE", 225, 244], ["glutamate", "CHEMICAL", 150, 159], ["glutamate dehydrogenase", "GENE_OR_GENE_PRODUCT", 150, 173], ["Ebola virus", "ORGANISM", 225, 236], ["glutamate dehydrogenase", "PROTEIN", 150, 173], ["Ebola virus", "SPECIES", 225, 236], ["Ebola virus", "SPECIES", 225, 236], ["SARS", "PROBLEM", 94, 98], ["Marburg hemorrhagic fever", "PROBLEM", 100, 125], ["hyperinsulinism", "PROBLEM", 127, 142], ["glutamate dehydrogenase deficiency", "PROBLEM", 150, 184], ["hereditary hemorrhagic telangiectasia", "PROBLEM", 186, 223], ["Ebola virus disease", "PROBLEM", 225, 244], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18], ["glutamate dehydrogenase deficiency", "OBSERVATION", 150, 184], ["hereditary", "OBSERVATION_MODIFIER", 186, 196], ["hemorrhagic", "OBSERVATION_MODIFIER", 197, 208], ["telangiectasia", "OBSERVATION", 209, 223], ["Ebola virus disease", "OBSERVATION", 225, 244]]], ["Enriched terms not enriched in virus-related network but containing virusrelated genes were kallikrein hypertension, coarctation of aorta dominant.", [["aorta", "ANATOMY", 132, 137], ["hypertension", "DISEASE", 103, 115], ["coarctation of aorta dominant", "DISEASE", 117, 146], ["kallikrein", "GENE_OR_GENE_PRODUCT", 92, 102], ["aorta", "MULTI-TISSUE_STRUCTURE", 132, 137], ["virusrelated genes", "DNA", 68, 86], ["kallikrein hypertension", "PROBLEM", 92, 115], ["coarctation of aorta dominant", "PROBLEM", 117, 146], ["virus", "OBSERVATION", 31, 36], ["kallikrein hypertension", "OBSERVATION", 92, 115], ["coarctation", "OBSERVATION", 117, 128], ["aorta", "ANATOMY", 132, 137], ["dominant", "OBSERVATION_MODIFIER", 138, 146]]], ["Analysis focused on 11 virus-related proteins and diseases shared with other networks showed that the most significant were, except for mentioned ones also Krabbe leukodystrophy.DiscussionIn the current study, we characterized the interaction between SARS-CoV-2 infection and ACE2 functional networks with a focus on CVD.", [["Krabbe leukodystrophy", "DISEASE", 156, 177], ["CVD", "DISEASE", 317, 320], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 251, 261], ["ACE2", "GENE_OR_GENE_PRODUCT", 276, 280], ["ACE2", "PROTEIN", 276, 280], ["SARS-CoV", "SPECIES", 251, 259], ["Analysis", "TEST", 0, 8], ["11 virus", "PROBLEM", 20, 28], ["diseases", "PROBLEM", 50, 58], ["Krabbe leukodystrophy", "PROBLEM", 156, 177], ["the current study", "TEST", 191, 208], ["SARS", "PROBLEM", 251, 255], ["CoV-2 infection", "PROBLEM", 256, 271], ["ACE2 functional networks", "PROBLEM", 276, 300], ["CVD", "PROBLEM", 317, 320], ["Krabbe leukodystrophy", "OBSERVATION", 156, 177]]], ["Using data mining and bioinformatic tools, we described the ACE2 interaction network and evaluated its expression.", [["ACE2", "GENE_OR_GENE_PRODUCT", 60, 64], ["ACE2", "PROTEIN", 60, 64], ["bioinformatic tools", "TEST", 22, 41]]], ["The main findings of this analysis are the following:Discussion(1) Expression of ACE2 is similar in lungs and heart, which provides a rationale why the cardiovascular system is also a target of SARS-CoV-2 infection; (2) Change in the heart-relevant ACE2 interaction network by SARS-CoV-2 binding to the receptor likely leads to disturbances in signaling pathways linked to cardiac adverse outcomes; (3) Genes, which are altered in patients with cardiovascular risk factors (as DPP4, CCL2 and ANPEP) are extensively connected with top regulators of the ACE2 network; (4) Specific miRNAs (miR-302c-5p, miR-1305, miR-587, miR-26b-5p, and miR-27a-3p) are shared as top regulators between the heart-specific network, complete ACE2 network, virus-infection related proteins network, lung, and nervous system networks;The high expression of ACE2 in cardiovascular system explains why SARS-CoV-2 infection may target the heart.Recently published studies suggested that the highest expression of ACE2 was found in the digestive tract, followed by testis and kidney.", [["lungs", "ANATOMY", 100, 105], ["heart", "ANATOMY", 110, 115], ["cardiovascular system", "ANATOMY", 152, 173], ["heart", "ANATOMY", 234, 239], ["cardiac", "ANATOMY", 373, 380], ["cardiovascular", "ANATOMY", 445, 459], ["heart", "ANATOMY", 688, 693], ["lung", "ANATOMY", 777, 781], ["nervous system networks", "ANATOMY", 787, 810], ["cardiovascular system", "ANATOMY", 842, 863], ["heart", "ANATOMY", 913, 918], ["digestive tract", "ANATOMY", 1009, 1024], ["testis", "ANATOMY", 1038, 1044], ["kidney", "ANATOMY", 1049, 1055], ["infection", "DISEASE", 205, 214], ["infection", "DISEASE", 741, 750], ["SARS", "DISEASE", 877, 881], ["infection", "DISEASE", 888, 897], ["ACE2", "GENE_OR_GENE_PRODUCT", 81, 85], ["lungs", "ORGAN", 100, 105], ["heart", "ORGAN", 110, 115], ["cardiovascular", "ANATOMICAL_SYSTEM", 152, 166], ["SARS-CoV-2", "ORGANISM", 194, 204], ["heart", "ORGAN", 234, 239], ["ACE2", "GENE_OR_GENE_PRODUCT", 249, 253], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 277, 287], ["patients", "ORGANISM", 431, 439], ["cardiovascular risk factors", "GENE_OR_GENE_PRODUCT", 445, 472], ["DPP4", "GENE_OR_GENE_PRODUCT", 477, 481], ["CCL2", "GENE_OR_GENE_PRODUCT", 483, 487], ["ANPEP", "GENE_OR_GENE_PRODUCT", 492, 497], ["ACE2", "GENE_OR_GENE_PRODUCT", 552, 556], ["miR-302c-5p", "GENE_OR_GENE_PRODUCT", 587, 598], ["miR-1305", "GENE_OR_GENE_PRODUCT", 600, 608], ["miR-587", "GENE_OR_GENE_PRODUCT", 610, 617], ["miR-26b-5p", "GENE_OR_GENE_PRODUCT", 619, 629], ["miR-27a-3p", "GENE_OR_GENE_PRODUCT", 635, 645], ["heart", "ORGAN", 688, 693], ["ACE2", "GENE_OR_GENE_PRODUCT", 721, 725], ["lung", "ORGAN", 777, 781], ["nervous system networks", "MULTI-TISSUE_STRUCTURE", 787, 810], ["ACE2", "GENE_OR_GENE_PRODUCT", 834, 838], ["cardiovascular", "ANATOMICAL_SYSTEM", 842, 856], ["system", "ANATOMICAL_SYSTEM", 857, 863], ["SARS-CoV-2", "ORGANISM", 877, 887], ["heart", "ORGAN", 913, 918], ["ACE2", "GENE_OR_GENE_PRODUCT", 987, 991], ["digestive tract", "ORGAN", 1009, 1024], ["testis", "ORGAN", 1038, 1044], ["kidney", "ORGAN", 1049, 1055], ["ACE2", "PROTEIN", 81, 85], ["ACE2", "PROTEIN", 249, 253], ["cardiovascular risk factors", "PROTEIN", 445, 472], ["DPP4", "PROTEIN", 477, 481], ["CCL2", "PROTEIN", 483, 487], ["ANPEP", "PROTEIN", 492, 497], ["ACE2", "PROTEIN", 552, 556], ["miR", "DNA", 600, 603], ["miR", "DNA", 610, 613], ["miR-26b-5p", "DNA", 619, 629], ["miR-27a-3p", "DNA", 635, 645], ["ACE2", "PROTEIN", 721, 725], ["ACE2", "PROTEIN", 834, 838], ["ACE2", "PROTEIN", 987, 991], ["patients", "SPECIES", 431, 439], ["this analysis", "TEST", 21, 34], ["ACE2", "TEST", 81, 85], ["SARS", "PROBLEM", 194, 198], ["CoV-2 infection", "PROBLEM", 199, 214], ["Change in the heart", "PROBLEM", 220, 239], ["disturbances in signaling pathways", "PROBLEM", 328, 362], ["cardiac adverse outcomes", "PROBLEM", 373, 397], ["cardiovascular risk factors", "PROBLEM", 445, 472], ["DPP4", "TEST", 477, 481], ["miR", "TEST", 610, 613], ["miR", "TEST", 619, 622], ["miR", "TEST", 635, 638], ["complete ACE2 network", "TEST", 712, 733], ["virus", "PROBLEM", 735, 740], ["infection", "PROBLEM", 741, 750], ["ACE2 in cardiovascular system", "PROBLEM", 834, 863], ["SARS", "PROBLEM", 877, 881], ["CoV-2 infection", "PROBLEM", 882, 897], ["Recently published studies", "TEST", 919, 945], ["the highest expression of ACE2", "PROBLEM", 961, 991], ["main", "OBSERVATION_MODIFIER", 4, 8], ["lungs", "ANATOMY", 100, 105], ["heart", "ANATOMY", 110, 115], ["infection", "OBSERVATION", 205, 214], ["heart", "ANATOMY", 234, 239], ["heart", "ANATOMY", 688, 693], ["lung", "ANATOMY", 777, 781], ["high", "OBSERVATION_MODIFIER", 815, 819], ["cardiovascular system", "ANATOMY", 842, 863], ["infection", "OBSERVATION", 888, 897], ["heart", "ANATOMY", 913, 918], ["digestive tract", "ANATOMY", 1009, 1024], ["testis", "ANATOMY", 1038, 1044], ["kidney", "ANATOMY", 1049, 1055]]], ["31, 32 Our analysis shows the highest expression of ACE2 in the genitourinary tract and related tissues.", [["genitourinary tract", "ANATOMY", 64, 83], ["tissues", "ANATOMY", 96, 103], ["ACE2", "GENE_OR_GENE_PRODUCT", 52, 56], ["genitourinary tract", "ORGAN", 64, 83], ["tissues", "TISSUE", 96, 103], ["ACE2", "PROTEIN", 52, 56], ["Our analysis", "TEST", 7, 19], ["ACE2 in the genitourinary tract", "PROBLEM", 52, 83], ["highest", "OBSERVATION_MODIFIER", 30, 37], ["expression", "OBSERVATION_MODIFIER", 38, 48], ["ACE2", "OBSERVATION", 52, 56], ["genitourinary tract", "ANATOMY", 64, 83]]], ["Moreover, we found in the genitourinary tract the highest co-expression of TMPRSS2 gene that is known to positively regulate viral entry into the host cell via proteolytic cleavage of ACE2.", [["genitourinary tract", "ANATOMY", 26, 45], ["cell", "ANATOMY", 151, 155], ["genitourinary tract", "ORGAN", 26, 45], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 75, 82], ["host cell", "CELL", 146, 155], ["ACE2", "GENE_OR_GENE_PRODUCT", 184, 188], ["TMPRSS2 gene", "DNA", 75, 87], ["ACE2", "PROTEIN", 184, 188], ["TMPRSS2 gene", "PROBLEM", 75, 87], ["proteolytic cleavage of ACE2", "TREATMENT", 160, 188], ["genitourinary tract", "ANATOMY", 26, 45], ["viral", "OBSERVATION", 125, 130], ["host cell", "OBSERVATION", 146, 155]]], ["Our analysis also supports the findings of a previous study using integrated analyses of single-cell atlases showing a high expression of ACE2 in ventricular cardiomyocytes, heart macrophages, and pericytes of the heart, lung, and kidney.", [["cell", "ANATOMY", 96, 100], ["ventricular cardiomyocytes", "ANATOMY", 146, 172], ["heart macrophages", "ANATOMY", 174, 191], ["pericytes", "ANATOMY", 197, 206], ["heart", "ANATOMY", 214, 219], ["lung", "ANATOMY", 221, 225], ["kidney", "ANATOMY", 231, 237], ["single-cell", "CELL", 89, 100], ["ACE2", "GENE_OR_GENE_PRODUCT", 138, 142], ["ventricular cardiomyocytes", "CELL", 146, 172], ["heart macrophages", "CELL", 174, 191], ["pericytes", "CELL", 197, 206], ["heart", "ORGAN", 214, 219], ["lung", "ORGAN", 221, 225], ["kidney", "ORGAN", 231, 237], ["ACE2", "PROTEIN", 138, 142], ["ventricular cardiomyocytes", "CELL_TYPE", 146, 172], ["heart macrophages", "CELL_TYPE", 174, 191], ["pericytes", "CELL_TYPE", 197, 206], ["Our analysis", "TEST", 0, 12], ["a previous study", "TEST", 43, 59], ["single-cell atlases", "TEST", 89, 108], ["ACE2 in ventricular cardiomyocytes", "PROBLEM", 138, 172], ["pericytes of the heart, lung, and kidney", "PROBLEM", 197, 237], ["high expression", "OBSERVATION", 119, 134], ["ventricular cardiomyocytes", "ANATOMY", 146, 172], ["heart", "ANATOMY", 174, 179], ["macrophages", "OBSERVATION", 180, 191], ["pericytes", "OBSERVATION", 197, 206], ["heart", "ANATOMY", 214, 219], ["lung", "ANATOMY", 221, 225], ["kidney", "ANATOMY", 231, 237]]], ["33 Therefore, the disturbances in the ACE2 interaction network, by SARS-CoV-2 binding in the ACE2 receptor on cardiomyocytes, might explain cardiac abnormalities presented in COVID-19 patients, including elevated troponin, myocarditis, and sudden cardiac death.", [["cardiomyocytes", "ANATOMY", 110, 124], ["cardiac", "ANATOMY", 140, 147], ["cardiac", "ANATOMY", 247, 254], ["cardiac abnormalities", "DISEASE", 140, 161], ["myocarditis", "DISEASE", 223, 234], ["sudden cardiac death", "DISEASE", 240, 260], ["ACE2", "GENE_OR_GENE_PRODUCT", 38, 42], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 67, 77], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 93, 106], ["cardiomyocytes", "CELL", 110, 124], ["cardiac", "ORGAN", 140, 147], ["patients", "ORGANISM", 184, 192], ["troponin", "GENE_OR_GENE_PRODUCT", 213, 221], ["cardiac", "ORGAN", 247, 254], ["ACE2", "PROTEIN", 38, 42], ["ACE2 receptor", "PROTEIN", 93, 106], ["cardiomyocytes", "CELL_TYPE", 110, 124], ["troponin", "PROTEIN", 213, 221], ["patients", "SPECIES", 184, 192], ["the disturbances", "PROBLEM", 14, 30], ["cardiac abnormalities", "PROBLEM", 140, 161], ["elevated troponin", "PROBLEM", 204, 221], ["myocarditis", "PROBLEM", 223, 234], ["sudden cardiac death", "PROBLEM", 240, 260], ["cardiomyocytes", "ANATOMY", 110, 124], ["cardiac", "ANATOMY", 140, 147], ["abnormalities", "OBSERVATION", 148, 161], ["myocarditis", "OBSERVATION", 223, 234], ["cardiac", "ANATOMY", 247, 254], ["death", "OBSERVATION", 255, 260]]], ["34 Moreover, as myocardial complex interaction network of ACE and its own expression is increased in patients with coexisting CVD, SARS-CoV-2 infection may result in greater damage to cardiomyocytes, and account for greater disease acuity and poorer survival in these patients.Cardiovascular risk factors related to signaling pathways affected by SARS-CoV-2 binding to ACE2 receptor in heart tissue.Our analysis of ACE2 interaction network, as well as analysis only focused on heart-tissue specific genes, showed that change in ACE2 receptor activity can lead to significant disturbances in signaling pathways linked to wellknown complications in COVID-19 disease.", [["myocardial", "ANATOMY", 16, 26], ["cardiomyocytes", "ANATOMY", 184, 198], ["Cardiovascular", "ANATOMY", 277, 291], ["heart tissue", "ANATOMY", 386, 398], ["heart-tissue", "ANATOMY", 477, 489], ["CVD", "DISEASE", 126, 129], ["SARS", "DISEASE", 131, 135], ["infection", "DISEASE", 142, 151], ["myocardial", "MULTI-TISSUE_STRUCTURE", 16, 26], ["ACE", "GENE_OR_GENE_PRODUCT", 58, 61], ["patients", "ORGANISM", 101, 109], ["SARS-CoV-2", "ORGANISM", 131, 141], ["cardiomyocytes", "CELL", 184, 198], ["patients", "ORGANISM", 268, 276], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 347, 357], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 369, 382], ["heart tissue", "TISSUE", 386, 398], ["ACE2", "GENE_OR_GENE_PRODUCT", 415, 419], ["heart-tissue", "TISSUE", 477, 489], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 528, 541], ["COVID-19 disease", "CANCER", 647, 663], ["ACE", "PROTEIN", 58, 61], ["cardiomyocytes", "CELL_TYPE", 184, 198], ["ACE2 receptor", "PROTEIN", 369, 382], ["ACE2", "PROTEIN", 415, 419], ["heart-tissue specific genes", "DNA", 477, 504], ["ACE2", "PROTEIN", 528, 532], ["patients", "SPECIES", 101, 109], ["patients", "SPECIES", 268, 276], ["SARS-CoV", "SPECIES", 131, 139], ["ACE", "TREATMENT", 58, 61], ["coexisting CVD", "PROBLEM", 115, 129], ["SARS", "PROBLEM", 131, 135], ["CoV-2 infection", "PROBLEM", 136, 151], ["greater damage to cardiomyocytes", "PROBLEM", 166, 198], ["greater disease acuity", "PROBLEM", 216, 238], ["Cardiovascular risk factors", "PROBLEM", 277, 304], ["signaling pathways", "PROBLEM", 316, 334], ["SARS", "PROBLEM", 347, 351], ["CoV", "TEST", 352, 355], ["Our analysis", "TEST", 399, 411], ["ACE2 interaction network", "TEST", 415, 439], ["analysis", "TEST", 452, 460], ["change in ACE2 receptor activity", "PROBLEM", 518, 550], ["significant disturbances in signaling pathways", "PROBLEM", 563, 609], ["complications in COVID-19 disease", "PROBLEM", 630, 663], ["myocardial", "ANATOMY", 16, 26], ["increased", "OBSERVATION_MODIFIER", 88, 97], ["infection", "OBSERVATION", 142, 151], ["greater", "OBSERVATION_MODIFIER", 166, 173], ["damage", "OBSERVATION", 174, 180], ["cardiomyocytes", "ANATOMY", 184, 198], ["heart tissue", "ANATOMY", 386, 398], ["heart", "ANATOMY", 477, 482]]], ["Those pathways included RAS, AGE-RAGE signaling pathway in diabetic complications, neuroactive ligand-receptor interaction, innate immune system, neutrophil degranulation and intrinsic pathway of clot formation.", [["immune system", "ANATOMY", 131, 144], ["neutrophil", "ANATOMY", 146, 156], ["clot", "ANATOMY", 196, 200], ["diabetic complications", "DISEASE", 59, 81], ["RAS", "GENE_OR_GENE_PRODUCT", 24, 27], ["AGE-RAGE", "GENE_OR_GENE_PRODUCT", 29, 37], ["neutrophil", "CELL", 146, 156], ["clot", "ORGANISM_SUBSTANCE", 196, 200], ["AGE", "PROTEIN", 29, 32], ["RAGE", "PROTEIN", 33, 37], ["RAS", "TEST", 24, 27], ["diabetic complications", "PROBLEM", 59, 81], ["neutrophil degranulation", "PROBLEM", 146, 170], ["clot formation", "PROBLEM", 196, 210], ["diabetic", "OBSERVATION_MODIFIER", 59, 67], ["complications", "OBSERVATION", 68, 81], ["neutrophil degranulation", "OBSERVATION", 146, 170], ["clot", "OBSERVATION", 196, 200]]], ["Moreover, signaling pathways identified as specific for the heart-relevant ACE2 interaction network were associated with adrenergic signaling in cardiomyocytes, FOXO2 signaling pathway, relaxin signaling pathway, platelet degranulation and VEGFR2 mediated vascular permeability.", [["heart", "ANATOMY", 60, 65], ["cardiomyocytes", "ANATOMY", 145, 159], ["platelet", "ANATOMY", 213, 221], ["vascular", "ANATOMY", 256, 264], ["heart", "ORGAN", 60, 65], ["ACE2", "GENE_OR_GENE_PRODUCT", 75, 79], ["cardiomyocytes", "CELL", 145, 159], ["FOXO2", "GENE_OR_GENE_PRODUCT", 161, 166], ["relaxin", "GENE_OR_GENE_PRODUCT", 186, 193], ["platelet", "CELL", 213, 221], ["VEGFR2", "GENE_OR_GENE_PRODUCT", 240, 246], ["vascular", "MULTI-TISSUE_STRUCTURE", 256, 264], ["ACE2", "PROTEIN", 75, 79], ["cardiomyocytes", "CELL_TYPE", 145, 159], ["FOXO2", "PROTEIN", 161, 166], ["VEGFR2", "PROTEIN", 240, 246], ["signaling pathways", "PROBLEM", 10, 28], ["adrenergic signaling in cardiomyocytes", "PROBLEM", 121, 159], ["relaxin signaling pathway", "TEST", 186, 211], ["platelet degranulation", "PROBLEM", 213, 235], ["VEGFR2 mediated vascular permeability", "PROBLEM", 240, 277], ["heart", "ANATOMY", 60, 65], ["cardiomyocytes", "ANATOMY", 145, 159], ["platelet degranulation", "OBSERVATION", 213, 235], ["vascular", "ANATOMY", 256, 264], ["permeability", "OBSERVATION_MODIFIER", 265, 277]]], ["In these networks, the closest interactors of ACE2 were REN, INS, KNG1, and AGT.", [["ACE2", "GENE_OR_GENE_PRODUCT", 46, 50], ["REN", "GENE_OR_GENE_PRODUCT", 56, 59], ["INS", "GENE_OR_GENE_PRODUCT", 61, 64], ["KNG1", "GENE_OR_GENE_PRODUCT", 66, 70], ["AGT", "GENE_OR_GENE_PRODUCT", 76, 79], ["ACE2", "PROTEIN", 46, 50], ["REN", "PROTEIN", 56, 59], ["INS", "PROTEIN", 61, 64], ["KNG1", "PROTEIN", 66, 70], ["AGT", "PROTEIN", 76, 79], ["ACE2", "TEST", 46, 50], ["KNG1", "TEST", 66, 70], ["AGT", "TEST", 76, 79]]], ["Those results were supported by our subsequent analysis showing that genes from the ACE2 network have strongest connection with rare diseases related to high blood pressure, respiratory diseases (i.e. SARS and Goodpasture syndrome), renal diseases, coagulation disorders and several phenotypes like obesity, hypertension, DM that are known to be a risk factors for severe course of COVID-19.RAS/ACE2, AGE-RAGE, and Apelin signaling as fundamental mediators of the blood pressure dysregulation mediated through ACE2 in COVID-19.Moreover, in our in silico analysis using ACE2 functional networks, we found that RAS/ACE2, AGE-RAGE, and Apelin signaling pathways play an important role in SARS-CoV-2 infection.", [["blood", "ANATOMY", 158, 163], ["respiratory", "ANATOMY", 174, 185], ["renal", "ANATOMY", 233, 238], ["blood", "ANATOMY", 464, 469], ["high blood pressure", "DISEASE", 153, 172], ["respiratory diseases", "DISEASE", 174, 194], ["SARS", "DISEASE", 201, 205], ["Goodpasture syndrome", "DISEASE", 210, 230], ["renal diseases", "DISEASE", 233, 247], ["coagulation disorders", "DISEASE", 249, 270], ["obesity", "DISEASE", 299, 306], ["hypertension", "DISEASE", 308, 320], ["DM", "DISEASE", 322, 324], ["infection", "DISEASE", 696, 705], ["COVID-19", "CHEMICAL", 382, 390], ["ACE2", "GENE_OR_GENE_PRODUCT", 84, 88], ["blood", "ORGANISM_SUBSTANCE", 158, 163], ["renal", "ORGAN", 233, 238], ["RAS", "GENE_OR_GENE_PRODUCT", 391, 394], ["ACE2", "GENE_OR_GENE_PRODUCT", 395, 399], ["AGE-RAGE", "GENE_OR_GENE_PRODUCT", 401, 409], ["Apelin", "GENE_OR_GENE_PRODUCT", 415, 421], ["blood", "ORGANISM_SUBSTANCE", 464, 469], ["ACE2", "GENE_OR_GENE_PRODUCT", 510, 514], ["ACE2", "GENE_OR_GENE_PRODUCT", 569, 573], ["RAS", "GENE_OR_GENE_PRODUCT", 609, 612], ["ACE2", "GENE_OR_GENE_PRODUCT", 613, 617], ["AGE-RAGE", "GENE_OR_GENE_PRODUCT", 619, 627], ["Apelin", "GENE_OR_GENE_PRODUCT", 633, 639], ["SARS-CoV-2", "ORGANISM", 685, 695], ["ACE2", "PROTEIN", 84, 88], ["RAS", "PROTEIN", 391, 394], ["ACE2", "PROTEIN", 395, 399], ["AGE", "PROTEIN", 401, 404], ["RAGE", "PROTEIN", 405, 409], ["Apelin", "PROTEIN", 415, 421], ["ACE2", "PROTEIN", 510, 514], ["ACE2", "PROTEIN", 569, 573], ["RAS", "PROTEIN", 609, 612], ["ACE2", "PROTEIN", 613, 617], ["AGE", "PROTEIN", 619, 622], ["RAGE", "PROTEIN", 623, 627], ["Apelin", "PROTEIN", 633, 639], ["SARS-CoV-2", "SPECIES", 685, 695], ["our subsequent analysis", "TEST", 32, 55], ["rare diseases", "PROBLEM", 128, 141], ["high blood pressure", "PROBLEM", 153, 172], ["respiratory diseases", "PROBLEM", 174, 194], ["SARS", "PROBLEM", 201, 205], ["Goodpasture syndrome", "PROBLEM", 210, 230], ["renal diseases", "PROBLEM", 233, 247], ["coagulation disorders", "PROBLEM", 249, 270], ["several phenotypes like obesity", "PROBLEM", 275, 306], ["hypertension", "PROBLEM", 308, 320], ["DM", "PROBLEM", 322, 324], ["COVID", "TEST", 382, 387], ["RAS", "TEST", 391, 394], ["ACE2", "TEST", 395, 399], ["Apelin signaling", "PROBLEM", 415, 431], ["the blood pressure dysregulation", "TEST", 460, 492], ["ACE2 in COVID", "TEST", 510, 523], ["RAS", "TEST", 609, 612], ["ACE2", "TEST", 613, 617], ["Apelin signaling pathways", "PROBLEM", 633, 658], ["SARS", "PROBLEM", 685, 689], ["CoV-2 infection", "PROBLEM", 690, 705], ["respiratory diseases", "OBSERVATION", 174, 194], ["Goodpasture syndrome", "OBSERVATION", 210, 230], ["renal", "ANATOMY", 233, 238], ["diseases", "OBSERVATION", 239, 247], ["obesity", "OBSERVATION", 299, 306], ["hypertension", "OBSERVATION", 308, 320], ["ACE2", "ANATOMY", 395, 399], ["infection", "OBSERVATION", 696, 705]]], ["These pathways have a crucial role in pathogenesis of DM, CVD and blood pressure regulations.", [["blood", "ANATOMY", 66, 71], ["DM", "DISEASE", 54, 56], ["CVD", "DISEASE", 58, 61], ["blood", "ORGANISM_SUBSTANCE", 66, 71], ["DM", "PROBLEM", 54, 56], ["CVD", "PROBLEM", 58, 61], ["blood pressure regulations", "TREATMENT", 66, 92], ["crucial", "OBSERVATION_MODIFIER", 22, 29], ["DM", "OBSERVATION", 54, 56]]], ["Therefore, binding of the SARS-CoV-2 to the ACE2 receptor leading to disturbances in the pathways of these key regulators might explain the adverse outcome in COVID-19 patients with coexistence of CVD.", [["SARS", "DISEASE", 26, 30], ["CVD", "DISEASE", 197, 200], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 26, 36], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 44, 57], ["patients", "ORGANISM", 168, 176], ["SARS-CoV-2", "PROTEIN", 26, 36], ["ACE2 receptor", "PROTEIN", 44, 57], ["patients", "SPECIES", 168, 176], ["the SARS", "PROBLEM", 22, 30], ["the ACE2 receptor", "TREATMENT", 40, 57], ["disturbances", "PROBLEM", 69, 81], ["CVD", "PROBLEM", 197, 200]]], ["Abnormalities of ACE2/RAS pathway signaling and deregulation of angiotensin II as a fundamental mediator of this axis are closely related to pathophysiology of hypertension and progression of cardiovascular remodeling.", [["cardiovascular", "ANATOMY", 192, 206], ["angiotensin II", "CHEMICAL", 64, 78], ["hypertension", "DISEASE", 160, 172], ["ACE2", "GENE_OR_GENE_PRODUCT", 17, 21], ["RAS", "GENE_OR_GENE_PRODUCT", 22, 25], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 64, 78], ["cardiovascular", "ANATOMICAL_SYSTEM", 192, 206], ["ACE2", "PROTEIN", 17, 21], ["RAS", "PROTEIN", 22, 25], ["angiotensin II", "PROTEIN", 64, 78], ["Abnormalities of ACE2/RAS pathway signaling", "PROBLEM", 0, 43], ["deregulation of angiotensin II", "PROBLEM", 48, 78], ["hypertension", "PROBLEM", 160, 172], ["cardiovascular remodeling", "PROBLEM", 192, 217], ["angiotensin II", "OBSERVATION_MODIFIER", 64, 78], ["hypertension", "OBSERVATION", 160, 172], ["progression", "OBSERVATION_MODIFIER", 177, 188], ["cardiovascular remodeling", "OBSERVATION", 192, 217]]], ["35 Furthermore, increased ACE2 expression attenuates hypertension-linked pathophysiological changes and protects against elevated blood pressure whereas loss of ACE2 function exacerbates hypertension.", [["blood", "ANATOMY", 130, 135], ["hypertension", "DISEASE", 53, 65], ["hypertension", "DISEASE", 187, 199], ["ACE2", "GENE_OR_GENE_PRODUCT", 26, 30], ["blood", "ORGANISM_SUBSTANCE", 130, 135], ["ACE2", "GENE_OR_GENE_PRODUCT", 161, 165], ["ACE2", "PROTEIN", 26, 30], ["ACE2", "PROTEIN", 161, 165], ["increased ACE2 expression attenuates hypertension", "PROBLEM", 16, 65], ["pathophysiological changes", "PROBLEM", 73, 99], ["elevated blood pressure", "PROBLEM", 121, 144], ["loss of ACE2 function", "PROBLEM", 153, 174], ["hypertension", "PROBLEM", 187, 199], ["increased", "OBSERVATION_MODIFIER", 16, 25], ["ACE2 expression", "OBSERVATION", 26, 41], ["attenuates", "OBSERVATION_MODIFIER", 42, 52], ["hypertension", "OBSERVATION", 53, 65], ["ACE2 function", "OBSERVATION", 161, 174]]], ["36 Apelin signaling is involved in many physiological processes such as energy metabolism, blood pressure regulation, and cardiac contractility and plays an important role in organ and tissue pathologies including, DM, obesity, HF as well as HIV-1 infection.", [["blood", "ANATOMY", 91, 96], ["cardiac", "ANATOMY", 122, 129], ["organ", "ANATOMY", 175, 180], ["tissue", "ANATOMY", 185, 191], ["DM", "DISEASE", 215, 217], ["obesity", "DISEASE", 219, 226], ["HF", "DISEASE", 228, 230], ["HIV-1 infection", "DISEASE", 242, 257], ["Apelin", "GENE_OR_GENE_PRODUCT", 3, 9], ["blood", "ORGANISM_SUBSTANCE", 91, 96], ["cardiac", "ORGAN", 122, 129], ["organ", "ORGAN", 175, 180], ["tissue", "TISSUE", 185, 191], ["HIV-1", "ORGANISM", 242, 247], ["Apelin", "PROTEIN", 3, 9], ["HIV-1", "SPECIES", 242, 247], ["HIV-1", "SPECIES", 242, 247], ["energy metabolism", "PROBLEM", 72, 89], ["blood pressure regulation", "TEST", 91, 116], ["organ and tissue pathologies", "PROBLEM", 175, 203], ["DM", "PROBLEM", 215, 217], ["obesity", "PROBLEM", 219, 226], ["HF", "PROBLEM", 228, 230], ["HIV", "PROBLEM", 242, 245], ["1 infection", "PROBLEM", 246, 257], ["energy metabolism", "OBSERVATION", 72, 89], ["cardiac", "ANATOMY", 122, 129], ["contractility", "OBSERVATION", 130, 143], ["tissue", "ANATOMY", 185, 191], ["pathologies", "OBSERVATION", 192, 203], ["obesity", "OBSERVATION", 219, 226], ["infection", "OBSERVATION", 248, 257]]], ["37 In vitro analysis showed that apelin is a second catalytic substrate for ACE2 and it can effect as an inotropic and cardioprotective peptide.", [["apelin", "CHEMICAL", 33, 39], ["apelin", "GENE_OR_GENE_PRODUCT", 33, 39], ["ACE2", "GENE_OR_GENE_PRODUCT", 76, 80], ["ACE2", "PROTEIN", 76, 80], ["vitro analysis", "TEST", 6, 20], ["ACE2", "PROBLEM", 76, 80], ["an inotropic", "TREATMENT", 102, 114], ["cardioprotective peptide", "TREATMENT", 119, 143]]], ["38, 39 Thromboembolic complications in COVID-19: the role of KNG1, one of the top ACE2 interactors.", [["COVID-19", "CHEMICAL", 39, 47], ["KNG1", "GENE_OR_GENE_PRODUCT", 61, 65], ["ACE2", "GENE_OR_GENE_PRODUCT", 82, 86], ["KNG1", "PROTEIN", 61, 65], ["ACE2 interactors", "PROTEIN", 82, 98], ["Thromboembolic complications", "PROBLEM", 7, 35], ["COVID", "TEST", 39, 44], ["KNG1", "TREATMENT", 61, 65], ["Thromboembolic", "OBSERVATION_MODIFIER", 7, 21], ["complications", "OBSERVATION", 22, 35]]], ["In this study we found a strong connection between ACE2 and KNG1 which as a part of Kalikrein-Kinin system (KKS) encoding precursors of kinins.", [["ACE2", "GENE_OR_GENE_PRODUCT", 51, 55], ["KNG1", "GENE_OR_GENE_PRODUCT", 60, 64], ["Kalikrein-Kinin", "GENE_OR_GENE_PRODUCT", 84, 99], ["KKS", "GENE_OR_GENE_PRODUCT", 108, 111], ["kinins", "GENE_OR_GENE_PRODUCT", 136, 142], ["ACE2", "PROTEIN", 51, 55], ["KNG1", "PROTEIN", 60, 64], ["Kalikrein-Kinin system", "PROTEIN", 84, 106], ["KKS", "PROTEIN", 108, 111], ["kinins", "PROTEIN", 136, 142], ["this study", "TEST", 3, 13], ["ACE2", "TEST", 51, 55], ["Kalikrein-Kinin system", "TREATMENT", 84, 106]]], ["40 KKS mediators are involved in vessel wall remodeling, intimal hyperplasia 41 and affect nitric oxide and prostacyclin production.", [["vessel wall", "ANATOMY", 33, 44], ["intimal hyperplasia", "ANATOMY", 57, 76], ["nitric oxide", "CHEMICAL", 91, 103], ["prostacyclin", "CHEMICAL", 108, 120], ["nitric oxide", "CHEMICAL", 91, 103], ["prostacyclin", "CHEMICAL", 108, 120], ["KKS", "GENE_OR_GENE_PRODUCT", 3, 6], ["vessel wall", "MULTI-TISSUE_STRUCTURE", 33, 44], ["intimal", "TISSUE", 57, 64], ["nitric oxide", "SIMPLE_CHEMICAL", 91, 103], ["prostacyclin", "SIMPLE_CHEMICAL", 108, 120], ["KKS mediators", "PROTEIN", 3, 16], ["vessel wall remodeling", "PROBLEM", 33, 55], ["intimal hyperplasia", "PROBLEM", 57, 76], ["nitric oxide", "TREATMENT", 91, 103], ["prostacyclin production", "PROBLEM", 108, 131], ["vessel", "ANATOMY", 33, 39], ["wall", "ANATOMY_MODIFIER", 40, 44], ["intimal", "OBSERVATION_MODIFIER", 57, 64], ["hyperplasia", "OBSERVATION", 65, 76], ["nitric oxide", "OBSERVATION", 91, 103], ["prostacyclin production", "OBSERVATION", 108, 131]]], ["42 Moreover, high molecular weight kininogen (HK) is essential in surface-binding and activity of factor XI, a component of intrinsic pathway of blood coagulation.", [["surface", "ANATOMY", 66, 73], ["blood", "ANATOMY", 145, 150], ["blood coagulation", "DISEASE", 145, 162], ["high molecular weight kininogen", "GENE_OR_GENE_PRODUCT", 13, 44], ["HK", "GENE_OR_GENE_PRODUCT", 46, 48], ["surface", "CELLULAR_COMPONENT", 66, 73], ["factor XI", "GENE_OR_GENE_PRODUCT", 98, 107], ["blood", "ORGANISM_SUBSTANCE", 145, 150], ["high molecular weight kininogen", "PROTEIN", 13, 44], ["HK", "PROTEIN", 46, 48], ["factor XI", "PROTEIN", 98, 107], ["high molecular weight kininogen (HK)", "PROBLEM", 13, 49], ["factor XI", "PROBLEM", 98, 107], ["blood coagulation", "TEST", 145, 162], ["surface", "OBSERVATION_MODIFIER", 66, 73]]], ["43 Plasma kininogen may induce the development of arterial thrombosis, especially under pathologic conditions.", [["arterial", "ANATOMY", 50, 58], ["arterial thrombosis", "DISEASE", 50, 69], ["Plasma kininogen", "GENE_OR_GENE_PRODUCT", 3, 19], ["arterial", "MULTI-TISSUE_STRUCTURE", 50, 58], ["Plasma kininogen", "TEST", 3, 19], ["arterial thrombosis", "PROBLEM", 50, 69], ["arterial", "ANATOMY", 50, 58], ["thrombosis", "OBSERVATION", 59, 69]]], ["44 2-chain HKa was also found to inhibit PAI-1 function, interfere with platelet activation and mediate platelet-leukocyte interaction 45, 46 and therefore, deregulation of KKS may result in thromboembolic complications and lead to sepsis exacerbation in infections.", [["platelet", "ANATOMY", 72, 80], ["platelet-leukocyte", "ANATOMY", 104, 122], ["KKS", "DISEASE", 173, 176], ["thromboembolic", "DISEASE", 191, 205], ["sepsis", "DISEASE", 232, 238], ["infections", "DISEASE", 255, 265], ["2-chain HKa", "SIMPLE_CHEMICAL", 3, 14], ["PAI-1", "GENE_OR_GENE_PRODUCT", 41, 46], ["platelet", "CELL", 72, 80], ["platelet", "CELL", 104, 112], ["leukocyte", "CELL", 113, 122], ["KKS", "GENE_OR_GENE_PRODUCT", 173, 176], ["PAI", "PROTEIN", 41, 44], ["platelet", "CELL_TYPE", 104, 112], ["KKS", "PROTEIN", 173, 176], ["PAI", "TEST", 41, 44], ["platelet activation", "TEST", 72, 91], ["platelet", "TEST", 104, 112], ["leukocyte interaction", "TEST", 113, 134], ["deregulation of KKS", "PROBLEM", 157, 176], ["thromboembolic complications", "PROBLEM", 191, 219], ["sepsis exacerbation", "PROBLEM", 232, 251], ["infections", "PROBLEM", 255, 265], ["thromboembolic", "OBSERVATION", 191, 205], ["sepsis", "OBSERVATION", 232, 238], ["infections", "OBSERVATION", 255, 265]]], ["[47] [48] [49] Pro-inflammatory cytokines modulated by ACE2, a putative mechanism for generalized inflammatory response.", [["[47] [48] [49", "SIMPLE_CHEMICAL", 0, 13], ["ACE2", "GENE_OR_GENE_PRODUCT", 55, 59], ["[47] [48] [49] Pro-inflammatory cytokines", "PROTEIN", 0, 41], ["ACE2", "PROTEIN", 55, 59], ["Pro-inflammatory cytokines", "TEST", 15, 41], ["ACE2", "TEST", 55, 59], ["generalized inflammatory response", "PROBLEM", 86, 119], ["inflammatory", "OBSERVATION", 98, 110]]], ["Several experimental studies indicated that ACE2 is able to modify acute and chronic inflammatory response.", [["ACE2", "GENE_OR_GENE_PRODUCT", 44, 48], ["ACE2", "PROTEIN", 44, 48], ["Several experimental studies", "TEST", 0, 28], ["ACE2", "PROBLEM", 44, 48], ["acute and chronic inflammatory response", "PROBLEM", 67, 106], ["chronic", "OBSERVATION_MODIFIER", 77, 84], ["inflammatory", "OBSERVATION", 85, 97]]], ["50, 51 In line, we found in our analysis a strong interaction of ACE2 with several genes related with inflammatory response including CCL2 and TGFB1.", [["ACE2", "GENE_OR_GENE_PRODUCT", 65, 69], ["CCL2", "GENE_OR_GENE_PRODUCT", 134, 138], ["TGFB1", "GENE_OR_GENE_PRODUCT", 143, 148], ["ACE2", "PROTEIN", 65, 69], ["CCL2", "PROTEIN", 134, 138], ["TGFB1", "PROTEIN", 143, 148], ["inflammatory response", "PROBLEM", 102, 123], ["TGFB1", "PROBLEM", 143, 148], ["inflammatory", "OBSERVATION_MODIFIER", 102, 114]]], ["Loss of function of ACE2 in mutant mice resulted in enhanced production of inflammatory cytokine and collagenase levels, increased ROS, neutrophilic infiltration and MAPK activation.", [["neutrophilic", "ANATOMY", 136, 148], ["ROS", "CHEMICAL", 131, 134], ["ACE2", "GENE_OR_GENE_PRODUCT", 20, 24], ["mutant mice", "ORGANISM", 28, 39], ["collagenase", "GENE_OR_GENE_PRODUCT", 101, 112], ["ROS", "SIMPLE_CHEMICAL", 131, 134], ["MAPK", "GENE_OR_GENE_PRODUCT", 166, 170], ["ACE2", "PROTEIN", 20, 24], ["inflammatory cytokine", "PROTEIN", 75, 96], ["collagenase", "PROTEIN", 101, 112], ["MAPK", "PROTEIN", 166, 170], ["mice", "SPECIES", 35, 39], ["mice", "SPECIES", 35, 39], ["inflammatory cytokine and collagenase levels", "PROBLEM", 75, 119], ["increased ROS", "PROBLEM", 121, 134], ["neutrophilic infiltration", "PROBLEM", 136, 161], ["MAPK activation", "PROBLEM", 166, 181], ["inflammatory cytokine", "OBSERVATION", 75, 96], ["increased", "OBSERVATION_MODIFIER", 121, 130], ["ROS", "OBSERVATION_MODIFIER", 131, 134], ["neutrophilic infiltration", "OBSERVATION", 136, 161], ["MAPK activation", "OBSERVATION", 166, 181]]], ["52 Diminished ACE2 function may deregulate RAS and induce inflammation and vessel permeability and lung edema.", [["vessel", "ANATOMY", 75, 81], ["lung", "ANATOMY", 99, 103], ["inflammation", "DISEASE", 58, 70], ["lung edema", "DISEASE", 99, 109], ["ACE2", "GENE_OR_GENE_PRODUCT", 14, 18], ["RAS", "GENE_OR_GENE_PRODUCT", 43, 46], ["vessel", "MULTI-TISSUE_STRUCTURE", 75, 81], ["lung", "ORGAN", 99, 103], ["edema", "PATHOLOGICAL_FORMATION", 104, 109], ["ACE2", "PROTEIN", 14, 18], ["RAS", "PROTEIN", 43, 46], ["Diminished ACE2 function", "PROBLEM", 3, 27], ["inflammation", "PROBLEM", 58, 70], ["vessel permeability", "PROBLEM", 75, 94], ["lung edema", "PROBLEM", 99, 109], ["inflammation", "OBSERVATION", 58, 70], ["vessel", "ANATOMY", 75, 81], ["permeability", "OBSERVATION_MODIFIER", 82, 94], ["lung", "ANATOMY", 99, 103], ["edema", "OBSERVATION", 104, 109]]], ["53 It is worth to mention that among SARS-CoV-infected patients the level of pro-inflammatory cytokines, especially CCL2 and TGF-\u03b21 were increased in cells expressing ACE2, while this could not be seen in tissue with undetectable ACE2 expression 54 A comparable pattern of inflammatory cytokines was found in SARS-CoV-2 infection as well.", [["cells", "ANATOMY", 150, 155], ["tissue", "ANATOMY", 205, 211], ["SARS-CoV-infected", "DISEASE", 37, 54], ["infection", "DISEASE", 320, 329], ["SARS-CoV", "ORGANISM", 37, 45], ["patients", "ORGANISM", 55, 63], ["CCL2", "GENE_OR_GENE_PRODUCT", 116, 120], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 125, 131], ["cells", "CELL", 150, 155], ["ACE2", "GENE_OR_GENE_PRODUCT", 167, 171], ["tissue", "TISSUE", 205, 211], ["ACE2", "GENE_OR_GENE_PRODUCT", 230, 234], ["SARS-CoV-2", "ORGANISM", 309, 319], ["pro-inflammatory cytokines", "PROTEIN", 77, 103], ["CCL2", "PROTEIN", 116, 120], ["TGF-\u03b21", "PROTEIN", 125, 131], ["ACE2", "PROTEIN", 167, 171], ["ACE2", "PROTEIN", 230, 234], ["inflammatory cytokines", "PROTEIN", 273, 295], ["patients", "SPECIES", 55, 63], ["SARS-CoV", "SPECIES", 37, 45], ["SARS-CoV-2", "SPECIES", 309, 319], ["pro-inflammatory cytokines", "TEST", 77, 103], ["CCL2", "TEST", 116, 120], ["TGF", "TEST", 125, 128], ["ACE2", "TEST", 167, 171], ["inflammatory cytokines", "PROBLEM", 273, 295], ["SARS", "PROBLEM", 309, 313], ["CoV-2 infection", "PROBLEM", 314, 329], ["pro-inflammatory cytokines", "OBSERVATION", 77, 103], ["inflammatory", "OBSERVATION_MODIFIER", 273, 285], ["infection", "OBSERVATION", 320, 329]]], ["55 The role of virus-infection related proteins from ACE2 network in COVID-19 adverse outcomes.", [["infection", "DISEASE", 21, 30], ["ACE2", "GENE_OR_GENE_PRODUCT", 53, 57], ["ACE2", "PROTEIN", 53, 57], ["virus-infection", "PROBLEM", 15, 30], ["ACE2 network", "TEST", 53, 65], ["COVID", "TEST", 69, 74], ["virus", "OBSERVATION", 15, 20], ["infection", "OBSERVATION", 21, 30]]], ["Additional analysis of ACE2 interaction network identified 11 virus-infection related proteins involved in significantly enriched pathways.", [["infection", "DISEASE", 68, 77], ["ACE2", "GENE_OR_GENE_PRODUCT", 23, 27], ["ACE2", "PROTEIN", 23, 27], ["Additional analysis", "TEST", 0, 19], ["ACE2 interaction network", "PROBLEM", 23, 47], ["11 virus", "PROBLEM", 59, 67], ["infection", "PROBLEM", 68, 77]]], ["Three of them (ACE2, CLEC4M and TMPRSS2) directly interact with virus glycoprotein S. We identified 10 virus-infection related proteins in the heart-specific interaction network, (except for TMPRSS2) suggesting that the heart tissue could be capable of being as strongly affected as the respiratory system.", [["heart", "ANATOMY", 143, 148], ["heart tissue", "ANATOMY", 220, 232], ["respiratory system", "ANATOMY", 287, 305], ["infection", "DISEASE", 109, 118], ["ACE2", "GENE_OR_GENE_PRODUCT", 15, 19], ["CLEC4M", "GENE_OR_GENE_PRODUCT", 21, 27], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 32, 39], ["heart", "ORGAN", 143, 148], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 191, 198], ["heart tissue", "TISSUE", 220, 232], ["ACE2", "PROTEIN", 15, 19], ["CLEC4M", "PROTEIN", 21, 27], ["TMPRSS2", "PROTEIN", 32, 39], ["TMPRSS2", "PROTEIN", 191, 198], ["ACE2", "TEST", 15, 19], ["virus glycoprotein S.", "TREATMENT", 64, 85], ["10 virus", "PROBLEM", 100, 108], ["infection", "PROBLEM", 109, 118], ["TMPRSS2", "PROBLEM", 191, 198], ["the heart tissue", "PROBLEM", 216, 232], ["heart", "ANATOMY", 143, 148], ["heart", "ANATOMY", 220, 225], ["tissue", "OBSERVATION", 226, 232], ["respiratory system", "ANATOMY", 287, 305]]], ["Three of those genes: DPP4, CCL2 and ANPEP showed especially extensive connections with top regulators of the network.", [["DPP4", "GENE_OR_GENE_PRODUCT", 22, 26], ["CCL2", "GENE_OR_GENE_PRODUCT", 28, 32], ["ANPEP", "GENE_OR_GENE_PRODUCT", 37, 42], ["DPP4", "PROTEIN", 22, 26], ["CCL2", "PROTEIN", 28, 32], ["ANPEP", "DNA", 37, 42], ["DPP4", "TEST", 22, 26], ["CCL2", "TEST", 28, 32], ["ANPEP", "TEST", 37, 42]]], ["Interestingly, higher plasma DPP4 can be found among patients with obesity, metabolic syndrome and DM, who are at risk of a severe course of COVID-19.", [["plasma", "ANATOMY", 22, 28], ["obesity", "DISEASE", 67, 74], ["metabolic syndrome", "DISEASE", 76, 94], ["DM", "DISEASE", 99, 101], ["COVID-19", "CHEMICAL", 141, 149], ["plasma", "ORGANISM_SUBSTANCE", 22, 28], ["DPP4", "GENE_OR_GENE_PRODUCT", 29, 33], ["patients", "ORGANISM", 53, 61], ["plasma DPP4", "PROTEIN", 22, 33], ["patients", "SPECIES", 53, 61], ["higher plasma DPP4", "PROBLEM", 15, 33], ["obesity", "PROBLEM", 67, 74], ["metabolic syndrome", "PROBLEM", 76, 94], ["DM", "PROBLEM", 99, 101], ["COVID", "TEST", 141, 146], ["obesity", "OBSERVATION", 67, 74], ["metabolic syndrome", "OBSERVATION", 76, 94], ["severe", "OBSERVATION_MODIFIER", 124, 130]]], ["56 Moreover, in experimental models of ARDS, DPP4 inhibitors suppressed pro-inflammatory cytokine production and attenuated LPS-induced lung injury.", [["lung", "ANATOMY", 136, 140], ["ARDS", "DISEASE", 39, 43], ["LPS", "CHEMICAL", 124, 127], ["lung injury", "DISEASE", 136, 147], ["DPP4", "GENE_OR_GENE_PRODUCT", 45, 49], ["LPS", "SIMPLE_CHEMICAL", 124, 127], ["lung", "ORGAN", 136, 140], ["pro-inflammatory cytokine", "PROTEIN", 72, 97], ["ARDS", "PROBLEM", 39, 43], ["DPP4 inhibitors", "TREATMENT", 45, 60], ["pro-inflammatory cytokine production", "PROBLEM", 72, 108], ["attenuated LPS", "PROBLEM", 113, 127], ["lung injury", "PROBLEM", 136, 147], ["ARDS", "OBSERVATION", 39, 43], ["LPS", "OBSERVATION_MODIFIER", 124, 127], ["lung", "ANATOMY", 136, 140], ["injury", "OBSERVATION", 141, 147]]], ["57 DPP4 knockin mice were found more susceptible to MERS-CoV infections which resulted in severe inflammatory response and lethal lung disease.", [["lung", "ANATOMY", 130, 134], ["infections", "DISEASE", 61, 71], ["lung disease", "DISEASE", 130, 142], ["DPP4", "GENE_OR_GENE_PRODUCT", 3, 7], ["mice", "ORGANISM", 16, 20], ["MERS-CoV", "ORGANISM", 52, 60], ["lung", "ORGAN", 130, 134], ["DPP4", "PROTEIN", 3, 7], ["mice", "SPECIES", 16, 20], ["mice", "SPECIES", 16, 20], ["MERS-CoV", "SPECIES", 52, 60], ["MERS", "PROBLEM", 52, 56], ["CoV infections", "PROBLEM", 57, 71], ["severe inflammatory response", "PROBLEM", 90, 118], ["lethal lung disease", "PROBLEM", 123, 142], ["CoV", "OBSERVATION_MODIFIER", 57, 60], ["infections", "OBSERVATION", 61, 71], ["severe", "OBSERVATION_MODIFIER", 90, 96], ["inflammatory response", "OBSERVATION", 97, 118], ["lethal", "OBSERVATION_MODIFIER", 123, 129], ["lung", "ANATOMY", 130, 134], ["disease", "OBSERVATION", 135, 142]]], ["58, 59 Therefore, it should be further investigated whether DPP4 inhibitors, widely used for the treatment of DM, may act as therapeutic drugs for ARDS caused by SARS-CoV-2 infection.", [["DM", "DISEASE", 110, 112], ["ARDS", "DISEASE", 147, 151], ["SARS-CoV-2 infection", "DISEASE", 162, 182], ["DPP4", "GENE_OR_GENE_PRODUCT", 60, 64], ["SARS-CoV-2", "ORGANISM", 162, 172], ["SARS-CoV", "SPECIES", 162, 170], ["DPP4 inhibitors", "TREATMENT", 60, 75], ["DM", "PROBLEM", 110, 112], ["therapeutic drugs", "TREATMENT", 125, 142], ["ARDS", "PROBLEM", 147, 151], ["SARS", "PROBLEM", 162, 166], ["CoV-2 infection", "PROBLEM", 167, 182], ["infection", "OBSERVATION", 173, 182]]], ["60 Interestingly, DPP4 inhibitors are able to at least partially reverse the olfactory dysfunction observed in DM, suggesting that DPP4 pathway may be involved in anosmia which occurs commonly among COVID-19 patients.", [["olfactory", "ANATOMY", 77, 86], ["olfactory dysfunction", "DISEASE", 77, 98], ["DM", "DISEASE", 111, 113], ["anosmia", "DISEASE", 163, 170], ["DPP4", "GENE_OR_GENE_PRODUCT", 18, 22], ["olfactory", "ANATOMICAL_SYSTEM", 77, 86], ["DPP4", "GENE_OR_GENE_PRODUCT", 131, 135], ["patients", "ORGANISM", 208, 216], ["DPP4", "PROTEIN", 131, 135], ["patients", "SPECIES", 208, 216], ["DPP4 inhibitors", "TREATMENT", 18, 33], ["the olfactory dysfunction", "PROBLEM", 73, 98], ["DM", "PROBLEM", 111, 113], ["DPP4 pathway", "PROBLEM", 131, 143], ["anosmia", "PROBLEM", 163, 170], ["olfactory dysfunction", "OBSERVATION", 77, 98]]], ["61, 62 This evidence show that DPP4 could be a crucial factor in regulation of multiple pathological processes associated with COVID-19.RAS/ACE2, AGE-RAGE, and Apelin signaling as fundamental mediators of the blood pressure dysregulation mediated through ACE2 in COVID-19.Second crucial cytokine in the network is the chemokine CCL2 also referred to as MCP-1.", [["blood", "ANATOMY", 209, 214], ["COVID-19", "CHEMICAL", 127, 135], ["DPP4", "GENE_OR_GENE_PRODUCT", 31, 35], ["COVID-19", "GENE_OR_GENE_PRODUCT", 127, 135], ["RAS", "GENE_OR_GENE_PRODUCT", 136, 139], ["ACE2", "GENE_OR_GENE_PRODUCT", 140, 144], ["AGE-RAGE", "GENE_OR_GENE_PRODUCT", 146, 154], ["Apelin", "GENE_OR_GENE_PRODUCT", 160, 166], ["blood", "ORGANISM_SUBSTANCE", 209, 214], ["ACE2", "GENE_OR_GENE_PRODUCT", 255, 259], ["CCL2", "GENE_OR_GENE_PRODUCT", 328, 332], ["MCP-1", "GENE_OR_GENE_PRODUCT", 353, 358], ["DPP4", "PROTEIN", 31, 35], ["RAS", "PROTEIN", 136, 139], ["ACE2", "PROTEIN", 140, 144], ["AGE", "PROTEIN", 146, 149], ["RAGE", "PROTEIN", 150, 154], ["Apelin", "PROTEIN", 160, 166], ["ACE2", "PROTEIN", 255, 259], ["cytokine", "PROTEIN", 287, 295], ["chemokine", "PROTEIN", 318, 327], ["CCL2", "PROTEIN", 328, 332], ["MCP", "PROTEIN", 353, 356], ["DPP4", "PROBLEM", 31, 35], ["a crucial factor", "PROBLEM", 45, 61], ["multiple pathological processes", "PROBLEM", 79, 110], ["COVID", "TEST", 127, 132], ["RAS", "TEST", 136, 139], ["ACE2", "TEST", 140, 144], ["Apelin signaling", "PROBLEM", 160, 176], ["the blood pressure dysregulation", "TEST", 205, 237], ["ACE2 in COVID", "TEST", 255, 268], ["MCP", "TEST", 353, 356], ["multiple", "OBSERVATION_MODIFIER", 79, 87], ["pathological", "OBSERVATION", 88, 100], ["ACE2", "ANATOMY", 140, 144], ["crucial", "OBSERVATION_MODIFIER", 279, 286], ["cytokine", "OBSERVATION", 287, 295]]], ["It has been shown that the CCL2 expression was increased among patients infected with SARS-CoV.", [["SARS-CoV", "DISEASE", 86, 94], ["CCL2", "GENE_OR_GENE_PRODUCT", 27, 31], ["patients", "ORGANISM", 63, 71], ["SARS-CoV", "ORGANISM", 86, 94], ["CCL2", "PROTEIN", 27, 31], ["patients", "SPECIES", 63, 71], ["SARS-CoV", "SPECIES", 86, 94], ["the CCL2 expression", "TREATMENT", 23, 42], ["CCL2 expression", "OBSERVATION", 27, 42], ["increased", "OBSERVATION_MODIFIER", 47, 56], ["infected", "OBSERVATION_MODIFIER", 72, 80]]], ["63, 64 Possibly, ACE2 mediates viral entry and leads to activation of ERK1/2/AP-1 pathway and upregulation of CCL2.", [["ACE2", "GENE_OR_GENE_PRODUCT", 17, 21], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 70, 76], ["AP-1", "GENE_OR_GENE_PRODUCT", 77, 81], ["CCL2", "GENE_OR_GENE_PRODUCT", 110, 114], ["ACE2", "PROTEIN", 17, 21], ["ERK1", "PROTEIN", 70, 74], ["AP", "PROTEIN", 77, 79], ["CCL2", "PROTEIN", 110, 114], ["ACE2 mediates viral entry", "PROBLEM", 17, 42], ["ERK1", "TEST", 70, 74], ["AP", "TEST", 77, 79], ["upregulation of CCL2", "PROBLEM", 94, 114], ["viral entry", "OBSERVATION", 31, 42], ["CCL2", "ANATOMY", 110, 114]]], ["CCL2 protein has been implicated in lung inflammatory disorders and contributes to development of pulmonary fibrosis.", [["lung", "ANATOMY", 36, 40], ["pulmonary", "ANATOMY", 98, 107], ["lung inflammatory disorders", "DISEASE", 36, 63], ["pulmonary fibrosis", "DISEASE", 98, 116], ["CCL2", "GENE_OR_GENE_PRODUCT", 0, 4], ["lung", "ORGAN", 36, 40], ["pulmonary", "ORGAN", 98, 107], ["CCL2 protein", "PROTEIN", 0, 12], ["CCL2 protein", "TEST", 0, 12], ["lung inflammatory disorders", "PROBLEM", 36, 63], ["pulmonary fibrosis", "PROBLEM", 98, 116], ["lung", "ANATOMY", 36, 40], ["inflammatory", "OBSERVATION", 41, 53], ["pulmonary", "ANATOMY", 98, 107], ["fibrosis", "OBSERVATION", 108, 116]]], ["19, 65 Besides, in the late stage of disease CCL2 expression levels are constantly elevated among severe SARS patients in comparison to non-severe controls and associated with diffuse pulmonary infiltrates, higher body temperatures and longer hospitalization.", [["pulmonary", "ANATOMY", 184, 193], ["body", "ANATOMY", 214, 218], ["SARS", "DISEASE", 105, 109], ["CCL2", "GENE_OR_GENE_PRODUCT", 45, 49], ["patients", "ORGANISM", 110, 118], ["pulmonary", "ORGAN", 184, 193], ["body", "ORGANISM_SUBDIVISION", 214, 218], ["CCL2", "PROTEIN", 45, 49], ["patients", "SPECIES", 110, 118], ["disease CCL2 expression levels", "PROBLEM", 37, 67], ["constantly elevated", "PROBLEM", 72, 91], ["severe SARS", "PROBLEM", 98, 109], ["non-severe controls", "PROBLEM", 136, 155], ["diffuse pulmonary infiltrates", "PROBLEM", 176, 205], ["higher body temperatures", "PROBLEM", 207, 231], ["late stage", "OBSERVATION_MODIFIER", 23, 33], ["disease", "OBSERVATION", 37, 44], ["CCL2 expression", "OBSERVATION", 45, 60], ["elevated", "OBSERVATION_MODIFIER", 83, 91], ["severe", "OBSERVATION_MODIFIER", 98, 104], ["diffuse", "OBSERVATION_MODIFIER", 176, 183], ["pulmonary", "ANATOMY", 184, 193], ["infiltrates", "OBSERVATION", 194, 205], ["higher", "OBSERVATION_MODIFIER", 207, 213], ["body temperatures", "OBSERVATION_MODIFIER", 214, 231]]], ["66 It is worth to mention that among SARS-CoV-infected patients the level of pro-inflammatory cytokines, especially CCL2 and TGF-\u03b21 were increased in cells expressing ACE2, while this could not be seen in tissue with undetectable ACE2 expression.", [["cells", "ANATOMY", 150, 155], ["tissue", "ANATOMY", 205, 211], ["SARS-CoV-infected", "DISEASE", 37, 54], ["SARS-CoV", "ORGANISM", 37, 45], ["patients", "ORGANISM", 55, 63], ["CCL2", "GENE_OR_GENE_PRODUCT", 116, 120], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 125, 131], ["cells", "CELL", 150, 155], ["ACE2", "GENE_OR_GENE_PRODUCT", 167, 171], ["tissue", "TISSUE", 205, 211], ["ACE2", "GENE_OR_GENE_PRODUCT", 230, 234], ["pro-inflammatory cytokines", "PROTEIN", 77, 103], ["CCL2", "PROTEIN", 116, 120], ["TGF-\u03b21", "PROTEIN", 125, 131], ["ACE2", "PROTEIN", 167, 171], ["ACE2", "PROTEIN", 230, 234], ["patients", "SPECIES", 55, 63], ["SARS-CoV", "SPECIES", 37, 45], ["pro-inflammatory cytokines", "TEST", 77, 103], ["CCL2", "TEST", 116, 120], ["TGF", "TEST", 125, 128], ["ACE2", "TEST", 167, 171], ["pro-inflammatory cytokines", "OBSERVATION", 77, 103], ["ACE2 expression", "OBSERVATION", 230, 245]]], ["54 A comparable pattern of inflammatory cytokines was found in SARS-CoV-2 infection as well.", [["SARS", "DISEASE", 63, 67], ["infection", "DISEASE", 74, 83], ["SARS-CoV-2", "ORGANISM", 63, 73], ["inflammatory cytokines", "PROTEIN", 27, 49], ["SARS-CoV-2", "SPECIES", 63, 73], ["inflammatory cytokines", "PROBLEM", 27, 49], ["SARS", "PROBLEM", 63, 67], ["CoV", "PROBLEM", 68, 71], ["2 infection", "PROBLEM", 72, 83], ["inflammatory", "OBSERVATION_MODIFIER", 27, 39], ["cytokines", "OBSERVATION", 40, 49], ["SARS", "OBSERVATION", 63, 67], ["CoV", "OBSERVATION_MODIFIER", 68, 71], ["infection", "OBSERVATION", 74, 83]]], ["55 Significant association of the CCL2 with malaria disease pathway in our study, target of chloroquine, a potent anti inflammatory agent (regulating also ACE2 and INS) make it a promising link between ACE2 and cytokine storm associated with severe COVID-19 disease.RAS/ACE2, AGE-RAGE, and Apelin signaling as fundamental mediators of the blood pressure dysregulation mediated through ACE2 in COVID-19.The third gene with extensive ACE2 network connection, ANPEP encodes aminopeptidase N (APN, CD13), which similarly to ACE2 and DDP2 is also recognized as a target for coronavirus named HCoV-22944.", [["blood", "ANATOMY", 339, 344], ["malaria disease", "DISEASE", 44, 59], ["chloroquine", "CHEMICAL", 92, 103], ["HCoV-22944", "CHEMICAL", 587, 597], ["chloroquine", "CHEMICAL", 92, 103], ["CCL2", "GENE_OR_GENE_PRODUCT", 34, 38], ["chloroquine", "SIMPLE_CHEMICAL", 92, 103], ["ACE2", "GENE_OR_GENE_PRODUCT", 155, 159], ["INS", "GENE_OR_GENE_PRODUCT", 164, 167], ["ACE2", "GENE_OR_GENE_PRODUCT", 202, 206], ["RAS", "GENE_OR_GENE_PRODUCT", 266, 269], ["ACE2", "GENE_OR_GENE_PRODUCT", 270, 274], ["AGE-RAGE", "GENE_OR_GENE_PRODUCT", 276, 284], ["Apelin", "GENE_OR_GENE_PRODUCT", 290, 296], ["blood", "ORGANISM_SUBSTANCE", 339, 344], ["ACE2", "GENE_OR_GENE_PRODUCT", 385, 389], ["ACE2", "GENE_OR_GENE_PRODUCT", 432, 436], ["ANPEP", "GENE_OR_GENE_PRODUCT", 457, 462], ["aminopeptidase N", "GENE_OR_GENE_PRODUCT", 471, 487], ["APN", "GENE_OR_GENE_PRODUCT", 489, 492], ["CD13", "GENE_OR_GENE_PRODUCT", 494, 498], ["ACE2", "GENE_OR_GENE_PRODUCT", 520, 524], ["DDP2", "GENE_OR_GENE_PRODUCT", 529, 533], ["coronavirus", "ORGANISM", 569, 580], ["HCoV-22944", "CELL", 587, 597], ["CCL2", "PROTEIN", 34, 38], ["ACE2", "PROTEIN", 155, 159], ["INS", "PROTEIN", 164, 167], ["ACE2", "PROTEIN", 202, 206], ["cytokine", "PROTEIN", 211, 219], ["RAS", "PROTEIN", 266, 269], ["ACE2", "PROTEIN", 270, 274], ["AGE", "PROTEIN", 276, 279], ["RAGE", "PROTEIN", 280, 284], ["Apelin", "PROTEIN", 290, 296], ["ACE2", "PROTEIN", 385, 389], ["ACE2", "PROTEIN", 432, 436], ["ANPEP", "PROTEIN", 457, 462], ["aminopeptidase N", "PROTEIN", 471, 487], ["APN", "PROTEIN", 489, 492], ["CD13", "PROTEIN", 494, 498], ["ACE2", "PROTEIN", 520, 524], ["DDP2", "PROTEIN", 529, 533], ["HCoV-22944", "SPECIES", 587, 597], ["the CCL2", "PROBLEM", 30, 38], ["malaria disease pathway", "PROBLEM", 44, 67], ["our study", "TEST", 71, 80], ["chloroquine", "TREATMENT", 92, 103], ["a potent anti inflammatory agent", "TREATMENT", 105, 137], ["ACE2 and INS)", "TREATMENT", 155, 168], ["ACE2 and cytokine storm", "TREATMENT", 202, 225], ["severe COVID-19 disease", "PROBLEM", 242, 265], ["RAS", "TEST", 266, 269], ["ACE2", "TEST", 270, 274], ["Apelin signaling", "PROBLEM", 290, 306], ["the blood pressure dysregulation", "TEST", 335, 367], ["ACE2 in COVID", "TEST", 385, 398], ["extensive ACE2 network connection", "TREATMENT", 422, 455], ["ANPEP encodes aminopeptidase N (APN, CD13", "TREATMENT", 457, 498], ["ACE2", "TEST", 520, 524], ["DDP2", "TREATMENT", 529, 533], ["coronavirus", "PROBLEM", 569, 580], ["malaria", "OBSERVATION", 44, 51], ["cytokine storm", "OBSERVATION", 211, 225], ["ACE2", "ANATOMY", 270, 274]]], ["67 APN plays a role in inflammatory response by regulating the activity of various hormones, chemokines and cytokines and was found to be increased in some inflammatory diseases.", [["APN", "GENE_OR_GENE_PRODUCT", 3, 6], ["APN", "PROTEIN", 3, 6], ["chemokines", "PROTEIN", 93, 103], ["cytokines", "PROTEIN", 108, 117], ["inflammatory response", "PROBLEM", 23, 44], ["chemokines and cytokines", "TREATMENT", 93, 117], ["some inflammatory diseases", "PROBLEM", 151, 177], ["inflammatory", "OBSERVATION", 23, 35], ["increased", "OBSERVATION_MODIFIER", 138, 147], ["some", "OBSERVATION_MODIFIER", 151, 155], ["inflammatory diseases", "OBSERVATION", 156, 177]]], ["68 APN may influence on controlling blood pressure by regulating the metabolism of Ang III.", [["blood", "ANATOMY", 36, 41], ["Ang", "CHEMICAL", 83, 86], ["APN", "GENE_OR_GENE_PRODUCT", 3, 6], ["blood", "ORGANISM_SUBSTANCE", 36, 41], ["Ang III", "GENE_OR_GENE_PRODUCT", 83, 90], ["APN", "PROTEIN", 3, 6], ["Ang III", "PROTEIN", 83, 90], ["blood pressure", "TEST", 36, 50]]], ["69miRNAs as promising antiviral modulators of the ACE2 network and potential biomarker of HF associated with COVID-19.In the next step of our study, we searched for miRNAs that may regulate expression of ACE2 networks and related processes.", [["HF", "DISEASE", 90, 92], ["COVID-19", "CHEMICAL", 109, 117], ["69miRNAs", "GENE_OR_GENE_PRODUCT", 0, 8], ["ACE2", "GENE_OR_GENE_PRODUCT", 50, 54], ["ACE2", "GENE_OR_GENE_PRODUCT", 204, 208], ["69miRNAs", "PROTEIN", 0, 8], ["ACE2", "PROTEIN", 50, 54], ["ACE2", "PROTEIN", 204, 208], ["the ACE2 network", "PROBLEM", 46, 62], ["HF", "PROBLEM", 90, 92], ["COVID", "TEST", 109, 114], ["our study", "TEST", 138, 147], ["miRNAs", "TREATMENT", 165, 171], ["ACE2 networks", "TREATMENT", 204, 217], ["antiviral modulators", "OBSERVATION", 22, 42]]], ["Our prediction model revealed that miR-302c-5p, miR-1305, miR-587, miR-26b-5p, and miR-27a-3p are top regulators of complete ACE2 network, heart-specific network as well as virus-infection related network.", [["heart", "ANATOMY", 139, 144], ["infection", "DISEASE", 179, 188], ["miR-302c-5p", "GENE_OR_GENE_PRODUCT", 35, 46], ["miR-1305", "GENE_OR_GENE_PRODUCT", 48, 56], ["miR-587", "GENE_OR_GENE_PRODUCT", 58, 65], ["miR-26b-5p", "GENE_OR_GENE_PRODUCT", 67, 77], ["miR-27a-3p", "GENE_OR_GENE_PRODUCT", 83, 93], ["ACE2", "GENE_OR_GENE_PRODUCT", 125, 129], ["heart", "ORGAN", 139, 144], ["miR-302c-5p", "DNA", 35, 46], ["miR", "DNA", 48, 51], ["miR", "DNA", 58, 61], ["miR-26b-5p", "DNA", 67, 77], ["miR-27a-3p", "DNA", 83, 93], ["ACE2", "PROTEIN", 125, 129], ["miR", "TEST", 58, 61], ["miR", "TEST", 67, 70], ["miR", "TEST", 83, 86], ["infection", "PROBLEM", 179, 188], ["heart", "ANATOMY", 139, 144], ["infection", "OBSERVATION", 179, 188]]], ["To our best knowledge, we present here novel results on a potential role of miRNAs as a diagnostic and prognostic tool in heart muscle injury in the course of SARS-CoV-2 infection.miRNAs as promising antiviral modulators of the ACE2 network and potential biomarker of HF associated with COVID-19.miR-1305 and miR-587: TGF-\u03b2 signaling pathway regulators in HF progression.", [["heart muscle", "ANATOMY", 122, 134], ["heart muscle injury", "DISEASE", 122, 141], ["SARS-CoV-2 infection", "DISEASE", 159, 179], ["HF", "DISEASE", 268, 270], ["HF", "DISEASE", 356, 358], ["COVID-19", "CHEMICAL", 287, 295], ["heart muscle", "MULTI-TISSUE_STRUCTURE", 122, 134], ["SARS-CoV-2", "ORGANISM", 159, 169], ["ACE2", "GENE_OR_GENE_PRODUCT", 228, 232], ["miR-1305", "GENE_OR_GENE_PRODUCT", 296, 304], ["miR-587", "GENE_OR_GENE_PRODUCT", 309, 316], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 318, 323], ["ACE2", "PROTEIN", 228, 232], ["TGF-\u03b2", "PROTEIN", 318, 323], ["SARS-CoV-2", "SPECIES", 159, 169], ["heart muscle injury", "PROBLEM", 122, 141], ["SARS", "PROBLEM", 159, 163], ["CoV", "PROBLEM", 164, 167], ["2 infection", "PROBLEM", 168, 179], ["HF", "PROBLEM", 268, 270], ["COVID", "TEST", 287, 292], ["TGF", "TEST", 318, 321], ["HF progression", "PROBLEM", 356, 370], ["heart muscle", "ANATOMY", 122, 134], ["injury", "OBSERVATION", 135, 141], ["infection", "OBSERVATION", 170, 179], ["antiviral modulators", "OBSERVATION", 200, 220]]], ["MiR-1305 and miR-587 were found to regulate the expression of TGF-\u03b2 pathway members, SMAD3 and SMAD4.", [["MiR-1305", "CHEMICAL", 0, 8], ["MiR-1305", "GENE_OR_GENE_PRODUCT", 0, 8], ["miR-587", "GENE_OR_GENE_PRODUCT", 13, 20], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 62, 67], ["SMAD3", "GENE_OR_GENE_PRODUCT", 85, 90], ["SMAD4", "GENE_OR_GENE_PRODUCT", 95, 100], ["TGF-\u03b2 pathway members", "PROTEIN", 62, 83], ["SMAD3", "PROTEIN", 85, 90], ["SMAD4", "PROTEIN", 95, 100]]], ["70, 71 SMAD3 negatively regulates the inflammatory response and modulates T-cell activation.", [["T-cell", "ANATOMY", 74, 80], ["SMAD3", "GENE_OR_GENE_PRODUCT", 7, 12], ["T-cell", "CELL", 74, 80], ["SMAD3", "PROTEIN", 7, 12], ["the inflammatory response", "PROBLEM", 34, 59], ["inflammatory response", "OBSERVATION", 38, 59]]], ["72 The TGF-\u03b2/SMAD signaling pathway has been directly related to viral infections.", [["viral infections", "DISEASE", 65, 81], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 7, 12], ["SMAD", "GENE_OR_GENE_PRODUCT", 13, 17], ["TGF-\u03b2", "PROTEIN", 7, 12], ["SMAD", "PROTEIN", 13, 17], ["The TGF", "TEST", 3, 10], ["SMAD signaling pathway", "PROBLEM", 13, 35], ["viral infections", "PROBLEM", 65, 81], ["directly related to", "UNCERTAINTY", 45, 64], ["viral", "OBSERVATION_MODIFIER", 65, 70], ["infections", "OBSERVATION", 71, 81]]], ["73 Moreover, this pathway deregulation has been also implicated to ventricular remodeling, myocardial fibrosis and hypertrophy and, as a result, HF progression.", [["ventricular", "ANATOMY", 67, 78], ["myocardial", "ANATOMY", 91, 101], ["myocardial fibrosis", "DISEASE", 91, 110], ["hypertrophy", "DISEASE", 115, 126], ["HF", "DISEASE", 145, 147], ["ventricular", "MULTI-TISSUE_STRUCTURE", 67, 78], ["myocardial", "MULTI-TISSUE_STRUCTURE", 91, 101], ["ventricular remodeling", "PROBLEM", 67, 89], ["myocardial fibrosis", "PROBLEM", 91, 110], ["hypertrophy", "PROBLEM", 115, 126], ["HF progression", "PROBLEM", 145, 159], ["ventricular", "ANATOMY", 67, 78], ["remodeling", "OBSERVATION", 79, 89], ["myocardial", "ANATOMY", 91, 101], ["fibrosis", "OBSERVATION", 102, 110], ["hypertrophy", "OBSERVATION", 115, 126], ["progression", "OBSERVATION_MODIFIER", 148, 159]]], ["74 The highest expression of miR-587 was found in platelets of patients with acute coronary syndrome and was closely related to the severity of coronary artery stenosis.", [["platelets", "ANATOMY", 50, 59], ["coronary", "ANATOMY", 83, 91], ["coronary artery", "ANATOMY", 144, 159], ["acute coronary syndrome", "DISEASE", 77, 100], ["coronary artery stenosis", "DISEASE", 144, 168], ["miR-587", "GENE_OR_GENE_PRODUCT", 29, 36], ["platelets", "CELL", 50, 59], ["patients", "ORGANISM", 63, 71], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 144, 159], ["miR-587", "DNA", 29, 36], ["platelets", "CELL_TYPE", 50, 59], ["patients", "SPECIES", 63, 71], ["acute coronary syndrome", "PROBLEM", 77, 100], ["coronary artery stenosis", "PROBLEM", 144, 168], ["acute", "OBSERVATION_MODIFIER", 77, 82], ["coronary", "ANATOMY", 83, 91], ["syndrome", "OBSERVATION", 92, 100], ["coronary artery", "ANATOMY", 144, 159], ["stenosis", "OBSERVATION", 160, 168]]], ["75 miR-26b-5p: anti-fibrotic agent and AGTR1-dependent hypertension modulator.", [["miR-26b-5p", "CHEMICAL", 3, 13], ["hypertension", "DISEASE", 55, 67], ["miR-26b", "GENE_OR_GENE_PRODUCT", 3, 10], ["AGTR1", "SIMPLE_CHEMICAL", 39, 44], ["miR-26b-5p", "DNA", 3, 13], ["AGTR1", "PROTEIN", 39, 44], ["anti-fibrotic agent", "TREATMENT", 15, 34], ["AGTR1-dependent hypertension modulator", "PROBLEM", 39, 77], ["dependent", "OBSERVATION_MODIFIER", 45, 54], ["hypertension", "OBSERVATION", 55, 67]]], ["In our study we found that miR-26b-5p may play an important role in pathogenesis of HF in COVID-19 patients as showed by an interaction of ACE2 with ENPEP, AGT, CCN2, CALM1, CCL2, and AGTR1.", [["miR-26b-5p", "CHEMICAL", 27, 37], ["HF", "DISEASE", 84, 86], ["miR-26b-5p", "GENE_OR_GENE_PRODUCT", 27, 37], ["patients", "ORGANISM", 99, 107], ["ACE2", "GENE_OR_GENE_PRODUCT", 139, 143], ["ENPEP", "GENE_OR_GENE_PRODUCT", 149, 154], ["AGT", "GENE_OR_GENE_PRODUCT", 156, 159], ["CCN2", "GENE_OR_GENE_PRODUCT", 161, 165], ["CALM1", "GENE_OR_GENE_PRODUCT", 167, 172], ["CCL2", "GENE_OR_GENE_PRODUCT", 174, 178], ["AGTR1", "GENE_OR_GENE_PRODUCT", 184, 189], ["miR-26b-5p", "DNA", 27, 37], ["ACE2", "PROTEIN", 139, 143], ["ENPEP", "PROTEIN", 149, 154], ["AGT", "PROTEIN", 156, 159], ["CCN2", "PROTEIN", 161, 165], ["CALM1", "PROTEIN", 167, 172], ["CCL2", "PROTEIN", 174, 178], ["AGTR1", "PROTEIN", 184, 189], ["patients", "SPECIES", 99, 107], ["our study", "TEST", 3, 12], ["HF", "PROBLEM", 84, 86], ["COVID", "TEST", 90, 95], ["ACE2", "TEST", 139, 143], ["ENPEP", "TEST", 149, 154], ["AGT", "TEST", 156, 159], ["AGTR1", "TREATMENT", 184, 189]]], ["Noteworthy, previous study showed that in the miRNA-differentially expressed genes (DEG) regulatory network, hsa-miR-26b-5p was one of the most important miRNA and AGTR1 was the most outstanding up-regulated DEGs in the PPI network.", [["hsa-miR-26b-5p", "GENE_OR_GENE_PRODUCT", 109, 123], ["AGTR1", "GENE_OR_GENE_PRODUCT", 164, 169], ["PPI network", "MULTI-TISSUE_STRUCTURE", 220, 231], ["miRNA-differentially expressed genes", "DNA", 46, 82], ["DEG", "DNA", 84, 87], ["hsa-miR-26b-5p", "DNA", 109, 123], ["miRNA", "DNA", 154, 159], ["AGTR1", "DNA", 164, 169], ["DEGs", "DNA", 208, 212], ["previous study", "TEST", 12, 26], ["hsa-miR", "TEST", 109, 116], ["the PPI network", "TREATMENT", 216, 231]]], ["76 It has been suggested that AGTR1 can modulate hypertension, via the regulation of miR-26b-5p in arachidonic acid metabolism.", [["AGTR1", "CHEMICAL", 30, 35], ["hypertension", "DISEASE", 49, 61], ["arachidonic acid", "CHEMICAL", 99, 115], ["arachidonic acid", "CHEMICAL", 99, 115], ["AGTR1", "GENE_OR_GENE_PRODUCT", 30, 35], ["miR-26b-5p", "GENE_OR_GENE_PRODUCT", 85, 95], ["arachidonic acid", "SIMPLE_CHEMICAL", 99, 115], ["AGTR1", "PROTEIN", 30, 35], ["miR-26b-5p", "DNA", 85, 95], ["AGTR1 can modulate hypertension", "PROBLEM", 30, 61], ["arachidonic acid metabolism", "TREATMENT", 99, 126], ["hypertension", "OBSERVATION", 49, 61], ["arachidonic acid metabolism", "OBSERVATION", 99, 126]]], ["The anti-fibrotic effect of miR-26b-5p was shown in the liver, in the diabetic mouse myocardium and in Ang-II-induced mouse cardiac fibroblasts .", [["liver", "ANATOMY", 56, 61], ["myocardium", "ANATOMY", 85, 95], ["cardiac fibroblasts", "ANATOMY", 124, 143], ["miR-26b-5p", "CHEMICAL", 28, 38], ["diabetic", "DISEASE", 70, 78], ["Ang-II", "CHEMICAL", 103, 109], ["miR-26b-5p", "GENE_OR_GENE_PRODUCT", 28, 38], ["liver", "ORGAN", 56, 61], ["mouse", "ORGANISM", 79, 84], ["myocardium", "MULTI-TISSUE_STRUCTURE", 85, 95], ["Ang-II", "GENE_OR_GENE_PRODUCT", 103, 109], ["mouse", "ORGANISM", 118, 123], ["cardiac fibroblasts", "CELL", 124, 143], ["miR-26b-5p", "DNA", 28, 38], ["Ang-II-induced mouse cardiac fibroblasts", "CELL_LINE", 103, 143], ["mouse", "SPECIES", 79, 84], ["mouse", "SPECIES", 118, 123], ["mouse", "SPECIES", 79, 84], ["mouse", "SPECIES", 118, 123], ["the diabetic mouse myocardium", "PROBLEM", 66, 95], ["induced mouse cardiac fibroblasts", "PROBLEM", 110, 143], ["anti-fibrotic", "OBSERVATION_MODIFIER", 4, 17], ["liver", "ANATOMY", 56, 61], ["diabetic", "OBSERVATION", 70, 78], ["mouse myocardium", "ANATOMY", 79, 95], ["mouse", "ANATOMY_MODIFIER", 118, 123], ["cardiac", "ANATOMY", 124, 131], ["fibroblasts", "OBSERVATION", 132, 143]]], ["77 miR-302c-5p: potential antiviral therapeutic and biomarker of HF.", [["HF", "DISEASE", 65, 67], ["miR-302c-5p", "GENE_OR_GENE_PRODUCT", 3, 14], ["miR-302c-5p", "DNA", 3, 14], ["HF", "PROBLEM", 65, 67], ["antiviral therapeutic", "OBSERVATION_MODIFIER", 26, 47], ["HF", "OBSERVATION", 65, 67]]], ["Another regulating miRNA from our network was miR-302c-5p playing an important role in many viral infections.", [["miR-302c-5p", "CHEMICAL", 46, 57], ["viral infections", "DISEASE", 92, 108], ["miR-302c-5p", "GENE_OR_GENE_PRODUCT", 46, 57], ["miR-302c-5p", "DNA", 46, 57], ["many viral infections", "PROBLEM", 87, 108], ["viral", "OBSERVATION_MODIFIER", 92, 97], ["infections", "OBSERVATION", 98, 108]]], ["[78] [79] [80] A study reported an association between the miR-302, KPNA2 axis and EV71-related cytokine storm and showed the potential of miR-302 as an antiviral therapeutic.", [["miR-302", "CHEMICAL", 139, 146], ["[78] [79] [80", "SIMPLE_CHEMICAL", 0, 13], ["miR-302", "GENE_OR_GENE_PRODUCT", 59, 66], ["KPNA2", "GENE_OR_GENE_PRODUCT", 68, 73], ["EV71", "ORGANISM", 83, 87], ["miR-302", "GENE_OR_GENE_PRODUCT", 139, 146], ["KPNA2", "PROTEIN", 68, 73], ["cytokine", "PROTEIN", 96, 104], ["A study", "TEST", 15, 22], ["the miR", "TEST", 55, 62], ["KPNA2 axis", "TEST", 68, 78], ["EV71", "TEST", 83, 87], ["miR", "TEST", 139, 142], ["an antiviral therapeutic", "TREATMENT", 150, 174], ["cytokine storm", "OBSERVATION", 96, 110]]], ["80 Our bioinformatic analysis for the first time showed the importance of miR-302c-5p in SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 89, 109], ["miR-302c-5p", "GENE_OR_GENE_PRODUCT", 74, 85], ["SARS-CoV-2", "ORGANISM", 89, 99], ["miR-302c-5p", "DNA", 74, 85], ["SARS-CoV-2", "SPECIES", 89, 99], ["Our bioinformatic analysis", "TEST", 3, 29], ["miR", "TEST", 74, 77], ["SARS", "PROBLEM", 89, 93], ["CoV", "PROBLEM", 94, 97], ["2 infection", "PROBLEM", 98, 109], ["infection", "OBSERVATION", 100, 109]]], ["Apart from the crucial function of miR-302 in viral infections, it may be also associated with CVD, 81,82 as circulating miR-302 was positively correlated with NT-proBNP levels in acute HF patients and showed strong potential as a novel biomarker for the diagnosis and the differentiation of disease severity of acute HF.", [["miR-302", "CHEMICAL", 35, 42], ["viral infections", "DISEASE", 46, 62], ["CVD", "DISEASE", 95, 98], ["NT-proBNP", "CHEMICAL", 160, 169], ["acute HF", "DISEASE", 180, 188], ["HF", "DISEASE", 318, 320], ["miR-302", "GENE_OR_GENE_PRODUCT", 35, 42], ["miR-302", "GENE_OR_GENE_PRODUCT", 121, 128], ["NT-proBNP", "GENE_OR_GENE_PRODUCT", 160, 169], ["patients", "ORGANISM", 189, 197], ["miR-302", "DNA", 35, 42], ["patients", "SPECIES", 189, 197], ["viral infections", "PROBLEM", 46, 62], ["CVD", "PROBLEM", 95, 98], ["circulating miR", "TEST", 109, 124], ["NT-proBNP levels", "TEST", 160, 176], ["acute HF", "PROBLEM", 180, 188], ["acute HF", "PROBLEM", 312, 320], ["crucial", "OBSERVATION_MODIFIER", 15, 22], ["function", "OBSERVATION_MODIFIER", 23, 31], ["viral infections", "OBSERVATION", 46, 62], ["acute", "OBSERVATION_MODIFIER", 180, 185], ["acute", "OBSERVATION_MODIFIER", 312, 317], ["HF", "OBSERVATION", 318, 320]]], ["81 miR-27a-3p: a potential biomarker of acute HF and NF-\u03baB signaling regulator.", [["miR-27a-3p", "GENE_OR_GENE_PRODUCT", 3, 13], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 53, 58], ["miR-27a-3p", "DNA", 3, 13], ["NF-\u03baB", "PROTEIN", 53, 58], ["acute HF", "PROBLEM", 40, 48], ["NF", "PROBLEM", 53, 55], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["HF", "OBSERVATION", 46, 48]]], ["Also miR-27a-3p was found to be involved in inflammatory response and oxidative stress through several pathways including PPAR-\u03b3, NF-\u03baB and PI3K/ AKT/Nrf2 signaling.", [["miR-27a-3p", "GENE_OR_GENE_PRODUCT", 5, 15], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 122, 128], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 130, 135], ["PI3K", "GENE_OR_GENE_PRODUCT", 140, 144], ["AKT", "GENE_OR_GENE_PRODUCT", 146, 149], ["Nrf2", "GENE_OR_GENE_PRODUCT", 150, 154], ["miR-27a-3p", "DNA", 5, 15], ["PPAR", "PROTEIN", 122, 126], ["PI3K", "PROTEIN", 140, 144], ["AKT", "PROTEIN", 146, 149], ["Nrf2", "PROTEIN", 150, 154], ["inflammatory response", "PROBLEM", 44, 65], ["oxidative stress", "PROBLEM", 70, 86], ["PPAR", "TEST", 122, 126], ["NF", "TEST", 130, 132], ["Nrf2 signaling", "PROBLEM", 150, 164], ["inflammatory response", "OBSERVATION", 44, 65], ["Nrf2 signaling", "OBSERVATION", 150, 164]]], ["[83] [84] [85] In animal model of acute lung injury, expression of miR-27a-3p in alveolar macrophages was significantly decreased, while overexpression of miR-27a-3p suppressed NF-\u03baB activation and alleviated acute lung injury by binding to its target NFKB1.", [["lung", "ANATOMY", 40, 44], ["alveolar macrophages", "ANATOMY", 81, 101], ["lung", "ANATOMY", 215, 219], ["acute lung injury", "DISEASE", 34, 51], ["acute lung injury", "DISEASE", 209, 226], ["lung", "ORGAN", 40, 44], ["miR-27a-3p", "GENE_OR_GENE_PRODUCT", 67, 77], ["alveolar macrophages", "CELL", 81, 101], ["miR-27a-3p", "GENE_OR_GENE_PRODUCT", 155, 165], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 177, 182], ["lung", "ORGAN", 215, 219], ["NFKB1", "GENE_OR_GENE_PRODUCT", 252, 257], ["miR-27a-3p", "DNA", 67, 77], ["alveolar macrophages", "CELL_TYPE", 81, 101], ["miR-27a-3p", "DNA", 155, 165], ["NF-\u03baB", "PROTEIN", 177, 182], ["NFKB1", "PROTEIN", 252, 257], ["acute lung injury", "PROBLEM", 34, 51], ["miR", "TEST", 67, 70], ["alveolar macrophages", "PROBLEM", 81, 101], ["B activation", "PROBLEM", 181, 193], ["alleviated acute lung injury", "PROBLEM", 198, 226], ["acute", "OBSERVATION_MODIFIER", 34, 39], ["lung", "ANATOMY", 40, 44], ["injury", "OBSERVATION", 45, 51], ["alveolar", "ANATOMY", 81, 89], ["macrophages", "OBSERVATION", 90, 101], ["significantly", "OBSERVATION_MODIFIER", 106, 119], ["decreased", "OBSERVATION_MODIFIER", 120, 129], ["alleviated", "OBSERVATION_MODIFIER", 198, 208], ["acute", "OBSERVATION_MODIFIER", 209, 214], ["lung", "ANATOMY", 215, 219], ["injury", "OBSERVATION", 220, 226]]], ["83 Moreover, it was also found that miR-27a-3p may target pathways related to atherosclerosis, and may act as a potential biomarker of acute HF.", [["atherosclerosis", "DISEASE", 78, 93], ["HF", "DISEASE", 141, 143], ["miR-27a-3p", "GENE_OR_GENE_PRODUCT", 36, 46], ["miR-27a-3p", "DNA", 36, 46], ["atherosclerosis", "PROBLEM", 78, 93], ["acute HF", "PROBLEM", 135, 143], ["atherosclerosis", "OBSERVATION", 78, 93], ["acute", "OBSERVATION_MODIFIER", 135, 140], ["HF", "OBSERVATION", 141, 143]]], ["86, 87ConclusionThis comprehensive analysis provides novel information regarding the complexity of signaling pathways of SARS-CoV-2 infection affecting the cardiovascular system and forms a basis for a creation of predictive tools and introduction of therapy to improve outcome in COVID-19, and therefore has a potential to reduce economic consequences of the global pandemic.", [["cardiovascular system", "ANATOMY", 156, 177], ["SARS", "DISEASE", 121, 125], ["infection", "DISEASE", 132, 141], ["SARS-CoV-2", "ORGANISM", 121, 131], ["cardiovascular", "ANATOMICAL_SYSTEM", 156, 170], ["system", "ANATOMICAL_SYSTEM", 171, 177], ["SARS-CoV-2", "SPECIES", 121, 131], ["This comprehensive analysis", "TEST", 16, 43], ["SARS", "PROBLEM", 121, 125], ["CoV-2 infection", "PROBLEM", 126, 141], ["predictive tools", "TEST", 214, 230], ["therapy", "TREATMENT", 251, 258], ["COVID", "TEST", 281, 286], ["the global pandemic", "PROBLEM", 356, 375], ["infection", "OBSERVATION", 132, 141], ["cardiovascular system", "ANATOMY", 156, 177], ["global", "OBSERVATION_MODIFIER", 360, 366], ["pandemic", "OBSERVATION", 367, 375]]], ["We believe that the results of our analysis could be further validated in laboratory and clinical settings and help to create a paradigm for future studies in this field.", [["our analysis", "TEST", 31, 43], ["future studies", "TEST", 141, 155]]], ["MiRNAs identified for the first time in this study can serve as potential biomarkers helping with identification of the pathological changes in COVID-19 or serve as therapeutic targets due to their stability in the serum, forming a basis for personalized therapy in patients with or at risk for CVD as those with obesity, DM or hypertension suffering from COVID-19.", [["serum", "ANATOMY", 215, 220], ["CVD", "DISEASE", 295, 298], ["obesity", "DISEASE", 313, 320], ["DM", "DISEASE", 322, 324], ["hypertension", "DISEASE", 328, 340], ["COVID-19", "CHEMICAL", 144, 152], ["COVID-19", "CELL", 144, 152], ["serum", "ORGANISM_SUBSTANCE", 215, 220], ["patients", "ORGANISM", 266, 274], ["MiRNAs", "DNA", 0, 6], ["patients", "SPECIES", 266, 274], ["this study", "TEST", 40, 50], ["potential biomarkers", "TEST", 64, 84], ["the pathological changes", "PROBLEM", 116, 140], ["COVID", "TEST", 144, 149], ["the serum", "TEST", 211, 220], ["personalized therapy", "TREATMENT", 242, 262], ["CVD", "PROBLEM", 295, 298], ["obesity", "PROBLEM", 313, 320], ["DM", "PROBLEM", 322, 324], ["hypertension", "PROBLEM", 328, 340], ["COVID", "TEST", 356, 361], ["obesity", "OBSERVATION", 313, 320], ["hypertension", "OBSERVATION", 328, 340]]]], "PMC3474735": [["In fact, Koch himself abandoned his first postulate when he discovered that the causative agent of cholera could also be carried asymptomatically [1].", [["cholera", "DISEASE", 99, 106], ["cholera", "ORGANISM", 99, 106], ["cholera", "TREATMENT", 99, 106]]], ["Since then, it is increasingly acknowledged that human diseases, including respiratory tract infections like otitis media and pneumonia, are polymicrobial\u2013resulting from synergistic and antagonistic interactions between pathogens [4],[5].IntroductionThe human nasopharynx is considered the niche from which respiratory tract infections originate [6].", [["respiratory tract", "ANATOMY", 75, 92], ["nasopharynx", "ANATOMY", 260, 271], ["respiratory tract", "ANATOMY", 307, 324], ["respiratory tract infections", "DISEASE", 75, 103], ["otitis media", "DISEASE", 109, 121], ["pneumonia", "DISEASE", 126, 135], ["respiratory tract infections", "DISEASE", 307, 335], ["human", "ORGANISM", 49, 54], ["respiratory tract", "ORGANISM", 75, 92], ["human", "ORGANISM", 254, 259], ["nasopharynx", "ORGAN", 260, 271], ["tract", "ORGANISM_SUBDIVISION", 319, 324], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 254, 259], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 254, 259], ["human diseases", "PROBLEM", 49, 63], ["respiratory tract infections", "PROBLEM", 75, 103], ["otitis media", "PROBLEM", 109, 121], ["pneumonia", "PROBLEM", 126, 135], ["polymicrobial\u2013resulting", "PROBLEM", 141, 164], ["synergistic and antagonistic interactions between pathogens", "PROBLEM", 170, 229], ["respiratory tract infections", "PROBLEM", 307, 335], ["respiratory tract", "ANATOMY", 75, 92], ["otitis", "OBSERVATION", 109, 115], ["pneumonia", "OBSERVATION", 126, 135], ["human nasopharynx", "ANATOMY", 254, 271], ["respiratory tract", "ANATOMY", 307, 324]]], ["Several residents of the nasopharyngeal microbiome, including Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and Staphylococcus aureus, are major contributors to disease in childhood.", [["nasopharyngeal microbiome", "ANATOMY", 25, 50], ["Streptococcus pneumoniae", "DISEASE", 62, 86], ["Haemophilus influenzae", "DISEASE", 88, 110], ["Staphylococcus aureus", "DISEASE", 138, 159], ["nasopharyngeal", "ORGAN", 25, 39], ["Streptococcus pneumoniae", "ORGANISM", 62, 86], ["Haemophilus influenzae", "ORGANISM", 88, 110], ["Moraxella catarrhalis", "ORGANISM", 112, 133], ["Staphylococcus aureus", "ORGANISM", 138, 159], ["Streptococcus pneumoniae", "SPECIES", 62, 86], ["Haemophilus influenzae", "SPECIES", 88, 110], ["Moraxella catarrhalis", "SPECIES", 112, 133], ["Staphylococcus aureus", "SPECIES", 138, 159], ["Streptococcus pneumoniae", "SPECIES", 62, 86], ["Haemophilus influenzae", "SPECIES", 88, 110], ["Moraxella catarrhalis", "SPECIES", 112, 133], ["Staphylococcus aureus", "SPECIES", 138, 159], ["the nasopharyngeal microbiome", "TREATMENT", 21, 50], ["Streptococcus pneumoniae", "PROBLEM", 62, 86], ["Haemophilus influenzae", "PROBLEM", 88, 110], ["Moraxella catarrhalis", "PROBLEM", 112, 133], ["Staphylococcus aureus", "PROBLEM", 138, 159], ["disease", "PROBLEM", 187, 194], ["nasopharyngeal microbiome", "ANATOMY", 25, 50], ["Streptococcus pneumoniae", "OBSERVATION", 62, 86], ["Moraxella catarrhalis", "OBSERVATION", 112, 133], ["Staphylococcus aureus", "OBSERVATION", 138, 159]]], ["However, they are also common, transient colonizers of the nasopharynx of healthy children, especially in the youngest, whose immune systems are still maturing.", [["nasopharynx", "ANATOMY", 59, 70], ["nasopharynx", "ORGAN", 59, 70], ["children", "ORGANISM", 82, 90], ["children", "SPECIES", 82, 90], ["transient", "OBSERVATION_MODIFIER", 31, 40], ["colonizers", "OBSERVATION", 41, 51], ["nasopharynx", "ANATOMY", 59, 70]]], ["Colonization of this niche in the upper respiratory tract appears to be a dynamic process of acquisition and elimination of various microbes, during which they interact with the host, its maturing immune system and each other [6].", [["niche", "ANATOMY", 21, 26], ["upper respiratory tract", "ANATOMY", 34, 57], ["upper respiratory", "ORGANISM_SUBDIVISION", 34, 51], ["tract", "ORGANISM_SUBDIVISION", 52, 57], ["Colonization of this niche in the upper respiratory tract", "PROBLEM", 0, 57], ["various microbes", "PROBLEM", 124, 140], ["upper", "ANATOMY_MODIFIER", 34, 39], ["respiratory tract", "ANATOMY", 40, 57]]], ["In a balanced state, this bacterial ecosystem is assumed to be beneficial for health, for example by stimulating the immune system and functioning as a protective barrier against invading pathogens [7].IntroductionViruses can also be frequently detected in nasopharyngeal samples of healthy children [8]\u2013[10].", [["immune system", "ANATOMY", 117, 130], ["nasopharyngeal samples", "ANATOMY", 257, 279], ["nasopharyngeal samples", "CANCER", 257, 279], ["children", "ORGANISM", 291, 299], ["children", "SPECIES", 291, 299], ["this bacterial ecosystem", "PROBLEM", 21, 45], ["a protective barrier", "TREATMENT", 150, 170], ["invading pathogens", "PROBLEM", 179, 197]]], ["Episodes of new bacterial or viral acquisition potentially disturb the equilibrium of this ecosystem, upon which pathogens could have an opportunity to invade, disseminate and cause diseases like acute otitis media, pneumonia or even meningitis [4].", [["acute otitis media", "DISEASE", 196, 214], ["pneumonia", "DISEASE", 216, 225], ["meningitis", "DISEASE", 234, 244], ["new bacterial or viral acquisition", "PROBLEM", 12, 46], ["diseases", "PROBLEM", 182, 190], ["acute otitis media", "PROBLEM", 196, 214], ["pneumonia", "PROBLEM", 216, 225], ["meningitis", "PROBLEM", 234, 244], ["new", "OBSERVATION_MODIFIER", 12, 15], ["bacterial", "OBSERVATION", 16, 25], ["viral", "OBSERVATION", 29, 34], ["acute", "OBSERVATION_MODIFIER", 196, 201], ["otitis", "OBSERVATION", 202, 208], ["pneumonia", "OBSERVATION", 216, 225], ["meningitis", "OBSERVATION", 234, 244]]], ["Importantly, dynamics in exposure to viruses and bacteria are influenced by environmental factors, like crowding at day care or siblings living in the same household [6].", [["viruses", "PROBLEM", 37, 44], ["bacteria", "PROBLEM", 49, 57], ["viruses", "OBSERVATION", 37, 44]]], ["Knowledge about the prevalence of bacteria and viruses in the nasopharynx of healthy children as well as specific associations between these pathogens is important to interpret findings during disease and to ultimately better understand pathogenesis of respiratory infections.", [["nasopharynx", "ANATOMY", 62, 73], ["respiratory", "ANATOMY", 253, 264], ["respiratory infections", "DISEASE", 253, 275], ["nasopharynx", "ORGAN", 62, 73], ["children", "ORGANISM", 85, 93], ["children", "SPECIES", 85, 93], ["bacteria", "PROBLEM", 34, 42], ["viruses", "PROBLEM", 47, 54], ["these pathogens", "PROBLEM", 135, 150], ["respiratory infections", "PROBLEM", 253, 275], ["bacteria", "OBSERVATION", 34, 42], ["viruses", "OBSERVATION", 47, 54], ["nasopharynx", "ANATOMY", 62, 73], ["respiratory", "ANATOMY", 253, 264], ["infections", "OBSERVATION", 265, 275]]], ["However, this is still a rather unexplored field of research.IntroductionHere, we describe the results of a post-hoc analysis in 986 nasopharyngeal swab samples from healthy 6- to 24-month-old children who had participated in a pneumococcal vaccination trial.", [["nasopharyngeal swab samples", "ANATOMY", 133, 160], ["nasopharyngeal swab samples", "CANCER", 133, 160], ["children", "ORGANISM", 193, 201], ["children", "SPECIES", 193, 201], ["pneumococcal", "SPECIES", 228, 240], ["a post-hoc analysis", "TEST", 106, 125], ["nasopharyngeal swab samples", "TEST", 133, 160], ["a pneumococcal vaccination trial", "TREATMENT", 226, 258]]], ["We aimed to evaluate the prevalence of a wide range of common respiratory viruses as well as co-occurrence patterns with four of the most commonly detected bacterial pathogens in clinical practice (S. pneumoniae, H. influenzae, M. catarrhalis and S. aureus), while taking well described epidemiologic and environmental determinants into account.Ethics Statement ::: Materials and MethodsAn acknowledged Independent Ethics Committee from the Netherlands (Stichting Therapeutische Evaluatie Geneesmiddelen) approved the study protocol.", [["respiratory viruses", "DISEASE", 62, 81], ["S. pneumoniae", "ORGANISM", 198, 211], ["H. influenzae", "ORGANISM", 213, 226], ["M. catarrhalis", "ORGANISM", 228, 242], ["S. aureus", "ORGANISM", 247, 256], ["S. pneumoniae", "SPECIES", 198, 211], ["H. influenzae", "SPECIES", 213, 226], ["M. catarrhalis", "SPECIES", 228, 242], ["S. aureus", "SPECIES", 247, 256], ["S. pneumoniae", "SPECIES", 198, 211], ["H. influenzae", "SPECIES", 213, 226], ["M. catarrhalis", "SPECIES", 228, 242], ["S. aureus", "SPECIES", 247, 256], ["common respiratory viruses", "PROBLEM", 55, 81], ["bacterial pathogens", "PROBLEM", 156, 175], ["S. pneumoniae", "PROBLEM", 198, 211], ["H. influenzae", "PROBLEM", 213, 226], ["M. catarrhalis", "PROBLEM", 228, 242], ["S. aureus", "PROBLEM", 247, 256], ["the study protocol", "TEST", 514, 532], ["respiratory viruses", "OBSERVATION", 62, 81], ["bacterial", "OBSERVATION_MODIFIER", 156, 165], ["pathogens", "OBSERVATION", 166, 175]]], ["Written informed consent was obtained from each subject\u2019s parent(s) or legal guardian(s) before enrolment.Study Population and Design ::: Materials and MethodsWe selected 986 nasopharyngeal samples obtained from children who had participated in a randomized controlled trial (ClinicalTrials.gov Identifier NCT00189020)[11].", [["nasopharyngeal samples", "ANATOMY", 175, 197], ["nasopharyngeal samples", "CANCER", 175, 197], ["children", "ORGANISM", 212, 220], ["children", "SPECIES", 212, 220], ["nasopharyngeal samples", "TEST", 175, 197]]], ["This trial, designed to assess the effects of reduced-dose schedules of 7-valent pneumococcal conjugate vaccine (PCV-7) on nasopharyngeal pneumococcal colonization, was conducted in the Netherlands between July 2005 and February 2008.", [["nasopharyngeal", "ANATOMY", 123, 137], ["PCV-7", "CHEMICAL", 113, 118], ["nasopharyngeal pneumococcal colonization", "DISEASE", 123, 163], ["7-valent pneumococcal conjugate", "SIMPLE_CHEMICAL", 72, 103], ["nasopharyngeal pneumococcal", "ORGANISM", 123, 150], ["pneumococcal", "SPECIES", 81, 93], ["pneumococcal", "SPECIES", 138, 150], ["reduced-dose schedules", "TREATMENT", 46, 68], ["7-valent pneumococcal conjugate vaccine", "TREATMENT", 72, 111], ["PCV", "TEST", 113, 116], ["nasopharyngeal pneumococcal colonization", "TREATMENT", 123, 163], ["nasopharyngeal", "ANATOMY", 123, 137], ["pneumococcal colonization", "OBSERVATION", 138, 163]]], ["Details of the trial and bacterial carriage rates have been reported previously [11]\u2013[13].", [["bacterial carriage rates", "PROBLEM", 25, 49]]], ["In short, a total of 1003 healthy infants were enrolled and randomly assigned to receive either (1) PCV-7 at 2 and 4 months of age, (2) PCV-7 at 2, 4 and 11 months of age, or (3) no dosage (control group).", [["infants", "ORGANISM", 34, 41], ["infants", "SPECIES", 34, 41], ["PCV", "TREATMENT", 100, 103], ["PCV", "TEST", 136, 139]]], ["Children were visited at home to obtain nasopharyngeal samples at the age of 6 weeks, 6, 12, 18 and 24 months.", [["nasopharyngeal samples", "ANATOMY", 40, 62], ["Children", "ORGANISM", 0, 8], ["nasopharyngeal samples", "CANCER", 40, 62], ["Children", "SPECIES", 0, 8], ["nasopharyngeal", "ANATOMY", 40, 54]]], ["Children were generally healthy at the time they were visited\u2013i.e., visits were postponed when parents deemed their child unfit for the study procedures, for example in case of fever or acute symptoms of an infection.", [["fever", "DISEASE", 177, 182], ["infection", "DISEASE", 207, 216], ["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8], ["the study procedures", "TEST", 132, 152], ["fever", "PROBLEM", 177, 182], ["acute symptoms", "PROBLEM", 186, 200], ["an infection", "PROBLEM", 204, 216], ["acute", "OBSERVATION_MODIFIER", 186, 191], ["infection", "OBSERVATION", 207, 216]]], ["At each visit, a questionnaire collecting information on day care attendance, the presence of siblings, and administration of antibiotics was obtained from the parents.Study Population and Design ::: Materials and MethodsFor the present study, nasopharyngeal samples were selected from children in the unvaccinated control group and the 2+1-dose schedule group based on availability of sufficient quantity of remaining materials.", [["nasopharyngeal samples", "ANATOMY", 244, 266], ["nasopharyngeal samples", "CANCER", 244, 266], ["children", "ORGANISM", 286, 294], ["children", "SPECIES", 286, 294], ["antibiotics", "TREATMENT", 126, 137], ["the present study", "TEST", 225, 242], ["nasopharyngeal samples", "TREATMENT", 244, 266], ["the 2+1-dose schedule group", "TREATMENT", 333, 360], ["nasopharyngeal", "ANATOMY", 244, 258]]], ["Ultimately, 497 samples from the 2+1-dose schedule group and 489 samples from the control group were analyzed.", [["samples", "ANATOMY", 16, 23], ["samples", "ANATOMY", 65, 72], ["the 2+1-dose schedule group", "TREATMENT", 29, 56]]], ["These 986 samples were taken from a total of 433 children: 212 were paired samples from the same children at 6 and 18 months of age, 121 were paired samples from the same children at 12 and 24 months of age, samples from 74 children were collected at four consecutive time points, while from another 26 children only one sample was used.Nasopharyngeal Samples and Laboratory Procedures ::: Materials and MethodsNasopharyngeal samples were taken transnasally with a flexible, sterile swab (Transnasal Pernasal Plain, Medical Wire and Equipment Co, Corsham Wiltshire, England) by trained study staff according to World Health Organization standard procedures [14].", [["samples", "ANATOMY", 10, 17], ["samples", "ANATOMY", 75, 82], ["samples", "ANATOMY", 149, 156], ["samples", "ANATOMY", 208, 215], ["Nasopharyngeal Samples", "ANATOMY", 337, 359], ["Nasopharyngeal samples", "ANATOMY", 411, 433], ["children", "ORGANISM", 49, 57], ["children", "ORGANISM", 97, 105], ["children", "ORGANISM", 171, 179], ["children", "ORGANISM", 224, 232], ["children", "ORGANISM", 303, 311], ["Nasopharyngeal samples", "CANCER", 411, 433], ["children", "SPECIES", 49, 57], ["children", "SPECIES", 97, 105], ["children", "SPECIES", 171, 179], ["children", "SPECIES", 224, 232], ["children", "SPECIES", 303, 311], ["samples", "TEST", 208, 215], ["MethodsNasopharyngeal samples", "TEST", 404, 433], ["a flexible, sterile swab", "TREATMENT", 463, 487], ["Nasopharyngeal", "ANATOMY", 411, 425]]], ["Culture and bacterial identification occurred according to standard procedures, as previously described in detail [11]\u2013[13].", [["Culture", "TEST", 0, 7], ["bacterial identification", "TEST", 12, 36]]], ["After plating, the swabs were rinsed in 1 mL of saline and stored at \u221280\u00b0C until further analysis.Nasopharyngeal Samples and Laboratory Procedures ::: Materials and MethodsNucleic acids were extracted from one aliquot of 200 \u00b5L swab \u2018rinse\u2019 solution using the MagNa pure LC total nucleic isolation (Roche Diagnostics, Basel, Switzerland), as previously described [15].", [["swabs", "ANATOMY", 19, 24], ["Nasopharyngeal Samples", "ANATOMY", 98, 120], ["saline", "SIMPLE_CHEMICAL", 48, 54], ["MethodsNucleic acids", "SIMPLE_CHEMICAL", 165, 185], ["plating", "TREATMENT", 6, 13], ["the swabs", "TREATMENT", 15, 24], ["saline", "TREATMENT", 48, 54], ["further analysis", "TEST", 81, 97], ["Nasopharyngeal Samples", "TEST", 98, 120], ["MethodsNucleic acids", "TREATMENT", 165, 185], ["the MagNa pure LC total nucleic isolation", "TREATMENT", 256, 297]]], ["Samples were tested using real-time PCR specific for human bocavirus, polyomaviruses (WU and KI), respiratory syncytial virus (A and B), human influenza virus A and B, parainfluenza virus 1\u20134, human rhinoviruses, adenoviruses, human coronavirus OC43, NL63, HKU and 229E, human metapneumovirus, human parechovirus, and enteroviruses.", [["Samples", "ANATOMY", 0, 7], ["respiratory syncytial virus", "DISEASE", 98, 125], ["influenza virus", "DISEASE", 143, 158], ["human metapneumovirus", "DISEASE", 271, 292], ["enteroviruses", "DISEASE", 318, 331], ["human", "ORGANISM", 53, 58], ["bocavirus", "GENE_OR_GENE_PRODUCT", 59, 68], ["polyomaviruses", "ORGANISM", 70, 84], ["KI", "ORGANISM", 93, 95], ["respiratory syncytial virus", "ORGANISM", 98, 125], ["A and B", "ORGANISM", 127, 134], ["human influenza virus A", "ORGANISM", 137, 160], ["B", "GENE_OR_GENE_PRODUCT", 165, 166], ["parainfluenza virus 1\u20134", "ORGANISM", 168, 191], ["human", "ORGANISM", 193, 198], ["rhinoviruses", "ORGANISM", 199, 211], ["adenoviruses", "ORGANISM", 213, 225], ["human", "ORGANISM", 227, 232], ["coronavirus OC43", "ORGANISM", 233, 249], ["NL63", "GENE_OR_GENE_PRODUCT", 251, 255], ["HKU", "GENE_OR_GENE_PRODUCT", 257, 260], ["229E", "GENE_OR_GENE_PRODUCT", 265, 269], ["human", "ORGANISM", 271, 276], ["metapneumovirus", "ORGANISM", 277, 292], ["human", "ORGANISM", 294, 299], ["parechovirus", "CANCER", 300, 312], ["enteroviruses", "ORGANISM", 318, 331], ["human", "SPECIES", 53, 58], ["respiratory syncytial virus", "SPECIES", 98, 125], ["human influenza virus", "SPECIES", 137, 158], ["parainfluenza virus 1\u20134", "SPECIES", 168, 191], ["human", "SPECIES", 193, 198], ["human", "SPECIES", 227, 232], ["coronavirus", "SPECIES", 233, 244], ["human", "SPECIES", 271, 276], ["metapneumovirus", "SPECIES", 277, 292], ["human", "SPECIES", 294, 299], ["human bocavirus", "SPECIES", 53, 68], ["respiratory syncytial virus", "SPECIES", 98, 125], ["A", "SPECIES", 127, 128], ["human influenza virus A", "SPECIES", 137, 160], ["parainfluenza virus 1\u20134", "SPECIES", 168, 191], ["human rhinoviruses", "SPECIES", 193, 211], ["human coronavirus", "SPECIES", 227, 244], ["human metapneumovirus", "SPECIES", 271, 292], ["human parechovirus", "SPECIES", 294, 312], ["Samples", "TEST", 0, 7], ["real-time PCR", "TEST", 26, 39], ["human bocavirus", "PROBLEM", 53, 68], ["polyomaviruses", "TEST", 70, 84], ["KI", "TEST", 93, 95], ["respiratory syncytial virus", "PROBLEM", 98, 125], ["human influenza virus A", "PROBLEM", 137, 160], ["parainfluenza virus", "PROBLEM", 168, 187], ["human rhinoviruses", "PROBLEM", 193, 211], ["adenoviruses", "PROBLEM", 213, 225], ["human coronavirus OC43", "TEST", 227, 249], ["NL63", "TEST", 251, 255], ["HKU", "TEST", 257, 260], ["human metapneumovirus", "PROBLEM", 271, 292], ["human parechovirus", "PROBLEM", 294, 312], ["enteroviruses", "PROBLEM", 318, 331], ["respiratory syncytial", "ANATOMY", 98, 119]]], ["Primers, probes and PCR assay conditions used for this study have been previously reported in detail [15]\u2013[17].", [["[15]\u2013[17]", "SIMPLE_CHEMICAL", 101, 110], ["Primers", "TEST", 0, 7], ["PCR assay conditions", "TEST", 20, 40], ["this study", "TEST", 50, 60]]], ["The presence of human parechovirus and enteroviruses was determined in a subgroup of 831 samples due to limited amounts of nucleic acids that had remained available to run these final tests.Statistical Analysis ::: Materials and MethodsThe bacterial colonization rate was defined as the proportion of nasopharyngeal samples positive for a particular bacterium by conventional culture.", [["samples", "ANATOMY", 89, 96], ["nasopharyngeal samples", "ANATOMY", 301, 323], ["nucleic acids", "CHEMICAL", 123, 136], ["human", "ORGANISM", 16, 21], ["parechovirus", "CANCER", 22, 34], ["enteroviruses", "ORGANISM", 39, 52], ["nucleic acids", "SIMPLE_CHEMICAL", 123, 136], ["nasopharyngeal samples", "CANCER", 301, 323], ["human", "SPECIES", 16, 21], ["human", "SPECIES", 16, 21], ["human parechovirus", "PROBLEM", 16, 34], ["enteroviruses", "PROBLEM", 39, 52], ["nucleic acids", "TREATMENT", 123, 136], ["these final tests", "TEST", 172, 189], ["Materials", "TREATMENT", 215, 224], ["The bacterial colonization rate", "PROBLEM", 236, 267], ["nasopharyngeal samples", "TEST", 301, 323], ["a particular bacterium", "PROBLEM", 337, 359], ["conventional culture", "TEST", 363, 383], ["human parechovirus", "OBSERVATION", 16, 34], ["enteroviruses", "OBSERVATION", 39, 52], ["bacterial colonization", "OBSERVATION", 240, 262], ["nasopharyngeal", "ANATOMY", 301, 315]]], ["Likewise, the viral detection rate was defined as the proportion of samples positive for a particular virus by real-time PCR.", [["samples", "ANATOMY", 68, 75], ["the viral detection rate", "TEST", 10, 34], ["samples positive", "PROBLEM", 68, 84], ["a particular virus", "PROBLEM", 89, 107]]], ["For convenience of statistical analyses, cycle threshold (Ct) values were dichotomized and the different subtypes of viruses belonging to a specific group (e.g., parainfluenza viruses) were pooled.", [["parainfluenza viruses", "DISEASE", 162, 183], ["parainfluenza", "ORGANISM", 162, 175], ["parainfluenza", "SPECIES", 162, 175], ["statistical analyses", "TEST", 19, 39], ["cycle threshold", "TEST", 41, 56], ["Ct) values", "TEST", 58, 68], ["viruses", "PROBLEM", 117, 124], ["parainfluenza viruses", "PROBLEM", 162, 183], ["viruses", "OBSERVATION", 117, 124]]], ["Ct values <45 were defined as positive, i.e., if the sample did not become positive after 45 cycles, viruses assayed for were defined to not be present.Statistical Analysis ::: Materials and MethodsFirst, we explored univariate associations amongst the four bacteria and between each bacterium and risk factors for bacterial colonization\u2013i.e., age, presence of siblings, day care attendance, recent antibiotic use (i.e., within two months before sampling), and vaccination with PCV-7.", [["PCV-7", "SPECIES", 478, 483], ["Ct values", "TEST", 0, 9], ["the sample", "TEST", 49, 59], ["viruses", "TREATMENT", 101, 108], ["MethodsFirst", "TREATMENT", 191, 203], ["the four bacteria", "PROBLEM", 249, 266], ["each bacterium", "PROBLEM", 279, 293], ["bacterial colonization\u2013i.e.", "PROBLEM", 315, 342], ["recent antibiotic use", "TREATMENT", 392, 413], ["PCV", "TREATMENT", 478, 481]]], ["We calculated the risk and 95% confidence interval (CI) for each bacterium to co-occur with another bacterium (or risk factor) relative to the presence of that bacterium in absence of another bacterium (or risk factor).", [["CI", "TEST", 52, 54], ["each bacterium", "PROBLEM", 60, 74], ["another bacterium", "PROBLEM", 92, 109], ["that bacterium", "PROBLEM", 155, 169], ["another bacterium", "PROBLEM", 184, 201]]], ["Similarly, we assessed the co-occurrence of each of the bacteria with a particular virus (or pooled group of subtypes).", [["the bacteria", "PROBLEM", 52, 64], ["a particular virus", "PROBLEM", 70, 88]]], ["Again, we calculated the risk and 95% CI for each of the bacteria to be present when a particular virus (or pooled group of subtypes) co-occurred relative to the presence of each bacterium in absence of that virus.Statistical Analysis ::: Materials and MethodsNext, we used logistic regression models to examine independent associations between the isolation of bacteria, detection of viruses, and risk factors.", [["the bacteria", "PROBLEM", 53, 65], ["a particular virus", "PROBLEM", 85, 103], ["each bacterium", "PROBLEM", 174, 188], ["that virus", "PROBLEM", 203, 213], ["logistic regression models", "TREATMENT", 274, 300], ["bacteria", "PROBLEM", 362, 370], ["viruses", "PROBLEM", 385, 392], ["viruses", "OBSERVATION", 385, 392]]], ["All associations with a P value of <0.1 in univariate regression analysis were subsequently entered in multivariate regression models.", [["a P value", "TEST", 22, 31], ["univariate regression analysis", "TEST", 43, 73]]], ["We verified the age-related distribution of each of the covariates included in the various models, which turned out to be linear.", [["distribution", "OBSERVATION_MODIFIER", 28, 40], ["linear", "OBSERVATION_MODIFIER", 122, 128]]], ["Adjusted odds ratios with their 95% CI\u2019s were computed.", [["CI\u2019s", "TEST", 36, 40]]], ["In order to retain sufficient statistical power in models that included enterovirus and human parechovirus, missing values were imputed by the single imputation procedure, which suffices in case the number of missing values is limited as in our study [18].", [["enterovirus", "ORGANISM", 72, 83], ["human", "ORGANISM", 88, 93], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 88, 93], ["enterovirus", "PROBLEM", 72, 83], ["human parechovirus", "PROBLEM", 88, 106], ["the single imputation procedure", "TREATMENT", 139, 170], ["our study", "TEST", 241, 250]]], ["We verified our primary analyses using a repeated measurements model taking more than one measurement per child into account using generalized linear models with an autoregressive correlation structure [19].", [["a repeated measurements model", "TREATMENT", 39, 68], ["generalized linear models", "PROBLEM", 131, 156]]], ["Results from the primary analyses are presented here.", [["the primary analyses", "TEST", 13, 33]]], ["All these analyses were performed with SPSS Statistics version 17.0.Statistical Analysis ::: Materials and MethodsFinally, all variables for which statistically significant associations were found in multivariate analysis were subsequently entered into a single partial correlation matrix.", [["matrix", "CELLULAR_COMPONENT", 282, 288], ["All these analyses", "TEST", 0, 18], ["SPSS Statistics version", "TEST", 39, 62], ["multivariate analysis", "TEST", 200, 221]]], ["This analysis identifies all independent correlations between any two given parameters in the matrix after correcting for the remaining variables with P-values of 0.01 and 0.05 used as cut-off.", [["matrix", "CELLULAR_COMPONENT", 94, 100], ["This analysis", "TEST", 0, 13], ["P-values", "TEST", 151, 159]]], ["This analysis was performed in software package R 2.7 (function cor2por [package for R; available at: http://cran.r-project.org/web/packages/corpcor/index.html]) and visualized using the complex network analysis in Cytoscape (version 2.7) [20].", [["This analysis", "TEST", 0, 13]]], ["Rather than correcting for multiple comparisons, correlations at different levels of significance are visualized.", [["multiple comparisons", "TEST", 27, 47]]], ["Still, significant results should be interpreted with caution.ResultsCharacteristics of the children, nasopharyngeal bacterial colonization and viral detection rates are shown in Table 1.", [["nasopharyngeal bacterial", "ANATOMY", 102, 126], ["children", "ORGANISM", 92, 100], ["nasopharyngeal bacterial", "MULTI-TISSUE_STRUCTURE", 102, 126], ["children", "SPECIES", 92, 100], ["nasopharyngeal bacterial colonization", "PROBLEM", 102, 139], ["viral detection rates", "TEST", 144, 165], ["nasopharyngeal", "ANATOMY", 102, 116], ["bacterial colonization", "OBSERVATION", 117, 139]]], ["Bacterial colonization rates in the present study were similar to results of the main trial [11]\u2013[13].", [["Bacterial colonization rates", "PROBLEM", 0, 28], ["colonization", "OBSERVATION", 10, 22]]], ["Respiratory viruses were detected in almost 70% of samples, with 29% of samples showing evidence of multiple viruses.", [["samples", "ANATOMY", 51, 58], ["samples", "ANATOMY", 72, 79], ["samples", "CANCER", 51, 58], ["samples", "CANCER", 72, 79], ["Respiratory viruses", "PROBLEM", 0, 19], ["samples", "TEST", 72, 79], ["multiple viruses", "PROBLEM", 100, 116], ["viruses", "OBSERVATION", 12, 19], ["evidence of", "UNCERTAINTY", 88, 99], ["multiple", "OBSERVATION_MODIFIER", 100, 108], ["viruses", "OBSERVATION", 109, 116]]], ["Human rhinoviruses were detected most frequently, ranging from 31% to 50% of samples (Table 1).ResultsResults of univariate analyses are shown in detail in the supporting information (Figures S1 and S2).", [["samples", "ANATOMY", 77, 84], ["Human", "ORGANISM", 0, 5], ["rhinoviruses", "ORGANISM", 6, 18], ["Human", "SPECIES", 0, 5], ["Human rhinoviruses", "SPECIES", 0, 18], ["Human rhinoviruses", "PROBLEM", 0, 18], ["univariate analyses", "TEST", 113, 132], ["rhinoviruses", "OBSERVATION", 6, 18], ["S2", "ANATOMY", 199, 201]]], ["To summarize, S. pneumoniae, H. influenzae and M. catarrhalis were positively associated with each other (Figure S1A\u2013C), whereas each of them was negatively associated with S. aureus (Figure S1D).", [["S. pneumoniae", "ORGANISM", 14, 27], ["H. influenzae", "ORGANISM", 29, 42], ["M. catarrhalis", "ORGANISM", 47, 61], ["S. aureus", "ORGANISM", 173, 182], ["S. pneumoniae", "SPECIES", 14, 27], ["H. influenzae", "SPECIES", 29, 42], ["M. catarrhalis", "SPECIES", 47, 61], ["S. aureus", "SPECIES", 173, 182], ["S. pneumoniae", "SPECIES", 14, 27], ["H. influenzae", "SPECIES", 29, 42], ["M. catarrhalis", "SPECIES", 47, 61], ["S. aureus", "SPECIES", 173, 182], ["S. pneumoniae", "PROBLEM", 14, 27], ["H. influenzae", "PROBLEM", 29, 42], ["M. catarrhalis", "PROBLEM", 47, 61], ["S. aureus", "PROBLEM", 173, 182], ["pneumoniae", "OBSERVATION", 17, 27], ["catarrhalis", "OBSERVATION", 50, 61], ["aureus", "OBSERVATION", 176, 182]]], ["Day care attendance and presence of siblings in the household were associated with an increased risk of colonization with all bacteria except S. aureus (Figure S1).", [["S. aureus", "ORGANISM", 142, 151], ["S. aureus", "SPECIES", 142, 151], ["S. aureus", "SPECIES", 142, 151], ["colonization", "PROBLEM", 104, 116], ["all bacteria", "PROBLEM", 122, 134], ["S. aureus", "PROBLEM", 142, 151], ["increased", "OBSERVATION_MODIFIER", 86, 95], ["colonization", "OBSERVATION", 104, 116], ["aureus", "OBSERVATION", 145, 151]]], ["Recent use of antibiotics was associated with a significant decreased risk of pneumococcal colonization as was PCV-7 vaccination, which corresponds to previously described results [11].", [["pneumococcal", "ORGANISM", 78, 90], ["pneumococcal", "SPECIES", 78, 90], ["antibiotics", "TREATMENT", 14, 25], ["pneumococcal colonization", "PROBLEM", 78, 103], ["PCV", "TEST", 111, 114], ["significant", "OBSERVATION_MODIFIER", 48, 59], ["decreased", "OBSERVATION_MODIFIER", 60, 69], ["pneumococcal", "OBSERVATION_MODIFIER", 78, 90], ["colonization", "OBSERVATION", 91, 103]]], ["In general, S. pneumoniae, H. influenzae, and M. catarrhalis were more likely to be present in the nasopharynx in combination with (multiple) respiratory viruses (Figure S2A\u2013C).ResultsIn multivariate analyses, we observed persistent positive associations between S. pneumoniae colonization and the presence of H. influenzae and M. catarrhalis, the presence of siblings, day care attendance, human rhinoviruses, and enteroviruses (Table 2).", [["nasopharynx", "ANATOMY", 99, 110], ["human rhinoviruses", "DISEASE", 391, 409], ["enteroviruses", "DISEASE", 415, 428], ["S. pneumoniae", "ORGANISM", 12, 25], ["H. influenzae", "ORGANISM", 27, 40], ["M. catarrhalis", "ORGANISM", 46, 60], ["nasopharynx", "ORGAN", 99, 110], ["S. pneumoniae", "ORGANISM", 263, 276], ["H. influenzae", "ORGANISM", 310, 323], ["M. catarrhalis", "ORGANISM", 328, 342], ["human", "ORGANISM", 391, 396], ["S. pneumoniae", "SPECIES", 12, 25], ["H. influenzae", "SPECIES", 27, 40], ["M. catarrhalis", "SPECIES", 46, 60], ["S. pneumoniae", "SPECIES", 263, 276], ["H. influenzae", "SPECIES", 310, 323], ["M. catarrhalis", "SPECIES", 328, 342], ["human", "SPECIES", 391, 396], ["S. pneumoniae", "SPECIES", 12, 25], ["H. influenzae", "SPECIES", 27, 40], ["M. catarrhalis", "SPECIES", 46, 60], ["S. pneumoniae", "SPECIES", 263, 276], ["H. influenzae", "SPECIES", 310, 323], ["M. catarrhalis", "SPECIES", 328, 342], ["human rhinoviruses", "SPECIES", 391, 409], ["S. pneumoniae", "PROBLEM", 12, 25], ["H. influenzae", "PROBLEM", 27, 40], ["M. catarrhalis", "PROBLEM", 46, 60], ["multiple) respiratory viruses", "PROBLEM", 132, 161], ["multivariate analyses", "TEST", 187, 208], ["persistent positive associations", "PROBLEM", 222, 254], ["S. pneumoniae colonization", "PROBLEM", 263, 289], ["H. influenzae", "PROBLEM", 310, 323], ["M. catarrhalis", "PROBLEM", 328, 342], ["human rhinoviruses", "PROBLEM", 391, 409], ["enteroviruses", "PROBLEM", 415, 428], ["pneumoniae", "OBSERVATION", 15, 25], ["influenzae", "OBSERVATION", 30, 40], ["catarrhalis", "OBSERVATION", 49, 60], ["nasopharynx", "ANATOMY", 99, 110], ["respiratory viruses", "OBSERVATION", 142, 161], ["persistent", "OBSERVATION_MODIFIER", 222, 232], ["pneumoniae", "OBSERVATION", 266, 276], ["influenzae", "OBSERVATION", 313, 323]]], ["S. aureus carriage, recent antibiotic use, and PCV-7 vaccination remained inversely related with pneumococcal colonization in multivariate analysis.", [["S. aureus", "ORGANISM", 0, 9], ["PCV-7", "ORGANISM", 47, 52], ["S. aureus", "SPECIES", 0, 9], ["S. aureus", "SPECIES", 0, 9], ["pneumococcal", "SPECIES", 97, 109], ["S. aureus carriage", "PROBLEM", 0, 18], ["recent antibiotic use", "TREATMENT", 20, 41], ["PCV", "TEST", 47, 50], ["pneumococcal colonization", "PROBLEM", 97, 122], ["multivariate analysis", "TEST", 126, 147], ["aureus", "OBSERVATION", 3, 9], ["pneumococcal colonization", "OBSERVATION", 97, 122]]], ["We found no major differences between the risk of co-occurrence of the most prevalent respiratory viruses with pneumococcal vaccine or non-vaccine serotypes.", [["respiratory viruses", "DISEASE", 86, 105], ["pneumococcal", "SPECIES", 111, 123], ["the most prevalent respiratory viruses", "PROBLEM", 67, 105], ["pneumococcal vaccine", "TREATMENT", 111, 131], ["non-vaccine serotypes", "PROBLEM", 135, 156], ["no", "UNCERTAINTY", 9, 11], ["viruses", "OBSERVATION", 98, 105]]], ["Likewise, we found no differences upon stratification of the analyses for vaccination status.", [["the analyses", "TEST", 57, 69], ["vaccination status", "PROBLEM", 74, 92]]], ["H. influenzae colonization was positively associated with the presence of S. pneumoniae, human rhinoviruses and respiratory syncytial viruses, the presence of siblings, and day care attendance.", [["respiratory syncytial viruses", "DISEASE", 112, 141], ["H. influenzae", "ORGANISM", 0, 13], ["S. pneumoniae", "ORGANISM", 74, 87], ["human", "ORGANISM", 89, 94], ["rhinoviruses", "ORGANISM", 95, 107], ["respiratory syncytial viruses", "ORGANISM", 112, 141], ["H. influenzae", "SPECIES", 0, 13], ["S. pneumoniae", "SPECIES", 74, 87], ["human", "SPECIES", 89, 94], ["H. influenzae", "SPECIES", 0, 13], ["S. pneumoniae", "SPECIES", 74, 87], ["human rhinoviruses", "SPECIES", 89, 107], ["respiratory syncytial viruses", "SPECIES", 112, 141], ["H. influenzae colonization", "PROBLEM", 0, 26], ["S. pneumoniae", "PROBLEM", 74, 87], ["human rhinoviruses", "PROBLEM", 89, 107], ["respiratory syncytial viruses", "PROBLEM", 112, 141], ["pneumoniae", "OBSERVATION", 77, 87], ["respiratory syncytial viruses", "OBSERVATION", 112, 141]]], ["M. catarrhalis colonization remained positively correlated with the presence of S. pneumoniae, coronaviruses, adenoviruses and the presence of siblings.", [["M. catarrhalis", "ORGANISM", 0, 14], ["S. pneumoniae", "ORGANISM", 80, 93], ["coronaviruses", "ORGANISM", 95, 108], ["adenoviruses", "ORGANISM", 110, 122], ["M. catarrhalis", "SPECIES", 0, 14], ["S. pneumoniae", "SPECIES", 80, 93], ["M. catarrhalis", "SPECIES", 0, 14], ["S. pneumoniae", "SPECIES", 80, 93], ["M. catarrhalis colonization", "PROBLEM", 0, 27], ["S. pneumoniae", "PROBLEM", 80, 93], ["coronaviruses", "PROBLEM", 95, 108], ["adenoviruses", "PROBLEM", 110, 122], ["catarrhalis", "OBSERVATION", 3, 14], ["pneumoniae", "OBSERVATION", 83, 93]]], ["A negative association was found between M. catarrhalis and S. aureus, with an adjusted odds ratio being even more profound than that between S. aureus and S. pneumoniae colonization (0.42 vs 0.56, respectively).", [["M. catarrhalis", "ORGANISM", 41, 55], ["S. aureus", "ORGANISM", 60, 69], ["S. aureus", "ORGANISM", 142, 151], ["S. pneumoniae", "ORGANISM", 156, 169], ["M. catarrhalis", "SPECIES", 41, 55], ["S. aureus", "SPECIES", 60, 69], ["S. aureus", "SPECIES", 142, 151], ["S. pneumoniae", "SPECIES", 156, 169], ["M. catarrhalis", "SPECIES", 41, 55], ["S. aureus", "SPECIES", 60, 69], ["S. aureus", "SPECIES", 142, 151], ["S. pneumoniae", "SPECIES", 156, 169], ["M. catarrhalis", "PROBLEM", 41, 55], ["S. aureus", "PROBLEM", 60, 69], ["an adjusted odds ratio", "TEST", 76, 98], ["S. aureus", "PROBLEM", 142, 151], ["S. pneumoniae colonization", "PROBLEM", 156, 182], ["negative", "OBSERVATION", 2, 10], ["catarrhalis", "OBSERVATION", 44, 55], ["aureus", "OBSERVATION", 63, 69], ["more profound", "OBSERVATION_MODIFIER", 110, 123], ["aureus", "OBSERVATION", 145, 151], ["pneumoniae", "OBSERVATION_MODIFIER", 159, 169]]], ["The positive association between the presence of S. aureus and the pooled group of influenza viruses persisted in the multivariate model (Table 2).ResultsMultivariate models for independent associations with the most frequently detected viruses are shown in Table 3.", [["influenza viruses", "DISEASE", 83, 100], ["S. aureus", "ORGANISM", 49, 58], ["S. aureus", "SPECIES", 49, 58], ["S. aureus", "SPECIES", 49, 58], ["S. aureus", "PROBLEM", 49, 58], ["influenza viruses", "PROBLEM", 83, 100], ["positive", "OBSERVATION", 4, 12], ["aureus", "OBSERVATION", 52, 58], ["influenza viruses", "OBSERVATION", 83, 100], ["viruses", "OBSERVATION", 237, 244]]], ["Human rhinoviruses were positively associated with the presence of siblings as well as with enteroviruses, and negatively associated with coronaviruses.", [["enteroviruses", "DISEASE", 92, 105], ["Human", "ORGANISM", 0, 5], ["rhinoviruses", "ORGANISM", 6, 18], ["Human", "SPECIES", 0, 5], ["Human rhinoviruses", "SPECIES", 0, 18], ["Human rhinoviruses", "PROBLEM", 0, 18], ["enteroviruses", "PROBLEM", 92, 105], ["coronaviruses", "PROBLEM", 138, 151], ["rhinoviruses", "OBSERVATION", 6, 18], ["enteroviruses", "OBSERVATION", 92, 105]]], ["In addition, enteroviruses were positively associated with the presence of human bocavirus, WU polyomavirus, parainfluenza viruses and human parechovirus.", [["parainfluenza viruses", "DISEASE", 109, 130], ["enteroviruses", "ORGANISM", 13, 26], ["human", "ORGANISM", 75, 80], ["bocavirus", "GENE_OR_GENE_PRODUCT", 81, 90], ["WU polyomavirus", "ORGANISM", 92, 107], ["parainfluenza viruses", "ORGANISM", 109, 130], ["human", "ORGANISM", 135, 140], ["parechovirus", "ORGANISM", 141, 153], ["human", "SPECIES", 75, 80], ["parainfluenza", "SPECIES", 109, 122], ["human", "SPECIES", 135, 140], ["human bocavirus", "SPECIES", 75, 90], ["WU polyomavirus", "SPECIES", 92, 107], ["parainfluenza viruses", "SPECIES", 109, 130], ["human", "SPECIES", 135, 140], ["enteroviruses", "PROBLEM", 13, 26], ["human bocavirus", "PROBLEM", 75, 90], ["WU polyomavirus", "PROBLEM", 92, 107], ["parainfluenza viruses", "PROBLEM", 109, 130], ["human parechovirus", "PROBLEM", 135, 153], ["enteroviruses", "OBSERVATION", 13, 26], ["bocavirus", "OBSERVATION", 81, 90], ["parainfluenza viruses", "OBSERVATION", 109, 130]]], ["Human bocavirus was also associated with day care attendance and the presence of WU polyomavirus (Table 2).Results", [["Human", "ORGANISM", 0, 5], ["WU polyomavirus", "ORGANISM", 81, 96], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["WU polyomavirus", "SPECIES", 81, 96], ["Human bocavirus", "PROBLEM", 0, 15], ["WU polyomavirus", "PROBLEM", 81, 96], ["polyomavirus", "OBSERVATION", 84, 96]]]]}